immport_study_accession,study_title,study_brief_desc,study_min_age,study_max_age,immport_subject_accession,gender,race,immport_immune_exposure_material_id,vaccine,biosample_id,immport_vaccination_time,immport_vaccination_time_unit,day_0_def,biosample_type,subtype,immport_biosample_accession,expsample_repository_name,gsm,expsample_to_multiple_gsm_flag,gse,gpl,platform_desc,batch_factor,type_subtype,age_group
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174084,Female,White,VO_0000124,Zostavax,BS934465,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067535,GEO,GSM2094438,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174108,Female,White,VO_0000124,Zostavax,BS934489,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067536,GEO,GSM2094439,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174132,Female,Black or African American,VO_0000124,Zostavax,BS934513,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067537,GEO,GSM2094440,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174087,Female,White,VO_0000124,Zostavax,BS934468,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067538,GEO,GSM2094441,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174111,Female,White,VO_0000124,Zostavax,BS934492,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067539,GEO,GSM2094442,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174135,Female,White,VO_0000124,Zostavax,BS934516,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067540,GEO,GSM2094443,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174093,Male,White,VO_0000124,Zostavax,BS934474,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067541,GEO,GSM2094447,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174090,Male,Black or African American,VO_0000124,Zostavax,BS934471,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067542,GEO,GSM2094444,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174114,Female,White,VO_0000124,Zostavax,BS934495,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067543,GEO,GSM2094445,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174138,Female,Black or African American,VO_0000124,Zostavax,BS934519,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067544,GEO,GSM2094446,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174117,Female,Black or African American,VO_0000124,Zostavax,BS934498,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067545,GEO,GSM2094448,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174141,Female,White,VO_0000124,Zostavax,BS934522,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067546,GEO,GSM2094449,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174096,Male,Black or African American,VO_0000124,Zostavax,BS934477,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067547,GEO,GSM2094450,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174120,Male,Unknown,VO_0000124,Zostavax,BS934501,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067548,GEO,GSM2094451,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174144,Female,Black or African American,VO_0000124,Zostavax,BS934525,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067549,GEO,GSM2094452,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174099,Female,White,VO_0000124,Zostavax,BS934480,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067550,GEO,GSM2094453,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174123,Male,White,VO_0000124,Zostavax,BS934504,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067551,GEO,GSM2094454,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174147,Male,White,VO_0000124,Zostavax,BS934528,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067552,GEO,GSM2094455,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174102,Male,Black or African American,VO_0000124,Zostavax,BS934483,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067553,GEO,GSM2094456,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174091,Female,White,VO_0000124,Zostavax,BS934472,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067554,GEO,GSM2094468,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174126,Male,White,VO_0000124,Zostavax,BS934507,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067555,GEO,GSM2094457,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174085,Female,White,VO_0000124,Zostavax,BS934466,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067556,GEO,GSM2094462,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174109,Female,White,VO_0000124,Zostavax,BS934490,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067557,GEO,GSM2094463,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174150,Female,White,VO_0000124,Zostavax,BS934531,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067558,GEO,GSM2094458,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174105,Female,White,VO_0000124,Zostavax,BS934486,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067559,GEO,GSM2094459,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174115,Female,White,VO_0000124,Zostavax,BS934496,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067560,GEO,GSM2094469,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174129,Female,White,VO_0000124,Zostavax,BS934510,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067561,GEO,GSM2094460,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174153,Male,White,VO_0000124,Zostavax,BS934534,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067562,GEO,GSM2094461,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174133,Male,White,VO_0000124,Zostavax,BS934514,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067563,GEO,GSM2094464,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174088,Male,White,VO_0000124,Zostavax,BS934469,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067564,GEO,GSM2094465,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174112,Male,White,VO_0000124,Zostavax,BS934493,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067565,GEO,GSM2094466,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174136,Female,Black or African American,VO_0000124,Zostavax,BS934517,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067566,GEO,GSM2094467,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174139,Male,Unknown,VO_0000124,Zostavax,BS934520,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067567,GEO,GSM2094470,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174094,Female,White,VO_0000124,Zostavax,BS934475,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067568,GEO,GSM2094471,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174118,Female,Black or African American,VO_0000124,Zostavax,BS934499,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067569,GEO,GSM2094472,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174142,Female,White,VO_0000124,Zostavax,BS934523,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067570,GEO,GSM2094473,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174097,Male,White,VO_0000124,Zostavax,BS934478,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067571,GEO,GSM2094474,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174100,Male,White,VO_0000124,Zostavax,BS934481,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067572,GEO,GSM2094477,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174124,Female,White,VO_0000124,Zostavax,BS934505,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067573,GEO,GSM2094478,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174121,Female,White,VO_0000124,Zostavax,BS934502,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067574,GEO,GSM2094475,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174145,Male,White,VO_0000124,Zostavax,BS934526,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067575,GEO,GSM2094476,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174148,Female,Asian,VO_0000124,Zostavax,BS934529,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067576,GEO,GSM2094479,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174103,Female,White,VO_0000124,Zostavax,BS934484,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067577,GEO,GSM2094480,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174127,Male,White,VO_0000124,Zostavax,BS934508,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067578,GEO,GSM2094481,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174131,Female,Unknown,VO_0000124,Zostavax,BS934512,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067579,GEO,GSM2094488,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174151,Female,White,VO_0000124,Zostavax,BS934532,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067580,GEO,GSM2094482,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174154,Female,White,VO_0000124,Zostavax,BS934535,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067581,GEO,GSM2094485,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174106,Male,White,VO_0000124,Zostavax,BS934487,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067582,GEO,GSM2094483,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174130,Female,White,VO_0000124,Zostavax,BS934511,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067583,GEO,GSM2094484,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174083,Female,White,VO_0000124,Zostavax,BS934464,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067584,GEO,GSM2094486,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174107,Female,White,VO_0000124,Zostavax,BS934488,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067585,GEO,GSM2094487,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174086,Male,White,VO_0000124,Zostavax,BS934467,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067586,GEO,GSM2094489,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174110,Male,White,VO_0000124,Zostavax,BS934491,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067587,GEO,GSM2094490,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174119,Female,White,VO_0000124,Zostavax,BS934500,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067588,GEO,GSM2094499,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174134,Female,White,VO_0000124,Zostavax,BS934515,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067589,GEO,GSM2094491,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174089,Male,White,VO_0000124,Zostavax,BS934470,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067590,GEO,GSM2094492,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174113,Male,White,VO_0000124,Zostavax,BS934494,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067591,GEO,GSM2094493,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174116,Female,White,VO_0000124,Zostavax,BS934497,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067592,GEO,GSM2094496,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174137,Female,White,VO_0000124,Zostavax,BS934518,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067593,GEO,GSM2094494,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174098,Male,White,VO_0000124,Zostavax,BS934479,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067594,GEO,GSM2094501,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174122,Female,White,VO_0000124,Zostavax,BS934503,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067595,GEO,GSM2094502,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174140,Female,Asian,VO_0000124,Zostavax,BS934521,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067596,GEO,GSM2094497,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174092,Male,White,VO_0000124,Zostavax,BS934473,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067597,GEO,GSM2094495,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174143,Female,White,VO_0000124,Zostavax,BS934524,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067598,GEO,GSM2094500,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174095,Male,White,VO_0000124,Zostavax,BS934476,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067599,GEO,GSM2094498,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174146,Female,White,VO_0000124,Zostavax,BS934527,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067600,GEO,GSM2094503,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174101,Female,Black or African American,VO_0000124,Zostavax,BS934482,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067601,GEO,GSM2094504,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174149,Female,White,VO_0000124,Zostavax,BS934530,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067602,GEO,GSM2094506,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174125,Female,White,VO_0000124,Zostavax,BS934506,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067603,GEO,GSM2094505,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174104,Male,White,VO_0000124,Zostavax,BS934485,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067604,GEO,GSM2094507,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174128,Female,White,VO_0000124,Zostavax,BS934509,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067605,GEO,GSM2094508,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174152,Male,White,VO_0000124,Zostavax,BS934533,0.0,Days,Time of initial vaccine administration,PBMC,,ES1067606,GEO,GSM2094509,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174084,Female,White,VO_0000124,Zostavax,BS934681,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067607,GEO,GSM2094510,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174108,Female,White,VO_0000124,Zostavax,BS934705,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067608,GEO,GSM2094511,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174132,Female,Black or African American,VO_0000124,Zostavax,BS934729,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067609,GEO,GSM2094512,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174087,Female,White,VO_0000124,Zostavax,BS934684,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067610,GEO,GSM2094513,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174111,Female,White,VO_0000124,Zostavax,BS934708,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067611,GEO,GSM2094514,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174135,Female,White,VO_0000124,Zostavax,BS934732,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067612,GEO,GSM2094515,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174093,Male,White,VO_0000124,Zostavax,BS934690,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067613,GEO,GSM2094519,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174090,Male,Black or African American,VO_0000124,Zostavax,BS934687,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067614,GEO,GSM2094516,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174114,Female,White,VO_0000124,Zostavax,BS934711,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067615,GEO,GSM2094517,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174138,Female,Black or African American,VO_0000124,Zostavax,BS934735,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067616,GEO,GSM2094518,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174117,Female,Black or African American,VO_0000124,Zostavax,BS934714,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067617,GEO,GSM2094520,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174141,Female,White,VO_0000124,Zostavax,BS934738,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067618,GEO,GSM2094521,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174096,Male,Black or African American,VO_0000124,Zostavax,BS934693,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067619,GEO,GSM2094522,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174120,Male,Unknown,VO_0000124,Zostavax,BS934717,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067620,GEO,GSM2094523,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174144,Female,Black or African American,VO_0000124,Zostavax,BS934741,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067621,GEO,GSM2094524,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174099,Female,White,VO_0000124,Zostavax,BS934696,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067622,GEO,GSM2094525,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174123,Male,White,VO_0000124,Zostavax,BS934720,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067623,GEO,GSM2094526,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174147,Male,White,VO_0000124,Zostavax,BS934744,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067624,GEO,GSM2094527,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174102,Male,Black or African American,VO_0000124,Zostavax,BS934699,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067625,GEO,GSM2094528,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174091,Female,White,VO_0000124,Zostavax,BS934688,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067626,GEO,GSM2094540,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174126,Male,White,VO_0000124,Zostavax,BS934723,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067627,GEO,GSM2094529,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174085,Female,White,VO_0000124,Zostavax,BS934682,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067628,GEO,GSM2094534,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174109,Female,White,VO_0000124,Zostavax,BS934706,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067629,GEO,GSM2094535,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174150,Female,White,VO_0000124,Zostavax,BS934747,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067630,GEO,GSM2094530,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174105,Female,White,VO_0000124,Zostavax,BS934702,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067631,GEO,GSM2094531,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174115,Female,White,VO_0000124,Zostavax,BS934712,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067632,GEO,GSM2094541,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174129,Female,White,VO_0000124,Zostavax,BS934726,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067633,GEO,GSM2094532,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174153,Male,White,VO_0000124,Zostavax,BS934750,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067634,GEO,GSM2094533,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174133,Male,White,VO_0000124,Zostavax,BS934730,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067635,GEO,GSM2094536,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174088,Male,White,VO_0000124,Zostavax,BS934685,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067636,GEO,GSM2094537,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174112,Male,White,VO_0000124,Zostavax,BS934709,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067637,GEO,GSM2094538,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174136,Female,Black or African American,VO_0000124,Zostavax,BS934733,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067638,GEO,GSM2094539,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174139,Male,Unknown,VO_0000124,Zostavax,BS934736,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067639,GEO,GSM2094542,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174094,Female,White,VO_0000124,Zostavax,BS934691,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067640,GEO,GSM2094543,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174118,Female,Black or African American,VO_0000124,Zostavax,BS934715,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067641,GEO,GSM2094544,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174142,Female,White,VO_0000124,Zostavax,BS934739,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067642,GEO,GSM2094545,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174097,Male,White,VO_0000124,Zostavax,BS934694,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067643,GEO,GSM2094546,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174100,Male,White,VO_0000124,Zostavax,BS934697,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067644,GEO,GSM2094549,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174124,Female,White,VO_0000124,Zostavax,BS934721,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067645,GEO,GSM2094550,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174121,Female,White,VO_0000124,Zostavax,BS934718,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067646,GEO,GSM2094547,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174145,Male,White,VO_0000124,Zostavax,BS934742,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067647,GEO,GSM2094548,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174148,Female,Asian,VO_0000124,Zostavax,BS934745,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067648,GEO,GSM2094551,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174103,Female,White,VO_0000124,Zostavax,BS934700,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067649,GEO,GSM2094552,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174127,Male,White,VO_0000124,Zostavax,BS934724,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067650,GEO,GSM2094553,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174131,Female,Unknown,VO_0000124,Zostavax,BS934728,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067651,GEO,GSM2094560,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174151,Female,White,VO_0000124,Zostavax,BS934748,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067652,GEO,GSM2094554,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174154,Female,White,VO_0000124,Zostavax,BS934751,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067653,GEO,GSM2094557,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174106,Male,White,VO_0000124,Zostavax,BS934703,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067654,GEO,GSM2094555,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174130,Female,White,VO_0000124,Zostavax,BS934727,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067655,GEO,GSM2094556,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174083,Female,White,VO_0000124,Zostavax,BS934680,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067656,GEO,GSM2094558,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174107,Female,White,VO_0000124,Zostavax,BS934704,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067657,GEO,GSM2094559,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174086,Male,White,VO_0000124,Zostavax,BS934683,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067658,GEO,GSM2094561,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174110,Male,White,VO_0000124,Zostavax,BS934707,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067659,GEO,GSM2094562,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174119,Female,White,VO_0000124,Zostavax,BS934716,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067660,GEO,GSM2094571,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174134,Female,White,VO_0000124,Zostavax,BS934731,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067661,GEO,GSM2094563,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174089,Male,White,VO_0000124,Zostavax,BS934686,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067662,GEO,GSM2094564,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174113,Male,White,VO_0000124,Zostavax,BS934710,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067663,GEO,GSM2094565,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174116,Female,White,VO_0000124,Zostavax,BS934713,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067664,GEO,GSM2094568,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174137,Female,White,VO_0000124,Zostavax,BS934734,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067665,GEO,GSM2094566,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174098,Male,White,VO_0000124,Zostavax,BS934695,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067666,GEO,GSM2094573,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174122,Female,White,VO_0000124,Zostavax,BS934719,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067667,GEO,GSM2094574,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174140,Female,Asian,VO_0000124,Zostavax,BS934737,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067668,GEO,GSM2094569,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174092,Male,White,VO_0000124,Zostavax,BS934689,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067669,GEO,GSM2094567,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174143,Female,White,VO_0000124,Zostavax,BS934740,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067670,GEO,GSM2094572,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174095,Male,White,VO_0000124,Zostavax,BS934692,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067671,GEO,GSM2094570,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174146,Female,White,VO_0000124,Zostavax,BS934743,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067672,GEO,GSM2094575,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174101,Female,Black or African American,VO_0000124,Zostavax,BS934698,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067673,GEO,GSM2094576,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174149,Female,White,VO_0000124,Zostavax,BS934746,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067674,GEO,GSM2094578,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174125,Female,White,VO_0000124,Zostavax,BS934722,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067675,GEO,GSM2094577,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174104,Male,White,VO_0000124,Zostavax,BS934701,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067676,GEO,GSM2094579,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174128,Female,White,VO_0000124,Zostavax,BS934725,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067677,GEO,GSM2094580,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174152,Male,White,VO_0000124,Zostavax,BS934749,1.0,Days,Time of initial vaccine administration,PBMC,,ES1067678,GEO,GSM2094581,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174084,Female,White,VO_0000124,Zostavax,BS934897,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067679,GEO,GSM2094582,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174108,Female,White,VO_0000124,Zostavax,BS934921,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067680,GEO,GSM2094583,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174132,Female,Black or African American,VO_0000124,Zostavax,BS934945,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067681,GEO,GSM2094584,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174087,Female,White,VO_0000124,Zostavax,BS934900,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067682,GEO,GSM2094585,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174111,Female,White,VO_0000124,Zostavax,BS934924,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067683,GEO,GSM2094586,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174135,Female,White,VO_0000124,Zostavax,BS934948,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067684,GEO,GSM2094587,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174093,Male,White,VO_0000124,Zostavax,BS934906,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067685,GEO,GSM2094591,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174090,Male,Black or African American,VO_0000124,Zostavax,BS934903,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067686,GEO,GSM2094588,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174114,Female,White,VO_0000124,Zostavax,BS934927,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067687,GEO,GSM2094589,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174138,Female,Black or African American,VO_0000124,Zostavax,BS934951,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067688,GEO,GSM2094590,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174117,Female,Black or African American,VO_0000124,Zostavax,BS934930,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067689,GEO,GSM2094592,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174141,Female,White,VO_0000124,Zostavax,BS934954,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067690,GEO,GSM2094593,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174096,Male,Black or African American,VO_0000124,Zostavax,BS934909,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067691,GEO,GSM2094594,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174120,Male,Unknown,VO_0000124,Zostavax,BS934933,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067692,GEO,GSM2094595,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174144,Female,Black or African American,VO_0000124,Zostavax,BS934957,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067693,GEO,GSM2094596,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174099,Female,White,VO_0000124,Zostavax,BS934912,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067694,GEO,GSM2094597,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174123,Male,White,VO_0000124,Zostavax,BS934936,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067695,GEO,GSM2094598,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174147,Male,White,VO_0000124,Zostavax,BS934960,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067696,GEO,GSM2094599,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174102,Male,Black or African American,VO_0000124,Zostavax,BS934915,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067697,GEO,GSM2094600,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174091,Female,White,VO_0000124,Zostavax,BS934904,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067698,GEO,GSM2094612,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174126,Male,White,VO_0000124,Zostavax,BS934939,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067699,GEO,GSM2094601,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174085,Female,White,VO_0000124,Zostavax,BS934898,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067700,GEO,GSM2094606,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174109,Female,White,VO_0000124,Zostavax,BS934922,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067701,GEO,GSM2094607,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174150,Female,White,VO_0000124,Zostavax,BS934963,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067702,GEO,GSM2094602,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174105,Female,White,VO_0000124,Zostavax,BS934918,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067703,GEO,GSM2094603,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174115,Female,White,VO_0000124,Zostavax,BS934928,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067704,GEO,GSM2094613,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174129,Female,White,VO_0000124,Zostavax,BS934942,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067705,GEO,GSM2094604,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174153,Male,White,VO_0000124,Zostavax,BS934966,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067706,GEO,GSM2094605,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174133,Male,White,VO_0000124,Zostavax,BS934946,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067707,GEO,GSM2094608,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174088,Male,White,VO_0000124,Zostavax,BS934901,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067708,GEO,GSM2094609,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174112,Male,White,VO_0000124,Zostavax,BS934925,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067709,GEO,GSM2094610,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174136,Female,Black or African American,VO_0000124,Zostavax,BS934949,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067710,GEO,GSM2094611,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174139,Male,Unknown,VO_0000124,Zostavax,BS934952,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067711,GEO,GSM2094614,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174094,Female,White,VO_0000124,Zostavax,BS934907,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067712,GEO,GSM2094615,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174118,Female,Black or African American,VO_0000124,Zostavax,BS934931,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067713,GEO,GSM2094616,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174142,Female,White,VO_0000124,Zostavax,BS934955,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067714,GEO,GSM2094617,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174097,Male,White,VO_0000124,Zostavax,BS934910,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067715,GEO,GSM2094618,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174100,Male,White,VO_0000124,Zostavax,BS934913,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067716,GEO,GSM2094621,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174124,Female,White,VO_0000124,Zostavax,BS934937,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067717,GEO,GSM2094622,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174121,Female,White,VO_0000124,Zostavax,BS934934,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067718,GEO,GSM2094619,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174145,Male,White,VO_0000124,Zostavax,BS934958,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067719,GEO,GSM2094620,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174148,Female,Asian,VO_0000124,Zostavax,BS934961,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067720,GEO,GSM2094623,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174103,Female,White,VO_0000124,Zostavax,BS934916,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067721,GEO,GSM2094624,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174127,Male,White,VO_0000124,Zostavax,BS934940,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067722,GEO,GSM2094625,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174131,Female,Unknown,VO_0000124,Zostavax,BS934944,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067723,GEO,GSM2094632,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174151,Female,White,VO_0000124,Zostavax,BS934964,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067724,GEO,GSM2094626,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174154,Female,White,VO_0000124,Zostavax,BS934967,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067725,GEO,GSM2094629,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174106,Male,White,VO_0000124,Zostavax,BS934919,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067726,GEO,GSM2094627,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174130,Female,White,VO_0000124,Zostavax,BS934943,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067727,GEO,GSM2094628,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174083,Female,White,VO_0000124,Zostavax,BS934896,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067728,GEO,GSM2094630,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174107,Female,White,VO_0000124,Zostavax,BS934920,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067729,GEO,GSM2094631,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174086,Male,White,VO_0000124,Zostavax,BS934899,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067730,GEO,GSM2094633,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174110,Male,White,VO_0000124,Zostavax,BS934923,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067731,GEO,GSM2094634,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174119,Female,White,VO_0000124,Zostavax,BS934932,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067732,GEO,GSM2094643,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174134,Female,White,VO_0000124,Zostavax,BS934947,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067733,GEO,GSM2094635,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174089,Male,White,VO_0000124,Zostavax,BS934902,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067734,GEO,GSM2094636,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174113,Male,White,VO_0000124,Zostavax,BS934926,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067735,GEO,GSM2094637,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174116,Female,White,VO_0000124,Zostavax,BS934929,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067736,GEO,GSM2094640,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174137,Female,White,VO_0000124,Zostavax,BS934950,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067737,GEO,GSM2094638,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174098,Male,White,VO_0000124,Zostavax,BS934911,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067738,GEO,GSM2094645,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174122,Female,White,VO_0000124,Zostavax,BS934935,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067739,GEO,GSM2094646,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174140,Female,Asian,VO_0000124,Zostavax,BS934953,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067740,GEO,GSM2094641,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174092,Male,White,VO_0000124,Zostavax,BS934905,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067741,GEO,GSM2094639,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174143,Female,White,VO_0000124,Zostavax,BS934956,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067742,GEO,GSM2094644,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174095,Male,White,VO_0000124,Zostavax,BS934908,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067743,GEO,GSM2094642,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174146,Female,White,VO_0000124,Zostavax,BS934959,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067744,GEO,GSM2094647,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174101,Female,Black or African American,VO_0000124,Zostavax,BS934914,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067745,GEO,GSM2094648,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174149,Female,White,VO_0000124,Zostavax,BS934962,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067746,GEO,GSM2094650,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174125,Female,White,VO_0000124,Zostavax,BS934938,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067747,GEO,GSM2094649,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174104,Male,White,VO_0000124,Zostavax,BS934917,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067748,GEO,GSM2094651,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174128,Female,White,VO_0000124,Zostavax,BS934941,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067749,GEO,GSM2094652,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174152,Male,White,VO_0000124,Zostavax,BS934965,3.0,Days,Time of initial vaccine administration,PBMC,,ES1067750,GEO,GSM2094653,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174084,Female,White,VO_0000124,Zostavax,BS935113,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067751,GEO,GSM2094654,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174108,Female,White,VO_0000124,Zostavax,BS935137,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067752,GEO,GSM2094655,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174132,Female,Black or African American,VO_0000124,Zostavax,BS935161,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067753,GEO,GSM2094656,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174087,Female,White,VO_0000124,Zostavax,BS935116,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067754,GEO,GSM2094657,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174111,Female,White,VO_0000124,Zostavax,BS935140,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067755,GEO,GSM2094658,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174135,Female,White,VO_0000124,Zostavax,BS935164,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067756,GEO,GSM2094659,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174093,Male,White,VO_0000124,Zostavax,BS935122,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067757,GEO,GSM2094663,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174090,Male,Black or African American,VO_0000124,Zostavax,BS935119,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067758,GEO,GSM2094660,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174114,Female,White,VO_0000124,Zostavax,BS935143,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067759,GEO,GSM2094661,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174138,Female,Black or African American,VO_0000124,Zostavax,BS935167,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067760,GEO,GSM2094662,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174117,Female,Black or African American,VO_0000124,Zostavax,BS935146,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067761,GEO,GSM2094664,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174141,Female,White,VO_0000124,Zostavax,BS935170,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067762,GEO,GSM2094665,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174096,Male,Black or African American,VO_0000124,Zostavax,BS935125,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067763,GEO,GSM2094666,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174120,Male,Unknown,VO_0000124,Zostavax,BS935149,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067764,GEO,GSM2094667,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174144,Female,Black or African American,VO_0000124,Zostavax,BS935173,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067765,GEO,GSM2094668,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174099,Female,White,VO_0000124,Zostavax,BS935128,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067766,GEO,GSM2094669,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174123,Male,White,VO_0000124,Zostavax,BS935152,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067767,GEO,GSM2094670,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174147,Male,White,VO_0000124,Zostavax,BS935176,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067768,GEO,GSM2094671,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174102,Male,Black or African American,VO_0000124,Zostavax,BS935131,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067769,GEO,GSM2094672,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174091,Female,White,VO_0000124,Zostavax,BS935120,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067770,GEO,GSM2094684,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174126,Male,White,VO_0000124,Zostavax,BS935155,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067771,GEO,GSM2094673,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174085,Female,White,VO_0000124,Zostavax,BS935114,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067772,GEO,GSM2094678,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174109,Female,White,VO_0000124,Zostavax,BS935138,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067773,GEO,GSM2094679,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174150,Female,White,VO_0000124,Zostavax,BS935179,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067774,GEO,GSM2094674,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174105,Female,White,VO_0000124,Zostavax,BS935134,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067775,GEO,GSM2094675,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174115,Female,White,VO_0000124,Zostavax,BS935144,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067776,GEO,GSM2094685,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174129,Female,White,VO_0000124,Zostavax,BS935158,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067777,GEO,GSM2094676,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174153,Male,White,VO_0000124,Zostavax,BS935182,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067778,GEO,GSM2094677,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174133,Male,White,VO_0000124,Zostavax,BS935162,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067779,GEO,GSM2094680,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174088,Male,White,VO_0000124,Zostavax,BS935117,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067780,GEO,GSM2094681,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174112,Male,White,VO_0000124,Zostavax,BS935141,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067781,GEO,GSM2094682,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174136,Female,Black or African American,VO_0000124,Zostavax,BS935165,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067782,GEO,GSM2094683,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174139,Male,Unknown,VO_0000124,Zostavax,BS935168,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067783,GEO,GSM2094686,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174094,Female,White,VO_0000124,Zostavax,BS935123,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067784,GEO,GSM2094687,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174118,Female,Black or African American,VO_0000124,Zostavax,BS935147,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067785,GEO,GSM2094688,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174142,Female,White,VO_0000124,Zostavax,BS935171,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067786,GEO,GSM2094689,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174097,Male,White,VO_0000124,Zostavax,BS935126,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067787,GEO,GSM2094690,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174100,Male,White,VO_0000124,Zostavax,BS935129,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067788,GEO,GSM2094693,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174124,Female,White,VO_0000124,Zostavax,BS935153,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067789,GEO,GSM2094694,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174121,Female,White,VO_0000124,Zostavax,BS935150,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067790,GEO,GSM2094691,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174145,Male,White,VO_0000124,Zostavax,BS935174,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067791,GEO,GSM2094692,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174148,Female,Asian,VO_0000124,Zostavax,BS935177,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067792,GEO,GSM2094695,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174103,Female,White,VO_0000124,Zostavax,BS935132,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067793,GEO,GSM2094696,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174127,Male,White,VO_0000124,Zostavax,BS935156,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067794,GEO,GSM2094697,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174131,Female,Unknown,VO_0000124,Zostavax,BS935160,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067795,GEO,GSM2094704,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174151,Female,White,VO_0000124,Zostavax,BS935180,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067796,GEO,GSM2094698,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174154,Female,White,VO_0000124,Zostavax,BS935183,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067797,GEO,GSM2094701,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174106,Male,White,VO_0000124,Zostavax,BS935135,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067798,GEO,GSM2094699,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174130,Female,White,VO_0000124,Zostavax,BS935159,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067799,GEO,GSM2094700,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174083,Female,White,VO_0000124,Zostavax,BS935112,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067800,GEO,GSM2094702,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174107,Female,White,VO_0000124,Zostavax,BS935136,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067801,GEO,GSM2094703,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174086,Male,White,VO_0000124,Zostavax,BS935115,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067802,GEO,GSM2094705,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174110,Male,White,VO_0000124,Zostavax,BS935139,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067803,GEO,GSM2094706,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174119,Female,White,VO_0000124,Zostavax,BS935148,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067804,GEO,GSM2094715,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174134,Female,White,VO_0000124,Zostavax,BS935163,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067805,GEO,GSM2094707,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174089,Male,White,VO_0000124,Zostavax,BS935118,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067806,GEO,GSM2094708,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174113,Male,White,VO_0000124,Zostavax,BS935142,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067807,GEO,GSM2094709,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174116,Female,White,VO_0000124,Zostavax,BS935145,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067808,GEO,GSM2094712,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174137,Female,White,VO_0000124,Zostavax,BS935166,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067809,GEO,GSM2094710,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174098,Male,White,VO_0000124,Zostavax,BS935127,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067810,GEO,GSM2094717,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174122,Female,White,VO_0000124,Zostavax,BS935151,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067811,GEO,GSM2094718,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174140,Female,Asian,VO_0000124,Zostavax,BS935169,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067812,GEO,GSM2094713,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174092,Male,White,VO_0000124,Zostavax,BS935121,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067813,GEO,GSM2094711,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174143,Female,White,VO_0000124,Zostavax,BS935172,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067814,GEO,GSM2094716,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174095,Male,White,VO_0000124,Zostavax,BS935124,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067815,GEO,GSM2094714,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174146,Female,White,VO_0000124,Zostavax,BS935175,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067816,GEO,GSM2094719,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174101,Female,Black or African American,VO_0000124,Zostavax,BS935130,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067817,GEO,GSM2094720,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174149,Female,White,VO_0000124,Zostavax,BS935178,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067818,GEO,GSM2094722,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174125,Female,White,VO_0000124,Zostavax,BS935154,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067819,GEO,GSM2094721,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174104,Male,White,VO_0000124,Zostavax,BS935133,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067820,GEO,GSM2094723,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174128,Female,White,VO_0000124,Zostavax,BS935157,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067821,GEO,GSM2094724,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY984,Zoster vaccine in young and elderly,"Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine.",25.0,79.0,SUB174152,Male,White,VO_0000124,Zostavax,BS935181,7.0,Days,Time of initial vaccine administration,PBMC,,ES1067822,GEO,GSM2094725,false,GSE79396,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE79396,PBMC : NA,25.0 - 79.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179643,Female,Not Specified,VO_0000047,Fluzone,BS946609,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087056,GEO,GSM1934468,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179643,Female,Not Specified,VO_0000047,Fluzone,BS946687,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087057,GEO,GSM1934469,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179643,Female,Not Specified,VO_0000047,Fluzone,BS946765,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087058,GEO,GSM1934470,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179644,Female,Not Specified,VO_0000047,Fluzone,BS946610,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087059,GEO,GSM1934471,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179644,Female,Not Specified,VO_0000047,Fluzone,BS946688,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087060,GEO,GSM1934472,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179644,Female,Not Specified,VO_0000047,Fluzone,BS946766,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087061,GEO,GSM1934473,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179645,Female,Not Specified,VO_0000047,Fluzone,BS946611,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087062,GEO,GSM1934474,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179645,Female,Not Specified,VO_0000047,Fluzone,BS946689,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087063,GEO,GSM1934475,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179645,Female,Not Specified,VO_0000047,Fluzone,BS946767,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087064,GEO,GSM1934476,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179647,Male,Not Specified,VO_0000047,Fluzone,BS946613,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087065,GEO,GSM1934477,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179647,Male,Not Specified,VO_0000047,Fluzone,BS946691,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087066,GEO,GSM1934478,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179647,Male,Not Specified,VO_0000047,Fluzone,BS946769,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087067,GEO,GSM1934479,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179648,Female,Not Specified,VO_0000047,Fluzone,BS946614,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087068,GEO,GSM1934480,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179648,Female,Not Specified,VO_0000047,Fluzone,BS946770,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087069,GEO,GSM1934481,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179649,Male,Not Specified,VO_0000047,Fluzone,BS946615,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087070,GEO,GSM1934482,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179649,Male,Not Specified,VO_0000047,Fluzone,BS946693,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087071,GEO,GSM1934483,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179649,Male,Not Specified,VO_0000047,Fluzone,BS946771,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087072,GEO,GSM1934484,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179650,Male,Not Specified,VO_0000047,Fluzone,BS946616,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087073,GEO,GSM1934485,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179650,Male,Not Specified,VO_0000047,Fluzone,BS946694,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087074,GEO,GSM1934486,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179650,Male,Not Specified,VO_0000047,Fluzone,BS946772,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087075,GEO,GSM1934487,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179651,Female,Not Specified,VO_0000047,Fluzone,BS946617,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087076,GEO,GSM1934488,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179651,Female,Not Specified,VO_0000047,Fluzone,BS946695,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087077,GEO,GSM1934489,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179651,Female,Not Specified,VO_0000047,Fluzone,BS946773,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087078,GEO,GSM1934490,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179653,Female,Not Specified,VO_0000047,Fluzone,BS946619,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087079,GEO,GSM1934491,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179653,Female,Not Specified,VO_0000047,Fluzone,BS946697,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087080,GEO,GSM1934492,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179653,Female,Not Specified,VO_0000047,Fluzone,BS946775,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087081,GEO,GSM1934493,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179654,Female,Not Specified,VO_0000047,Fluzone,BS946620,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087082,GEO,GSM1934494,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179654,Female,Not Specified,VO_0000047,Fluzone,BS946698,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087083,GEO,GSM1934495,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179654,Female,Not Specified,VO_0000047,Fluzone,BS946776,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087084,GEO,GSM1934496,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179655,Female,Not Specified,VO_0000047,Fluzone,BS946621,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087085,GEO,GSM1934497,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179655,Female,Not Specified,VO_0000047,Fluzone,BS946699,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087086,GEO,GSM1934498,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179655,Female,Not Specified,VO_0000047,Fluzone,BS946777,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087087,GEO,GSM1934499,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179656,Female,Not Specified,VO_0000047,Fluzone,BS946622,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087088,GEO,GSM1934500,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179656,Female,Not Specified,VO_0000047,Fluzone,BS946700,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087089,GEO,GSM1934501,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179656,Female,Not Specified,VO_0000047,Fluzone,BS946778,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087090,GEO,GSM1934502,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179657,Male,Not Specified,VO_0000047,Fluzone,BS946623,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087091,GEO,GSM1934503,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179657,Male,Not Specified,VO_0000047,Fluzone,BS946701,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087092,GEO,GSM1934504,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179657,Male,Not Specified,VO_0000047,Fluzone,BS946779,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087093,GEO,GSM1934505,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179658,Female,Not Specified,VO_0000047,Fluzone,BS946624,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087094,GEO,GSM1934506,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179658,Female,Not Specified,VO_0000047,Fluzone,BS946702,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087095,GEO,GSM1934507,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179658,Female,Not Specified,VO_0000047,Fluzone,BS946780,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087096,GEO,GSM1934508,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179659,Male,Not Specified,VO_0000047,Fluzone,BS946625,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087097,GEO,GSM1934509,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179659,Male,Not Specified,VO_0000047,Fluzone,BS946703,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087098,GEO,GSM1934510,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179659,Male,Not Specified,VO_0000047,Fluzone,BS946781,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087099,GEO,GSM1934511,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179661,Female,Not Specified,VO_0000047,Fluzone,BS946627,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087100,GEO,GSM1934512,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179661,Female,Not Specified,VO_0000047,Fluzone,BS946705,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087101,GEO,GSM1934513,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179661,Female,Not Specified,VO_0000047,Fluzone,BS946783,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087102,GEO,GSM1934514,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179662,Male,Not Specified,VO_0000047,Fluzone,BS946628,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087103,GEO,GSM1934515,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179662,Male,Not Specified,VO_0000047,Fluzone,BS946706,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087104,GEO,GSM1934516,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179662,Male,Not Specified,VO_0000047,Fluzone,BS946784,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087105,GEO,GSM1934517,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179664,Female,Not Specified,VO_0000047,Fluzone,BS946630,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087106,GEO,GSM1934518,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179664,Female,Not Specified,VO_0000047,Fluzone,BS946708,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087107,GEO,GSM1934519,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179664,Female,Not Specified,VO_0000047,Fluzone,BS946786,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087108,GEO,GSM1934520,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179665,Female,Not Specified,VO_0000047,Fluzone,BS946631,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087109,GEO,GSM1934521,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179665,Female,Not Specified,VO_0000047,Fluzone,BS946709,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087110,GEO,GSM1934522,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179665,Female,Not Specified,VO_0000047,Fluzone,BS946787,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087111,GEO,GSM1934523,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179666,Female,Not Specified,VO_0000047,Fluzone,BS946632,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087112,GEO,GSM1934524,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179666,Female,Not Specified,VO_0000047,Fluzone,BS946710,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087113,GEO,GSM1934525,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179666,Female,Not Specified,VO_0000047,Fluzone,BS946788,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087114,GEO,GSM1934526,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179668,Male,Not Specified,VO_0000047,Fluzone,BS946634,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087115,GEO,GSM1934527,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179668,Male,Not Specified,VO_0000047,Fluzone,BS946712,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087116,GEO,GSM1934528,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179668,Male,Not Specified,VO_0000047,Fluzone,BS946790,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087117,GEO,GSM1934529,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179669,Female,Not Specified,VO_0000047,Fluzone,BS946635,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087118,GEO,GSM1934530,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179669,Female,Not Specified,VO_0000047,Fluzone,BS946713,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087119,GEO,GSM1934531,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179669,Female,Not Specified,VO_0000047,Fluzone,BS946791,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087120,GEO,GSM1934532,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179671,Female,Not Specified,VO_0000047,Fluzone,BS946637,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087121,GEO,GSM1934533,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179671,Female,Not Specified,VO_0000047,Fluzone,BS946715,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087122,GEO,GSM1934534,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179671,Female,Not Specified,VO_0000047,Fluzone,BS946793,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087123,GEO,GSM1934535,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179672,Female,Not Specified,VO_0000047,Fluzone,BS946638,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087124,GEO,GSM1934536,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179672,Female,Not Specified,VO_0000047,Fluzone,BS946716,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087125,GEO,GSM1934537,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179672,Female,Not Specified,VO_0000047,Fluzone,BS946794,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087126,GEO,GSM1934538,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179673,Male,Not Specified,VO_0000047,Fluzone,BS946639,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087127,GEO,GSM1934539,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179673,Male,Not Specified,VO_0000047,Fluzone,BS946717,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087128,GEO,GSM1934540,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179673,Male,Not Specified,VO_0000047,Fluzone,BS946795,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087129,GEO,GSM1934541,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179687,Female,Not Specified,VO_0000047,Fluzone,BS946653,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087130,GEO,GSM1934542,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179687,Female,Not Specified,VO_0000047,Fluzone,BS946731,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087131,GEO,GSM1934543,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179687,Female,Not Specified,VO_0000047,Fluzone,BS946809,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087132,GEO,GSM1934544,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179688,Female,Not Specified,VO_0000047,Fluzone,BS946654,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087133,GEO,GSM1934545,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179688,Female,Not Specified,VO_0000047,Fluzone,BS946732,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087134,GEO,GSM1934546,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179688,Female,Not Specified,VO_0000047,Fluzone,BS946810,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087135,GEO,GSM1934547,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179695,Male,Not Specified,VO_0000047,Fluzone,BS946661,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087136,GEO,GSM1934548,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179695,Male,Not Specified,VO_0000047,Fluzone,BS946739,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087137,GEO,GSM1934549,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179695,Male,Not Specified,VO_0000047,Fluzone,BS946817,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087138,GEO,GSM1934550,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179699,Female,Not Specified,VO_0000047,Fluzone,BS946665,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087139,GEO,GSM1934551,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179699,Female,Not Specified,VO_0000047,Fluzone,BS946743,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087140,GEO,GSM1934552,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179699,Female,Not Specified,VO_0000047,Fluzone,BS946821,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087141,GEO,GSM1934553,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179700,Female,Not Specified,VO_0000047,Fluzone,BS946666,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087142,GEO,GSM1934554,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179700,Female,Not Specified,VO_0000047,Fluzone,BS946744,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087143,GEO,GSM1934555,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179700,Female,Not Specified,VO_0000047,Fluzone,BS946822,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087144,GEO,GSM1934556,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179642,Male,Not Specified,VO_0000047,Fluzone,BS946608,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087145,GEO,GSM1934557,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179642,Male,Not Specified,VO_0000047,Fluzone,BS946764,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087146,GEO,GSM1934558,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179652,Female,Not Specified,VO_0000047,Fluzone,BS946618,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087147,GEO,GSM1934559,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179652,Female,Not Specified,VO_0000047,Fluzone,BS946774,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087148,GEO,GSM1934560,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179660,Female,Not Specified,VO_0000047,Fluzone,BS946626,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087149,GEO,GSM1934561,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179660,Female,Not Specified,VO_0000047,Fluzone,BS946782,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087150,GEO,GSM1934562,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179667,Male,Not Specified,VO_0000047,Fluzone,BS946633,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087151,GEO,GSM1934563,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179667,Male,Not Specified,VO_0000047,Fluzone,BS946789,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087152,GEO,GSM1934564,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179670,Female,Not Specified,VO_0000047,Fluzone,BS946636,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087153,GEO,GSM1934565,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179670,Female,Not Specified,VO_0000047,Fluzone,BS946792,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087154,GEO,GSM1934566,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179674,Male,Not Specified,VO_0000047,Fluzone,BS946640,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087155,GEO,GSM1934567,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179674,Male,Not Specified,VO_0000047,Fluzone,BS946796,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087156,GEO,GSM1934568,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179675,Male,Not Specified,VO_0000047,Fluzone,BS946641,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087157,GEO,GSM1934569,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179675,Male,Not Specified,VO_0000047,Fluzone,BS946797,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087158,GEO,GSM1934570,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179676,Female,Not Specified,VO_0000047,Fluzone,BS946642,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087159,GEO,GSM1934571,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179676,Female,Not Specified,VO_0000047,Fluzone,BS946798,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087160,GEO,GSM1934572,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179677,Female,Not Specified,VO_0000047,Fluzone,BS946643,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087161,GEO,GSM1934573,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179677,Female,Not Specified,VO_0000047,Fluzone,BS946799,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087162,GEO,GSM1934574,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179678,Female,Not Specified,VO_0000047,Fluzone,BS946644,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087163,GEO,GSM1934575,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179678,Female,Not Specified,VO_0000047,Fluzone,BS946800,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087164,GEO,GSM1934576,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179679,Female,Not Specified,VO_0000047,Fluzone,BS946645,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087165,GEO,GSM1934577,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179679,Female,Not Specified,VO_0000047,Fluzone,BS946801,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087166,GEO,GSM1934578,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179680,Male,Not Specified,VO_0000047,Fluzone,BS946646,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087167,GEO,GSM1934579,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179680,Male,Not Specified,VO_0000047,Fluzone,BS946802,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087168,GEO,GSM1934580,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179682,Female,Not Specified,VO_0000047,Fluzone,BS946648,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087169,GEO,GSM1934581,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179682,Female,Not Specified,VO_0000047,Fluzone,BS946804,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087170,GEO,GSM1934582,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179683,Female,Not Specified,VO_0000047,Fluzone,BS946649,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087171,GEO,GSM1934583,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179683,Female,Not Specified,VO_0000047,Fluzone,BS946805,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087172,GEO,GSM1934584,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179685,Male,Not Specified,VO_0000047,Fluzone,BS946651,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087173,GEO,GSM1934585,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179685,Male,Not Specified,VO_0000047,Fluzone,BS946807,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087174,GEO,GSM1934586,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179689,Female,Not Specified,VO_0000047,Fluzone,BS946655,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087175,GEO,GSM1934587,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179689,Female,Not Specified,VO_0000047,Fluzone,BS946811,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087176,GEO,GSM1934588,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179690,Female,Not Specified,VO_0000047,Fluzone,BS946656,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087177,GEO,GSM1934589,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179690,Female,Not Specified,VO_0000047,Fluzone,BS946812,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087178,GEO,GSM1934590,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179691,Female,Not Specified,VO_0000047,Fluzone,BS946657,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087179,GEO,GSM1934591,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179691,Female,Not Specified,VO_0000047,Fluzone,BS946813,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087180,GEO,GSM1934592,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179692,Male,Not Specified,VO_0000047,Fluzone,BS946658,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087181,GEO,GSM1934593,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179692,Male,Not Specified,VO_0000047,Fluzone,BS946736,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087182,GEO,GSM1934594,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179693,Female,Not Specified,VO_0000047,Fluzone,BS946659,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087183,GEO,GSM1934595,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179693,Female,Not Specified,VO_0000047,Fluzone,BS946815,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087184,GEO,GSM1934596,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179694,Female,Not Specified,VO_0000047,Fluzone,BS946660,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087185,GEO,GSM1934597,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179694,Female,Not Specified,VO_0000047,Fluzone,BS946816,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087186,GEO,GSM1934598,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179696,Male,Not Specified,VO_0000047,Fluzone,BS946662,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087187,GEO,GSM1934599,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179696,Male,Not Specified,VO_0000047,Fluzone,BS946818,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087188,GEO,GSM1934600,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179698,Female,Not Specified,VO_0000047,Fluzone,BS946664,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087189,GEO,GSM1934601,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179698,Female,Not Specified,VO_0000047,Fluzone,BS946820,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087190,GEO,GSM1934602,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179701,Male,Not Specified,VO_0000047,Fluzone,BS946667,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087191,GEO,GSM1934603,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179701,Male,Not Specified,VO_0000047,Fluzone,BS946823,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087192,GEO,GSM1934604,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179702,Female,Not Specified,VO_0000047,Fluzone,BS946668,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087193,GEO,GSM1934605,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179702,Female,Not Specified,VO_0000047,Fluzone,BS946824,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087194,GEO,GSM1934606,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179703,Male,Not Specified,VO_0000047,Fluzone,BS946669,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087195,GEO,GSM1934607,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179703,Male,Not Specified,VO_0000047,Fluzone,BS946825,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087196,GEO,GSM1934608,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179704,Male,Not Specified,VO_0000047,Fluzone,BS946670,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087197,GEO,GSM1934609,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179704,Male,Not Specified,VO_0000047,Fluzone,BS946826,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087198,GEO,GSM1934610,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179705,Female,Not Specified,VO_0000047,Fluzone,BS946671,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087199,GEO,GSM1934611,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179705,Female,Not Specified,VO_0000047,Fluzone,BS946827,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087200,GEO,GSM1934612,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179706,Male,Not Specified,VO_0000047,Fluzone,BS946672,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087201,GEO,GSM1934613,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179706,Male,Not Specified,VO_0000047,Fluzone,BS946828,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087202,GEO,GSM1934614,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179707,Female,Not Specified,VO_0000047,Fluzone,BS946673,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087203,GEO,GSM1934615,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179707,Female,Not Specified,VO_0000047,Fluzone,BS946751,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087204,GEO,GSM1934616,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179707,Female,Not Specified,VO_0000047,Fluzone,BS946829,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087205,GEO,GSM1934617,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179709,Female,Not Specified,VO_0000047,Fluzone,BS946675,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087206,GEO,GSM1934618,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179709,Female,Not Specified,VO_0000047,Fluzone,BS946831,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087207,GEO,GSM1934619,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179710,Female,Not Specified,VO_0000047,Fluzone,BS946676,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087208,GEO,GSM1934620,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179710,Female,Not Specified,VO_0000047,Fluzone,BS946754,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087209,GEO,GSM1934621,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179710,Female,Not Specified,VO_0000047,Fluzone,BS946832,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087210,GEO,GSM1934622,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179711,Female,Not Specified,VO_0000047,Fluzone,BS946677,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087211,GEO,GSM1934623,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179711,Female,Not Specified,VO_0000047,Fluzone,BS946755,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087212,GEO,GSM1934624,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179711,Female,Not Specified,VO_0000047,Fluzone,BS946833,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087213,GEO,GSM1934625,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179712,Female,Not Specified,VO_0000047,Fluzone,BS946678,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087214,GEO,GSM1934626,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179712,Female,Not Specified,VO_0000047,Fluzone,BS946756,3.0,Days,Time of initial vaccine administration,PBMC,,ES1087215,GEO,GSM1934627,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179712,Female,Not Specified,VO_0000047,Fluzone,BS946834,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087216,GEO,GSM1934628,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179713,Male,Not Specified,VO_0000047,Fluzone,BS946679,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087217,GEO,GSM1934629,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179713,Male,Not Specified,VO_0000047,Fluzone,BS946835,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087218,GEO,GSM1934630,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179715,Female,Not Specified,VO_0000047,Fluzone,BS946681,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087219,GEO,GSM1934631,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179715,Female,Not Specified,VO_0000047,Fluzone,BS946837,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087220,GEO,GSM1934632,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179716,Male,Not Specified,VO_0000047,Fluzone,BS946682,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087221,GEO,GSM1934633,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179716,Male,Not Specified,VO_0000047,Fluzone,BS946838,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087222,GEO,GSM1934634,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179717,Male,Not Specified,VO_0000047,Fluzone,BS946683,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087223,GEO,GSM1934635,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179717,Male,Not Specified,VO_0000047,Fluzone,BS946839,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087224,GEO,GSM1934636,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179718,Female,Not Specified,VO_0000047,Fluzone,BS946684,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087225,GEO,GSM1934637,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179718,Female,Not Specified,VO_0000047,Fluzone,BS946840,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087226,GEO,GSM1934638,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179681,Female,Not Specified,VO_0000047,Fluzone,BS946647,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087227,GEO,GSM1934639,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179681,Female,Not Specified,VO_0000047,Fluzone,BS946803,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087228,GEO,GSM1934640,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179684,Female,Not Specified,VO_0000047,Fluzone,BS946650,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087229,GEO,GSM1934641,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179684,Female,Not Specified,VO_0000047,Fluzone,BS946806,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087230,GEO,GSM1934642,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179686,Male,Not Specified,VO_0000047,Fluzone,BS946652,0.0,Days,Time of initial vaccine administration,PBMC,,ES1087231,GEO,GSM1934643,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY1119,"Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010)","Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination, and used to Identify signatures of innate immunity, plasmablasts, lymphocytes and monocytes which correlate with antibody responses to the vaccine.",20.0,80.0,SUB179686,Male,Not Specified,VO_0000047,Fluzone,BS946808,7.0,Days,Time of initial vaccine administration,PBMC,,ES1087232,GEO,GSM1934644,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,20.0 - 80.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146654,Female,White,VO_0000642,Influenza virus vaccine,BS752797,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167274,GEO,GSM2712782,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146654,Female,White,VO_0000642,Influenza virus vaccine,BS752856,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167275,GEO,GSM2712783,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146654,Female,White,VO_0000642,Influenza virus vaccine,BS752916,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167276,GEO,GSM2712784,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146656,Female,White,VO_0000642,Influenza virus vaccine,BS752739,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167277,GEO,GSM2712785,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146656,Female,White,VO_0000642,Influenza virus vaccine,BS752799,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167278,GEO,GSM2712786,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146656,Female,White,VO_0000642,Influenza virus vaccine,BS752858,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167279,GEO,GSM2712787,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146656,Female,White,VO_0000642,Influenza virus vaccine,BS752917,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167280,GEO,GSM2712788,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146657,Female,White,VO_0000642,Influenza virus vaccine,BS752740,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167281,GEO,GSM2712789,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146657,Female,White,VO_0000642,Influenza virus vaccine,BS752800,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167282,GEO,GSM2712790,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146657,Female,White,VO_0000642,Influenza virus vaccine,BS752859,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167283,GEO,GSM2712791,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146657,Female,White,VO_0000642,Influenza virus vaccine,BS752918,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167284,GEO,GSM2712792,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146673,Male,White,VO_0000642,Influenza virus vaccine,BS752801,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167285,GEO,GSM2712793,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146674,Female,White,VO_0000642,Influenza virus vaccine,BS752742,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167286,GEO,GSM2712794,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146674,Female,White,VO_0000642,Influenza virus vaccine,BS752802,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167287,GEO,GSM2712795,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146674,Female,White,VO_0000642,Influenza virus vaccine,BS752861,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167288,GEO,GSM2712796,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146674,Female,White,VO_0000642,Influenza virus vaccine,BS752920,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167289,GEO,GSM2712797,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146658,Male,White,VO_0000642,Influenza virus vaccine,BS752743,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167290,GEO,GSM2712798,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146658,Male,White,VO_0000642,Influenza virus vaccine,BS752803,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167291,GEO,GSM2712799,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146658,Male,White,VO_0000642,Influenza virus vaccine,BS752921,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167292,GEO,GSM2712800,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146659,Female,White,VO_0000642,Influenza virus vaccine,BS752744,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167293,GEO,GSM2712801,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146659,Female,White,VO_0000642,Influenza virus vaccine,BS752804,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167294,GEO,GSM2712802,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146659,Female,White,VO_0000642,Influenza virus vaccine,BS752863,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167295,GEO,GSM2712803,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146659,Female,White,VO_0000642,Influenza virus vaccine,BS752922,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167296,GEO,GSM2712804,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146677,Female,White,VO_0000642,Influenza virus vaccine,BS752754,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167297,GEO,GSM2712805,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146677,Female,White,VO_0000642,Influenza virus vaccine,BS752814,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167298,GEO,GSM2712806,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146677,Female,White,VO_0000642,Influenza virus vaccine,BS752873,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167299,GEO,GSM2712807,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146677,Female,White,VO_0000642,Influenza virus vaccine,BS752932,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167300,GEO,GSM2712808,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146678,Female,White,VO_0000642,Influenza virus vaccine,BS752755,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167301,GEO,GSM2712809,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146678,Female,White,VO_0000642,Influenza virus vaccine,BS752815,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167302,GEO,GSM2712810,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146678,Female,White,VO_0000642,Influenza virus vaccine,BS752874,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167303,GEO,GSM2712811,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146678,Female,White,VO_0000642,Influenza virus vaccine,BS752933,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167304,GEO,GSM2712812,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146668,Female,White,VO_0000642,Influenza virus vaccine,BS752759,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167305,GEO,GSM2712813,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146668,Female,White,VO_0000642,Influenza virus vaccine,BS752819,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167306,GEO,GSM2712814,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146668,Female,White,VO_0000642,Influenza virus vaccine,BS752878,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167307,GEO,GSM2712815,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146668,Female,White,VO_0000642,Influenza virus vaccine,BS752937,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167308,GEO,GSM2712816,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146681,Male,White,VO_0000642,Influenza virus vaccine,BS752760,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167309,GEO,GSM2712817,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146681,Male,White,VO_0000642,Influenza virus vaccine,BS752820,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167310,GEO,GSM2712818,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146681,Male,White,VO_0000642,Influenza virus vaccine,BS752879,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167311,GEO,GSM2712819,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146681,Male,White,VO_0000642,Influenza virus vaccine,BS752938,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167312,GEO,GSM2712820,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146670,Female,White,VO_0000642,Influenza virus vaccine,BS752762,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167313,GEO,GSM2712821,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146670,Female,White,VO_0000642,Influenza virus vaccine,BS752822,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167314,GEO,GSM2712822,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146670,Female,White,VO_0000642,Influenza virus vaccine,BS752881,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167315,GEO,GSM2712823,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146670,Female,White,VO_0000642,Influenza virus vaccine,BS752940,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167316,GEO,GSM2712824,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146685,Female,White,VO_0000642,Influenza virus vaccine,BS752766,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167317,GEO,GSM2712825,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146685,Female,White,VO_0000642,Influenza virus vaccine,BS752826,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167318,GEO,GSM2712826,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146685,Female,White,VO_0000642,Influenza virus vaccine,BS752944,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167319,GEO,GSM2712827,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146686,Female,White,VO_0000642,Influenza virus vaccine,BS752767,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167320,GEO,GSM2712828,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146686,Female,White,VO_0000642,Influenza virus vaccine,BS752886,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167321,GEO,GSM2712830,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146686,Female,White,VO_0000642,Influenza virus vaccine,BS752945,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167323,GEO,GSM2712831,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146688,Male,Asian,VO_0000642,Influenza virus vaccine,BS752770,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167324,GEO,GSM2712832,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146688,Male,Asian,VO_0000642,Influenza virus vaccine,BS752829,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167325,GEO,GSM2712833,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146688,Male,Asian,VO_0000642,Influenza virus vaccine,BS752889,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167326,GEO,GSM2712834,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146688,Male,Asian,VO_0000642,Influenza virus vaccine,BS752972,43.0,Days,Time of initial vaccine administration,Whole blood,,ES1167327,GEO,GSM2712835,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146690,Male,White,VO_0000642,Influenza virus vaccine,BS752772,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167328,GEO,GSM2712836,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146690,Male,White,VO_0000642,Influenza virus vaccine,BS752831,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167329,GEO,GSM2712837,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146690,Male,White,VO_0000642,Influenza virus vaccine,BS752891,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167330,GEO,GSM2712838,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146690,Male,White,VO_0000642,Influenza virus vaccine,BS752949,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167331,GEO,GSM2712839,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146693,Female,White,VO_0000642,Influenza virus vaccine,BS752775,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167332,GEO,GSM2712840,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146693,Female,White,VO_0000642,Influenza virus vaccine,BS752834,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167333,GEO,GSM2712841,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146693,Female,White,VO_0000642,Influenza virus vaccine,BS752893,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167334,GEO,GSM2712842,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146693,Female,White,VO_0000642,Influenza virus vaccine,BS752950,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167335,GEO,GSM2712843,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146672,Male,White,VO_0000642,Influenza virus vaccine,BS752777,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167336,GEO,GSM2712844,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146672,Male,White,VO_0000642,Influenza virus vaccine,BS752836,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167337,GEO,GSM2712845,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146672,Male,White,VO_0000642,Influenza virus vaccine,BS752895,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167338,GEO,GSM2712846,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146672,Male,White,VO_0000642,Influenza virus vaccine,BS752952,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167339,GEO,GSM2712847,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146697,Female,Asian,VO_0000642,Influenza virus vaccine,BS752779,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167340,GEO,GSM2712848,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146697,Female,Asian,VO_0000642,Influenza virus vaccine,BS752838,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167341,GEO,GSM2712849,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146697,Female,Asian,VO_0000642,Influenza virus vaccine,BS752897,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167342,GEO,GSM2712850,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146697,Female,Asian,VO_0000642,Influenza virus vaccine,BS752954,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167343,GEO,GSM2712851,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146700,Female,White,VO_0000642,Influenza virus vaccine,BS752782,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167344,GEO,GSM2712852,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146700,Female,White,VO_0000642,Influenza virus vaccine,BS752841,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167345,GEO,GSM2712853,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146700,Female,White,VO_0000642,Influenza virus vaccine,BS752900,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167346,GEO,GSM2712854,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146700,Female,White,VO_0000642,Influenza virus vaccine,BS752973,43.0,Days,Time of initial vaccine administration,Whole blood,,ES1167347,GEO,GSM2712855,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146701,Male,White,VO_0000642,Influenza virus vaccine,BS752783,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167348,GEO,GSM2712856,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146701,Male,White,VO_0000642,Influenza virus vaccine,BS752842,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167349,GEO,GSM2712857,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146701,Male,White,VO_0000642,Influenza virus vaccine,BS752901,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167350,GEO,GSM2712858,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146701,Male,White,VO_0000642,Influenza virus vaccine,BS752957,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167351,GEO,GSM2712859,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146702,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS752784,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167352,GEO,GSM2712860,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146702,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS752843,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167353,GEO,GSM2712861,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146702,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS752902,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167354,GEO,GSM2712862,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146702,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS752958,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167355,GEO,GSM2712863,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146703,Female,White,VO_0000642,Influenza virus vaccine,BS752785,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167356,GEO,GSM2712864,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146703,Female,White,VO_0000642,Influenza virus vaccine,BS752844,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167357,GEO,GSM2712865,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146703,Female,White,VO_0000642,Influenza virus vaccine,BS752903,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167358,GEO,GSM2712866,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146703,Female,White,VO_0000642,Influenza virus vaccine,BS752959,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167359,GEO,GSM2712867,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146704,Male,White,VO_0000642,Influenza virus vaccine,BS752786,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167360,GEO,GSM2712868,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146704,Male,White,VO_0000642,Influenza virus vaccine,BS752845,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167361,GEO,GSM2712869,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146704,Male,White,VO_0000642,Influenza virus vaccine,BS752904,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167362,GEO,GSM2712870,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146704,Male,White,VO_0000642,Influenza virus vaccine,BS752960,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167363,GEO,GSM2712871,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146710,Male,White,VO_0000642,Influenza virus vaccine,BS752792,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167364,GEO,GSM2712872,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146710,Male,White,VO_0000642,Influenza virus vaccine,BS752851,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167365,GEO,GSM2712873,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146710,Male,White,VO_0000642,Influenza virus vaccine,BS752910,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167366,GEO,GSM2712874,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146710,Male,White,VO_0000642,Influenza virus vaccine,BS752966,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167367,GEO,GSM2712875,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146714,Male,White,VO_0000642,Influenza virus vaccine,BS752796,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167368,GEO,GSM2712876,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146714,Male,White,VO_0000642,Influenza virus vaccine,BS752855,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167369,GEO,GSM2712877,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146714,Male,White,VO_0000642,Influenza virus vaccine,BS752914,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167370,GEO,GSM2712878,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146714,Male,White,VO_0000642,Influenza virus vaccine,BS752970,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167371,GEO,GSM2712879,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156914,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799828,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167372,GEO,GSM2712880,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156914,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799865,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167373,GEO,GSM2712881,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156914,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799900,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167374,GEO,GSM2712882,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156914,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799940,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167375,GEO,GSM2712883,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156918,Male,White,VO_0000642,Trivalent inactivated influenza,BS799832,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167376,GEO,GSM2712884,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156918,Male,White,VO_0000642,Trivalent inactivated influenza,BS799869,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167377,GEO,GSM2712885,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156918,Male,White,VO_0000642,Trivalent inactivated influenza,BS799944,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167378,GEO,GSM2712886,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156919,Female,White,VO_0000642,Trivalent inactivated influenza,BS799833,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167379,GEO,GSM2712887,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156919,Female,White,VO_0000642,Trivalent inactivated influenza,BS799870,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167380,GEO,GSM2712888,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156919,Female,White,VO_0000642,Trivalent inactivated influenza,BS799905,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167381,GEO,GSM2712889,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156919,Female,White,VO_0000642,Trivalent inactivated influenza,BS799945,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167382,GEO,GSM2712890,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156920,Female,White,VO_0000642,Trivalent inactivated influenza,BS799834,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167383,GEO,GSM2712891,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156920,Female,White,VO_0000642,Trivalent inactivated influenza,BS799871,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167384,GEO,GSM2712892,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156920,Female,White,VO_0000642,Trivalent inactivated influenza,BS799906,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167385,GEO,GSM2712893,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156920,Female,White,VO_0000642,Trivalent inactivated influenza,BS799946,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167386,GEO,GSM2712894,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156923,Male,White,VO_0000642,Trivalent inactivated influenza,BS799837,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167387,GEO,GSM2712895,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156923,Male,White,VO_0000642,Trivalent inactivated influenza,BS799874,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167388,GEO,GSM2712896,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156923,Male,White,VO_0000642,Trivalent inactivated influenza,BS799908,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167389,GEO,GSM2712897,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156923,Male,White,VO_0000642,Trivalent inactivated influenza,BS799949,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167390,GEO,GSM2712898,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156927,Male,White,VO_0000642,Trivalent inactivated influenza,BS799841,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167391,GEO,GSM2712899,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156927,Male,White,VO_0000642,Trivalent inactivated influenza,BS799878,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167392,GEO,GSM2712900,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156927,Male,White,VO_0000642,Trivalent inactivated influenza,BS799912,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167393,GEO,GSM2712901,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156927,Male,White,VO_0000642,Trivalent inactivated influenza,BS799936,25.0,Days,Time of initial vaccine administration,Whole blood,,ES1167394,GEO,GSM2712902,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156931,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799845,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167395,GEO,GSM2712903,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156931,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799881,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167396,GEO,GSM2712904,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156931,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799915,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167397,GEO,GSM2712905,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156931,Female,Asian,VO_0000642,Trivalent inactivated influenza,BS799939,25.0,Days,Time of initial vaccine administration,Whole blood,,ES1167398,GEO,GSM2712906,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156933,Female,White,VO_0000642,Trivalent inactivated influenza,BS799847,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167399,GEO,GSM2712907,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156933,Female,White,VO_0000642,Trivalent inactivated influenza,BS799882,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167400,GEO,GSM2712908,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156933,Female,White,VO_0000642,Trivalent inactivated influenza,BS799917,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167401,GEO,GSM2712909,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156933,Female,White,VO_0000642,Trivalent inactivated influenza,BS799954,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167402,GEO,GSM2712910,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156936,Male,White,VO_0000642,Trivalent inactivated influenza,BS799850,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167403,GEO,GSM2712911,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156936,Male,White,VO_0000642,Trivalent inactivated influenza,BS799885,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167404,GEO,GSM2712912,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156936,Male,White,VO_0000642,Trivalent inactivated influenza,BS799920,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167405,GEO,GSM2712913,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156936,Male,White,VO_0000642,Trivalent inactivated influenza,BS799957,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167406,GEO,GSM2712914,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156938,Female,White,VO_0000642,Trivalent inactivated influenza,BS799852,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167407,GEO,GSM2712915,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156938,Female,White,VO_0000642,Trivalent inactivated influenza,BS799887,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167408,GEO,GSM2712916,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156938,Female,White,VO_0000642,Trivalent inactivated influenza,BS799922,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167409,GEO,GSM2712917,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156938,Female,White,VO_0000642,Trivalent inactivated influenza,BS799959,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167410,GEO,GSM2712918,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156939,Male,White,VO_0000642,Trivalent inactivated influenza,BS799853,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167411,GEO,GSM2712919,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156939,Male,White,VO_0000642,Trivalent inactivated influenza,BS799888,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167412,GEO,GSM2712920,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156939,Male,White,VO_0000642,Trivalent inactivated influenza,BS799923,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167413,GEO,GSM2712921,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156939,Male,White,VO_0000642,Trivalent inactivated influenza,BS799970,37.0,Days,Time of initial vaccine administration,Whole blood,,ES1167414,GEO,GSM2712922,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156940,Male,Unknown,VO_0000642,Trivalent inactivated influenza,BS799854,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167415,GEO,GSM2712923,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156940,Male,Unknown,VO_0000642,Trivalent inactivated influenza,BS799889,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167416,GEO,GSM2712924,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156940,Male,Unknown,VO_0000642,Trivalent inactivated influenza,BS799924,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167417,GEO,GSM2712925,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156940,Male,Unknown,VO_0000642,Trivalent inactivated influenza,BS799960,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167418,GEO,GSM2712926,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156941,Female,White,VO_0000642,Trivalent inactivated influenza,BS799855,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167419,GEO,GSM2712927,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156941,Female,White,VO_0000642,Trivalent inactivated influenza,BS799890,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167420,GEO,GSM2712928,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156941,Female,White,VO_0000642,Trivalent inactivated influenza,BS799925,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167421,GEO,GSM2712929,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156941,Female,White,VO_0000642,Trivalent inactivated influenza,BS799961,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167422,GEO,GSM2712930,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156943,Male,Asian,VO_0000642,Trivalent inactivated influenza,BS799857,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167423,GEO,GSM2712931,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156943,Male,Asian,VO_0000642,Trivalent inactivated influenza,BS799892,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167424,GEO,GSM2712932,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156943,Male,Asian,VO_0000642,Trivalent inactivated influenza,BS799927,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167425,GEO,GSM2712933,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156943,Male,Asian,VO_0000642,Trivalent inactivated influenza,BS799963,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167426,GEO,GSM2712934,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156945,Female,White,VO_0000642,Trivalent inactivated influenza,BS799859,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167427,GEO,GSM2712935,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156945,Female,White,VO_0000642,Trivalent inactivated influenza,BS799894,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167428,GEO,GSM2712936,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156945,Female,White,VO_0000642,Trivalent inactivated influenza,BS799929,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167429,GEO,GSM2712937,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156945,Female,White,VO_0000642,Trivalent inactivated influenza,BS799965,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167430,GEO,GSM2712938,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156946,Male,White,VO_0000642,Trivalent inactivated influenza,BS799860,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167431,GEO,GSM2712939,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156946,Male,White,VO_0000642,Trivalent inactivated influenza,BS799895,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167432,GEO,GSM2712940,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156946,Male,White,VO_0000642,Trivalent inactivated influenza,BS799930,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167433,GEO,GSM2712941,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156946,Male,White,VO_0000642,Trivalent inactivated influenza,BS799966,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167434,GEO,GSM2712942,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156947,Female,White,VO_0000642,Trivalent inactivated influenza,BS799861,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167435,GEO,GSM2712943,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156947,Female,White,VO_0000642,Trivalent inactivated influenza,BS799896,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167436,GEO,GSM2712944,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156947,Female,White,VO_0000642,Trivalent inactivated influenza,BS799931,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167437,GEO,GSM2712945,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156947,Female,White,VO_0000642,Trivalent inactivated influenza,BS799967,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167438,GEO,GSM2712946,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156948,Male,White,VO_0000642,Trivalent inactivated influenza,BS799862,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167439,GEO,GSM2712947,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156948,Male,White,VO_0000642,Trivalent inactivated influenza,BS799897,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167440,GEO,GSM2712948,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156948,Male,White,VO_0000642,Trivalent inactivated influenza,BS799932,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167441,GEO,GSM2712949,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156948,Male,White,VO_0000642,Trivalent inactivated influenza,BS799971,41.0,Days,Time of initial vaccine administration,Whole blood,,ES1167442,GEO,GSM2712950,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156949,Female,White,VO_0000642,Trivalent inactivated influenza,BS799863,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167443,GEO,GSM2712951,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156949,Female,White,VO_0000642,Trivalent inactivated influenza,BS799898,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167444,GEO,GSM2712952,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156949,Female,White,VO_0000642,Trivalent inactivated influenza,BS799933,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167445,GEO,GSM2712953,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156949,Female,White,VO_0000642,Trivalent inactivated influenza,BS799968,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167446,GEO,GSM2712954,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156950,Male,White,VO_0000642,Trivalent inactivated influenza,BS799864,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1167447,GEO,GSM2712955,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156950,Male,White,VO_0000642,Trivalent inactivated influenza,BS799899,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167448,GEO,GSM2712956,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156950,Male,White,VO_0000642,Trivalent inactivated influenza,BS799934,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1167449,GEO,GSM2712957,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY640,Immunologic and genomic signatures of influenza vaccine response - 2014,Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014,22.0,90.0,SUB156950,Male,White,VO_0000642,Trivalent inactivated influenza,BS799969,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1167450,GEO,GSM2712958,false,GSE101710,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101710,Whole blood : NA,22.0 - 90.0
SDY520,"Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013,21.0,87.0,SUB146686,Female,White,VO_0000642,Influenza virus vaccine,BS799827,2.0,Days,Time of initial vaccine administration,Whole blood,,ES1167451,GEO,GSM2712829,false,GSE101709,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE101709,Whole blood : NA,21.0 - 87.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974293,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179799,GEO,GSM343922,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187452,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974294,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179800,GEO,GSM343923,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187452,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974295,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179801,GEO,GSM343924,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187452,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974296,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179802,GEO,GSM343925,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187453,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974297,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179803,GEO,GSM343926,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187453,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974298,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179804,GEO,GSM343927,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187453,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974299,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179805,GEO,GSM343928,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974300,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179806,GEO,GSM343929,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974301,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179807,GEO,GSM343930,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974302,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179808,GEO,GSM343931,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974303,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179809,GEO,GSM343932,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974304,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179810,GEO,GSM343933,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974305,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179811,GEO,GSM343934,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974306,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179812,GEO,GSM343935,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187452,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974307,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179813,GEO,GSM343936,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187452,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974308,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179814,GEO,GSM343937,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974309,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179815,GEO,GSM343938,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974310,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179816,GEO,GSM343939,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974311,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179817,GEO,GSM343940,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187456,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974312,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179818,GEO,GSM343941,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187456,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974313,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179819,GEO,GSM343942,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187457,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974314,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179820,GEO,GSM343943,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187453,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974315,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179821,GEO,GSM343944,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187453,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974316,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179822,GEO,GSM343945,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974317,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179823,GEO,GSM343946,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974318,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179824,GEO,GSM343947,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974319,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179825,GEO,GSM343948,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187454,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974320,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179826,GEO,GSM343949,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974321,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179827,GEO,GSM343950,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187451,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974322,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179828,GEO,GSM343951,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187457,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974323,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179829,GEO,GSM343952,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187458,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974324,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179830,GEO,GSM343953,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187452,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974325,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179831,GEO,GSM343954,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187458,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974326,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179832,GEO,GSM343955,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187458,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974327,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179833,GEO,GSM343956,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974328,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179834,GEO,GSM343957,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974329,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179835,GEO,GSM343958,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974330,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179836,GEO,GSM343959,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187455,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974331,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179837,GEO,GSM343960,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187459,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974332,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179838,GEO,GSM343961,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187459,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974333,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179839,GEO,GSM343962,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187459,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974334,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179840,GEO,GSM343963,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187459,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974335,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179841,GEO,GSM343964,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187460,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974336,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179842,GEO,GSM343965,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187460,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974337,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179843,GEO,GSM343966,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187460,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974338,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179844,GEO,GSM343967,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974339,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179845,GEO,GSM343968,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974340,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179846,GEO,GSM343969,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974341,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179847,GEO,GSM343970,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187462,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974342,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179848,GEO,GSM343971,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187462,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974343,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179849,GEO,GSM343972,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187462,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974344,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179850,GEO,GSM343973,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187463,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974345,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179851,GEO,GSM343974,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187463,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974346,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179852,GEO,GSM343975,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187463,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974347,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179853,GEO,GSM343976,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974348,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179854,GEO,GSM343977,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974349,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179855,GEO,GSM343978,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974350,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179856,GEO,GSM343979,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974351,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179857,GEO,GSM343980,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187465,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974352,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179858,GEO,GSM343981,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187465,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974353,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179859,GEO,GSM343982,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187465,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974354,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179860,GEO,GSM343983,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187465,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974355,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179861,GEO,GSM343984,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187459,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974356,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179862,GEO,GSM343985,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187459,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974357,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179863,GEO,GSM343986,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187466,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974358,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179864,GEO,GSM343987,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187466,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974359,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179865,GEO,GSM343988,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187466,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974360,60.0,Days,Time of initial vaccine administration,Whole blood,,ES1179866,GEO,GSM343989,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187460,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974361,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179867,GEO,GSM343990,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187460,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974362,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179868,GEO,GSM343991,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974363,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179869,GEO,GSM343992,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974364,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179870,GEO,GSM343993,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974365,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179871,GEO,GSM343994,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187461,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974366,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179872,GEO,GSM343995,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187462,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974367,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179873,GEO,GSM343996,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187453,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974368,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179874,GEO,GSM343997,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187462,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974369,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179875,GEO,GSM343998,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187462,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974370,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179876,GEO,GSM343999,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187463,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974371,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179877,GEO,GSM344000,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187463,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974372,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179878,GEO,GSM344001,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187463,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974373,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179879,GEO,GSM344002,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974374,10.0,Days,Time of initial vaccine administration,Whole blood,,ES1179880,GEO,GSM344003,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974375,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1179881,GEO,GSM344004,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187464,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974376,28.0,Days,Time of initial vaccine administration,Whole blood,,ES1179882,GEO,GSM344005,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187465,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974377,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179883,GEO,GSM344006,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187465,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974378,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179884,GEO,GSM344007,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187456,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974379,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179885,GEO,GSM344008,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187456,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974380,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179886,GEO,GSM344009,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187457,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974381,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179887,GEO,GSM344010,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187458,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974382,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179888,GEO,GSM344011,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187457,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974383,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179889,GEO,GSM344012,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187457,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974384,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179890,GEO,GSM344013,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187456,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974385,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179891,GEO,GSM344014,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187467,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974386,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179892,GEO,GSM344024,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187467,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974387,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179893,GEO,GSM344025,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187467,Male,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974388,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179894,GEO,GSM344026,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187468,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974389,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179895,GEO,GSM344027,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187468,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974390,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179896,GEO,GSM344028,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187468,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974391,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179897,GEO,GSM344029,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187469,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974392,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179898,GEO,GSM344030,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187469,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974393,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179899,GEO,GSM344031,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187469,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974394,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179900,GEO,GSM344032,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187470,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974395,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179901,GEO,GSM344033,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187470,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974396,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179902,GEO,GSM344034,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187471,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974397,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179903,GEO,GSM344035,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187471,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974398,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179904,GEO,GSM344036,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187472,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974399,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179905,GEO,GSM344037,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187472,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974400,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179906,GEO,GSM344038,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187472,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974401,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179907,GEO,GSM344039,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187473,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974402,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179908,GEO,GSM344040,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187473,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974403,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179909,GEO,GSM344041,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187473,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974404,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179910,GEO,GSM344042,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187474,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974405,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179911,GEO,GSM344043,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187474,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974406,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179912,GEO,GSM344044,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187474,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974407,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179913,GEO,GSM344045,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187475,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974408,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179914,GEO,GSM344046,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187475,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974409,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179915,GEO,GSM344047,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187475,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974410,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179916,GEO,GSM344048,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187476,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974411,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179917,GEO,GSM344049,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187476,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974412,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179918,GEO,GSM344050,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187477,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974413,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1179919,GEO,GSM344051,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187477,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974414,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179920,GEO,GSM344052,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187477,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974415,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179921,GEO,GSM344053,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187476,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974416,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179922,GEO,GSM344054,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187470,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974417,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1179923,GEO,GSM344055,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187471,Female,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974418,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1179924,GEO,GSM344056,false,GSE13699,GPL6104,Illumina humanRef-8 v2.0 expression beadchip,GSE13699,Whole blood : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187478,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974419,3.0,Days,Time of initial vaccine administration,PBMC,,ES1179925,GEO,GSM344057,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187478,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974420,3.0,Days,Time of initial vaccine administration,PBMC,,ES1179926,GEO,GSM344058,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187479,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974421,3.0,Days,Time of initial vaccine administration,PBMC,,ES1179927,GEO,GSM344059,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187479,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974422,3.0,Days,Time of initial vaccine administration,PBMC,,ES1179928,GEO,GSM344060,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187480,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974423,3.0,Days,Time of initial vaccine administration,PBMC,,ES1179929,GEO,GSM344061,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187478,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974424,7.0,Days,Time of initial vaccine administration,PBMC,,ES1179930,GEO,GSM344062,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187478,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974425,7.0,Days,Time of initial vaccine administration,PBMC,,ES1179931,GEO,GSM344063,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187479,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974426,7.0,Days,Time of initial vaccine administration,PBMC,,ES1179932,GEO,GSM344064,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187479,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974427,7.0,Days,Time of initial vaccine administration,PBMC,,ES1179933,GEO,GSM344065,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187480,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974428,7.0,Days,Time of initial vaccine administration,PBMC,,ES1179934,GEO,GSM344066,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187480,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974429,7.0,Days,Time of initial vaccine administration,PBMC,,ES1179935,GEO,GSM344067,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187478,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974430,14.0,Days,Time of initial vaccine administration,PBMC,,ES1179936,GEO,GSM344068,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187478,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974431,14.0,Days,Time of initial vaccine administration,PBMC,,ES1179937,GEO,GSM344069,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187479,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974432,14.0,Days,Time of initial vaccine administration,PBMC,,ES1179938,GEO,GSM344070,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187479,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974433,14.0,Days,Time of initial vaccine administration,PBMC,,ES1179939,GEO,GSM344071,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1289,YFV integrated mulitlineage and polyfunctional responses,Immunization with YF17D leades to an integrated immune response.,18.0,65.0,SUB187480,Not Specified,Not Specified,VO_0000122,Yellow fever 17D vaccine vector,BS974434,14.0,Days,Time of initial vaccine administration,PBMC,,ES1179940,GEO,GSM344072,false,GSE13699,GPL6883,Illumina HumanRef-8 v3.0 expression beadchip,GSE13699,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187706,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974978,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180068,GEO,GSM457370,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187706,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974979,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180069,GEO,GSM457371,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187706,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974980,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180070,GEO,GSM457372,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187706,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974981,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180071,GEO,GSM457373,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187706,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974982,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180072,GEO,GSM457374,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187707,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974983,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180073,GEO,GSM457375,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187707,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974984,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180074,GEO,GSM457376,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187707,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974985,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180075,GEO,GSM457377,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187708,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974986,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180076,GEO,GSM457378,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187708,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974987,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180077,GEO,GSM457379,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187708,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974988,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180078,GEO,GSM457380,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187708,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974989,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180079,GEO,GSM457381,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187708,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974990,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180080,GEO,GSM457382,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187709,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974991,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180081,GEO,GSM457383,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187709,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974992,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180082,GEO,GSM457384,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187709,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974993,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180083,GEO,GSM457385,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187709,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974994,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180084,GEO,GSM457386,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187709,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974995,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180085,GEO,GSM457387,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187710,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974996,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180086,GEO,GSM457388,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187710,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974997,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180087,GEO,GSM457389,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187710,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974998,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180088,GEO,GSM457390,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187710,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS974999,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180089,GEO,GSM457391,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187710,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975000,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180090,GEO,GSM457392,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187711,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975001,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180091,GEO,GSM457393,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187711,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975002,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180092,GEO,GSM457394,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187711,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975003,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180093,GEO,GSM457395,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187711,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975004,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180094,GEO,GSM457396,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187711,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975005,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180095,GEO,GSM457397,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187712,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975006,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180096,GEO,GSM457398,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187712,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975007,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180097,GEO,GSM457399,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187712,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975008,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180098,GEO,GSM457400,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187712,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975009,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180099,GEO,GSM457401,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187712,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975010,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180100,GEO,GSM457402,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187713,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975011,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180101,GEO,GSM457403,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187713,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975012,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180102,GEO,GSM457404,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187713,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975013,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180103,GEO,GSM457405,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187714,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975014,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180104,GEO,GSM457406,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187714,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975015,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180105,GEO,GSM457407,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187714,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975016,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180106,GEO,GSM457408,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187714,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975017,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180107,GEO,GSM457409,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187714,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975018,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180108,GEO,GSM457410,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187715,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975019,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180109,GEO,GSM457411,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187715,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975020,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180110,GEO,GSM457412,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187715,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975021,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180111,GEO,GSM457413,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187716,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975022,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180112,GEO,GSM457414,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187716,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975023,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180113,GEO,GSM457415,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187716,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975024,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180114,GEO,GSM457416,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187717,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975025,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180115,GEO,GSM457417,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187717,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975026,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180116,GEO,GSM457418,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187717,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975027,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180117,GEO,GSM457419,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187717,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975028,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180118,GEO,GSM457420,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187717,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975029,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180119,GEO,GSM457421,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187718,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975030,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180120,GEO,GSM457422,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187718,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975031,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180121,GEO,GSM457423,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187718,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975032,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180122,GEO,GSM457424,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187718,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975033,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180123,GEO,GSM457425,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187718,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975034,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180124,GEO,GSM457426,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187719,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975035,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180125,GEO,GSM457427,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187719,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975036,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180126,GEO,GSM457428,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187719,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975037,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180127,GEO,GSM457429,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187719,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975038,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180128,GEO,GSM457430,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187719,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975039,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180129,GEO,GSM457431,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187720,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975040,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180130,GEO,GSM457432,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187720,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975041,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180131,GEO,GSM457433,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187720,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975042,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180132,GEO,GSM457434,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187720,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975043,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180133,GEO,GSM457435,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187720,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975044,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180134,GEO,GSM457436,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187721,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975045,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180135,GEO,GSM457437,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187721,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975046,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180136,GEO,GSM457438,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187721,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975047,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180137,GEO,GSM457439,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187721,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975048,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180138,GEO,GSM457440,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187721,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975049,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180139,GEO,GSM457441,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187722,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975050,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180140,GEO,GSM457442,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187722,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975051,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180141,GEO,GSM457443,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187722,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975052,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180142,GEO,GSM457444,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187722,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975053,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180143,GEO,GSM457445,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187723,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975054,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180144,GEO,GSM457446,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187723,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975055,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180145,GEO,GSM457447,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187723,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975056,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180146,GEO,GSM457448,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187723,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975057,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180147,GEO,GSM457449,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187723,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975058,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180148,GEO,GSM457450,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187724,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975059,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180149,GEO,GSM457451,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187724,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975060,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180150,GEO,GSM457452,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187724,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975061,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180151,GEO,GSM457453,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187724,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975062,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180152,GEO,GSM457454,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187724,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975063,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180153,GEO,GSM457455,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187725,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975064,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180154,GEO,GSM457456,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187725,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975065,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180155,GEO,GSM457457,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187725,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975066,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180156,GEO,GSM457458,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187726,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975067,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180157,GEO,GSM457459,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187726,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975068,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180158,GEO,GSM457460,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187726,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975069,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180159,GEO,GSM457461,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187726,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975070,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180160,GEO,GSM457462,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187726,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975071,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180161,GEO,GSM457463,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187727,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975072,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180162,GEO,GSM457464,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187727,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975073,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180163,GEO,GSM457465,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187727,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975074,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180164,GEO,GSM457466,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187727,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975075,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180165,GEO,GSM457467,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187727,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975076,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180166,GEO,GSM457468,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187728,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975077,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180167,GEO,GSM457469,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187728,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975078,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180168,GEO,GSM457470,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187728,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975079,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180169,GEO,GSM457471,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187728,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975080,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180170,GEO,GSM457472,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187728,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975081,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180171,GEO,GSM457473,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187729,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975082,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180172,GEO,GSM457474,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187729,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975083,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180173,GEO,GSM457475,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187729,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975084,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180174,GEO,GSM457476,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187729,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975085,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180175,GEO,GSM457477,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187729,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975086,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180176,GEO,GSM457478,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187730,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975087,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180177,GEO,GSM457479,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187730,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975088,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180178,GEO,GSM457480,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187730,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975089,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180179,GEO,GSM457481,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187730,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975090,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180180,GEO,GSM457482,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187730,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975091,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180181,GEO,GSM457483,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187731,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975092,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180182,GEO,GSM457484,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187731,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975093,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180183,GEO,GSM457485,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187731,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975094,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180184,GEO,GSM457486,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187731,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975095,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180185,GEO,GSM457487,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187731,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975096,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180186,GEO,GSM457488,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187732,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975097,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180187,GEO,GSM457489,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187732,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975098,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180188,GEO,GSM457490,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187732,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975099,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180189,GEO,GSM457491,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187732,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975100,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180190,GEO,GSM457492,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187732,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975101,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180191,GEO,GSM457493,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187733,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975102,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180192,GEO,GSM457494,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187733,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975103,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180193,GEO,GSM457495,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187733,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975104,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180194,GEO,GSM457496,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187733,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975105,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180195,GEO,GSM457497,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187733,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975106,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180196,GEO,GSM457498,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187734,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975107,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180197,GEO,GSM457499,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187734,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975108,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180198,GEO,GSM457500,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187734,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975109,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180199,GEO,GSM457501,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187734,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975110,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180200,GEO,GSM457502,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187734,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975111,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180201,GEO,GSM457503,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187735,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975112,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180202,GEO,GSM457504,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187735,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975113,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180203,GEO,GSM457505,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187735,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975114,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180204,GEO,GSM457506,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187735,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975115,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180205,GEO,GSM457507,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187735,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975116,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180206,GEO,GSM457508,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187736,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975117,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180207,GEO,GSM457509,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187736,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975118,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180208,GEO,GSM457510,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187736,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975119,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180209,GEO,GSM457511,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187737,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975120,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180210,GEO,GSM457512,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187737,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975121,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180211,GEO,GSM457513,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187737,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975122,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180212,GEO,GSM457514,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187737,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975123,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180213,GEO,GSM457515,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187738,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975124,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180214,GEO,GSM457516,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187738,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975125,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180215,GEO,GSM457517,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187738,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975126,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180216,GEO,GSM457518,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187738,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975127,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180217,GEO,GSM457519,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187738,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975128,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180218,GEO,GSM457520,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187739,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975129,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180219,GEO,GSM457521,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187739,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975130,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180220,GEO,GSM457522,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187739,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975131,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180221,GEO,GSM457523,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187740,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975132,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180222,GEO,GSM457524,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187740,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975133,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180223,GEO,GSM457525,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187740,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975134,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180224,GEO,GSM457526,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187740,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975135,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180225,GEO,GSM457527,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187740,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975136,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180226,GEO,GSM457528,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187741,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975137,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180227,GEO,GSM457529,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187741,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975138,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180228,GEO,GSM457530,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187741,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975139,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180229,GEO,GSM457531,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187742,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975140,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180230,GEO,GSM457532,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187742,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975141,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180231,GEO,GSM457533,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187742,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975142,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180232,GEO,GSM457534,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187742,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975143,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180233,GEO,GSM457535,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187742,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975144,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180234,GEO,GSM457536,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187743,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975145,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180235,GEO,GSM457537,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187743,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975146,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180236,GEO,GSM457538,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187743,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975147,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180237,GEO,GSM457539,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187743,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975148,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180238,GEO,GSM457540,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187743,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975149,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180239,GEO,GSM457541,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187744,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975150,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180240,GEO,GSM457542,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187744,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975151,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180241,GEO,GSM457543,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187744,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975152,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180242,GEO,GSM457544,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187745,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975153,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180243,GEO,GSM457545,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187745,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975154,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180244,GEO,GSM457546,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187745,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975155,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180245,GEO,GSM457547,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187745,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975156,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180246,GEO,GSM457548,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187745,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975157,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180247,GEO,GSM457549,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187746,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975158,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180248,GEO,GSM457550,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187746,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975159,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180249,GEO,GSM457551,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187746,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975160,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180250,GEO,GSM457552,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187746,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975161,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180251,GEO,GSM457553,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187746,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975162,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180252,GEO,GSM457554,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187747,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975163,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180253,GEO,GSM457555,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187747,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975164,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180254,GEO,GSM457556,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187747,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975165,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180255,GEO,GSM457557,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187747,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975166,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180256,GEO,GSM457558,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187747,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975167,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180257,GEO,GSM457559,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187748,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975168,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180258,GEO,GSM457560,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187748,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975169,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180259,GEO,GSM457561,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187748,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975170,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180260,GEO,GSM457562,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187748,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975171,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180261,GEO,GSM457563,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187748,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975172,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180262,GEO,GSM457564,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187749,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975173,61.0,Days,Time of initial vaccine administration,PBMC,,ES1180263,GEO,GSM457565,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187749,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975174,63.0,Days,Time of initial vaccine administration,PBMC,,ES1180264,GEO,GSM457566,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187749,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975175,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180265,GEO,GSM457567,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187749,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975176,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180266,GEO,GSM457568,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187749,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975177,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180267,GEO,GSM457569,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187750,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975178,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180268,GEO,GSM457570,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187750,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975179,0.0,Days,Time of initial vaccine administration,PBMC,,ES1180269,GEO,GSM457571,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187750,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975180,60.0,Days,Time of initial vaccine administration,PBMC,,ES1180270,GEO,GSM457572,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187751,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975181,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180271,GEO,GSM457573,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187752,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975182,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180272,GEO,GSM457574,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187753,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975183,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180273,GEO,GSM457575,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187754,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975184,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180274,GEO,GSM457576,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187755,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975185,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180275,GEO,GSM457577,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187756,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975186,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180276,GEO,GSM457578,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187757,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975187,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180277,GEO,GSM457579,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187758,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975188,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180278,GEO,GSM457580,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187759,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975189,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180279,GEO,GSM457581,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187760,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975190,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180280,GEO,GSM457582,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187761,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975191,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180281,GEO,GSM457583,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187762,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975192,74.0,Days,Time of initial vaccine administration,PBMC,,ES1180282,GEO,GSM457584,false,GSE18323,GPL571,[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187742,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975193,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180283,GEO,GSM457585,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187735,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975194,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180284,GEO,GSM457586,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187749,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975195,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180285,GEO,GSM457587,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187740,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975196,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180286,GEO,GSM457588,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187750,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975197,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180287,GEO,GSM457589,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187748,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975198,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180288,GEO,GSM457590,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187722,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975199,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180289,GEO,GSM457591,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187724,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975200,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180290,GEO,GSM457592,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187738,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975201,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180291,GEO,GSM457593,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187720,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975202,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180292,GEO,GSM457594,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187714,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975203,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180293,GEO,GSM457595,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187747,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975204,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180294,GEO,GSM457596,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187731,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975205,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180295,GEO,GSM457597,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187746,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975206,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180296,GEO,GSM457598,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187743,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975207,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180297,GEO,GSM457599,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187733,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975208,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180298,GEO,GSM457600,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187737,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975209,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180299,GEO,GSM457601,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187726,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975210,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180300,GEO,GSM457602,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187730,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975211,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180301,GEO,GSM457603,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187729,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975212,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180302,GEO,GSM457604,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187715,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975213,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180303,GEO,GSM457605,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187718,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975214,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180304,GEO,GSM457606,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187721,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975215,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180305,GEO,GSM457607,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187706,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975216,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180306,GEO,GSM457608,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187723,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975217,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180307,GEO,GSM457609,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187708,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975218,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180308,GEO,GSM457610,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187732,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975219,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180309,GEO,GSM457611,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187745,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975220,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180310,GEO,GSM457612,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187734,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975221,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180311,GEO,GSM457613,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187736,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975222,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180312,GEO,GSM457614,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187727,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975223,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180313,GEO,GSM457615,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187728,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975224,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180314,GEO,GSM457616,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187717,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975225,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180315,GEO,GSM457617,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187763,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975226,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180316,GEO,GSM457618,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187719,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975227,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180317,GEO,GSM457619,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187709,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975228,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180318,GEO,GSM457620,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187710,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975229,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180319,GEO,GSM457621,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187711,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975230,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180320,GEO,GSM457622,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1293,"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine.","The goals of the present study were to determine whether there is a gene expression profile that is predictive of an individual's response to the adjuvanted RTS,S malaria vaccine and to identify the time at which that profile can be discerned before challenge.",18.0,65.0,SUB187712,Not Specified,Not Specified,VO_0000087,Plasmodium falciparum vaccine,BS975231,79.0,Days,Time of initial vaccine administration,PBMC,,ES1180321,GEO,GSM457623,false,GSE18323,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE18323,PBMC : NA,18.0 - 65.0
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187908,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975713,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184621,GEO,GSM1165057,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187908,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976800,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184622,GEO,GSM1165058,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187908,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975829,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184623,GEO,GSM1165059,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187908,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976801,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184624,GEO,GSM1165060,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187909,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975714,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184625,GEO,GSM1165061,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187910,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975715,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184626,GEO,GSM1165062,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187910,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976802,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184627,GEO,GSM1165063,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187910,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976803,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184628,GEO,GSM1165064,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187911,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975716,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184629,GEO,GSM1165065,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187911,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976804,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184630,GEO,GSM1165066,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187911,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975832,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184631,GEO,GSM1165067,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187911,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976805,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184632,GEO,GSM1165068,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187912,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975717,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184633,GEO,GSM1165069,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187912,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976806,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184634,GEO,GSM1165070,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187912,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975833,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184635,GEO,GSM1165071,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187912,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976807,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184636,GEO,GSM1165072,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187913,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975718,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184637,GEO,GSM1165073,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187913,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976808,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184638,GEO,GSM1165074,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187913,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975834,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184639,GEO,GSM1165075,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187913,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976809,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184640,GEO,GSM1165076,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187914,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975719,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184641,GEO,GSM1165077,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187914,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976810,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184642,GEO,GSM1165078,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187914,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975835,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184643,GEO,GSM1165079,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187914,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976811,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184644,GEO,GSM1165080,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187915,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975720,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184645,GEO,GSM1165081,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187915,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976812,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184646,GEO,GSM1165082,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187915,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975836,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184647,GEO,GSM1165083,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187915,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976813,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184648,GEO,GSM1165084,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187916,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975721,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184649,GEO,GSM1165085,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187916,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976814,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184650,GEO,GSM1165086,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187916,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975837,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184651,GEO,GSM1165087,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187916,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976815,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184652,GEO,GSM1165088,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187917,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975722,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184653,GEO,GSM1165089,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187917,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976816,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184654,GEO,GSM1165090,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187917,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975838,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184655,GEO,GSM1165091,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187917,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976817,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184656,GEO,GSM1165092,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187918,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976818,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184657,GEO,GSM1165093,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187918,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975839,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184658,GEO,GSM1165094,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187918,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976819,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184659,GEO,GSM1165095,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187919,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975724,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184660,GEO,GSM1165096,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187919,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976820,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184661,GEO,GSM1165097,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187919,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975840,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184662,GEO,GSM1165098,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187919,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976821,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184663,GEO,GSM1165099,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187920,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975725,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184664,GEO,GSM1165100,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187920,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976822,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184665,GEO,GSM1165101,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187920,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975841,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184666,GEO,GSM1165102,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187920,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976823,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184667,GEO,GSM1165103,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187921,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975726,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184668,GEO,GSM1165104,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187921,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976824,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184669,GEO,GSM1165105,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187921,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975842,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184670,GEO,GSM1165106,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187921,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976825,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184671,GEO,GSM1165107,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187922,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975727,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184672,GEO,GSM1165108,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187922,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976826,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184673,GEO,GSM1165109,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187922,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975843,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184674,GEO,GSM1165110,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187922,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976827,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184675,GEO,GSM1165111,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187923,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975728,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184676,GEO,GSM1165112,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187923,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976828,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184677,GEO,GSM1165113,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187923,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975844,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184678,GEO,GSM1165114,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187923,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976829,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184679,GEO,GSM1165115,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187924,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975729,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184680,GEO,GSM1165116,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187924,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976830,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184681,GEO,GSM1165117,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187924,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975845,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184682,GEO,GSM1165118,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187924,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976831,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184683,GEO,GSM1165119,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187925,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975730,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184684,GEO,GSM1165120,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187925,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976832,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184685,GEO,GSM1165121,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187925,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975846,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184686,GEO,GSM1165122,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187925,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976833,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184687,GEO,GSM1165123,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187926,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975731,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184688,GEO,GSM1165124,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187926,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976834,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184689,GEO,GSM1165125,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187926,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975847,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184690,GEO,GSM1165126,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187926,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976835,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184691,GEO,GSM1165127,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187927,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975732,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184692,GEO,GSM1165128,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187927,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976836,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184693,GEO,GSM1165129,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187927,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975848,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184694,GEO,GSM1165130,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187927,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976837,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184695,GEO,GSM1165131,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187928,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975733,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184696,GEO,GSM1165132,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187928,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976838,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184697,GEO,GSM1165133,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187928,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975849,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184698,GEO,GSM1165134,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187928,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976839,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184699,GEO,GSM1165135,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187929,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975734,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184700,GEO,GSM1165136,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187929,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976840,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184701,GEO,GSM1165137,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187929,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975850,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184702,GEO,GSM1165138,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187930,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975735,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184703,GEO,GSM1165139,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187930,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976841,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184704,GEO,GSM1165140,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187930,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975851,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184705,GEO,GSM1165141,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187930,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976842,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184706,GEO,GSM1165142,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187931,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975736,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184707,GEO,GSM1165143,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187931,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976843,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184708,GEO,GSM1165144,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187931,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975852,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184709,GEO,GSM1165145,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187931,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976844,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184710,GEO,GSM1165146,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187932,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975737,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184711,GEO,GSM1165147,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187932,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976845,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184712,GEO,GSM1165148,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187932,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975853,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184713,GEO,GSM1165149,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187932,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976846,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184714,GEO,GSM1165150,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187933,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975738,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184715,GEO,GSM1165151,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187933,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976847,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184716,GEO,GSM1165152,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187933,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975854,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184717,GEO,GSM1165153,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187933,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976848,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184718,GEO,GSM1165154,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187934,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975739,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184719,GEO,GSM1165155,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187934,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976849,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184720,GEO,GSM1165156,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187934,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975855,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184721,GEO,GSM1165157,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187934,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976850,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184722,GEO,GSM1165158,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187935,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976851,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184723,GEO,GSM1165159,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187935,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975856,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184724,GEO,GSM1165160,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187935,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976852,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184725,GEO,GSM1165161,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187936,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975741,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184726,GEO,GSM1165162,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187936,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976853,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184727,GEO,GSM1165163,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187936,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975857,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184728,GEO,GSM1165164,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187936,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976854,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184729,GEO,GSM1165165,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187937,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976855,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184730,GEO,GSM1165166,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187937,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976856,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184731,GEO,GSM1165167,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187938,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975743,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184732,GEO,GSM1165168,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187938,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976857,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184733,GEO,GSM1165169,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187938,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975859,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184734,GEO,GSM1165170,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187938,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976858,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184735,GEO,GSM1165171,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187939,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975744,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184736,GEO,GSM1165172,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187939,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976859,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184737,GEO,GSM1165173,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187939,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975860,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184738,GEO,GSM1165174,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187939,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976860,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184739,GEO,GSM1165175,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187940,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975745,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184740,GEO,GSM1165176,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187940,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976861,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184741,GEO,GSM1165177,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187940,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975861,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184742,GEO,GSM1165178,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187940,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976862,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184743,GEO,GSM1165179,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187941,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975746,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184744,GEO,GSM1165180,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187941,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976863,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184745,GEO,GSM1165181,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187941,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975862,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184746,GEO,GSM1165182,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187942,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975747,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184747,GEO,GSM1165183,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187942,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976864,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184748,GEO,GSM1165184,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187942,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975863,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184749,GEO,GSM1165185,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187943,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975748,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184750,GEO,GSM1165186,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187943,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975864,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184751,GEO,GSM1165187,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187944,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975749,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184752,GEO,GSM1165188,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187944,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976865,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184753,GEO,GSM1165189,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187944,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975865,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184754,GEO,GSM1165190,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187944,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976866,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184755,GEO,GSM1165191,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187945,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975750,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184756,GEO,GSM1165192,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187945,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976867,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184757,GEO,GSM1165193,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187945,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975866,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184758,GEO,GSM1165194,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187946,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975751,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184759,GEO,GSM1165195,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187946,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976868,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184760,GEO,GSM1165196,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187946,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975867,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184761,GEO,GSM1165197,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187947,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975752,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184762,GEO,GSM1165198,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187947,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976869,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184763,GEO,GSM1165199,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187947,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975868,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184764,GEO,GSM1165200,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187947,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976870,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184765,GEO,GSM1165201,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187948,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975869,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184766,GEO,GSM1165202,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187949,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975754,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184767,GEO,GSM1165203,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187949,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976871,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184768,GEO,GSM1165204,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187949,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975870,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184769,GEO,GSM1165205,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187949,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976872,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184770,GEO,GSM1165206,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187950,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975755,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184771,GEO,GSM1165207,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187950,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976873,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184772,GEO,GSM1165208,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187950,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975871,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184773,GEO,GSM1165209,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187950,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976874,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184774,GEO,GSM1165210,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187951,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975756,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184775,GEO,GSM1165211,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187951,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976875,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184776,GEO,GSM1165212,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187951,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975872,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184777,GEO,GSM1165213,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187952,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975757,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184778,GEO,GSM1165214,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187952,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976876,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184779,GEO,GSM1165215,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187952,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975873,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184780,GEO,GSM1165216,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187952,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976877,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184781,GEO,GSM1165217,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187953,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975758,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184782,GEO,GSM1165218,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187953,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976878,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184783,GEO,GSM1165219,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187953,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975874,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184784,GEO,GSM1165220,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187953,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976879,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184785,GEO,GSM1165221,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187954,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975759,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184786,GEO,GSM1165222,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187954,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976880,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184787,GEO,GSM1165223,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187954,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975875,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184788,GEO,GSM1165224,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187954,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976881,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184789,GEO,GSM1165225,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187955,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975760,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184790,GEO,GSM1165226,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187955,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976882,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184791,GEO,GSM1165227,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187955,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975876,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184792,GEO,GSM1165228,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187955,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976883,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184793,GEO,GSM1165229,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187956,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975761,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184794,GEO,GSM1165230,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187956,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976884,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184795,GEO,GSM1165231,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187957,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975762,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184796,GEO,GSM1165232,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187957,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976885,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184797,GEO,GSM1165233,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187958,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975763,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184798,GEO,GSM1165234,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187958,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976886,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184799,GEO,GSM1165235,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187958,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975879,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184800,GEO,GSM1165236,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187959,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975764,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184801,GEO,GSM1165237,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187959,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976887,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184802,GEO,GSM1165238,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187959,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975880,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184803,GEO,GSM1165239,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187959,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976888,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184804,GEO,GSM1165240,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187960,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975765,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184805,GEO,GSM1165241,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187960,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976889,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184806,GEO,GSM1165242,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187960,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975881,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184807,GEO,GSM1165243,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187960,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976890,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184808,GEO,GSM1165244,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187961,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975766,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184809,GEO,GSM1165245,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187961,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976891,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184810,GEO,GSM1165246,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187961,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975882,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184811,GEO,GSM1165247,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187962,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975767,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184812,GEO,GSM1165248,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187962,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975883,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184813,GEO,GSM1165249,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187962,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976892,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184814,GEO,GSM1165250,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187963,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975768,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184815,GEO,GSM1165251,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187963,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976893,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184816,GEO,GSM1165252,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187963,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975884,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184817,GEO,GSM1165253,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187963,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976894,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184818,GEO,GSM1165254,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187964,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975769,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184819,GEO,GSM1165255,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187964,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976895,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184820,GEO,GSM1165256,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187964,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975885,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184821,GEO,GSM1165257,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187964,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976896,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184822,GEO,GSM1165258,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187965,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975770,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184823,GEO,GSM1165259,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187965,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976897,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184824,GEO,GSM1165260,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187965,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975886,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184825,GEO,GSM1165261,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187966,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975771,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184826,GEO,GSM1165262,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187966,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976898,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184827,GEO,GSM1165263,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187966,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975887,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184828,GEO,GSM1165264,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187966,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976899,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184829,GEO,GSM1165265,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187967,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975772,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184830,GEO,GSM1165266,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187967,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976900,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184831,GEO,GSM1165267,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187967,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975888,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184832,GEO,GSM1165268,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187967,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976901,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184833,GEO,GSM1165269,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187968,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975773,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184834,GEO,GSM1165270,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187968,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976902,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184835,GEO,GSM1165271,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187968,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975889,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184836,GEO,GSM1165272,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187968,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976903,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184837,GEO,GSM1165273,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187969,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975774,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184838,GEO,GSM1165274,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187969,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976904,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184839,GEO,GSM1165275,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187969,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975890,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184840,GEO,GSM1165276,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187969,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976905,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184841,GEO,GSM1165277,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187970,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975775,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184842,GEO,GSM1165278,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187970,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976906,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184843,GEO,GSM1165279,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187970,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975891,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184844,GEO,GSM1165280,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187970,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976907,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184845,GEO,GSM1165281,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187971,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975776,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184846,GEO,GSM1165282,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187971,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976908,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184847,GEO,GSM1165283,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187971,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975892,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184848,GEO,GSM1165284,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187971,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976909,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184849,GEO,GSM1165285,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187972,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975777,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184850,GEO,GSM1165286,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187972,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976910,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184851,GEO,GSM1165287,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187972,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975893,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184852,GEO,GSM1165288,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187972,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976911,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184853,GEO,GSM1165289,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187973,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975778,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184854,GEO,GSM1165290,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187973,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976912,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184855,GEO,GSM1165291,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187973,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975894,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184856,GEO,GSM1165292,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187973,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976913,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184857,GEO,GSM1165293,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187974,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975779,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184858,GEO,GSM1165294,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187974,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976914,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184859,GEO,GSM1165295,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187974,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975895,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184860,GEO,GSM1165296,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187974,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976915,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184861,GEO,GSM1165297,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187975,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975780,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184862,GEO,GSM1165298,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187975,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976916,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184863,GEO,GSM1165299,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187975,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975896,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184864,GEO,GSM1165300,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187975,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976917,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184865,GEO,GSM1165301,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187976,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975781,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184866,GEO,GSM1165302,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187976,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976918,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184867,GEO,GSM1165303,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187976,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975897,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184868,GEO,GSM1165304,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187976,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976919,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184869,GEO,GSM1165305,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187977,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975782,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184870,GEO,GSM1165306,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187977,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976920,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184871,GEO,GSM1165307,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187977,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975898,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184872,GEO,GSM1165308,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187977,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976921,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184873,GEO,GSM1165309,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187978,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975783,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184874,GEO,GSM1165310,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187978,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976922,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184875,GEO,GSM1165311,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187978,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975899,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184876,GEO,GSM1165312,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187978,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976923,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184877,GEO,GSM1165313,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187979,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975900,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184878,GEO,GSM1165314,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187979,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976924,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184879,GEO,GSM1165315,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187980,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975785,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184880,GEO,GSM1165316,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187980,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976925,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184881,GEO,GSM1165317,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187980,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975901,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184882,GEO,GSM1165318,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187980,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976926,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184883,GEO,GSM1165319,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187981,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975786,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184884,GEO,GSM1165320,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187981,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976927,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184885,GEO,GSM1165321,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187981,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975902,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184886,GEO,GSM1165322,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187981,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976928,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184887,GEO,GSM1165323,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187982,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975787,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184888,GEO,GSM1165324,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187982,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976929,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184889,GEO,GSM1165325,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187982,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975903,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184890,GEO,GSM1165326,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187982,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976930,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184891,GEO,GSM1165327,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187983,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975788,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184892,GEO,GSM1165328,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187983,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976931,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184893,GEO,GSM1165329,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187983,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975904,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184894,GEO,GSM1165330,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187983,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976932,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184895,GEO,GSM1165331,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187984,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975789,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184896,GEO,GSM1165332,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187984,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976933,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184897,GEO,GSM1165333,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187984,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975905,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184898,GEO,GSM1165334,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187984,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976934,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184899,GEO,GSM1165335,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187985,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975790,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184900,GEO,GSM1165336,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187985,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976935,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184901,GEO,GSM1165337,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187985,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975906,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184902,GEO,GSM1165338,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187985,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976936,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184903,GEO,GSM1165339,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187986,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975791,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184904,GEO,GSM1165340,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187986,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976937,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184905,GEO,GSM1165341,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187986,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975907,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184906,GEO,GSM1165342,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187987,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975792,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184907,GEO,GSM1165343,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187987,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976938,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184908,GEO,GSM1165344,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187987,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975908,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184909,GEO,GSM1165345,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187987,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976939,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184910,GEO,GSM1165346,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187988,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975793,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184911,GEO,GSM1165347,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187988,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976940,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184912,GEO,GSM1165348,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187988,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975909,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184913,GEO,GSM1165349,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187988,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976941,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184914,GEO,GSM1165350,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187989,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975794,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184915,GEO,GSM1165351,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187989,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976942,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184916,GEO,GSM1165352,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187989,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975910,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184917,GEO,GSM1165353,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187989,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976943,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184918,GEO,GSM1165354,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187990,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975795,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184919,GEO,GSM1165355,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187990,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976944,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184920,GEO,GSM1165356,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187990,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975911,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184921,GEO,GSM1165357,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187990,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976945,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184922,GEO,GSM1165358,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187991,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975796,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184923,GEO,GSM1165359,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187991,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976946,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184924,GEO,GSM1165360,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187991,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975912,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184925,GEO,GSM1165361,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187991,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976947,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184926,GEO,GSM1165362,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187992,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975797,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184927,GEO,GSM1165363,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187992,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976948,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184928,GEO,GSM1165364,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187992,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975913,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184929,GEO,GSM1165365,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187992,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976949,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184930,GEO,GSM1165366,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187993,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975798,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184931,GEO,GSM1165367,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187993,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976950,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184932,GEO,GSM1165368,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187993,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975914,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184933,GEO,GSM1165369,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187993,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976951,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184934,GEO,GSM1165370,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187994,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975799,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184935,GEO,GSM1165371,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187994,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976952,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184936,GEO,GSM1165372,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187994,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975915,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184937,GEO,GSM1165373,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187994,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976953,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184938,GEO,GSM1165374,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187995,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975800,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184939,GEO,GSM1165375,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187995,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976954,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184940,GEO,GSM1165376,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187995,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975916,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184941,GEO,GSM1165377,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187995,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976955,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184942,GEO,GSM1165378,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187996,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975801,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184943,GEO,GSM1165379,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187996,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976956,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184944,GEO,GSM1165380,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187996,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975917,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184945,GEO,GSM1165381,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187996,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976957,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184946,GEO,GSM1165382,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187997,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975802,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184947,GEO,GSM1165383,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187997,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976958,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184948,GEO,GSM1165384,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187997,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975918,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184949,GEO,GSM1165385,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187997,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976959,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184950,GEO,GSM1165386,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187998,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975803,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184951,GEO,GSM1165387,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187998,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976960,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184952,GEO,GSM1165388,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187998,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975919,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184953,GEO,GSM1165389,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187998,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976961,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184954,GEO,GSM1165390,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187999,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975804,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184955,GEO,GSM1165391,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187999,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976962,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184956,GEO,GSM1165392,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187999,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975920,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184957,GEO,GSM1165393,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB187999,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976963,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184958,GEO,GSM1165394,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188000,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975805,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184959,GEO,GSM1165395,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188000,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976964,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184960,GEO,GSM1165396,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188000,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975921,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184961,GEO,GSM1165397,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188000,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976965,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184962,GEO,GSM1165398,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188001,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975806,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184963,GEO,GSM1165399,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188001,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976966,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184964,GEO,GSM1165400,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188001,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975922,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184965,GEO,GSM1165401,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188001,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976967,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184966,GEO,GSM1165402,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188002,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975807,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184967,GEO,GSM1165403,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188002,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976968,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184968,GEO,GSM1165404,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188002,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975923,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184969,GEO,GSM1165405,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188002,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976969,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184970,GEO,GSM1165406,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188003,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975808,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184971,GEO,GSM1165407,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188003,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976970,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184972,GEO,GSM1165408,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188003,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975924,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184973,GEO,GSM1165409,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188003,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976971,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184974,GEO,GSM1165410,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188004,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975809,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184975,GEO,GSM1165411,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188004,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976972,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184976,GEO,GSM1165412,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188004,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975925,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184977,GEO,GSM1165413,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188004,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976973,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184978,GEO,GSM1165414,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188005,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975810,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184979,GEO,GSM1165415,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188005,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976974,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184980,GEO,GSM1165416,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188005,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975926,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184981,GEO,GSM1165417,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188005,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976975,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184982,GEO,GSM1165418,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188006,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975811,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184983,GEO,GSM1165419,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188006,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976976,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184984,GEO,GSM1165420,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188006,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975927,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184985,GEO,GSM1165421,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188006,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976977,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184986,GEO,GSM1165422,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188007,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975812,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184987,GEO,GSM1165423,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188007,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976978,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184988,GEO,GSM1165424,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188007,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975928,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184989,GEO,GSM1165425,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188007,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976979,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184990,GEO,GSM1165426,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188008,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975813,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184991,GEO,GSM1165427,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188008,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976980,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184992,GEO,GSM1165428,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188008,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975929,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1184993,GEO,GSM1165429,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188008,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976981,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184994,GEO,GSM1165430,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188009,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975814,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184995,GEO,GSM1165431,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188009,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976982,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184996,GEO,GSM1165432,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188009,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976983,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1184997,GEO,GSM1165433,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188010,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975815,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1184998,GEO,GSM1165434,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188010,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976984,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1184999,GEO,GSM1165435,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188010,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976985,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185000,GEO,GSM1165436,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188011,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975816,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185001,GEO,GSM1165437,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188011,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976986,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185002,GEO,GSM1165438,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188011,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975932,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185003,GEO,GSM1165439,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188011,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976987,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185004,GEO,GSM1165440,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188012,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975817,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185005,GEO,GSM1165441,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188012,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976988,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185006,GEO,GSM1165442,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188012,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975933,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185007,GEO,GSM1165443,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188012,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976989,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185008,GEO,GSM1165444,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188013,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975818,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185009,GEO,GSM1165445,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188013,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975934,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185010,GEO,GSM1165446,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188013,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976990,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185011,GEO,GSM1165447,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188014,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975819,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185012,GEO,GSM1165448,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188014,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976991,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185013,GEO,GSM1165449,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188014,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975935,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185014,GEO,GSM1165450,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188014,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976992,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185015,GEO,GSM1165451,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188015,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975820,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185016,GEO,GSM1165452,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188015,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976993,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185017,GEO,GSM1165453,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188015,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975936,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185018,GEO,GSM1165454,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188015,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976994,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185019,GEO,GSM1165455,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188016,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975821,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185020,GEO,GSM1165456,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188016,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976995,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185021,GEO,GSM1165457,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188016,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975937,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185022,GEO,GSM1165458,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188016,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976996,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185023,GEO,GSM1165459,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188017,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975822,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185024,GEO,GSM1165460,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188017,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976997,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185025,GEO,GSM1165461,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188017,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975938,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185026,GEO,GSM1165462,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188017,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976998,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185027,GEO,GSM1165463,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188018,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975823,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185028,GEO,GSM1165464,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188018,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976999,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185029,GEO,GSM1165465,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188018,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975939,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185030,GEO,GSM1165466,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188018,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977000,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185031,GEO,GSM1165467,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188019,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975824,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185032,GEO,GSM1165468,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188019,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977001,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185033,GEO,GSM1165469,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188019,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975940,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185034,GEO,GSM1165470,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188019,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977002,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185035,GEO,GSM1165471,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188020,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975825,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185036,GEO,GSM1165472,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188020,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977003,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185037,GEO,GSM1165473,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188020,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975941,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185038,GEO,GSM1165474,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188020,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977004,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185039,GEO,GSM1165475,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188021,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975826,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185040,GEO,GSM1165476,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188021,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977005,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185041,GEO,GSM1165477,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188021,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975942,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185042,GEO,GSM1165478,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188021,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977006,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185043,GEO,GSM1165479,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188022,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975827,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185044,GEO,GSM1165480,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188022,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977007,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185045,GEO,GSM1165481,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188022,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975943,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185046,GEO,GSM1165482,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188022,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977008,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185047,GEO,GSM1165483,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188023,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975828,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185048,GEO,GSM1165484,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188023,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977009,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185049,GEO,GSM1165485,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188023,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS975944,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185050,GEO,GSM1165486,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188023,Male,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977010,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185051,GEO,GSM1165487,false,GSE48024,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188024,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976061,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185052,GEO,GSM1165512,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188024,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977011,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185053,GEO,GSM1165513,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188024,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976171,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185054,GEO,GSM1165514,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188024,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977012,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185055,GEO,GSM1165515,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188025,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976062,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185056,GEO,GSM1165516,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188025,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977013,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185057,GEO,GSM1165517,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188025,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976172,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185058,GEO,GSM1165518,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188025,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977014,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185059,GEO,GSM1165519,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188026,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976063,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185060,GEO,GSM1165520,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188026,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977015,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185061,GEO,GSM1165521,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188026,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976173,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185062,GEO,GSM1165522,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188026,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977016,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185063,GEO,GSM1165523,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188027,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976064,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185064,GEO,GSM1165524,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188027,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977017,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185065,GEO,GSM1165525,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188027,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976174,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185066,GEO,GSM1165526,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188027,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977018,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185067,GEO,GSM1165527,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188028,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976065,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185068,GEO,GSM1165528,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188028,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977019,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185069,GEO,GSM1165529,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188028,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976175,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185070,GEO,GSM1165530,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188028,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977020,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185071,GEO,GSM1165531,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188029,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976066,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185072,GEO,GSM1165532,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188029,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977021,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185073,GEO,GSM1165533,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188029,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976176,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185074,GEO,GSM1165534,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188029,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977022,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185075,GEO,GSM1165535,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188030,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976067,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185076,GEO,GSM1165536,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188030,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977023,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185077,GEO,GSM1165537,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188030,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976177,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185078,GEO,GSM1165538,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188030,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977024,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185079,GEO,GSM1165539,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188031,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976068,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185080,GEO,GSM1165540,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188031,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977025,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185081,GEO,GSM1165541,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188031,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976178,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185082,GEO,GSM1165542,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188031,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977026,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185083,GEO,GSM1165543,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188032,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976069,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185084,GEO,GSM1165544,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188032,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977027,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185085,GEO,GSM1165545,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188032,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977028,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185086,GEO,GSM1165546,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188033,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976070,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185087,GEO,GSM1165547,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188033,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977029,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185088,GEO,GSM1165548,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188033,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976180,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185089,GEO,GSM1165549,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188033,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977030,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185090,GEO,GSM1165550,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188034,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976071,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185091,GEO,GSM1165551,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188034,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977031,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185092,GEO,GSM1165552,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188034,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976181,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185093,GEO,GSM1165553,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188035,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976072,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185094,GEO,GSM1165554,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188035,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977032,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185095,GEO,GSM1165555,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188035,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976182,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185096,GEO,GSM1165556,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188035,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977033,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185097,GEO,GSM1165557,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188036,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976073,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185098,GEO,GSM1165558,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188036,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977034,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185099,GEO,GSM1165559,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188036,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976183,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185100,GEO,GSM1165560,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188036,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977035,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185101,GEO,GSM1165561,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188037,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976074,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185102,GEO,GSM1165562,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188037,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977036,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185103,GEO,GSM1165563,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188037,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976184,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185104,GEO,GSM1165564,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188037,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977037,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185105,GEO,GSM1165565,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188038,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976075,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185106,GEO,GSM1165566,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188038,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977038,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185107,GEO,GSM1165567,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188038,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976185,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185108,GEO,GSM1165568,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188038,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977039,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185109,GEO,GSM1165569,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188039,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976076,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185110,GEO,GSM1165570,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188039,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977040,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185111,GEO,GSM1165571,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188039,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976186,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185112,GEO,GSM1165572,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188039,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977041,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185113,GEO,GSM1165573,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188040,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976077,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185114,GEO,GSM1165574,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188040,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976187,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185115,GEO,GSM1165575,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188040,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977042,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185116,GEO,GSM1165576,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188041,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976078,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185117,GEO,GSM1165577,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188041,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977043,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185118,GEO,GSM1165578,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188041,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976188,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185119,GEO,GSM1165579,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188041,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977044,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185120,GEO,GSM1165580,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188042,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976079,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185121,GEO,GSM1165581,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188042,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977045,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185122,GEO,GSM1165582,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188042,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976189,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185123,GEO,GSM1165583,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188042,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977046,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185124,GEO,GSM1165584,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188043,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976080,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185125,GEO,GSM1165585,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188043,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977047,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185126,GEO,GSM1165586,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188043,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976190,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185127,GEO,GSM1165587,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188043,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977048,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185128,GEO,GSM1165588,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188044,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976081,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185129,GEO,GSM1165589,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188044,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977049,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185130,GEO,GSM1165590,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188044,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976191,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185131,GEO,GSM1165591,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188044,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977050,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185132,GEO,GSM1165592,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188045,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976082,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185133,GEO,GSM1165593,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188045,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977051,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185134,GEO,GSM1165594,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188045,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976192,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185135,GEO,GSM1165595,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188045,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977052,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185136,GEO,GSM1165596,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188046,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976083,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185137,GEO,GSM1165597,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188046,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977053,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185138,GEO,GSM1165598,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188046,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976193,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185139,GEO,GSM1165599,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188046,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977054,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185140,GEO,GSM1165600,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188047,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976084,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185141,GEO,GSM1165601,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188047,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977055,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185142,GEO,GSM1165602,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188047,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976194,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185143,GEO,GSM1165603,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188047,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977056,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185144,GEO,GSM1165604,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188048,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976085,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185145,GEO,GSM1165605,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188048,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977057,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185146,GEO,GSM1165606,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188048,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976195,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185147,GEO,GSM1165607,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188048,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977058,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185148,GEO,GSM1165608,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188049,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976086,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185149,GEO,GSM1165609,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188049,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977059,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185150,GEO,GSM1165610,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188049,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976196,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185151,GEO,GSM1165611,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188049,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977060,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185152,GEO,GSM1165612,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188050,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976087,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185153,GEO,GSM1165613,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188050,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977061,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185154,GEO,GSM1165614,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188050,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977062,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185155,GEO,GSM1165615,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188051,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976088,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185156,GEO,GSM1165616,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188051,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977063,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185157,GEO,GSM1165617,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188051,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976198,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185158,GEO,GSM1165618,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188051,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977064,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185159,GEO,GSM1165619,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188052,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976089,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185160,GEO,GSM1165620,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188052,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977065,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185161,GEO,GSM1165621,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188052,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976199,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185162,GEO,GSM1165622,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188052,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977066,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185163,GEO,GSM1165623,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188053,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976090,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185164,GEO,GSM1165624,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188053,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977067,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185165,GEO,GSM1165625,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188053,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977068,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185166,GEO,GSM1165626,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188054,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976091,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185167,GEO,GSM1165627,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188054,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977069,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185168,GEO,GSM1165628,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188054,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977070,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185169,GEO,GSM1165629,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188055,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976092,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185170,GEO,GSM1165630,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188055,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977071,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185171,GEO,GSM1165631,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188055,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976202,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185172,GEO,GSM1165632,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188055,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977072,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185173,GEO,GSM1165633,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188056,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976093,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185174,GEO,GSM1165634,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188056,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977073,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185175,GEO,GSM1165635,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188056,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976203,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185176,GEO,GSM1165636,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188056,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977074,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185177,GEO,GSM1165637,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188057,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976094,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185178,GEO,GSM1165638,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188057,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977075,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185179,GEO,GSM1165639,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188057,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976204,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185180,GEO,GSM1165640,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188057,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977076,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185181,GEO,GSM1165641,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188058,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976095,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185182,GEO,GSM1165642,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188058,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977077,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185183,GEO,GSM1165643,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188058,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976205,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185184,GEO,GSM1165644,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188058,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977078,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185185,GEO,GSM1165645,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188059,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976096,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185186,GEO,GSM1165646,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188059,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977079,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185187,GEO,GSM1165647,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188059,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976206,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185188,GEO,GSM1165648,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188059,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977080,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185189,GEO,GSM1165649,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188060,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976097,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185190,GEO,GSM1165650,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188060,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977081,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185191,GEO,GSM1165651,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188060,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977082,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185192,GEO,GSM1165652,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188061,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976098,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185193,GEO,GSM1165653,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188061,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977083,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185194,GEO,GSM1165654,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188061,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976208,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185195,GEO,GSM1165655,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188061,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977084,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185196,GEO,GSM1165656,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188062,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976099,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185197,GEO,GSM1165657,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188062,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977085,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185198,GEO,GSM1165658,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188062,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976209,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185199,GEO,GSM1165659,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188062,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977086,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185200,GEO,GSM1165660,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188063,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976100,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185201,GEO,GSM1165661,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188063,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977087,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185202,GEO,GSM1165662,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188063,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976210,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185203,GEO,GSM1165663,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188063,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977088,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185204,GEO,GSM1165664,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188064,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976101,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185205,GEO,GSM1165665,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188064,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977089,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185206,GEO,GSM1165666,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188064,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976211,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185207,GEO,GSM1165667,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188064,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977090,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185208,GEO,GSM1165668,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188065,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976102,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185209,GEO,GSM1165669,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188065,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977091,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185210,GEO,GSM1165670,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188065,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976212,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185211,GEO,GSM1165671,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188065,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977092,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185212,GEO,GSM1165672,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188066,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976103,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185213,GEO,GSM1165673,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188066,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977093,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185214,GEO,GSM1165674,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188066,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976213,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185215,GEO,GSM1165675,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188066,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977094,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185216,GEO,GSM1165676,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188067,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976104,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185217,GEO,GSM1165677,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188067,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977095,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185218,GEO,GSM1165678,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188067,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976214,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185219,GEO,GSM1165679,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188067,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977096,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185220,GEO,GSM1165680,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188068,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976105,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185221,GEO,GSM1165681,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188068,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977097,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185222,GEO,GSM1165682,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188068,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977098,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185223,GEO,GSM1165683,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188069,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976106,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185224,GEO,GSM1165684,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188069,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977099,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185225,GEO,GSM1165685,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188069,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976216,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185226,GEO,GSM1165686,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188069,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977100,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185227,GEO,GSM1165687,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188070,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976107,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185228,GEO,GSM1165688,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188070,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977101,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185229,GEO,GSM1165689,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188070,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976217,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185230,GEO,GSM1165690,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188070,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977102,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185231,GEO,GSM1165691,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188071,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976108,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185232,GEO,GSM1165692,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188071,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977103,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185233,GEO,GSM1165693,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188071,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976218,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185234,GEO,GSM1165694,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188071,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977104,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185235,GEO,GSM1165695,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188072,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976109,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185236,GEO,GSM1165696,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188072,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977105,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185237,GEO,GSM1165697,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188072,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976219,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185238,GEO,GSM1165698,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188072,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977106,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185239,GEO,GSM1165699,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188073,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976110,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185240,GEO,GSM1165700,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188073,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977107,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185241,GEO,GSM1165701,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188073,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976220,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185242,GEO,GSM1165702,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188073,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977108,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185243,GEO,GSM1165703,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188074,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976111,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185244,GEO,GSM1165704,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188074,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977109,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185245,GEO,GSM1165705,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188074,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976221,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185246,GEO,GSM1165706,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188075,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976112,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185247,GEO,GSM1165707,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188075,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977110,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185248,GEO,GSM1165708,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188075,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976222,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185249,GEO,GSM1165709,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188075,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977111,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185250,GEO,GSM1165710,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188076,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977112,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185251,GEO,GSM1165711,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188076,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976223,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185252,GEO,GSM1165712,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188076,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977113,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185253,GEO,GSM1165713,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188077,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976114,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185254,GEO,GSM1165714,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188077,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977114,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185255,GEO,GSM1165715,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188077,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976224,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185256,GEO,GSM1165716,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188077,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977115,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185257,GEO,GSM1165717,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188078,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976115,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185258,GEO,GSM1165718,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188078,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977116,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185259,GEO,GSM1165719,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188078,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976225,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185260,GEO,GSM1165720,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188078,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977117,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185261,GEO,GSM1165721,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188079,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976116,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185262,GEO,GSM1165722,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188079,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977118,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185263,GEO,GSM1165723,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188079,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976226,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185264,GEO,GSM1165724,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188079,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977119,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185265,GEO,GSM1165725,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188080,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976117,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185266,GEO,GSM1165726,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188080,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977120,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185267,GEO,GSM1165727,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188080,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976227,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185268,GEO,GSM1165728,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188080,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977121,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185269,GEO,GSM1165729,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188081,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976118,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185270,GEO,GSM1165730,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188081,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976228,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185271,GEO,GSM1165731,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188081,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977122,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185272,GEO,GSM1165732,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188082,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976119,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185273,GEO,GSM1165733,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188082,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977123,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185274,GEO,GSM1165734,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188082,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976229,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185275,GEO,GSM1165735,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188082,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977124,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185276,GEO,GSM1165736,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188083,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976120,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185277,GEO,GSM1165737,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188083,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977125,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185278,GEO,GSM1165738,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188083,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977126,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185279,GEO,GSM1165739,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188084,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976121,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185280,GEO,GSM1165740,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188084,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977127,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185281,GEO,GSM1165741,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188084,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976231,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185282,GEO,GSM1165742,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188084,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977128,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185283,GEO,GSM1165743,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188085,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976122,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185284,GEO,GSM1165744,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188085,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977129,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185285,GEO,GSM1165745,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188085,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976232,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185286,GEO,GSM1165746,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188085,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977130,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185287,GEO,GSM1165747,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188086,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977131,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185288,GEO,GSM1165748,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188086,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976233,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185289,GEO,GSM1165749,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188086,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977132,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185290,GEO,GSM1165750,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188087,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976124,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185291,GEO,GSM1165751,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188087,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977133,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185292,GEO,GSM1165752,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188087,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976234,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185293,GEO,GSM1165753,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188087,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977134,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185294,GEO,GSM1165754,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188088,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976125,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185295,GEO,GSM1165755,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188088,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977135,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185296,GEO,GSM1165756,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188088,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977136,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185297,GEO,GSM1165757,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188089,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976126,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185298,GEO,GSM1165758,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188089,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977137,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185299,GEO,GSM1165759,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188089,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977138,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185300,GEO,GSM1165760,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188090,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976127,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185301,GEO,GSM1165761,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188090,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977139,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185302,GEO,GSM1165762,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188090,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976237,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185303,GEO,GSM1165763,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188090,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977140,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185304,GEO,GSM1165764,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188091,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976128,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185305,GEO,GSM1165765,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188091,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977141,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185306,GEO,GSM1165766,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188091,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976238,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185307,GEO,GSM1165767,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188091,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977142,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185308,GEO,GSM1165768,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188092,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976129,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185309,GEO,GSM1165769,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188092,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977143,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185310,GEO,GSM1165770,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188092,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977144,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185311,GEO,GSM1165771,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188093,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976130,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185312,GEO,GSM1165772,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188093,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977145,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185313,GEO,GSM1165773,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188093,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977146,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185314,GEO,GSM1165774,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188094,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976131,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185315,GEO,GSM1165775,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188094,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977147,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185316,GEO,GSM1165776,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188094,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976241,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185317,GEO,GSM1165777,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188094,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977148,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185318,GEO,GSM1165778,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188095,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976132,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185319,GEO,GSM1165779,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188095,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977149,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185320,GEO,GSM1165780,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188095,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976242,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185321,GEO,GSM1165781,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188095,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977150,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185322,GEO,GSM1165782,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188096,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976133,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185323,GEO,GSM1165783,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188096,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977151,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185324,GEO,GSM1165784,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188096,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976243,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185325,GEO,GSM1165785,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188096,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977152,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185326,GEO,GSM1165786,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188097,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976134,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185327,GEO,GSM1165787,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188097,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977153,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185328,GEO,GSM1165788,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188097,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976244,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185329,GEO,GSM1165789,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188097,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977154,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185330,GEO,GSM1165790,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188098,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976135,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185331,GEO,GSM1165791,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188098,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977155,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185332,GEO,GSM1165792,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188098,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976245,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185333,GEO,GSM1165793,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188098,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977156,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185334,GEO,GSM1165794,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188099,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976136,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185335,GEO,GSM1165795,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188099,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977157,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185336,GEO,GSM1165796,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188099,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976246,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185337,GEO,GSM1165797,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188099,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977158,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185338,GEO,GSM1165798,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188100,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976137,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185339,GEO,GSM1165799,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188100,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977159,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185340,GEO,GSM1165800,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188100,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976247,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185341,GEO,GSM1165801,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188101,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976138,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185342,GEO,GSM1165802,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188101,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977160,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185343,GEO,GSM1165803,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188101,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976248,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185344,GEO,GSM1165804,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188102,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977161,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185345,GEO,GSM1165805,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188102,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976249,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185346,GEO,GSM1165806,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188102,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977162,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185347,GEO,GSM1165807,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188103,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976140,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185348,GEO,GSM1165808,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188103,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977163,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185349,GEO,GSM1165809,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188103,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976250,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185350,GEO,GSM1165810,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188103,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977164,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185351,GEO,GSM1165811,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188104,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976141,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185352,GEO,GSM1165812,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188104,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977165,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185353,GEO,GSM1165813,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188104,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976251,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185354,GEO,GSM1165814,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188104,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977166,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185355,GEO,GSM1165815,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188105,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976142,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185356,GEO,GSM1165816,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188105,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977167,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185357,GEO,GSM1165817,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188105,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976252,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185358,GEO,GSM1165818,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188105,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977168,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185359,GEO,GSM1165819,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188106,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976143,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185360,GEO,GSM1165820,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188106,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977169,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185361,GEO,GSM1165821,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188106,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976253,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185362,GEO,GSM1165822,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188106,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977170,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185363,GEO,GSM1165823,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188107,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976144,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185364,GEO,GSM1165824,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188107,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977171,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185365,GEO,GSM1165825,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188107,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976254,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185366,GEO,GSM1165826,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188107,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977172,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185367,GEO,GSM1165827,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188108,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976145,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185368,GEO,GSM1165828,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188108,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977173,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185369,GEO,GSM1165829,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188108,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976255,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185370,GEO,GSM1165830,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188108,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977174,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185371,GEO,GSM1165831,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188109,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976146,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185372,GEO,GSM1165832,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188109,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977175,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185373,GEO,GSM1165833,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188109,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976256,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185374,GEO,GSM1165834,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188109,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977176,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185375,GEO,GSM1165835,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188110,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976147,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185376,GEO,GSM1165836,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188110,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977177,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185377,GEO,GSM1165837,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188110,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976257,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185378,GEO,GSM1165838,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188110,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977178,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185379,GEO,GSM1165839,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188111,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976148,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185380,GEO,GSM1165840,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188111,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977179,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185381,GEO,GSM1165841,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188111,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976258,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185382,GEO,GSM1165842,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188111,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977180,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185383,GEO,GSM1165843,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188112,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976149,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185384,GEO,GSM1165844,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188112,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977181,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185385,GEO,GSM1165845,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188112,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976259,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185386,GEO,GSM1165846,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188112,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977182,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185387,GEO,GSM1165847,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188113,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976150,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185388,GEO,GSM1165848,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188113,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977183,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185389,GEO,GSM1165849,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188113,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976260,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185390,GEO,GSM1165850,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188113,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977184,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185391,GEO,GSM1165851,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188114,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976151,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185392,GEO,GSM1165852,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188114,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977185,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185393,GEO,GSM1165853,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188114,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976261,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185394,GEO,GSM1165854,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188114,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977186,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185395,GEO,GSM1165855,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188115,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976152,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185396,GEO,GSM1165856,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188115,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977187,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185397,GEO,GSM1165857,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188115,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976262,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185398,GEO,GSM1165858,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188115,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977188,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185399,GEO,GSM1165859,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188116,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976153,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185400,GEO,GSM1165860,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188116,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977189,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185401,GEO,GSM1165861,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188116,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977190,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185402,GEO,GSM1165862,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188117,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976154,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185403,GEO,GSM1165863,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188117,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977191,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185404,GEO,GSM1165864,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188117,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976264,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185405,GEO,GSM1165865,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188117,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977192,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185406,GEO,GSM1165866,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188118,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976155,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185407,GEO,GSM1165867,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188118,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977193,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185408,GEO,GSM1165868,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188118,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976265,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185409,GEO,GSM1165869,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188118,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977194,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185410,GEO,GSM1165870,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188119,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976156,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185411,GEO,GSM1165871,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188119,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977195,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185412,GEO,GSM1165872,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188119,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976266,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185413,GEO,GSM1165873,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188120,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976157,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185414,GEO,GSM1165874,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188120,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977196,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185415,GEO,GSM1165875,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188120,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976267,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185416,GEO,GSM1165876,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188120,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977197,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185417,GEO,GSM1165877,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188121,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976158,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185418,GEO,GSM1165878,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188121,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977198,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185419,GEO,GSM1165879,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188121,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976268,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185420,GEO,GSM1165880,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188121,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977199,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185421,GEO,GSM1165881,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188122,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976159,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185422,GEO,GSM1165882,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188122,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977200,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185423,GEO,GSM1165883,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188122,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976269,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185424,GEO,GSM1165884,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188122,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977201,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185425,GEO,GSM1165885,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188123,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976160,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185426,GEO,GSM1165886,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188123,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977202,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185427,GEO,GSM1165887,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188123,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976270,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185428,GEO,GSM1165888,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188123,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977203,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185429,GEO,GSM1165889,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188124,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976161,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185430,GEO,GSM1165890,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188124,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977204,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185431,GEO,GSM1165891,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188124,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976271,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185432,GEO,GSM1165892,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188124,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977205,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185433,GEO,GSM1165893,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188125,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976162,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185434,GEO,GSM1165894,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188125,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976272,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185435,GEO,GSM1165895,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188125,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977206,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185436,GEO,GSM1165896,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188126,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976163,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185437,GEO,GSM1165897,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188126,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977207,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185438,GEO,GSM1165898,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188126,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976273,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185439,GEO,GSM1165899,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188126,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977208,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185440,GEO,GSM1165900,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188127,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976164,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185441,GEO,GSM1165901,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188127,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977209,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185442,GEO,GSM1165902,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188127,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976274,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185443,GEO,GSM1165903,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188127,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977210,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185444,GEO,GSM1165904,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188128,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976165,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185445,GEO,GSM1165905,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188128,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977211,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185446,GEO,GSM1165906,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188128,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976275,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185447,GEO,GSM1165907,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188128,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977212,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185448,GEO,GSM1165908,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188129,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976166,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185449,GEO,GSM1165909,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188129,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977213,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185450,GEO,GSM1165910,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188129,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976276,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185451,GEO,GSM1165911,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188129,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977214,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185452,GEO,GSM1165912,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188130,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976167,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185453,GEO,GSM1165913,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188130,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977215,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185454,GEO,GSM1165914,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188130,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976277,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185455,GEO,GSM1165915,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188130,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977216,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185456,GEO,GSM1165916,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188131,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976168,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185457,GEO,GSM1165917,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188131,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977217,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185458,GEO,GSM1165918,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188131,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976278,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185459,GEO,GSM1165919,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188131,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977218,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185460,GEO,GSM1165920,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188132,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976169,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185461,GEO,GSM1165921,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188132,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977219,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185462,GEO,GSM1165922,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188132,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976279,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185463,GEO,GSM1165923,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188132,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977220,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185464,GEO,GSM1165924,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188133,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976170,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1185465,GEO,GSM1165925,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188133,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977221,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1185466,GEO,GSM1165926,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188133,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS976280,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1185467,GEO,GSM1165927,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1276,Time series of global gene expression after trivalent influenza vaccination in humans,The relationship between gene expression patterns and humoral immune response to vaccination was analyzed in order to understand the interindividual variability among immune reponse to vaccination,18.2,40.2,SUB188133,Female,Not Specified,VO_0004809,2008-2009 trivalent influenza vaccine,BS977222,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1185468,GEO,GSM1165928,false,GSE48024,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE48024,Whole blood : NA,18.2 - 40.2
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188408,Not Specified,Not Specified,VO_0000071,Menactra,BS977552,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189750,GEO,GSM1261756,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188409,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977553,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189751,GEO,GSM1261759,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188410,Not Specified,Not Specified,VO_0000071,Menactra,BS977554,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189752,GEO,GSM1261762,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188411,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977555,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189753,GEO,GSM1261765,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188412,Not Specified,Not Specified,VO_0000071,Menactra,BS977556,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189754,GEO,GSM1261768,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188413,Not Specified,Not Specified,VO_0000071,Menactra,BS977557,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189755,GEO,GSM1261771,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188414,Not Specified,Not Specified,VO_0000071,Menactra,BS977558,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189756,GEO,GSM1261774,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188415,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977559,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189757,GEO,GSM1261777,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188416,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977560,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189758,GEO,GSM1261780,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188417,Not Specified,Not Specified,VO_0000071,Menactra,BS977561,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189759,GEO,GSM1261783,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188418,Not Specified,Not Specified,VO_0000071,Menactra,BS977562,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189760,GEO,GSM1261786,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188419,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977563,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189761,GEO,GSM1261789,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188420,Not Specified,Not Specified,VO_0000071,Menactra,BS977564,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189762,GEO,GSM1261792,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188421,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977565,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189763,GEO,GSM1261795,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188422,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977566,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189764,GEO,GSM1261798,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188423,Not Specified,Not Specified,VO_0000071,Menactra,BS977567,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189765,GEO,GSM1261801,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188424,Not Specified,Not Specified,VO_0000071,Menactra,BS977568,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189766,GEO,GSM1261804,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188425,Not Specified,Not Specified,VO_0000071,Menactra,BS977569,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189767,GEO,GSM1261807,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188426,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977570,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189768,GEO,GSM1261810,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188427,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977571,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189769,GEO,GSM1261813,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188428,Not Specified,Not Specified,VO_0000071,Menactra,BS977572,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189770,GEO,GSM1261816,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188429,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977573,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189771,GEO,GSM1261819,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188430,Not Specified,Not Specified,VO_0000071,Menactra,BS977574,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189772,GEO,GSM1261822,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188431,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977575,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189773,GEO,GSM1261825,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188432,Not Specified,Not Specified,VO_0000071,Menactra,BS977576,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189774,GEO,GSM1261828,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188433,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977577,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189775,GEO,GSM1261831,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188434,Not Specified,Not Specified,VO_0000071,Menactra,BS977578,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189776,GEO,GSM1261834,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188435,Not Specified,Not Specified,VO_0000071,Menactra,BS977579,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189777,GEO,GSM1261837,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188436,Not Specified,Not Specified,VO_0000071,Menactra,BS977580,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189778,GEO,GSM1261840,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188437,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977581,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189779,GEO,GSM1261843,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188408,Not Specified,Not Specified,VO_0000071,Menactra,BS977612,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189780,GEO,GSM1261757,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188409,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977613,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189781,GEO,GSM1261760,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188410,Not Specified,Not Specified,VO_0000071,Menactra,BS977614,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189782,GEO,GSM1261763,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188411,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977615,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189783,GEO,GSM1261766,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188412,Not Specified,Not Specified,VO_0000071,Menactra,BS977616,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189784,GEO,GSM1261769,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188413,Not Specified,Not Specified,VO_0000071,Menactra,BS977617,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189785,GEO,GSM1261772,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188414,Not Specified,Not Specified,VO_0000071,Menactra,BS977618,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189786,GEO,GSM1261775,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188415,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977619,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189787,GEO,GSM1261778,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188416,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977620,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189788,GEO,GSM1261781,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188417,Not Specified,Not Specified,VO_0000071,Menactra,BS977621,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189789,GEO,GSM1261784,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188418,Not Specified,Not Specified,VO_0000071,Menactra,BS977622,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189790,GEO,GSM1261787,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188419,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977623,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189791,GEO,GSM1261790,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188420,Not Specified,Not Specified,VO_0000071,Menactra,BS977624,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189792,GEO,GSM1261793,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188421,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977625,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189793,GEO,GSM1261796,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188422,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977626,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189794,GEO,GSM1261799,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188423,Not Specified,Not Specified,VO_0000071,Menactra,BS977627,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189795,GEO,GSM1261802,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188424,Not Specified,Not Specified,VO_0000071,Menactra,BS977628,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189796,GEO,GSM1261805,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188425,Not Specified,Not Specified,VO_0000071,Menactra,BS977629,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189797,GEO,GSM1261808,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188426,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977630,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189798,GEO,GSM1261811,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188427,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977631,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189799,GEO,GSM1261814,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188428,Not Specified,Not Specified,VO_0000071,Menactra,BS977632,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189800,GEO,GSM1261817,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188429,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977633,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189801,GEO,GSM1261820,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188430,Not Specified,Not Specified,VO_0000071,Menactra,BS977634,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189802,GEO,GSM1261823,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188431,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977635,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189803,GEO,GSM1261826,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188432,Not Specified,Not Specified,VO_0000071,Menactra,BS977636,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189804,GEO,GSM1261829,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188433,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977637,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189805,GEO,GSM1261832,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188434,Not Specified,Not Specified,VO_0000071,Menactra,BS977638,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189806,GEO,GSM1261835,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188435,Not Specified,Not Specified,VO_0000071,Menactra,BS977639,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189807,GEO,GSM1261838,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188436,Not Specified,Not Specified,VO_0000071,Menactra,BS977640,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189808,GEO,GSM1261841,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188437,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977641,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189809,GEO,GSM1261844,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188408,Not Specified,Not Specified,VO_0000071,Menactra,BS977672,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189810,GEO,GSM1261758,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188409,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977673,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189811,GEO,GSM1261761,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188410,Not Specified,Not Specified,VO_0000071,Menactra,BS977674,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189812,GEO,GSM1261764,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188411,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977675,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189813,GEO,GSM1261767,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188412,Not Specified,Not Specified,VO_0000071,Menactra,BS977676,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189814,GEO,GSM1261770,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188413,Not Specified,Not Specified,VO_0000071,Menactra,BS977677,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189815,GEO,GSM1261773,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188414,Not Specified,Not Specified,VO_0000071,Menactra,BS977678,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189816,GEO,GSM1261776,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188415,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977679,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189817,GEO,GSM1261779,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188416,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977680,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189818,GEO,GSM1261782,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188417,Not Specified,Not Specified,VO_0000071,Menactra,BS977681,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189819,GEO,GSM1261785,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188418,Not Specified,Not Specified,VO_0000071,Menactra,BS977682,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189820,GEO,GSM1261788,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188419,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977683,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189821,GEO,GSM1261791,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188420,Not Specified,Not Specified,VO_0000071,Menactra,BS977684,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189822,GEO,GSM1261794,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188421,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977685,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189823,GEO,GSM1261797,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188422,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977686,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189824,GEO,GSM1261800,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188423,Not Specified,Not Specified,VO_0000071,Menactra,BS977687,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189825,GEO,GSM1261803,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188424,Not Specified,Not Specified,VO_0000071,Menactra,BS977688,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189826,GEO,GSM1261806,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188425,Not Specified,Not Specified,VO_0000071,Menactra,BS977689,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189827,GEO,GSM1261809,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188426,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977690,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189828,GEO,GSM1261812,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188427,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977691,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189829,GEO,GSM1261815,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188428,Not Specified,Not Specified,VO_0000071,Menactra,BS977692,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189830,GEO,GSM1261818,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188429,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977693,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189831,GEO,GSM1261821,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188430,Not Specified,Not Specified,VO_0000071,Menactra,BS977694,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189832,GEO,GSM1261824,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188431,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977695,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189833,GEO,GSM1261827,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188432,Not Specified,Not Specified,VO_0000071,Menactra,BS977696,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189834,GEO,GSM1261830,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188433,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977697,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189835,GEO,GSM1261833,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188434,Not Specified,Not Specified,VO_0000071,Menactra,BS977698,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189836,GEO,GSM1261836,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188435,Not Specified,Not Specified,VO_0000071,Menactra,BS977699,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189837,GEO,GSM1261839,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188436,Not Specified,Not Specified,VO_0000071,Menactra,BS977700,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189838,GEO,GSM1261842,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1260,Correlation between human innate and adaptive immune responses to T-cell independent or dependent meningococcal vaccines.,"Thirty healthy adults (18-45 years of age) with no history of prior meningococcal vaccination and no contraindications to immunization will be vaccinated using either the meningococcal conjugate vaccine (MCV) or the meningococcal non-conjugate polysaccharide vaccine (MPSV). The study will be conducted as a randomized double blinded trial. Vaccine administration will be performed by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Blood samples will be collected on Days D0 (at enrollment) and D3, D7, D14, D30 and D180 post vaccination to study innate and adaptive immunity markers. Even though meningococcal vaccination is considered safe, volunteers are asked to report any local or systemic AEs for 30 days post vaccination and any SAEs for 180 days post vaccination.",18.0,45.0,SUB188437,Not Specified,Not Specified,VO_0010725,"Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C",BS977701,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189839,GEO,GSM1261845,false,GSE52245,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE52245,PBMC : NA,18.0 - 45.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS977942,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189892,GEO,GSM2184781,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS977943,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189893,GEO,GSM2184782,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS977944,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189894,GEO,GSM2184783,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS977945,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189895,GEO,GSM2184784,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS977946,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189896,GEO,GSM2184785,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS977947,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189897,GEO,GSM2184786,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS977948,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189898,GEO,GSM2184787,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS977949,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189899,GEO,GSM2184788,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS977950,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189900,GEO,GSM2184789,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS977951,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189901,GEO,GSM2184790,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS977952,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189902,GEO,GSM2184791,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS977953,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189903,GEO,GSM2184792,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS977954,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189904,GEO,GSM2184793,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS977955,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189905,GEO,GSM2184794,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS977956,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189906,GEO,GSM2184795,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS977957,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189907,GEO,GSM2184796,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS977958,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189908,GEO,GSM2184797,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS977959,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189909,GEO,GSM2184798,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS977960,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189910,GEO,GSM2184799,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS977961,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189911,GEO,GSM2184800,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188443,Male,Asian,VO_0003139,Stamaril,BS977962,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189912,GEO,GSM2184801,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188443,Male,Asian,VO_0003139,Stamaril,BS977963,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189913,GEO,GSM2184802,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188443,Male,Asian,VO_0003139,Stamaril,BS977964,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189914,GEO,GSM2184803,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188443,Male,Asian,VO_0003139,Stamaril,BS977965,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189915,GEO,GSM2184804,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188444,Female,Asian,VO_0003139,Stamaril,BS977966,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189916,GEO,GSM2184805,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188444,Female,Asian,VO_0003139,Stamaril,BS977967,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189917,GEO,GSM2184806,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188444,Female,Asian,VO_0003139,Stamaril,BS977968,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189918,GEO,GSM2184807,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188444,Female,Asian,VO_0003139,Stamaril,BS977969,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189919,GEO,GSM2184808,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188445,Male,Asian,VO_0003139,Stamaril,BS977970,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189920,GEO,GSM2184809,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188445,Male,Asian,VO_0003139,Stamaril,BS977971,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189921,GEO,GSM2184810,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188445,Male,Asian,VO_0003139,Stamaril,BS977972,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189922,GEO,GSM2184811,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188445,Male,Asian,VO_0003139,Stamaril,BS977973,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189923,GEO,GSM2184812,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188446,Female,Asian,VO_0003139,Stamaril,BS977974,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189924,GEO,GSM2184813,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188446,Female,Asian,VO_0003139,Stamaril,BS977975,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189925,GEO,GSM2184814,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188446,Female,Asian,VO_0003139,Stamaril,BS977976,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189926,GEO,GSM2184815,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188446,Female,Asian,VO_0003139,Stamaril,BS977977,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189927,GEO,GSM2184816,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188447,Female,Asian,VO_0003139,Stamaril,BS977978,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189928,GEO,GSM2184817,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188447,Female,Asian,VO_0003139,Stamaril,BS977979,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189929,GEO,GSM2184818,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188447,Female,Asian,VO_0003139,Stamaril,BS977980,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189930,GEO,GSM2184819,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188447,Female,Asian,VO_0003139,Stamaril,BS977981,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189931,GEO,GSM2184820,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188448,Female,Asian,VO_0003139,Stamaril,BS977982,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189932,GEO,GSM2184821,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188448,Female,Asian,VO_0003139,Stamaril,BS977983,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189933,GEO,GSM2184822,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188448,Female,Asian,VO_0003139,Stamaril,BS977984,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189934,GEO,GSM2184823,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188448,Female,Asian,VO_0003139,Stamaril,BS977985,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189935,GEO,GSM2184824,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188449,Female,Asian,VO_0003139,Stamaril,BS977986,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189936,GEO,GSM2184825,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188449,Female,Asian,VO_0003139,Stamaril,BS977987,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189937,GEO,GSM2184826,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188449,Female,Asian,VO_0003139,Stamaril,BS977988,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189938,GEO,GSM2184827,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188449,Female,Asian,VO_0003139,Stamaril,BS977989,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189939,GEO,GSM2184828,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188450,Female,Asian,VO_0003139,Stamaril,BS977990,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189940,GEO,GSM2184829,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188450,Female,Asian,VO_0003139,Stamaril,BS977991,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189941,GEO,GSM2184830,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188450,Female,Asian,VO_0003139,Stamaril,BS977992,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189942,GEO,GSM2184831,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188450,Female,Asian,VO_0003139,Stamaril,BS977993,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189943,GEO,GSM2184832,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188451,Male,Asian,VO_0003139,Stamaril,BS977994,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189944,GEO,GSM2184833,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188451,Male,Asian,VO_0003139,Stamaril,BS977995,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189945,GEO,GSM2184834,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188451,Male,Asian,VO_0003139,Stamaril,BS977996,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189946,GEO,GSM2184835,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188451,Male,Asian,VO_0003139,Stamaril,BS977997,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189947,GEO,GSM2184836,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188452,Male,Asian,VO_0003139,Stamaril,BS977998,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189948,GEO,GSM2184837,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188452,Male,Asian,VO_0003139,Stamaril,BS977999,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189949,GEO,GSM2184838,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188452,Male,Asian,VO_0003139,Stamaril,BS978000,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189950,GEO,GSM2184839,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188452,Male,Asian,VO_0003139,Stamaril,BS978001,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189951,GEO,GSM2184840,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188453,Male,Asian,VO_0003139,Stamaril,BS978002,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189952,GEO,GSM2184841,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188453,Male,Asian,VO_0003139,Stamaril,BS978003,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189953,GEO,GSM2184842,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188453,Male,Asian,VO_0003139,Stamaril,BS978004,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189954,GEO,GSM2184843,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188453,Male,Asian,VO_0003139,Stamaril,BS978005,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189955,GEO,GSM2184844,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188454,Male,Asian,VO_0003139,Stamaril,BS978006,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189956,GEO,GSM2184845,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188454,Male,Asian,VO_0003139,Stamaril,BS978007,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189957,GEO,GSM2184846,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188454,Male,Asian,VO_0003139,Stamaril,BS978008,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189958,GEO,GSM2184847,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188454,Male,Asian,VO_0003139,Stamaril,BS978009,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189959,GEO,GSM2184848,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188455,Male,Asian,VO_0003139,Stamaril,BS978010,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189960,GEO,GSM2184849,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188455,Male,Asian,VO_0003139,Stamaril,BS978011,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189961,GEO,GSM2184850,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188455,Male,Asian,VO_0003139,Stamaril,BS978012,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189962,GEO,GSM2184851,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188455,Male,Asian,VO_0003139,Stamaril,BS978013,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189963,GEO,GSM2184852,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188456,Female,Asian,VO_0003139,Stamaril,BS978014,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189964,GEO,GSM2184853,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188456,Female,Asian,VO_0003139,Stamaril,BS978015,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189965,GEO,GSM2184854,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188456,Female,Asian,VO_0003139,Stamaril,BS978016,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189966,GEO,GSM2184855,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188456,Female,Asian,VO_0003139,Stamaril,BS978017,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189967,GEO,GSM2184856,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188457,Male,Asian,VO_0003139,Stamaril,BS978018,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189968,GEO,GSM2184857,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188457,Male,Asian,VO_0003139,Stamaril,BS978019,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189969,GEO,GSM2184858,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188457,Male,Asian,VO_0003139,Stamaril,BS978020,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189970,GEO,GSM2184859,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188457,Male,Asian,VO_0003139,Stamaril,BS978021,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189971,GEO,GSM2184860,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188458,Female,Asian,VO_0003139,Stamaril,BS978022,0.0,Days,Time of initial vaccine administration,PBMC,,ES1189972,GEO,GSM2184861,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188458,Female,Asian,VO_0003139,Stamaril,BS978023,0.16,Days,Time of initial vaccine administration,PBMC,,ES1189973,GEO,GSM2184862,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188458,Female,Asian,VO_0003139,Stamaril,BS978024,7.0,Days,Time of initial vaccine administration,PBMC,,ES1189974,GEO,GSM2184863,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188458,Female,Asian,VO_0003139,Stamaril,BS978025,28.0,Days,Time of initial vaccine administration,PBMC,,ES1189975,GEO,GSM2184864,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS978026,1.0,Days,Time of initial vaccine administration,PBMC,,ES1189976,GEO,GSM2184865,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS978027,2.0,Days,Time of initial vaccine administration,PBMC,,ES1189977,GEO,GSM2184866,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS978028,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189978,GEO,GSM2184867,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS978029,5.0,Days,Time of initial vaccine administration,PBMC,,ES1189979,GEO,GSM2184868,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188438,Male,Asian,VO_0003139,Stamaril,BS978030,14.0,Days,Time of initial vaccine administration,PBMC,,ES1189980,GEO,GSM2184869,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS978031,1.0,Days,Time of initial vaccine administration,PBMC,,ES1189981,GEO,GSM2184870,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS978032,2.0,Days,Time of initial vaccine administration,PBMC,,ES1189982,GEO,GSM2184871,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS978033,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189983,GEO,GSM2184872,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS978034,5.0,Days,Time of initial vaccine administration,PBMC,,ES1189984,GEO,GSM2184873,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188439,Female,Asian,VO_0003139,Stamaril,BS978035,14.0,Days,Time of initial vaccine administration,PBMC,,ES1189985,GEO,GSM2184874,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS978036,1.0,Days,Time of initial vaccine administration,PBMC,,ES1189986,GEO,GSM2184875,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS978037,2.0,Days,Time of initial vaccine administration,PBMC,,ES1189987,GEO,GSM2184876,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS978038,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189988,GEO,GSM2184877,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS978039,5.0,Days,Time of initial vaccine administration,PBMC,,ES1189989,GEO,GSM2184878,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188440,Female,Asian,VO_0003139,Stamaril,BS978040,14.0,Days,Time of initial vaccine administration,PBMC,,ES1189990,GEO,GSM2184879,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS978041,1.0,Days,Time of initial vaccine administration,PBMC,,ES1189991,GEO,GSM2184880,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS978042,2.0,Days,Time of initial vaccine administration,PBMC,,ES1189992,GEO,GSM2184881,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS978043,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189993,GEO,GSM2184882,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS978044,5.0,Days,Time of initial vaccine administration,PBMC,,ES1189994,GEO,GSM2184883,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188441,Female,Asian,VO_0003139,Stamaril,BS978045,14.0,Days,Time of initial vaccine administration,PBMC,,ES1189995,GEO,GSM2184884,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS978046,1.0,Days,Time of initial vaccine administration,PBMC,,ES1189996,GEO,GSM2184885,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS978047,2.0,Days,Time of initial vaccine administration,PBMC,,ES1189997,GEO,GSM2184886,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS978048,3.0,Days,Time of initial vaccine administration,PBMC,,ES1189998,GEO,GSM2184887,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS978049,5.0,Days,Time of initial vaccine administration,PBMC,,ES1189999,GEO,GSM2184888,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1294,A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.,"In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity.",25.0,42.0,SUB188442,Male,Asian,VO_0003139,Stamaril,BS978050,14.0,Days,Time of initial vaccine administration,PBMC,,ES1190000,GEO,GSM2184889,false,GSE82152,GPL21975,[PrimeView] Affymetrix Human Gene Expression Array [Brainarray ENTREZG Version 17],GSE82152,PBMC : NA,25.0 - 42.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188636,Not Specified,Not Specified,VO_0003139,Stamaril,BS978397,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191003,GEO,GSM339820,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188636,Not Specified,Not Specified,VO_0003139,Stamaril,BS978398,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191004,GEO,GSM339821,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188636,Not Specified,Not Specified,VO_0003139,Stamaril,BS978399,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191005,GEO,GSM339822,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188637,Not Specified,Not Specified,VO_0003139,Stamaril,BS978400,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191006,GEO,GSM339823,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188637,Not Specified,Not Specified,VO_0003139,Stamaril,BS978401,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191007,GEO,GSM339824,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188637,Not Specified,Not Specified,VO_0003139,Stamaril,BS978402,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191008,GEO,GSM339825,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188638,Not Specified,Not Specified,VO_0003139,Stamaril,BS978403,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191009,GEO,GSM339826,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188638,Not Specified,Not Specified,VO_0003139,Stamaril,BS978404,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191010,GEO,GSM339827,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188638,Not Specified,Not Specified,VO_0003139,Stamaril,BS978405,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191011,GEO,GSM339828,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188639,Not Specified,Not Specified,VO_0003139,Stamaril,BS978406,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191012,GEO,GSM339829,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188639,Not Specified,Not Specified,VO_0003139,Stamaril,BS978407,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191013,GEO,GSM339830,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188639,Not Specified,Not Specified,VO_0003139,Stamaril,BS978408,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191014,GEO,GSM339831,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188640,Not Specified,Not Specified,VO_0003139,Stamaril,BS978409,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191015,GEO,GSM339832,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188640,Not Specified,Not Specified,VO_0003139,Stamaril,BS978410,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191016,GEO,GSM339833,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188640,Not Specified,Not Specified,VO_0003139,Stamaril,BS978411,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191017,GEO,GSM339834,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188641,Not Specified,Not Specified,VO_0003139,Stamaril,BS978412,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191018,GEO,GSM339835,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188641,Not Specified,Not Specified,VO_0003139,Stamaril,BS978413,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191019,GEO,GSM339836,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188641,Not Specified,Not Specified,VO_0003139,Stamaril,BS978414,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191020,GEO,GSM339837,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188642,Not Specified,Not Specified,VO_0003139,Stamaril,BS978415,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191021,GEO,GSM339838,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188642,Not Specified,Not Specified,VO_0003139,Stamaril,BS978416,1.0,Days,Time of initial vaccine administration,PBMC,,ES1191022,GEO,GSM339839,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188642,Not Specified,Not Specified,VO_0003139,Stamaril,BS978417,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191023,GEO,GSM339840,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188642,Not Specified,Not Specified,VO_0003139,Stamaril,BS978418,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191024,GEO,GSM339841,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188642,Not Specified,Not Specified,VO_0003139,Stamaril,BS978419,21.0,Days,Time of initial vaccine administration,PBMC,,ES1191025,GEO,GSM339842,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188643,Not Specified,Not Specified,VO_0003139,Stamaril,BS978420,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191026,GEO,GSM339843,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188643,Not Specified,Not Specified,VO_0003139,Stamaril,BS978421,1.0,Days,Time of initial vaccine administration,PBMC,,ES1191027,GEO,GSM339844,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188643,Not Specified,Not Specified,VO_0003139,Stamaril,BS978422,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191028,GEO,GSM339845,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188643,Not Specified,Not Specified,VO_0003139,Stamaril,BS978423,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191029,GEO,GSM339846,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188643,Not Specified,Not Specified,VO_0003139,Stamaril,BS978424,21.0,Days,Time of initial vaccine administration,PBMC,,ES1191030,GEO,GSM339847,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188644,Not Specified,Not Specified,VO_0003139,Stamaril,BS978425,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191031,GEO,GSM339848,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188644,Not Specified,Not Specified,VO_0003139,Stamaril,BS978426,1.0,Days,Time of initial vaccine administration,PBMC,,ES1191032,GEO,GSM339849,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188644,Not Specified,Not Specified,VO_0003139,Stamaril,BS978427,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191033,GEO,GSM339850,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188644,Not Specified,Not Specified,VO_0003139,Stamaril,BS978428,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191034,GEO,GSM339851,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188644,Not Specified,Not Specified,VO_0003139,Stamaril,BS978429,21.0,Days,Time of initial vaccine administration,PBMC,,ES1191035,GEO,GSM339852,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188645,Not Specified,Not Specified,VO_0003139,Stamaril,BS978430,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191036,GEO,GSM339853,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188645,Not Specified,Not Specified,VO_0003139,Stamaril,BS978431,1.0,Days,Time of initial vaccine administration,PBMC,,ES1191037,GEO,GSM339854,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188645,Not Specified,Not Specified,VO_0003139,Stamaril,BS978432,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191038,GEO,GSM339855,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188645,Not Specified,Not Specified,VO_0003139,Stamaril,BS978433,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191039,GEO,GSM339856,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188645,Not Specified,Not Specified,VO_0003139,Stamaril,BS978434,21.0,Days,Time of initial vaccine administration,PBMC,,ES1191040,GEO,GSM339857,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188646,Not Specified,Not Specified,VO_0003139,Stamaril,BS978435,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191041,GEO,GSM339858,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188646,Not Specified,Not Specified,VO_0003139,Stamaril,BS978436,1.0,Days,Time of initial vaccine administration,PBMC,,ES1191042,GEO,GSM339859,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188646,Not Specified,Not Specified,VO_0003139,Stamaril,BS978437,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191043,GEO,GSM339860,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188646,Not Specified,Not Specified,VO_0003139,Stamaril,BS978438,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191044,GEO,GSM339861,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188646,Not Specified,Not Specified,VO_0003139,Stamaril,BS978439,21.0,Days,Time of initial vaccine administration,PBMC,,ES1191045,GEO,GSM339862,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188647,Not Specified,Not Specified,VO_0003139,Stamaril,BS978440,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191046,GEO,GSM339863,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188647,Not Specified,Not Specified,VO_0003139,Stamaril,BS978441,1.0,Days,Time of initial vaccine administration,PBMC,,ES1191047,GEO,GSM339864,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188647,Not Specified,Not Specified,VO_0003139,Stamaril,BS978442,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191048,GEO,GSM339865,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188647,Not Specified,Not Specified,VO_0003139,Stamaril,BS978443,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191049,GEO,GSM339866,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188647,Not Specified,Not Specified,VO_0003139,Stamaril,BS978444,21.0,Days,Time of initial vaccine administration,PBMC,,ES1191050,GEO,GSM339867,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188648,Not Specified,Not Specified,VO_0003139,Stamaril,BS978445,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191051,GEO,GSM339868,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188648,Not Specified,Not Specified,VO_0003139,Stamaril,BS978446,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191052,GEO,GSM339869,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188648,Not Specified,Not Specified,VO_0003139,Stamaril,BS978447,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191053,GEO,GSM339870,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188649,Not Specified,Not Specified,VO_0003139,Stamaril,BS978448,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191054,GEO,GSM339871,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188649,Not Specified,Not Specified,VO_0003139,Stamaril,BS978449,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191055,GEO,GSM339872,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188649,Not Specified,Not Specified,VO_0003139,Stamaril,BS978450,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191056,GEO,GSM339873,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188650,Not Specified,Not Specified,VO_0003139,Stamaril,BS978451,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191057,GEO,GSM339874,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188650,Not Specified,Not Specified,VO_0003139,Stamaril,BS978452,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191058,GEO,GSM339875,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188650,Not Specified,Not Specified,VO_0003139,Stamaril,BS978453,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191059,GEO,GSM339876,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188651,Not Specified,Not Specified,VO_0003139,Stamaril,BS978454,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191060,GEO,GSM339877,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188651,Not Specified,Not Specified,VO_0003139,Stamaril,BS978455,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191061,GEO,GSM339878,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188651,Not Specified,Not Specified,VO_0003139,Stamaril,BS978456,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191062,GEO,GSM339879,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188652,Not Specified,Not Specified,VO_0003139,Stamaril,BS978457,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191063,GEO,GSM339880,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188652,Not Specified,Not Specified,VO_0003139,Stamaril,BS978458,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191064,GEO,GSM339881,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188652,Not Specified,Not Specified,VO_0003139,Stamaril,BS978459,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191065,GEO,GSM339882,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188653,Not Specified,Not Specified,VO_0003139,Stamaril,BS978460,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191066,GEO,GSM339883,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188653,Not Specified,Not Specified,VO_0003139,Stamaril,BS978461,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191067,GEO,GSM339884,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188653,Not Specified,Not Specified,VO_0003139,Stamaril,BS978462,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191068,GEO,GSM339885,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188654,Not Specified,Not Specified,VO_0003139,Stamaril,BS978463,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191069,GEO,GSM339886,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188654,Not Specified,Not Specified,VO_0003139,Stamaril,BS978464,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191070,GEO,GSM339887,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188654,Not Specified,Not Specified,VO_0003139,Stamaril,BS978465,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191071,GEO,GSM339888,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188655,Not Specified,Not Specified,VO_0003139,Stamaril,BS978466,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191072,GEO,GSM339889,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188655,Not Specified,Not Specified,VO_0003139,Stamaril,BS978467,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191073,GEO,GSM339890,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188655,Not Specified,Not Specified,VO_0003139,Stamaril,BS978468,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191074,GEO,GSM339891,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188656,Not Specified,Not Specified,VO_0003139,Stamaril,BS978469,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191075,GEO,GSM339892,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188656,Not Specified,Not Specified,VO_0003139,Stamaril,BS978470,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191076,GEO,GSM339893,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188656,Not Specified,Not Specified,VO_0003139,Stamaril,BS978471,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191077,GEO,GSM339894,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188657,Not Specified,Not Specified,VO_0003139,Stamaril,BS978472,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191078,GEO,GSM339895,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188657,Not Specified,Not Specified,VO_0003139,Stamaril,BS978473,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191079,GEO,GSM339896,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188657,Not Specified,Not Specified,VO_0003139,Stamaril,BS978474,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191080,GEO,GSM339897,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188658,Not Specified,Not Specified,VO_0003139,Stamaril,BS978475,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191081,GEO,GSM339898,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188658,Not Specified,Not Specified,VO_0003139,Stamaril,BS978476,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191082,GEO,GSM339899,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188658,Not Specified,Not Specified,VO_0003139,Stamaril,BS978477,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191083,GEO,GSM339900,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188659,Not Specified,Not Specified,VO_0003139,Stamaril,BS978478,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191084,GEO,GSM339901,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188659,Not Specified,Not Specified,VO_0003139,Stamaril,BS978479,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191085,GEO,GSM339902,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188659,Not Specified,Not Specified,VO_0003139,Stamaril,BS978480,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191086,GEO,GSM339903,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188660,Not Specified,Not Specified,VO_0003139,Stamaril,BS978481,0.0,Days,Time of initial vaccine administration,PBMC,,ES1191087,GEO,GSM339904,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188660,Not Specified,Not Specified,VO_0003139,Stamaril,BS978482,3.0,Days,Time of initial vaccine administration,PBMC,,ES1191088,GEO,GSM339905,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1264,Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene signatures that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4, an orchestrator of the integrated stress response that correlated with and predicted YF-17D CD8+ T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.",18.0,45.0,SUB188660,Not Specified,Not Specified,VO_0003139,Stamaril,BS978483,7.0,Days,Time of initial vaccine administration,PBMC,,ES1191089,GEO,GSM339906,false,GSE13485,GPL7567,Human Genome U133 Plus 2.0 Custom CDF Version 9,GSE13485,PBMC : NA,18.0 - 45.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983057,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199777,GEO,GSM999731,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983058,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199778,GEO,GSM999743,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983059,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199779,GEO,GSM999755,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983060,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199780,GEO,GSM999767,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983057,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199781,GEO,GSM999683,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983058,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199782,GEO,GSM999695,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983059,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199783,GEO,GSM999707,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983060,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199784,GEO,GSM999719,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983058,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199785,GEO,GSM999696,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983057,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199786,GEO,GSM999684,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983059,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199787,GEO,GSM999708,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983060,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199788,GEO,GSM999720,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983057,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199789,GEO,GSM999732,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983058,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199790,GEO,GSM999744,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983059,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199791,GEO,GSM999756,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983060,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199792,GEO,GSM999768,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192085,Not Specified,Not Specified,VO_0003120,MVA85A,BS983061,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199793,GEO,GSM999674,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192085,Not Specified,Not Specified,VO_0003120,MVA85A,BS983062,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199794,GEO,GSM999675,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192085,Not Specified,Not Specified,VO_0003120,MVA85A,BS983063,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199795,GEO,GSM999676,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192107,Not Specified,Not Specified,VO_0003120,MVA85A,BS983064,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199796,GEO,GSM999758,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192107,Not Specified,Not Specified,VO_0003120,MVA85A,BS983065,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199797,GEO,GSM999759,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192107,Not Specified,Not Specified,VO_0003120,MVA85A,BS983066,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199798,GEO,GSM999760,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192086,Not Specified,Not Specified,VO_0003120,MVA85A,BS983067,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199799,GEO,GSM999677,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192086,Not Specified,Not Specified,VO_0003120,MVA85A,BS983068,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199800,GEO,GSM999678,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192086,Not Specified,Not Specified,VO_0003120,MVA85A,BS983069,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199801,GEO,GSM999679,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192091,Not Specified,Not Specified,VO_0003120,MVA85A,BS983070,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199802,GEO,GSM999689,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192091,Not Specified,Not Specified,VO_0003120,MVA85A,BS983071,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199803,GEO,GSM999690,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192091,Not Specified,Not Specified,VO_0003120,MVA85A,BS983072,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199804,GEO,GSM999733,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192091,Not Specified,Not Specified,VO_0003120,MVA85A,BS983071,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199805,GEO,GSM999691,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192091,Not Specified,Not Specified,VO_0003120,MVA85A,BS983072,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199806,GEO,GSM999745,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192095,Not Specified,Not Specified,VO_0003120,MVA85A,BS983073,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199807,GEO,GSM999701,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192095,Not Specified,Not Specified,VO_0003120,MVA85A,BS983074,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199808,GEO,GSM999702,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192095,Not Specified,Not Specified,VO_0003120,MVA85A,BS983075,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199809,GEO,GSM999703,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192100,Not Specified,Not Specified,VO_0003120,MVA85A,BS983076,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199810,GEO,GSM999713,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192100,Not Specified,Not Specified,VO_0003120,MVA85A,BS983077,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199811,GEO,GSM999714,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192100,Not Specified,Not Specified,VO_0003120,MVA85A,BS983078,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199812,GEO,GSM999715,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192103,Not Specified,Not Specified,VO_0003120,MVA85A,BS983079,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199813,GEO,GSM999725,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192103,Not Specified,Not Specified,VO_0003120,MVA85A,BS983080,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199814,GEO,GSM999726,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192103,Not Specified,Not Specified,VO_0003120,MVA85A,BS983081,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199815,GEO,GSM999727,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983057,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199816,GEO,GSM999737,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983082,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199817,GEO,GSM999738,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192088,Not Specified,Not Specified,VO_0003120,MVA85A,BS983083,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199818,GEO,GSM999739,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983058,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199819,GEO,GSM999749,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983084,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199820,GEO,GSM999750,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192093,Not Specified,Not Specified,VO_0003120,MVA85A,BS983085,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199821,GEO,GSM999751,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192108,Not Specified,Not Specified,VO_0003120,MVA85A,BS983086,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199822,GEO,GSM999761,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192108,Not Specified,Not Specified,VO_0003120,MVA85A,BS983087,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199823,GEO,GSM999762,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192108,Not Specified,Not Specified,VO_0003120,MVA85A,BS983088,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199824,GEO,GSM999763,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192090,Not Specified,Not Specified,VO_0003120,MVA85A,BS983089,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199825,GEO,GSM999686,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192090,Not Specified,Not Specified,VO_0003120,MVA85A,BS983090,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199826,GEO,GSM999687,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192090,Not Specified,Not Specified,VO_0003120,MVA85A,BS983091,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199827,GEO,GSM999688,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192087,Not Specified,Not Specified,VO_0003120,MVA85A,BS983092,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199828,GEO,GSM999680,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192087,Not Specified,Not Specified,VO_0003120,MVA85A,BS983093,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199829,GEO,GSM999681,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192087,Not Specified,Not Specified,VO_0003120,MVA85A,BS983094,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199830,GEO,GSM999682,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192092,Not Specified,Not Specified,VO_0003120,MVA85A,BS983095,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199831,GEO,GSM999692,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192092,Not Specified,Not Specified,VO_0003120,MVA85A,BS983096,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199832,GEO,GSM999693,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192092,Not Specified,Not Specified,VO_0003120,MVA85A,BS983097,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199833,GEO,GSM999694,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192096,Not Specified,Not Specified,VO_0003120,MVA85A,BS983098,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199834,GEO,GSM999704,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192096,Not Specified,Not Specified,VO_0003120,MVA85A,BS983099,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199835,GEO,GSM999705,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192096,Not Specified,Not Specified,VO_0003120,MVA85A,BS983100,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199836,GEO,GSM999706,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192089,Not Specified,Not Specified,VO_0003120,MVA85A,BS983101,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199837,GEO,GSM999716,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192089,Not Specified,Not Specified,VO_0003120,MVA85A,BS983102,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199838,GEO,GSM999685,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192089,Not Specified,Not Specified,VO_0003120,MVA85A,BS983103,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199839,GEO,GSM999717,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192089,Not Specified,Not Specified,VO_0003120,MVA85A,BS983101,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199840,GEO,GSM999718,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192089,Not Specified,Not Specified,VO_0003120,MVA85A,BS983102,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199841,GEO,GSM999697,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192104,Not Specified,Not Specified,VO_0003120,MVA85A,BS983104,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199842,GEO,GSM999728,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192104,Not Specified,Not Specified,VO_0003120,MVA85A,BS983105,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199843,GEO,GSM999729,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192104,Not Specified,Not Specified,VO_0003120,MVA85A,BS983106,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199844,GEO,GSM999730,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983059,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199845,GEO,GSM999740,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983107,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199846,GEO,GSM999741,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192097,Not Specified,Not Specified,VO_0003120,MVA85A,BS983108,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199847,GEO,GSM999742,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983060,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199848,GEO,GSM999752,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983109,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199849,GEO,GSM999753,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983110,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199850,GEO,GSM999757,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983109,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199851,GEO,GSM999754,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192101,Not Specified,Not Specified,VO_0003120,MVA85A,BS983110,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199852,GEO,GSM999769,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192098,Not Specified,Not Specified,VO_0003120,MVA85A,BS983111,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199853,GEO,GSM999764,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192098,Not Specified,Not Specified,VO_0003120,MVA85A,BS983112,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199854,GEO,GSM999765,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192098,Not Specified,Not Specified,VO_0003120,MVA85A,BS983113,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199855,GEO,GSM999709,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192098,Not Specified,Not Specified,VO_0003120,MVA85A,BS983111,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199856,GEO,GSM999766,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192098,Not Specified,Not Specified,VO_0003120,MVA85A,BS983112,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199857,GEO,GSM999721,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192094,Not Specified,Not Specified,VO_0003120,MVA85A,BS983114,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199858,GEO,GSM999698,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192094,Not Specified,Not Specified,VO_0003120,MVA85A,BS983115,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199859,GEO,GSM999699,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192094,Not Specified,Not Specified,VO_0003120,MVA85A,BS983116,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199860,GEO,GSM999700,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192099,Not Specified,Not Specified,VO_0003120,MVA85A,BS983117,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199861,GEO,GSM999710,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192099,Not Specified,Not Specified,VO_0003120,MVA85A,BS983118,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199862,GEO,GSM999711,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192099,Not Specified,Not Specified,VO_0003120,MVA85A,BS983119,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199863,GEO,GSM999712,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192102,Not Specified,Not Specified,VO_0003120,MVA85A,BS983120,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199864,GEO,GSM999722,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192102,Not Specified,Not Specified,VO_0003120,MVA85A,BS983121,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199865,GEO,GSM999723,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192102,Not Specified,Not Specified,VO_0003120,MVA85A,BS983122,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199866,GEO,GSM999724,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192105,Not Specified,Not Specified,VO_0003120,MVA85A,BS983123,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199867,GEO,GSM999734,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192105,Not Specified,Not Specified,VO_0003120,MVA85A,BS983124,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199868,GEO,GSM999735,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192105,Not Specified,Not Specified,VO_0003120,MVA85A,BS983125,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199869,GEO,GSM999736,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192106,Not Specified,Not Specified,VO_0003120,MVA85A,BS983126,0.0,Days,Time of initial vaccine administration,PBMC,,ES1199870,GEO,GSM999746,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192106,Not Specified,Not Specified,VO_0003120,MVA85A,BS983127,2.0,Days,Time of initial vaccine administration,PBMC,,ES1199871,GEO,GSM999747,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1364,Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A,Characterization of early gene expression changes after MVA85A vaccination and connection to immune response mechanism and magnitude.,18.0,55.0,SUB192106,Not Specified,Not Specified,VO_0003120,MVA85A,BS983128,7.0,Days,Time of initial vaccine administration,PBMC,,ES1199872,GEO,GSM999748,false,GSE40719,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE40719,PBMC : NA,18.0 - 55.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188687,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983249,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200233,GEO,GSM563091,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188687,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983250,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200234,GEO,GSM563092,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188687,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983251,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200235,GEO,GSM563093,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188687,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983252,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200236,GEO,GSM563094,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188687,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983253,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200237,GEO,GSM563095,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188689,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983254,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200238,GEO,GSM563096,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188689,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983255,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200239,GEO,GSM563097,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188689,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983256,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200240,GEO,GSM563098,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188689,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983257,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200241,GEO,GSM563099,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188689,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983258,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200242,GEO,GSM563100,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188684,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983259,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200243,GEO,GSM563101,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188684,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983260,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200244,GEO,GSM563102,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188684,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983261,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200245,GEO,GSM563103,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188684,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983262,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200246,GEO,GSM563104,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188684,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983263,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200247,GEO,GSM563105,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188680,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983264,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200248,GEO,GSM563106,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188680,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983265,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200249,GEO,GSM563107,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188680,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983266,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200250,GEO,GSM563108,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188680,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983267,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200251,GEO,GSM563109,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188680,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983268,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200252,GEO,GSM563110,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188682,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983269,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200253,GEO,GSM563111,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188682,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983270,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200254,GEO,GSM563112,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188682,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983271,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200255,GEO,GSM563113,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188682,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983272,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200256,GEO,GSM563114,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188682,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983273,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200257,GEO,GSM563115,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188688,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983274,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200258,GEO,GSM563116,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188688,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983275,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200259,GEO,GSM563117,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188688,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983276,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200260,GEO,GSM563118,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188688,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983277,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200261,GEO,GSM563119,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188688,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983278,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200262,GEO,GSM563120,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188681,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983279,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200263,GEO,GSM563121,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188681,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983280,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200264,GEO,GSM563122,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188681,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983281,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200265,GEO,GSM563123,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188681,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983282,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200266,GEO,GSM563124,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188681,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983283,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200267,GEO,GSM563125,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188683,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983284,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200268,GEO,GSM563126,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188683,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983285,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200269,GEO,GSM563127,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188683,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983286,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200270,GEO,GSM563128,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188683,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983287,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200271,GEO,GSM563129,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188683,Female,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983288,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200272,GEO,GSM563130,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188685,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983289,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200273,GEO,GSM563131,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188685,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983290,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200274,GEO,GSM563132,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188685,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983291,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200275,GEO,GSM563133,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188685,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983292,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200276,GEO,GSM563134,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188685,Male,White,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983293,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200277,GEO,GSM563135,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188686,Male,Black or African American,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983294,0.0,Days,Time of initial vaccine administration,PBMC,,ES1200278,GEO,GSM563136,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188686,Male,Black or African American,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983295,0.25,Days,Time of initial vaccine administration,PBMC,,ES1200279,GEO,GSM563137,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188686,Male,Black or African American,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983296,1.0,Days,Time of initial vaccine administration,PBMC,,ES1200280,GEO,GSM563138,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188686,Male,Black or African American,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983297,3.0,Days,Time of initial vaccine administration,PBMC,,ES1200281,GEO,GSM563139,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1291,Merck Ad5/HIV induces broad innate immune activation that predicts CD8_ T-cell responses but is attenuated by preexisting Ad5 immunity.,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses.",22.0,43.0,SUB188686,Male,Black or African American,VO_0003133,MRKAd5 HIV-1 gag/pol/nef,BS983298,7.0,Days,Time of initial vaccine administration,PBMC,,ES1200282,GEO,GSM563140,false,GSE22768,GPL10647,"Affymetrix Human Exon 1.0 ST Array [CDF: Brainarray V 9.0, HsEx10stv2_Hs_ENTREZG]",GSE22768,PBMC : NA,22.0 - 43.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192172,Not Specified,Not Specified,VO_0001246,Menveo,BS983309,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200283,GEO,GSM2439287,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192172,Not Specified,Not Specified,VO_0001246,Menveo,BS983310,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200284,GEO,GSM2439296,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192172,Not Specified,Not Specified,VO_0001246,Menveo,BS983311,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200285,GEO,GSM2439311,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192173,Not Specified,Not Specified,VO_0001246,Menveo,BS983312,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200286,GEO,GSM2439261,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192173,Not Specified,Not Specified,VO_0001246,Menveo,BS983313,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200287,GEO,GSM2439272,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192173,Not Specified,Not Specified,VO_0001246,Menveo,BS983314,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200288,GEO,GSM2439275,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192174,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983315,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200289,GEO,GSM2439273,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192174,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983316,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200290,GEO,GSM2439279,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192174,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983317,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200291,GEO,GSM2439294,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192175,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983318,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200292,GEO,GSM2439286,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192175,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983319,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200293,GEO,GSM2439308,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192176,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983320,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200294,GEO,GSM2439259,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192176,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983321,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200295,GEO,GSM2439262,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192176,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983322,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200296,GEO,GSM2439288,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192177,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983323,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200297,GEO,GSM2439264,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192177,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983324,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200298,GEO,GSM2439298,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192177,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983325,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200299,GEO,GSM2439301,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192178,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983326,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200300,GEO,GSM2439277,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192178,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983327,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200301,GEO,GSM2439297,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192178,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983328,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200302,GEO,GSM2439305,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192179,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983329,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200303,GEO,GSM2439266,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192179,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983330,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200304,GEO,GSM2439290,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192179,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983331,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200305,GEO,GSM2439306,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192180,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983332,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200306,GEO,GSM2439258,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192180,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983333,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200307,GEO,GSM2439267,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192180,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983334,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200308,GEO,GSM2439315,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192181,Not Specified,Not Specified,VO_0001246,Menveo,BS983335,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200309,GEO,GSM2439265,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192181,Not Specified,Not Specified,VO_0001246,Menveo,BS983336,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200310,GEO,GSM2439285,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192181,Not Specified,Not Specified,VO_0001246,Menveo,BS983337,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200311,GEO,GSM2439316,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192182,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983338,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200312,GEO,GSM2439300,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192182,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983339,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200313,GEO,GSM2439313,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192182,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983340,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200314,GEO,GSM2439314,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192183,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983341,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200315,GEO,GSM2439280,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192183,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983342,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200316,GEO,GSM2439302,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192183,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983343,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200317,GEO,GSM2439303,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192184,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983344,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200318,GEO,GSM2439274,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192184,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983345,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200319,GEO,GSM2439282,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192184,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983346,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200320,GEO,GSM2439292,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192185,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983347,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200321,GEO,GSM2439268,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192185,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983348,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200322,GEO,GSM2439283,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192185,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983349,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200323,GEO,GSM2439310,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192186,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983350,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200324,GEO,GSM2439289,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192186,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983351,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200325,GEO,GSM2439304,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192186,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983352,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200326,GEO,GSM2439312,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192187,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983353,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200327,GEO,GSM2439278,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192187,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983354,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200328,GEO,GSM2439281,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192187,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983355,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200329,GEO,GSM2439291,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192188,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983356,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200330,GEO,GSM2439269,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192188,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983357,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200331,GEO,GSM2439270,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192188,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983358,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200332,GEO,GSM2439299,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192189,Not Specified,Not Specified,VO_0001246,Menveo,BS983359,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200333,GEO,GSM2439263,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192189,Not Specified,Not Specified,VO_0001246,Menveo,BS983360,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200334,GEO,GSM2439284,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192189,Not Specified,Not Specified,VO_0001246,Menveo,BS983361,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200335,GEO,GSM2439309,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192190,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983362,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200336,GEO,GSM2439271,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192190,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983363,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200337,GEO,GSM2439293,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192190,Not Specified,Not Specified,VO_0003138,ACWY Vax,BS983364,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200338,GEO,GSM2439295,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192191,Not Specified,Not Specified,VO_0001246,Menveo,BS983365,35.0,Days,Time of initial vaccine administration,Whole blood,,ES1200339,GEO,GSM2439260,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192191,Not Specified,Not Specified,VO_0001246,Menveo,BS983366,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1200340,GEO,GSM2439276,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY1325,B-cell responses to meningococcal vaccine.,Comparison of plain-polysaccharide and protein-polysaccharide conjugate vaccines.,30.0,70.0,SUB192191,Not Specified,Not Specified,VO_0001246,Menveo,BS983367,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1200341,GEO,GSM2439307,false,GSE92884,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE92884,Whole blood : NA,30.0 - 70.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112898,Female,White,VO_0000045,Fluarix,BS988500,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206982,GEO,GSM1934006,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112898,Female,White,VO_0000045,Fluarix,BS988501,3.0,Days,Time of initial vaccine administration,PBMC,,ES1206983,GEO,GSM1934007,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112898,Female,White,VO_0000045,Fluarix,BS988502,7.0,Days,Time of initial vaccine administration,PBMC,,ES1206984,GEO,GSM1934008,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112899,Female,White,VO_0000045,Fluarix,BS988503,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206985,GEO,GSM1934009,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112899,Female,White,VO_0000045,Fluarix,BS988504,3.0,Days,Time of initial vaccine administration,PBMC,,ES1206986,GEO,GSM1934010,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112899,Female,White,VO_0000045,Fluarix,BS988505,7.0,Days,Time of initial vaccine administration,PBMC,,ES1206987,GEO,GSM1934011,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112900,Female,Black or African American,VO_0000045,Fluarix,BS988506,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206988,GEO,GSM1934012,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112900,Female,Black or African American,VO_0000045,Fluarix,BS988507,3.0,Days,Time of initial vaccine administration,PBMC,,ES1206989,GEO,GSM1934013,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112900,Female,Black or African American,VO_0000045,Fluarix,BS988508,7.0,Days,Time of initial vaccine administration,PBMC,,ES1206990,GEO,GSM1934014,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112832,Male,White,VO_0000045,Fluarix,BS988509,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206991,GEO,GSM1934015,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112832,Male,White,VO_0000045,Fluarix,BS988510,7.0,Days,Time of initial vaccine administration,PBMC,,ES1206992,GEO,GSM1934016,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112834,Male,White,VO_0000045,Fluarix,BS988511,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206993,GEO,GSM1934017,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112834,Male,White,VO_0000045,Fluarix,BS988512,3.0,Days,Time of initial vaccine administration,PBMC,,ES1206994,GEO,GSM1934018,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112834,Male,White,VO_0000045,Fluarix,BS988513,7.0,Days,Time of initial vaccine administration,PBMC,,ES1206995,GEO,GSM1934019,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112841,Female,White,VO_0000045,Fluarix,BS988514,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206996,GEO,GSM1934020,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112841,Female,White,VO_0000045,Fluarix,BS988515,3.0,Days,Time of initial vaccine administration,PBMC,,ES1206997,GEO,GSM1934021,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112841,Female,White,VO_0000045,Fluarix,BS988516,7.0,Days,Time of initial vaccine administration,PBMC,,ES1206998,GEO,GSM1934022,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112843,Male,White,VO_0000045,Fluarix,BS988517,0.0,Days,Time of initial vaccine administration,PBMC,,ES1206999,GEO,GSM1934023,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112843,Male,White,VO_0000045,Fluarix,BS988518,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207000,GEO,GSM1934024,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112843,Male,White,VO_0000045,Fluarix,BS988519,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207001,GEO,GSM1934025,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112845,Female,White,VO_0000045,Fluarix,BS988520,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207002,GEO,GSM1934026,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112845,Female,White,VO_0000045,Fluarix,BS988521,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207003,GEO,GSM1934027,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112845,Female,White,VO_0000045,Fluarix,BS988522,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207004,GEO,GSM1934028,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS988523,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207005,GEO,GSM1934029,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS988524,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207006,GEO,GSM1934030,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS988525,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207007,GEO,GSM1934031,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS988526,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207008,GEO,GSM1934032,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS988527,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207009,GEO,GSM1934033,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS988528,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207010,GEO,GSM1934034,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112851,Female,Asian,VO_0000045,Fluarix,BS988529,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207011,GEO,GSM1934035,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112851,Female,Asian,VO_0000045,Fluarix,BS988530,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207012,GEO,GSM1934036,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112851,Female,Asian,VO_0000045,Fluarix,BS988531,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207013,GEO,GSM1934037,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS988532,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207014,GEO,GSM1934038,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS988533,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207015,GEO,GSM1934039,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS988534,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207016,GEO,GSM1934040,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112853,Female,White,VO_0000045,Fluarix,BS988535,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207017,GEO,GSM1934041,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112853,Female,White,VO_0000045,Fluarix,BS988536,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207018,GEO,GSM1934042,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112853,Female,White,VO_0000045,Fluarix,BS988537,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207019,GEO,GSM1934043,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112855,Female,Black or African American,VO_0000045,Fluarix,BS988538,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207020,GEO,GSM1934044,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112855,Female,Black or African American,VO_0000045,Fluarix,BS988539,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207021,GEO,GSM1934045,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112855,Female,Black or African American,VO_0000045,Fluarix,BS988540,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207022,GEO,GSM1934046,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112861,Male,White,VO_0000045,Fluarix,BS988541,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207023,GEO,GSM1934047,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112861,Male,White,VO_0000045,Fluarix,BS988542,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207024,GEO,GSM1934048,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112861,Male,White,VO_0000045,Fluarix,BS988543,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207025,GEO,GSM1934049,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS988544,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207026,GEO,GSM1934050,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS988545,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207027,GEO,GSM1934051,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS988546,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207028,GEO,GSM1934052,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112891,Female,Black or African American,VO_0000045,Fluarix,BS988547,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207029,GEO,GSM1934053,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112891,Female,Black or African American,VO_0000045,Fluarix,BS988548,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207030,GEO,GSM1934054,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112891,Female,Black or African American,VO_0000045,Fluarix,BS988549,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207031,GEO,GSM1934055,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112871,Female,Black or African American,VO_0000045,Fluarix,BS988550,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207032,GEO,GSM1934056,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112871,Female,Black or African American,VO_0000045,Fluarix,BS988551,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207033,GEO,GSM1934057,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112871,Female,Black or African American,VO_0000045,Fluarix,BS988552,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207034,GEO,GSM1934058,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112872,Female,White,VO_0000045,Fluarix,BS988553,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207035,GEO,GSM1934059,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112872,Female,White,VO_0000045,Fluarix,BS988554,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207036,GEO,GSM1934060,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112872,Female,White,VO_0000045,Fluarix,BS988555,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207037,GEO,GSM1934061,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112892,Male,White,VO_0000045,Fluarix,BS988556,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207038,GEO,GSM1934062,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112892,Male,White,VO_0000045,Fluarix,BS988557,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207039,GEO,GSM1934063,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112892,Male,White,VO_0000045,Fluarix,BS988558,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207040,GEO,GSM1934064,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112874,Female,White,VO_0000045,Fluarix,BS988559,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207041,GEO,GSM1934065,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112874,Female,White,VO_0000045,Fluarix,BS988560,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207042,GEO,GSM1934066,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112874,Female,White,VO_0000045,Fluarix,BS988561,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207043,GEO,GSM1934067,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112882,Female,White,VO_0000045,Fluarix,BS988562,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207044,GEO,GSM1934068,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112882,Female,White,VO_0000045,Fluarix,BS988563,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207045,GEO,GSM1934069,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112882,Female,White,VO_0000045,Fluarix,BS988564,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207046,GEO,GSM1934070,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112884,Male,White,VO_0000045,Fluarix,BS988565,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207047,GEO,GSM1934071,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112884,Male,White,VO_0000045,Fluarix,BS988566,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207048,GEO,GSM1934072,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112884,Male,White,VO_0000045,Fluarix,BS988567,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207049,GEO,GSM1934073,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112887,Female,White,VO_0000045,Fluarix,BS988568,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207050,GEO,GSM1934074,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112887,Female,White,VO_0000045,Fluarix,BS988569,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207051,GEO,GSM1934075,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112887,Female,White,VO_0000045,Fluarix,BS988570,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207052,GEO,GSM1934076,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112893,Female,Asian,VO_0000045,Fluarix,BS988571,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207053,GEO,GSM1934077,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112893,Female,Asian,VO_0000045,Fluarix,BS988572,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207054,GEO,GSM1934078,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112893,Female,Asian,VO_0000045,Fluarix,BS988573,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207055,GEO,GSM1934079,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112895,Female,Black or African American,VO_0000045,Fluarix,BS988574,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207056,GEO,GSM1934080,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112895,Female,Black or African American,VO_0000045,Fluarix,BS988575,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207057,GEO,GSM1934081,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112895,Female,Black or African American,VO_0000045,Fluarix,BS988576,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207058,GEO,GSM1934082,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112896,Female,White,VO_0000045,Fluarix,BS988577,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207059,GEO,GSM1934083,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112896,Female,White,VO_0000045,Fluarix,BS988578,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207060,GEO,GSM1934084,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112896,Female,White,VO_0000045,Fluarix,BS988579,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207061,GEO,GSM1934085,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112897,Male,White,VO_0000045,Fluarix,BS988580,0.0,Days,Time of initial vaccine administration,PBMC,,ES1207062,GEO,GSM1934086,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112897,Male,White,VO_0000045,Fluarix,BS988581,3.0,Days,Time of initial vaccine administration,PBMC,,ES1207063,GEO,GSM1934087,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY270,Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.,21.0,47.0,SUB112897,Male,White,VO_0000045,Fluarix,BS988582,7.0,Days,Time of initial vaccine administration,PBMC,,ES1207064,GEO,GSM1934088,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,21.0 - 47.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192109,Female,Not Specified,VO_0000124,Zostavax,BS988639,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207233,GEO,GSM2300413,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192109,Female,Not Specified,VO_0000124,Zostavax,BS988640,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207234,GEO,GSM2300408,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192110,Female,Not Specified,VO_0000124,Zostavax,BS988641,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207235,GEO,GSM2300402,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192110,Female,Not Specified,VO_0000124,Zostavax,BS988642,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207236,GEO,GSM2300403,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192111,Male,Not Specified,VO_0000124,Zostavax,BS988643,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207237,GEO,GSM2300398,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192111,Male,Not Specified,VO_0000124,Zostavax,BS988644,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207238,GEO,GSM2300399,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192112,Male,Not Specified,VO_0000124,Zostavax,BS988645,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207239,GEO,GSM2300411,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192112,Male,Not Specified,VO_0000124,Zostavax,BS988646,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207240,GEO,GSM2300406,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192113,Male,Not Specified,VO_0000124,Zostavax,BS988647,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207241,GEO,GSM2300412,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192113,Male,Not Specified,VO_0000124,Zostavax,BS988648,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207242,GEO,GSM2300397,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192114,Female,Not Specified,VO_0000124,Zostavax,BS988649,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207243,GEO,GSM2300396,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192114,Female,Not Specified,VO_0000124,Zostavax,BS988650,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207244,GEO,GSM2300407,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192115,Female,Not Specified,VO_0000124,Zostavax,BS988651,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207245,GEO,GSM2300401,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192115,Female,Not Specified,VO_0000124,Zostavax,BS988652,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207246,GEO,GSM2300400,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192116,Female,Not Specified,VO_0000124,Zostavax,BS988653,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207247,GEO,GSM2300409,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192116,Female,Not Specified,VO_0000124,Zostavax,BS988654,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207248,GEO,GSM2300410,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192117,Female,Not Specified,VO_0000124,Zostavax,BS988655,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207249,GEO,GSM2300404,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192117,Female,Not Specified,VO_0000124,Zostavax,BS988656,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207250,GEO,GSM2300405,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192118,Female,Not Specified,VO_0000124,Zostavax,BS988657,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207251,GEO,GSM2300391,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192118,Female,Not Specified,VO_0000124,Zostavax,BS988658,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207252,GEO,GSM2300394,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192119,Male,Not Specified,VO_0000124,Zostavax,BS988659,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207253,GEO,GSM2300389,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192119,Male,Not Specified,VO_0000124,Zostavax,BS988660,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207254,GEO,GSM2300382,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192120,Female,Not Specified,VO_0000124,Zostavax,BS988661,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207255,GEO,GSM2300379,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192120,Female,Not Specified,VO_0000124,Zostavax,BS988662,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207256,GEO,GSM2300383,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192121,Male,Not Specified,VO_0000124,Zostavax,BS988663,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207257,GEO,GSM2300384,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192121,Male,Not Specified,VO_0000124,Zostavax,BS988664,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207258,GEO,GSM2300387,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192122,Female,Not Specified,VO_0000124,Zostavax,BS988665,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207259,GEO,GSM2300393,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192122,Female,Not Specified,VO_0000124,Zostavax,BS988666,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207260,GEO,GSM2300392,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192123,Female,Not Specified,VO_0000124,Zostavax,BS988667,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207261,GEO,GSM2300385,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192123,Female,Not Specified,VO_0000124,Zostavax,BS988668,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207262,GEO,GSM2300381,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192124,Male,Not Specified,VO_0000124,Zostavax,BS988669,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207263,GEO,GSM2300395,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192124,Male,Not Specified,VO_0000124,Zostavax,BS988670,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207264,GEO,GSM2300386,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192125,Female,Not Specified,VO_0000124,Zostavax,BS988671,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207265,GEO,GSM2300378,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192125,Female,Not Specified,VO_0000124,Zostavax,BS988672,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207266,GEO,GSM2300380,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192126,Male,Not Specified,VO_0000124,Zostavax,BS988673,0.0,Days,Time of initial vaccine administration,Whole blood,,ES1207267,GEO,GSM2300388,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1368,Systems Biology of Varicella Zoster Vaccination,Comparison of VZV vaccination in individuals of different ages to decipher the molecular mechanisms underlying variable vaccine responses.,51.0,75.0,SUB192126,Male,Not Specified,VO_0000124,Zostavax,BS988674,1.0,Days,Time of initial vaccine administration,Whole blood,,ES1207268,GEO,GSM2300390,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Whole blood : NA,51.0 - 75.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205388,Female,Black or African American,VO_0000121,YF-Vax,BS1028391,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262322,GEO,GSM4041840,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205388,Female,Black or African American,VO_0000121,YF-Vax,BS1028392,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262323,GEO,GSM4041838,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205388,Female,Black or African American,VO_0000121,YF-Vax,BS1028393,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262324,GEO,GSM4041839,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205388,Female,Black or African American,VO_0000121,YF-Vax,BS1028394,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262325,GEO,GSM4041841,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205387,Male,Black or African American,VO_0000121,YF-Vax,BS1028396,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262327,GEO,GSM4041836,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205387,Male,Black or African American,VO_0000121,YF-Vax,BS1028397,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262328,GEO,GSM4041837,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205387,Male,Black or African American,VO_0000121,YF-Vax,BS1028398,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262329,GEO,GSM4041834,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205387,Male,Black or African American,VO_0000121,YF-Vax,BS1028399,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262330,GEO,GSM4041835,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205393,Male,Black or African American,VO_0000121,YF-Vax,BS1028401,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262332,GEO,GSM4041861,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205393,Male,Black or African American,VO_0000121,YF-Vax,BS1028402,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262333,GEO,GSM4041858,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205393,Male,Black or African American,VO_0000121,YF-Vax,BS1028403,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262334,GEO,GSM4041860,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205393,Male,Black or African American,VO_0000121,YF-Vax,BS1028404,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262335,GEO,GSM4041859,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205399,Male,Black or African American,VO_0000121,YF-Vax,BS1028406,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262337,GEO,GSM4041882,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205399,Male,Black or African American,VO_0000121,YF-Vax,BS1028407,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262338,GEO,GSM4041883,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205399,Male,Black or African American,VO_0000121,YF-Vax,BS1028408,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262339,GEO,GSM4041884,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205399,Male,Black or African American,VO_0000121,YF-Vax,BS1028409,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262340,GEO,GSM4041885,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205413,Female,Black or African American,VO_0000121,YF-Vax,BS1028411,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262342,GEO,GSM4041939,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205413,Female,Black or African American,VO_0000121,YF-Vax,BS1028412,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262343,GEO,GSM4041938,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205413,Female,Black or African American,VO_0000121,YF-Vax,BS1028413,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262344,GEO,GSM4041941,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205413,Female,Black or African American,VO_0000121,YF-Vax,BS1028414,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262345,GEO,GSM4041940,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205391,Male,Black or African American,VO_0000121,YF-Vax,BS1028416,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262347,GEO,GSM4041852,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205391,Male,Black or African American,VO_0000121,YF-Vax,BS1028417,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262348,GEO,GSM4041850,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205391,Male,Black or African American,VO_0000121,YF-Vax,BS1028418,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262349,GEO,GSM4041853,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205391,Male,Black or African American,VO_0000121,YF-Vax,BS1028419,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262350,GEO,GSM4041851,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205405,Male,Black or African American,VO_0000121,YF-Vax,BS1028421,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262352,GEO,GSM4041907,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205405,Male,Black or African American,VO_0000121,YF-Vax,BS1028422,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262353,GEO,GSM4041909,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205405,Male,Black or African American,VO_0000121,YF-Vax,BS1028423,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262354,GEO,GSM4041906,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205405,Male,Black or African American,VO_0000121,YF-Vax,BS1028424,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262355,GEO,GSM4041908,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205406,Male,Black or African American,VO_0000121,YF-Vax,BS1028426,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262357,GEO,GSM4041910,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205406,Male,Black or African American,VO_0000121,YF-Vax,BS1028427,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262358,GEO,GSM4041912,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205406,Male,Black or African American,VO_0000121,YF-Vax,BS1028428,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262359,GEO,GSM4041911,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205406,Male,Black or African American,VO_0000121,YF-Vax,BS1028429,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262360,GEO,GSM4041913,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205408,Female,Black or African American,VO_0000121,YF-Vax,BS1028431,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262362,GEO,GSM4041920,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205408,Female,Black or African American,VO_0000121,YF-Vax,BS1028432,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262363,GEO,GSM4041918,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205408,Female,Black or African American,VO_0000121,YF-Vax,BS1028433,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262364,GEO,GSM4041919,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205408,Female,Black or African American,VO_0000121,YF-Vax,BS1028434,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262365,GEO,GSM4041921,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205396,Male,Black or African American,VO_0000121,YF-Vax,BS1028436,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262367,GEO,GSM4041870,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205396,Male,Black or African American,VO_0000121,YF-Vax,BS1028437,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262368,GEO,GSM4041871,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205396,Male,Black or African American,VO_0000121,YF-Vax,BS1028438,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262369,GEO,GSM4041872,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205396,Male,Black or African American,VO_0000121,YF-Vax,BS1028439,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262370,GEO,GSM4041873,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205407,Male,Black or African American,VO_0000121,YF-Vax,BS1028441,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262372,GEO,GSM4041917,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205407,Male,Black or African American,VO_0000121,YF-Vax,BS1028442,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262373,GEO,GSM4041916,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205407,Male,Black or African American,VO_0000121,YF-Vax,BS1028443,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262374,GEO,GSM4041915,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205407,Male,Black or African American,VO_0000121,YF-Vax,BS1028444,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262375,GEO,GSM4041914,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205390,Male,Black or African American,VO_0000121,YF-Vax,BS1028446,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262377,GEO,GSM4041849,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205390,Male,Black or African American,VO_0000121,YF-Vax,BS1028447,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262378,GEO,GSM4041846,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205390,Male,Black or African American,VO_0000121,YF-Vax,BS1028448,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262379,GEO,GSM4041847,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205390,Male,Black or African American,VO_0000121,YF-Vax,BS1028449,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262380,GEO,GSM4041848,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205404,Male,Black or African American,VO_0000121,YF-Vax,BS1028451,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262382,GEO,GSM4041905,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205404,Male,Black or African American,VO_0000121,YF-Vax,BS1028452,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262383,GEO,GSM4041904,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205404,Male,Black or African American,VO_0000121,YF-Vax,BS1028453,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262384,GEO,GSM4041902,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205404,Male,Black or African American,VO_0000121,YF-Vax,BS1028454,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262385,GEO,GSM4041903,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205416,Female,Black or African American,VO_0000121,YF-Vax,BS1028456,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262387,GEO,GSM4041953,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205416,Female,Black or African American,VO_0000121,YF-Vax,BS1028457,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262388,GEO,GSM4041952,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205416,Female,Black or African American,VO_0000121,YF-Vax,BS1028458,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262389,GEO,GSM4041951,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205416,Female,Black or African American,VO_0000121,YF-Vax,BS1028459,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262390,GEO,GSM4041950,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205415,Female,Black or African American,VO_0000121,YF-Vax,BS1028461,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262392,GEO,GSM4041949,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205415,Female,Black or African American,VO_0000121,YF-Vax,BS1028462,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262393,GEO,GSM4041948,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205415,Female,Black or African American,VO_0000121,YF-Vax,BS1028463,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262394,GEO,GSM4041946,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205415,Female,Black or African American,VO_0000121,YF-Vax,BS1028464,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262395,GEO,GSM4041947,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205414,Female,Black or African American,VO_0000121,YF-Vax,BS1028466,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262397,GEO,GSM4041943,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205414,Female,Black or African American,VO_0000121,YF-Vax,BS1028467,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262398,GEO,GSM4041945,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205414,Female,Black or African American,VO_0000121,YF-Vax,BS1028468,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262399,GEO,GSM4041944,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205414,Female,Black or African American,VO_0000121,YF-Vax,BS1028469,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262400,GEO,GSM4041942,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205417,Female,Black or African American,VO_0000121,YF-Vax,BS1028471,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262402,GEO,GSM4041957,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205417,Female,Black or African American,VO_0000121,YF-Vax,BS1028472,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262403,GEO,GSM4041955,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205417,Female,Black or African American,VO_0000121,YF-Vax,BS1028473,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262404,GEO,GSM4041954,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205417,Female,Black or African American,VO_0000121,YF-Vax,BS1028474,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262405,GEO,GSM4041956,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205418,Female,Black or African American,VO_0000121,YF-Vax,BS1028476,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262407,GEO,GSM4041960,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205418,Female,Black or African American,VO_0000121,YF-Vax,BS1028477,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262408,GEO,GSM4041961,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205418,Female,Black or African American,VO_0000121,YF-Vax,BS1028478,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262409,GEO,GSM4041959,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205418,Female,Black or African American,VO_0000121,YF-Vax,BS1028479,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262410,GEO,GSM4041958,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205392,Male,Black or African American,VO_0000121,YF-Vax,BS1028481,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262412,GEO,GSM4041856,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205392,Male,Black or African American,VO_0000121,YF-Vax,BS1028482,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262413,GEO,GSM4041854,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205392,Male,Black or African American,VO_0000121,YF-Vax,BS1028483,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262414,GEO,GSM4041855,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205392,Male,Black or African American,VO_0000121,YF-Vax,BS1028484,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262415,GEO,GSM4041857,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205403,Male,Black or African American,VO_0000121,YF-Vax,BS1028486,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262417,GEO,GSM4041901,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205403,Male,Black or African American,VO_0000121,YF-Vax,BS1028487,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262418,GEO,GSM4041898,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205403,Male,Black or African American,VO_0000121,YF-Vax,BS1028488,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262419,GEO,GSM4041899,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205403,Male,Black or African American,VO_0000121,YF-Vax,BS1028489,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262420,GEO,GSM4041900,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205398,Male,Black or African American,VO_0000121,YF-Vax,BS1028491,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262422,GEO,GSM4041878,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205398,Male,Black or African American,VO_0000121,YF-Vax,BS1028492,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262423,GEO,GSM4041879,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205398,Male,Black or African American,VO_0000121,YF-Vax,BS1028493,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262424,GEO,GSM4041881,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205398,Male,Black or African American,VO_0000121,YF-Vax,BS1028494,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262425,GEO,GSM4041880,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205409,Male,Black or African American,VO_0000121,YF-Vax,BS1028496,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262427,GEO,GSM4041924,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205409,Male,Black or African American,VO_0000121,YF-Vax,BS1028497,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262428,GEO,GSM4041922,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205409,Male,Black or African American,VO_0000121,YF-Vax,BS1028498,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262429,GEO,GSM4041923,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205409,Male,Black or African American,VO_0000121,YF-Vax,BS1028499,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262430,GEO,GSM4041925,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205394,Male,Black or African American,VO_0000121,YF-Vax,BS1028501,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262432,GEO,GSM4041864,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205394,Male,Black or African American,VO_0000121,YF-Vax,BS1028502,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262433,GEO,GSM4041863,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205394,Male,Black or African American,VO_0000121,YF-Vax,BS1028503,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262434,GEO,GSM4041862,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205394,Male,Black or African American,VO_0000121,YF-Vax,BS1028504,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262435,GEO,GSM4041865,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205419,Female,Black or African American,VO_0000121,YF-Vax,BS1028506,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262437,GEO,GSM4041964,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205419,Female,Black or African American,VO_0000121,YF-Vax,BS1028507,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262438,GEO,GSM4041965,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205419,Female,Black or African American,VO_0000121,YF-Vax,BS1028508,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262439,GEO,GSM4041963,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205419,Female,Black or African American,VO_0000121,YF-Vax,BS1028509,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262440,GEO,GSM4041962,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205420,Female,Black or African American,VO_0000121,YF-Vax,BS1028511,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262442,GEO,GSM4041968,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205420,Female,Black or African American,VO_0000121,YF-Vax,BS1028512,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262443,GEO,GSM4041969,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205420,Female,Black or African American,VO_0000121,YF-Vax,BS1028513,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262444,GEO,GSM4041967,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205420,Female,Black or African American,VO_0000121,YF-Vax,BS1028514,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262445,GEO,GSM4041966,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205410,Male,Black or African American,VO_0000121,YF-Vax,BS1028516,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262447,GEO,GSM4041927,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205410,Male,Black or African American,VO_0000121,YF-Vax,BS1028517,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262448,GEO,GSM4041928,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205410,Male,Black or African American,VO_0000121,YF-Vax,BS1028518,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262449,GEO,GSM4041929,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205410,Male,Black or African American,VO_0000121,YF-Vax,BS1028519,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262450,GEO,GSM4041926,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205412,Female,Black or African American,VO_0000121,YF-Vax,BS1028521,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262452,GEO,GSM4041936,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205412,Female,Black or African American,VO_0000121,YF-Vax,BS1028522,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262453,GEO,GSM4041934,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205412,Female,Black or African American,VO_0000121,YF-Vax,BS1028523,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262454,GEO,GSM4041937,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205412,Female,Black or African American,VO_0000121,YF-Vax,BS1028524,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262455,GEO,GSM4041935,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205395,Male,Black or African American,VO_0000121,YF-Vax,BS1028526,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262457,GEO,GSM4041866,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205395,Male,Black or African American,VO_0000121,YF-Vax,BS1028527,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262458,GEO,GSM4041868,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205395,Male,Black or African American,VO_0000121,YF-Vax,BS1028528,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262459,GEO,GSM4041869,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205395,Male,Black or African American,VO_0000121,YF-Vax,BS1028529,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262460,GEO,GSM4041867,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205397,Female,Black or African American,VO_0000121,YF-Vax,BS1028531,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262462,GEO,GSM4041875,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205397,Female,Black or African American,VO_0000121,YF-Vax,BS1028532,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262463,GEO,GSM4041876,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205397,Female,Black or African American,VO_0000121,YF-Vax,BS1028533,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262464,GEO,GSM4041874,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205397,Female,Black or African American,VO_0000121,YF-Vax,BS1028534,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262465,GEO,GSM4041877,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205421,Female,Black or African American,VO_0000121,YF-Vax,BS1028536,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262467,GEO,GSM4041973,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205421,Female,Black or African American,VO_0000121,YF-Vax,BS1028537,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262468,GEO,GSM4041970,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205421,Female,Black or African American,VO_0000121,YF-Vax,BS1028538,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262469,GEO,GSM4041972,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205421,Female,Black or African American,VO_0000121,YF-Vax,BS1028539,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262470,GEO,GSM4041971,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205389,Male,Black or African American,VO_0000121,YF-Vax,BS1028541,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262472,GEO,GSM4041844,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205389,Male,Black or African American,VO_0000121,YF-Vax,BS1028542,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262473,GEO,GSM4041842,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205389,Male,Black or African American,VO_0000121,YF-Vax,BS1028543,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262474,GEO,GSM4041843,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205389,Male,Black or African American,VO_0000121,YF-Vax,BS1028544,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262475,GEO,GSM4041845,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205402,Female,Black or African American,VO_0000121,YF-Vax,BS1028546,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262477,GEO,GSM4041895,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205402,Female,Black or African American,VO_0000121,YF-Vax,BS1028547,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262478,GEO,GSM4041896,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205402,Female,Black or African American,VO_0000121,YF-Vax,BS1028548,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262479,GEO,GSM4041894,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205402,Female,Black or African American,VO_0000121,YF-Vax,BS1028549,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262480,GEO,GSM4041897,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205400,Male,Black or African American,VO_0000121,YF-Vax,BS1028551,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262482,GEO,GSM4041886,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205400,Male,Black or African American,VO_0000121,YF-Vax,BS1028552,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262483,GEO,GSM4041888,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205400,Male,Black or African American,VO_0000121,YF-Vax,BS1028553,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262484,GEO,GSM4041889,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205400,Male,Black or African American,VO_0000121,YF-Vax,BS1028554,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262485,GEO,GSM4041887,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205386,Male,Black or African American,VO_0000121,YF-Vax,BS1028556,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262487,GEO,GSM4041832,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205386,Male,Black or African American,VO_0000121,YF-Vax,BS1028557,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262488,GEO,GSM4041831,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205386,Male,Black or African American,VO_0000121,YF-Vax,BS1028558,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262489,GEO,GSM4041830,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205386,Male,Black or African American,VO_0000121,YF-Vax,BS1028559,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262490,GEO,GSM4041833,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205411,Female,Black or African American,VO_0000121,YF-Vax,BS1028561,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262492,GEO,GSM4041932,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205411,Female,Black or African American,VO_0000121,YF-Vax,BS1028562,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262493,GEO,GSM4041931,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205411,Female,Black or African American,VO_0000121,YF-Vax,BS1028563,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262494,GEO,GSM4041930,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205411,Female,Black or African American,VO_0000121,YF-Vax,BS1028564,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262495,GEO,GSM4041933,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205401,Male,Black or African American,VO_0000121,YF-Vax,BS1028566,14.0,Days,Time of initial vaccine administration,Whole blood,,ES1262497,GEO,GSM4041890,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205401,Male,Black or African American,VO_0000121,YF-Vax,BS1028567,3.0,Days,Time of initial vaccine administration,Whole blood,,ES1262498,GEO,GSM4041893,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205401,Male,Black or African American,VO_0000121,YF-Vax,BS1028568,7.0,Days,Time of initial vaccine administration,Whole blood,,ES1262499,GEO,GSM4041891,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY1529,Transcriptional profiling of yellow fever vaccine-naive participants bafore and after vaccination against yellow fever.,"Mechanisms of poor responses to vaccines remain unknown. Yellow fever-naive adults were vaccinated with a yellow fever vaccine (YF-17D, Stamaril). Transcriptomic profiling of blood collected pre-vaccination and post-vaccination (day 3, 7, 14 and 84) was performed in order to identify candidate biomarkers of antibody response to the vaccine.",19.0,49.0,SUB205401,Male,Black or African American,VO_0000121,YF-Vax,BS1028569,84.0,Days,Time of initial vaccine administration,Whole blood,,ES1262500,GEO,GSM4041892,false,GSE136163,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE136163,Whole blood : NA,19.0 - 49.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112995,Male,White,VO_0000642,Influenza virus vaccine,BS587920,0.0,Days,Time of initial vaccine administration,PBMC,,ES494421,GEO,GSM1441196,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112995,Male,White,VO_0000642,Influenza virus vaccine,BS587921,4.0,Days,Time of initial vaccine administration,PBMC,,ES494422,GEO,GSM1441197,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112995,Male,White,VO_0000642,Influenza virus vaccine,BS587922,7.0,Days,Time of initial vaccine administration,PBMC,,ES494423,GEO,GSM1441198,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112995,Male,White,VO_0000642,Influenza virus vaccine,BS587923,28.0,Days,Time of initial vaccine administration,PBMC,,ES494424,GEO,GSM1441199,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112987,Female,White,VO_0000642,Influenza virus vaccine,BS587966,0.0,Days,Time of initial vaccine administration,PBMC,,ES494425,GEO,GSM1441200,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112987,Female,White,VO_0000642,Influenza virus vaccine,BS587967,4.0,Days,Time of initial vaccine administration,PBMC,,ES494426,GEO,GSM1441201,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112987,Female,White,VO_0000642,Influenza virus vaccine,BS587968,28.0,Days,Time of initial vaccine administration,PBMC,,ES494427,GEO,GSM1441202,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112982,Female,White,VO_0000642,Influenza virus vaccine,BS587972,0.0,Days,Time of initial vaccine administration,PBMC,,ES494428,GEO,GSM1441203,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112982,Female,White,VO_0000642,Influenza virus vaccine,BS587973,4.0,Days,Time of initial vaccine administration,PBMC,,ES494429,GEO,GSM1441204,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112982,Female,White,VO_0000642,Influenza virus vaccine,BS587974,7.0,Days,Time of initial vaccine administration,PBMC,,ES494430,GEO,GSM1441205,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112982,Female,White,VO_0000642,Influenza virus vaccine,BS587975,28.0,Days,Time of initial vaccine administration,PBMC,,ES494431,GEO,GSM1441206,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112971,Female,Other,VO_0000642,Influenza virus vaccine,BS587976,0.0,Days,Time of initial vaccine administration,PBMC,,ES494432,GEO,GSM1441207,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112971,Female,Other,VO_0000642,Influenza virus vaccine,BS587977,5.0,Days,Time of initial vaccine administration,PBMC,,ES494433,GEO,GSM1441208,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112971,Female,Other,VO_0000642,Influenza virus vaccine,BS587978,7.0,Days,Time of initial vaccine administration,PBMC,,ES494434,GEO,GSM1441209,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112971,Female,Other,VO_0000642,Influenza virus vaccine,BS587979,28.0,Days,Time of initial vaccine administration,PBMC,,ES494435,GEO,GSM1441210,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112989,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587980,0.0,Days,Time of initial vaccine administration,PBMC,,ES494436,GEO,GSM1441211,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112989,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587981,4.0,Days,Time of initial vaccine administration,PBMC,,ES494437,GEO,GSM1441212,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112989,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587982,7.0,Days,Time of initial vaccine administration,PBMC,,ES494438,GEO,GSM1441213,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112989,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587983,28.0,Days,Time of initial vaccine administration,PBMC,,ES494439,GEO,GSM1441214,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112984,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS587969,0.0,Days,Time of initial vaccine administration,PBMC,,ES494440,GEO,GSM1441215,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112984,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS587970,4.0,Days,Time of initial vaccine administration,PBMC,,ES494441,GEO,GSM1441216,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112984,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS587971,7.0,Days,Time of initial vaccine administration,PBMC,,ES494442,GEO,GSM1441217,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112974,Male,White,VO_0000642,Influenza virus vaccine,BS587948,0.0,Days,Time of initial vaccine administration,PBMC,,ES494443,GEO,GSM1441218,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112974,Male,White,VO_0000642,Influenza virus vaccine,BS587949,4.0,Days,Time of initial vaccine administration,PBMC,,ES494444,GEO,GSM1441219,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112974,Male,White,VO_0000642,Influenza virus vaccine,BS587950,7.0,Days,Time of initial vaccine administration,PBMC,,ES494445,GEO,GSM1441220,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112974,Male,White,VO_0000642,Influenza virus vaccine,BS587951,28.0,Days,Time of initial vaccine administration,PBMC,,ES494446,GEO,GSM1441221,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112986,Female,White,VO_0000642,Influenza virus vaccine,BS587952,0.0,Days,Time of initial vaccine administration,PBMC,,ES494447,GEO,GSM1441222,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112986,Female,White,VO_0000642,Influenza virus vaccine,BS587953,4.0,Days,Time of initial vaccine administration,PBMC,,ES494448,GEO,GSM1441223,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112986,Female,White,VO_0000642,Influenza virus vaccine,BS587954,7.0,Days,Time of initial vaccine administration,PBMC,,ES494449,GEO,GSM1441224,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112986,Female,White,VO_0000642,Influenza virus vaccine,BS587955,28.0,Days,Time of initial vaccine administration,PBMC,,ES494450,GEO,GSM1441225,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112994,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587956,0.0,Days,Time of initial vaccine administration,PBMC,,ES494451,GEO,GSM1441226,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112994,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587957,4.0,Days,Time of initial vaccine administration,PBMC,,ES494452,GEO,GSM1441227,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112994,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587958,7.0,Days,Time of initial vaccine administration,PBMC,,ES494453,GEO,GSM1441228,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB112994,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587959,28.0,Days,Time of initial vaccine administration,PBMC,,ES494454,GEO,GSM1441229,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113000,Female,White,VO_0000642,Influenza virus vaccine,BS587912,0.0,Days,Time of initial vaccine administration,PBMC,,ES494455,GEO,GSM1441230,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113000,Female,White,VO_0000642,Influenza virus vaccine,BS587913,4.0,Days,Time of initial vaccine administration,PBMC,,ES494456,GEO,GSM1441231,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113000,Female,White,VO_0000642,Influenza virus vaccine,BS587914,7.0,Days,Time of initial vaccine administration,PBMC,,ES494457,GEO,GSM1441232,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113000,Female,White,VO_0000642,Influenza virus vaccine,BS587915,24.0,Days,Time of initial vaccine administration,PBMC,,ES494458,GEO,GSM1441233,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113001,Female,Asian,VO_0000642,Influenza virus vaccine,BS587916,0.0,Days,Time of initial vaccine administration,PBMC,,ES494459,GEO,GSM1441234,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113001,Female,Asian,VO_0000642,Influenza virus vaccine,BS587917,4.0,Days,Time of initial vaccine administration,PBMC,,ES494460,GEO,GSM1441235,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113001,Female,Asian,VO_0000642,Influenza virus vaccine,BS587918,7.0,Days,Time of initial vaccine administration,PBMC,,ES494461,GEO,GSM1441236,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113001,Female,Asian,VO_0000642,Influenza virus vaccine,BS587919,24.0,Days,Time of initial vaccine administration,PBMC,,ES494462,GEO,GSM1441237,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113005,Female,Asian,VO_0000642,Influenza virus vaccine,BS587936,0.0,Days,Time of initial vaccine administration,PBMC,,ES494463,GEO,GSM1441238,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113005,Female,Asian,VO_0000642,Influenza virus vaccine,BS587937,4.0,Days,Time of initial vaccine administration,PBMC,,ES494464,GEO,GSM1441239,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113005,Female,Asian,VO_0000642,Influenza virus vaccine,BS587938,7.0,Days,Time of initial vaccine administration,PBMC,,ES494465,GEO,GSM1441240,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113005,Female,Asian,VO_0000642,Influenza virus vaccine,BS587939,24.0,Days,Time of initial vaccine administration,PBMC,,ES494466,GEO,GSM1441241,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113006,Female,Asian,VO_0000642,Influenza virus vaccine,BS587963,0.0,Days,Time of initial vaccine administration,PBMC,,ES494467,GEO,GSM1441242,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113006,Female,Asian,VO_0000642,Influenza virus vaccine,BS587964,4.0,Days,Time of initial vaccine administration,PBMC,,ES494468,GEO,GSM1441243,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113006,Female,Asian,VO_0000642,Influenza virus vaccine,BS587965,7.0,Days,Time of initial vaccine administration,PBMC,,ES494469,GEO,GSM1441244,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113008,Female,Other,VO_0000642,Influenza virus vaccine,BS587924,0.0,Days,Time of initial vaccine administration,PBMC,,ES494470,GEO,GSM1441245,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113008,Female,Other,VO_0000642,Influenza virus vaccine,BS587925,4.0,Days,Time of initial vaccine administration,PBMC,,ES494471,GEO,GSM1441246,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113008,Female,Other,VO_0000642,Influenza virus vaccine,BS587926,7.0,Days,Time of initial vaccine administration,PBMC,,ES494472,GEO,GSM1441247,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113008,Female,Other,VO_0000642,Influenza virus vaccine,BS587927,28.0,Days,Time of initial vaccine administration,PBMC,,ES494473,GEO,GSM1441248,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113009,Female,White,VO_0000642,Influenza virus vaccine,BS587928,0.0,Days,Time of initial vaccine administration,PBMC,,ES494474,GEO,GSM1441249,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113009,Female,White,VO_0000642,Influenza virus vaccine,BS587929,4.0,Days,Time of initial vaccine administration,PBMC,,ES494475,GEO,GSM1441250,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113009,Female,White,VO_0000642,Influenza virus vaccine,BS587930,7.0,Days,Time of initial vaccine administration,PBMC,,ES494476,GEO,GSM1441251,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113009,Female,White,VO_0000642,Influenza virus vaccine,BS587931,28.0,Days,Time of initial vaccine administration,PBMC,,ES494477,GEO,GSM1441252,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113014,Female,White,VO_0000642,Influenza virus vaccine,BS587932,0.0,Days,Time of initial vaccine administration,PBMC,,ES494478,GEO,GSM1441253,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113014,Female,White,VO_0000642,Influenza virus vaccine,BS587933,4.0,Days,Time of initial vaccine administration,PBMC,,ES494479,GEO,GSM1441254,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113014,Female,White,VO_0000642,Influenza virus vaccine,BS587934,7.0,Days,Time of initial vaccine administration,PBMC,,ES494480,GEO,GSM1441255,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113014,Female,White,VO_0000642,Influenza virus vaccine,BS587935,28.0,Days,Time of initial vaccine administration,PBMC,,ES494481,GEO,GSM1441256,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113015,Female,White,VO_0000642,Influenza virus vaccine,BS587960,0.0,Days,Time of initial vaccine administration,PBMC,,ES494482,GEO,GSM1441257,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113015,Female,White,VO_0000642,Influenza virus vaccine,BS587961,4.0,Days,Time of initial vaccine administration,PBMC,,ES494483,GEO,GSM1441258,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113015,Female,White,VO_0000642,Influenza virus vaccine,BS587962,28.0,Days,Time of initial vaccine administration,PBMC,,ES494484,GEO,GSM1441259,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113016,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587940,0.0,Days,Time of initial vaccine administration,PBMC,,ES494485,GEO,GSM1441260,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113016,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587941,4.0,Days,Time of initial vaccine administration,PBMC,,ES494486,GEO,GSM1441261,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113016,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587942,7.0,Days,Time of initial vaccine administration,PBMC,,ES494487,GEO,GSM1441262,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113016,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS587943,28.0,Days,Time of initial vaccine administration,PBMC,,ES494488,GEO,GSM1441263,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113019,Female,White,VO_0000642,Influenza virus vaccine,BS587944,0.0,Days,Time of initial vaccine administration,PBMC,,ES494489,GEO,GSM1441264,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113019,Female,White,VO_0000642,Influenza virus vaccine,BS587945,4.0,Days,Time of initial vaccine administration,PBMC,,ES494490,GEO,GSM1441265,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113019,Female,White,VO_0000642,Influenza virus vaccine,BS587946,7.0,Days,Time of initial vaccine administration,PBMC,,ES494491,GEO,GSM1441266,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY63,"Immunologic and genomic signatures of influenza vaccine response - 2010 (see companion studies SDY400, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response.,21.0,80.0,SUB113019,Female,White,VO_0000642,Influenza virus vaccine,BS587947,28.0,Days,Time of initial vaccine administration,PBMC,,ES494492,GEO,GSM1441267,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_0,PBMC : NA,21.0 - 80.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112829,Male,White,VO_0000044,FluMist,BS586100,0.0,Days,Time of enrollment,PBMC,PBMC,ES497769,GEO,GSM733843,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112859,Male,White,VO_0000044,FluMist,BS586101,0.0,Days,Time of enrollment,PBMC,PBMC,ES497770,GEO,GSM733846,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112867,Male,White,VO_0000044,FluMist,BS586102,0.0,Days,Time of enrollment,PBMC,PBMC,ES497771,GEO,GSM733849,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112831,Male,Black or African American,VO_0000044,FluMist,BS586103,0.0,Days,Time of enrollment,PBMC,PBMC,ES497772,GEO,GSM733852,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112836,Female,White,VO_0000044,FluMist,BS586104,0.0,Days,Time of enrollment,PBMC,PBMC,ES497773,GEO,GSM733855,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112838,Male,White,VO_0000044,FluMist,BS586105,0.0,Days,Time of enrollment,PBMC,PBMC,ES497774,GEO,GSM733858,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS586106,0.0,Days,Time of enrollment,PBMC,PBMC,ES497775,GEO,GSM733861,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586107,0.0,Days,Time of enrollment,PBMC,PBMC,ES497776,GEO,GSM733864,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586108,0.0,Days,Time of enrollment,PBMC,PBMC,ES497777,GEO,GSM733867,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112849,Female,Black or African American,VO_0000044,FluMist,BS586109,0.0,Days,Time of enrollment,PBMC,PBMC,ES497778,GEO,GSM733870,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586110,0.0,Days,Time of enrollment,PBMC,PBMC,ES497779,GEO,GSM733873,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112854,Male,Black or African American,VO_0000044,FluMist,BS586111,0.0,Days,Time of enrollment,PBMC,PBMC,ES497780,GEO,GSM733876,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112858,Male,Asian,VO_0000044,FluMist,BS586112,0.0,Days,Time of enrollment,PBMC,PBMC,ES497781,GEO,GSM733878,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112860,Female,White,VO_0000044,FluMist,BS586113,0.0,Days,Time of enrollment,PBMC,PBMC,ES497782,GEO,GSM733881,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586114,0.0,Days,Time of enrollment,PBMC,PBMC,ES497783,GEO,GSM733884,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586115,0.0,Days,Time of enrollment,PBMC,PBMC,ES497784,GEO,GSM733887,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112865,Female,White,VO_0000044,FluMist,BS586116,0.0,Days,Time of enrollment,PBMC,PBMC,ES497785,GEO,GSM733890,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112866,Male,White,VO_0000044,FluMist,BS586117,0.0,Days,Time of enrollment,PBMC,PBMC,ES497786,GEO,GSM733893,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112868,Male,White,VO_0000044,FluMist,BS586118,0.0,Days,Time of enrollment,PBMC,PBMC,ES497787,GEO,GSM733896,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112869,Male,White,VO_0000044,FluMist,BS586119,0.0,Days,Time of enrollment,PBMC,PBMC,ES497788,GEO,GSM733899,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112870,Male,White,VO_0000044,FluMist,BS586120,0.0,Days,Time of enrollment,PBMC,PBMC,ES497789,GEO,GSM733902,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112873,Male,White,VO_0000044,FluMist,BS586121,0.0,Days,Time of enrollment,PBMC,PBMC,ES497790,GEO,GSM733905,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112876,Female,White,VO_0000044,FluMist,BS586122,0.0,Days,Time of enrollment,PBMC,PBMC,ES497791,GEO,GSM733908,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112880,Female,White,VO_0000044,FluMist,BS586123,0.0,Days,Time of enrollment,PBMC,PBMC,ES497792,GEO,GSM733911,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112881,Female,Black or African American,VO_0000044,FluMist,BS586124,0.0,Days,Time of enrollment,PBMC,PBMC,ES497793,GEO,GSM733914,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112883,Female,Asian,VO_0000044,FluMist,BS586125,0.0,Days,Time of enrollment,PBMC,PBMC,ES497794,GEO,GSM733917,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112885,Female,White,VO_0000044,FluMist,BS586126,0.0,Days,Time of enrollment,PBMC,PBMC,ES497795,GEO,GSM733920,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112886,Female,White,VO_0000044,FluMist,BS586127,0.0,Days,Time of enrollment,PBMC,PBMC,ES497796,GEO,GSM733923,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112834,Male,White,VO_0000045,Fluarix,BS586128,0.0,Days,Time of enrollment,PBMC,PBMC,ES497797,GEO,GSM733942,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112842,Male,White,VO_0000045,Fluarix,BS586129,0.0,Days,Time of enrollment,PBMC,PBMC,ES497798,GEO,GSM733950,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586130,0.0,Days,Time of enrollment,PBMC,PBMC,ES497799,GEO,GSM733965,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112832,Male,White,VO_0000045,Fluarix,BS586131,0.0,Days,Time of enrollment,PBMC,PBMC,ES497800,GEO,GSM733944,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112841,Female,White,VO_0000045,Fluarix,BS586132,0.0,Days,Time of enrollment,PBMC,PBMC,ES497801,GEO,GSM733947,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112843,Male,White,VO_0000045,Fluarix,BS586133,0.0,Days,Time of enrollment,PBMC,PBMC,ES497802,GEO,GSM733953,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112845,Female,White,VO_0000045,Fluarix,BS586134,0.0,Days,Time of enrollment,PBMC,PBMC,ES497803,GEO,GSM733956,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112846,Female,White,VO_0000045,Fluarix,BS586135,0.0,Days,Time of enrollment,PBMC,PBMC,ES497804,GEO,GSM733959,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586136,0.0,Days,Time of enrollment,PBMC,PBMC,ES497805,GEO,GSM733962,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112851,Female,Asian,VO_0000045,Fluarix,BS586137,0.0,Days,Time of enrollment,PBMC,PBMC,ES497806,GEO,GSM733967,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS586138,0.0,Days,Time of enrollment,PBMC,PBMC,ES497807,GEO,GSM733970,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112853,Female,White,VO_0000045,Fluarix,BS586139,0.0,Days,Time of enrollment,PBMC,PBMC,ES497808,GEO,GSM733973,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112855,Female,Black or African American,VO_0000045,Fluarix,BS586140,0.0,Days,Time of enrollment,PBMC,PBMC,ES497809,GEO,GSM733976,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586141,0.0,Days,Time of enrollment,PBMC,PBMC,ES497810,GEO,GSM733979,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586142,0.0,Days,Time of enrollment,PBMC,PBMC,ES497811,GEO,GSM733982,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112861,Male,White,VO_0000045,Fluarix,BS586143,0.0,Days,Time of enrollment,PBMC,PBMC,ES497812,GEO,GSM733985,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586144,0.0,Days,Time of enrollment,PBMC,PBMC,ES497813,GEO,GSM733987,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112871,Female,Black or African American,VO_0000045,Fluarix,BS586145,0.0,Days,Time of enrollment,PBMC,PBMC,ES497814,GEO,GSM733990,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112872,Female,White,VO_0000045,Fluarix,BS586146,0.0,Days,Time of enrollment,PBMC,PBMC,ES497815,GEO,GSM733993,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112874,Female,White,VO_0000045,Fluarix,BS586147,0.0,Days,Time of enrollment,PBMC,PBMC,ES497816,GEO,GSM733996,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112875,Female,White,VO_0000045,Fluarix,BS586148,0.0,Days,Time of enrollment,PBMC,PBMC,ES497817,GEO,GSM733999,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112877,Male,White,VO_0000045,Fluarix,BS586149,0.0,Days,Time of enrollment,PBMC,PBMC,ES497818,GEO,GSM734001,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112878,Female,White,VO_0000045,Fluarix,BS586150,0.0,Days,Time of enrollment,PBMC,PBMC,ES497819,GEO,GSM734004,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112879,Female,White,VO_0000045,Fluarix,BS586151,0.0,Days,Time of enrollment,PBMC,PBMC,ES497820,GEO,GSM734007,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112882,Female,White,VO_0000045,Fluarix,BS586152,0.0,Days,Time of enrollment,PBMC,PBMC,ES497821,GEO,GSM734010,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112884,Male,White,VO_0000045,Fluarix,BS586153,0.0,Days,Time of enrollment,PBMC,PBMC,ES497822,GEO,GSM734013,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112887,Female,White,VO_0000045,Fluarix,BS586154,0.0,Days,Time of enrollment,PBMC,PBMC,ES497823,GEO,GSM734016,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112888,Female,White,VO_0000045,Fluarix,BS586155,0.0,Days,Time of enrollment,PBMC,PBMC,ES497824,GEO,GSM734019,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112829,Male,White,VO_0000044,FluMist,BS586156,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497825,GEO,GSM733844,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112859,Male,White,VO_0000044,FluMist,BS586157,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497826,GEO,GSM733847,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112867,Male,White,VO_0000044,FluMist,BS586158,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497827,GEO,GSM733850,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112831,Male,Black or African American,VO_0000044,FluMist,BS586159,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497828,GEO,GSM733853,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112836,Female,White,VO_0000044,FluMist,BS586160,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497829,GEO,GSM733856,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112838,Male,White,VO_0000044,FluMist,BS586161,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497830,GEO,GSM733859,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS586162,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497831,GEO,GSM733862,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586163,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497832,GEO,GSM733865,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586164,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497833,GEO,GSM733868,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112849,Female,Black or African American,VO_0000044,FluMist,BS586165,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497834,GEO,GSM733871,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586166,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497835,GEO,GSM733874,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112854,Male,Black or African American,VO_0000044,FluMist,BS586167,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497836,GEO,GSM733877,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112858,Male,Asian,VO_0000044,FluMist,BS586168,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497837,GEO,GSM733879,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112860,Female,White,VO_0000044,FluMist,BS586169,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497838,GEO,GSM733882,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586170,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497839,GEO,GSM733885,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586171,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497840,GEO,GSM733888,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112865,Female,White,VO_0000044,FluMist,BS586172,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497841,GEO,GSM733891,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112866,Male,White,VO_0000044,FluMist,BS586173,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497842,GEO,GSM733894,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112868,Male,White,VO_0000044,FluMist,BS586174,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497843,GEO,GSM733897,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112869,Male,White,VO_0000044,FluMist,BS586175,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497844,GEO,GSM733900,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112870,Male,White,VO_0000044,FluMist,BS586176,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497845,GEO,GSM733903,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112873,Male,White,VO_0000044,FluMist,BS586177,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497846,GEO,GSM733906,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112876,Female,White,VO_0000044,FluMist,BS586178,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497847,GEO,GSM733909,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112880,Female,White,VO_0000044,FluMist,BS586179,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497848,GEO,GSM733912,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112881,Female,Black or African American,VO_0000044,FluMist,BS586180,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497849,GEO,GSM733915,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112883,Female,Asian,VO_0000044,FluMist,BS586181,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497850,GEO,GSM733918,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112885,Female,White,VO_0000044,FluMist,BS586182,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497851,GEO,GSM733921,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112886,Female,White,VO_0000044,FluMist,BS586183,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497852,GEO,GSM733924,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112842,Male,White,VO_0000045,Fluarix,BS586185,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497853,GEO,GSM733951,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586186,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497854,GEO,GSM733966,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112832,Male,White,VO_0000045,Fluarix,BS586187,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497855,GEO,GSM733945,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112841,Female,White,VO_0000045,Fluarix,BS586188,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497856,GEO,GSM733948,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112843,Male,White,VO_0000045,Fluarix,BS586189,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497857,GEO,GSM733954,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112845,Female,White,VO_0000045,Fluarix,BS586190,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497858,GEO,GSM733957,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112846,Female,White,VO_0000045,Fluarix,BS586191,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497859,GEO,GSM733960,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586192,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497860,GEO,GSM733963,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112851,Female,Asian,VO_0000045,Fluarix,BS586193,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497861,GEO,GSM733968,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS586194,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497862,GEO,GSM733971,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112853,Female,White,VO_0000045,Fluarix,BS586195,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497863,GEO,GSM733974,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112855,Female,Black or African American,VO_0000045,Fluarix,BS586196,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497864,GEO,GSM733977,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586197,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497865,GEO,GSM733980,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586198,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497866,GEO,GSM733983,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112861,Male,White,VO_0000045,Fluarix,BS586199,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497867,GEO,GSM733986,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586200,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497868,GEO,GSM733988,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112871,Female,Black or African American,VO_0000045,Fluarix,BS586201,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497869,GEO,GSM733991,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112872,Female,White,VO_0000045,Fluarix,BS586202,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497870,GEO,GSM733994,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112874,Female,White,VO_0000045,Fluarix,BS586203,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497871,GEO,GSM733997,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112877,Male,White,VO_0000045,Fluarix,BS586205,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497872,GEO,GSM734002,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112878,Female,White,VO_0000045,Fluarix,BS586206,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497873,GEO,GSM734005,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112879,Female,White,VO_0000045,Fluarix,BS586207,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497874,GEO,GSM734008,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112882,Female,White,VO_0000045,Fluarix,BS586208,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497875,GEO,GSM734011,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112884,Male,White,VO_0000045,Fluarix,BS586209,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497876,GEO,GSM734014,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112887,Female,White,VO_0000045,Fluarix,BS586210,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497877,GEO,GSM734017,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112888,Female,White,VO_0000045,Fluarix,BS586211,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497878,GEO,GSM734020,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112829,Male,White,VO_0000044,FluMist,BS586212,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497879,GEO,GSM733845,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112859,Male,White,VO_0000044,FluMist,BS586213,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497880,GEO,GSM733848,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112867,Male,White,VO_0000044,FluMist,BS586214,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497881,GEO,GSM733851,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112831,Male,Black or African American,VO_0000044,FluMist,BS586215,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497882,GEO,GSM733854,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112836,Female,White,VO_0000044,FluMist,BS586216,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497883,GEO,GSM733857,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112838,Male,White,VO_0000044,FluMist,BS586217,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497884,GEO,GSM733860,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS586218,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497885,GEO,GSM733863,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586219,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497886,GEO,GSM733866,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586220,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497887,GEO,GSM733869,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112849,Female,Black or African American,VO_0000044,FluMist,BS586221,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497888,GEO,GSM733872,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586222,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497889,GEO,GSM733875,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112858,Male,Asian,VO_0000044,FluMist,BS586224,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497890,GEO,GSM733880,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112860,Female,White,VO_0000044,FluMist,BS586225,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497891,GEO,GSM733883,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586226,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497892,GEO,GSM733886,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586227,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497893,GEO,GSM733889,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112865,Female,White,VO_0000044,FluMist,BS586228,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497894,GEO,GSM733892,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112866,Male,White,VO_0000044,FluMist,BS586229,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497895,GEO,GSM733895,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112868,Male,White,VO_0000044,FluMist,BS586230,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497896,GEO,GSM733898,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112869,Male,White,VO_0000044,FluMist,BS586231,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497897,GEO,GSM733901,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112870,Male,White,VO_0000044,FluMist,BS586232,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497898,GEO,GSM733904,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112873,Male,White,VO_0000044,FluMist,BS586233,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497899,GEO,GSM733907,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112876,Female,White,VO_0000044,FluMist,BS586234,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497900,GEO,GSM733910,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112880,Female,White,VO_0000044,FluMist,BS586235,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497901,GEO,GSM733913,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112881,Female,Black or African American,VO_0000044,FluMist,BS586236,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497902,GEO,GSM733916,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112883,Female,Asian,VO_0000044,FluMist,BS586237,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497903,GEO,GSM733919,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112885,Female,White,VO_0000044,FluMist,BS586238,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497904,GEO,GSM733922,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112886,Female,White,VO_0000044,FluMist,BS586239,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497905,GEO,GSM733925,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112834,Male,White,VO_0000045,Fluarix,BS586240,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497906,GEO,GSM733943,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112842,Male,White,VO_0000045,Fluarix,BS586241,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497907,GEO,GSM733952,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112832,Male,White,VO_0000045,Fluarix,BS586243,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497908,GEO,GSM733946,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112841,Female,White,VO_0000045,Fluarix,BS586244,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497909,GEO,GSM733949,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112843,Male,White,VO_0000045,Fluarix,BS586245,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497910,GEO,GSM733955,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112845,Female,White,VO_0000045,Fluarix,BS586246,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497911,GEO,GSM733958,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112846,Female,White,VO_0000045,Fluarix,BS586247,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497912,GEO,GSM733961,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586248,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497913,GEO,GSM733964,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112851,Female,Asian,VO_0000045,Fluarix,BS586249,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497914,GEO,GSM733969,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS586250,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497915,GEO,GSM733972,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112853,Female,White,VO_0000045,Fluarix,BS586251,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497916,GEO,GSM733975,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112855,Female,Black or African American,VO_0000045,Fluarix,BS586252,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497917,GEO,GSM733978,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586253,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497918,GEO,GSM733981,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586254,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497919,GEO,GSM733984,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586256,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497920,GEO,GSM733989,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112871,Female,Black or African American,VO_0000045,Fluarix,BS586257,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497921,GEO,GSM733992,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112872,Female,White,VO_0000045,Fluarix,BS586258,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497922,GEO,GSM733995,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112874,Female,White,VO_0000045,Fluarix,BS586259,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497923,GEO,GSM733998,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112875,Female,White,VO_0000045,Fluarix,BS586260,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497924,GEO,GSM734000,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112877,Male,White,VO_0000045,Fluarix,BS586261,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497925,GEO,GSM734003,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112878,Female,White,VO_0000045,Fluarix,BS586262,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497926,GEO,GSM734006,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112879,Female,White,VO_0000045,Fluarix,BS586263,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497927,GEO,GSM734009,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112882,Female,White,VO_0000045,Fluarix,BS586264,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497928,GEO,GSM734012,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112884,Male,White,VO_0000045,Fluarix,BS586265,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497929,GEO,GSM734015,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112887,Female,White,VO_0000045,Fluarix,BS586266,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497930,GEO,GSM734018,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112888,Female,White,VO_0000045,Fluarix,BS586267,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES497931,GEO,GSM734021,false,GSE29619,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE29619,PBMC : PBMC,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586941,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497932,GEO,GSM734029,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586942,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497933,GEO,GSM734036,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586943,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497934,GEO,GSM734059,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586944,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497935,GEO,GSM734083,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586945,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497936,GEO,GSM734099,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586946,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497937,GEO,GSM734051,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586947,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497938,GEO,GSM734043,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586949,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497939,GEO,GSM734068,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586950,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497940,GEO,GSM734075,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586951,0.0,Days,Time of enrollment,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497941,GEO,GSM734091,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586953,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497943,GEO,GSM734033,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586954,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497944,GEO,GSM734039,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586955,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497945,GEO,GSM734063,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586956,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497946,GEO,GSM734087,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586957,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497947,GEO,GSM734103,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586958,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497948,GEO,GSM734055,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586959,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497949,GEO,GSM734047,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586961,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497951,GEO,GSM734071,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586962,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497952,GEO,GSM734079,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586963,7.0,Days,Time of initial vaccine administration,PBMC,CD11c hi CD123 lo mDC cells isolated from PBMCs,ES497953,GEO,GSM734095,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD11c hi CD123 lo mDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS586964,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497954,GEO,GSM734024,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586965,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497955,GEO,GSM734031,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586966,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497956,GEO,GSM734038,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586967,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497957,GEO,GSM734061,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586968,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497958,GEO,GSM734085,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586969,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497959,GEO,GSM734101,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586970,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497960,GEO,GSM734053,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586971,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497961,GEO,GSM734045,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586973,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497963,GEO,GSM734070,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586974,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497964,GEO,GSM734077,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586975,0.0,Days,Time of enrollment,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497965,GEO,GSM734093,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS586976,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497966,GEO,GSM734027,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586977,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497967,GEO,GSM734035,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586978,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497968,GEO,GSM734041,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586979,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497969,GEO,GSM734065,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586980,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497970,GEO,GSM734089,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586981,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497971,GEO,GSM734105,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586982,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497972,GEO,GSM734057,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586983,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497973,GEO,GSM734049,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586985,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497975,GEO,GSM734073,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586986,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497976,GEO,GSM734081,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586987,7.0,Days,Time of initial vaccine administration,PBMC,CD123 hi CD11c lo pDC cells isolated from PBMCs,ES497977,GEO,GSM734097,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD123 hi CD11c lo pDC cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS586988,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497978,GEO,GSM734023,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS586989,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497979,GEO,GSM734030,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS586990,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497980,GEO,GSM734037,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS586991,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497981,GEO,GSM734060,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS586992,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497982,GEO,GSM734084,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS586993,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497983,GEO,GSM734100,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS586994,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497984,GEO,GSM734052,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586995,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497985,GEO,GSM734044,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS586997,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497986,GEO,GSM734069,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS586998,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497987,GEO,GSM734076,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS586999,0.0,Days,Time of enrollment,PBMC,CD14 + monocytes isolated from PBMCs,ES497988,GEO,GSM734092,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS587000,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497989,GEO,GSM734026,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS587001,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497990,GEO,GSM734034,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112844,Female,White,VO_0000044,FluMist,BS587002,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497991,GEO,GSM734040,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS587003,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497992,GEO,GSM734064,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS587004,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497993,GEO,GSM734088,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS587005,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497994,GEO,GSM734104,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS587006,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497995,GEO,GSM734056,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS587007,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497996,GEO,GSM734048,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112856,Female,Black or African American,VO_0000045,Fluarix,BS588649,7.0,Days,Time of initial vaccine administration,Other,,ES497997,GEO,GSM734072,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,Other : NA,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS587009,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497998,GEO,GSM734080,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS587010,7.0,Days,Time of initial vaccine administration,PBMC,CD14 + monocytes isolated from PBMCs,ES497999,GEO,GSM734096,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD14 + monocytes isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS587011,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498000,GEO,GSM734022,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS587012,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498001,GEO,GSM734028,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS587014,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498002,GEO,GSM734058,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS587015,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498003,GEO,GSM734082,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS587016,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498004,GEO,GSM734098,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS587017,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498005,GEO,GSM734050,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS587018,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498006,GEO,GSM734042,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS587019,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498007,GEO,GSM734066,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS587021,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498008,GEO,GSM734074,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS587022,0.0,Days,Time of enrollment,PBMC,CD19 + B cells isolated from PBMCs,ES498009,GEO,GSM734090,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112839,Female,White,VO_0000044,FluMist,BS587023,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498010,GEO,GSM734025,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112840,Female,White,VO_0000044,FluMist,BS587024,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498011,GEO,GSM734032,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112850,Male,White,VO_0000044,FluMist,BS587026,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498012,GEO,GSM734062,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112862,Female,Asian,VO_0000044,FluMist,BS587027,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498013,GEO,GSM734086,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112864,Female,White,VO_0000044,FluMist,BS587028,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498014,GEO,GSM734102,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112848,Female,White,VO_0000045,Fluarix,BS587030,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498015,GEO,GSM734054,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112847,Male,White,VO_0000045,Fluarix,BS587031,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498016,GEO,GSM734046,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112852,Female,Black or African American,VO_0000045,Fluarix,BS587032,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498017,GEO,GSM734067,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112857,Male,White,VO_0000045,Fluarix,BS587034,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498018,GEO,GSM734078,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY269,Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.,0.0,47.0,SUB112863,Female,White,VO_0000045,Fluarix,BS587035,7.0,Days,Time of initial vaccine administration,PBMC,CD19 + B cells isolated from PBMCs,ES498019,GEO,GSM734094,false,GSE29619,GPL3921,[HT_HG-U133A] Affymetrix HT Human Genome U133A Array,GSE29619,PBMC : CD19 + B cells isolated from PBMCs,0.0 - 47.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112830,Female,White,VO_0000045,Fluarix,BS586015,0.0,Days,Time of enrollment,PBMC,PBMC,ES498020,GEO,GSM733816,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112832,Male,White,VO_0000045,Fluarix,BS586016,0.0,Days,Time of enrollment,PBMC,PBMC,ES498021,GEO,GSM733819,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112833,Female,White,VO_0000045,Fluarix,BS586017,0.0,Days,Time of enrollment,PBMC,PBMC,ES498022,GEO,GSM733822,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112835,Male,White,VO_0000045,Fluarix,BS586018,0.0,Days,Time of enrollment,PBMC,PBMC,ES498023,GEO,GSM733825,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112837,Female,White,VO_0000045,Fluarix,BS586019,0.0,Days,Time of enrollment,PBMC,PBMC,ES498024,GEO,GSM733828,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112841,Female,White,VO_0000045,Fluarix,BS586020,0.0,Days,Time of enrollment,PBMC,PBMC,ES498025,GEO,GSM733831,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112843,Male,White,VO_0000045,Fluarix,BS586021,0.0,Days,Time of enrollment,PBMC,PBMC,ES498026,GEO,GSM733834,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112845,Female,White,VO_0000045,Fluarix,BS586022,0.0,Days,Time of enrollment,PBMC,PBMC,ES498027,GEO,GSM733837,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586023,0.0,Days,Time of enrollment,PBMC,PBMC,ES498028,GEO,GSM733840,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112830,Female,White,VO_0000045,Fluarix,BS586024,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498029,GEO,GSM733817,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112832,Male,White,VO_0000045,Fluarix,BS586025,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498030,GEO,GSM733820,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112833,Female,White,VO_0000045,Fluarix,BS586026,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498031,GEO,GSM733823,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112835,Male,White,VO_0000045,Fluarix,BS586027,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498032,GEO,GSM733826,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112837,Female,White,VO_0000045,Fluarix,BS586028,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498033,GEO,GSM733829,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112841,Female,White,VO_0000045,Fluarix,BS586029,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498034,GEO,GSM733832,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112843,Male,White,VO_0000045,Fluarix,BS586030,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498035,GEO,GSM733835,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112845,Female,White,VO_0000045,Fluarix,BS586031,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498036,GEO,GSM733838,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586032,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498037,GEO,GSM733841,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112830,Female,White,VO_0000045,Fluarix,BS586033,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498038,GEO,GSM733818,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112832,Male,White,VO_0000045,Fluarix,BS586034,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498039,GEO,GSM733821,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112833,Female,White,VO_0000045,Fluarix,BS586035,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498040,GEO,GSM733824,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112835,Male,White,VO_0000045,Fluarix,BS586036,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498041,GEO,GSM733827,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112837,Female,White,VO_0000045,Fluarix,BS586037,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498042,GEO,GSM733830,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112841,Female,White,VO_0000045,Fluarix,BS586038,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498043,GEO,GSM733833,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112843,Male,White,VO_0000045,Fluarix,BS586039,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498044,GEO,GSM733836,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112845,Female,White,VO_0000045,Fluarix,BS586040,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498045,GEO,GSM733839,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY61,Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine),Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.,0.0,46.0,SUB112847,Male,White,VO_0000045,Fluarix,BS586041,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES498046,GEO,GSM733842,false,GSE29619,GPL570,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,GSE29619,PBMC : PBMC,0.0 - 46.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114450,Male,White,VO_0000046,Fluvirin,BS630794,0.0,Days,Time of initial vaccine administration,PBMC,,ES571017,GEO,GSM1147758,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114451,Female,White,VO_0000046,Fluvirin,BS630795,0.0,Days,Time of initial vaccine administration,PBMC,,ES571018,GEO,GSM1147763,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114452,Male,Asian,VO_0000046,Fluvirin,BS630796,0.0,Days,Time of initial vaccine administration,PBMC,,ES571019,GEO,GSM1147768,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114453,Female,White,VO_0000046,Fluvirin,BS630797,0.0,Days,Time of initial vaccine administration,PBMC,,ES571020,GEO,GSM1147773,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114454,Female,White,VO_0000046,Fluvirin,BS630798,0.0,Days,Time of initial vaccine administration,PBMC,,ES571021,GEO,GSM1147778,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114455,Male,Asian,VO_0000046,Fluvirin,BS630799,0.0,Days,Time of initial vaccine administration,PBMC,,ES571022,GEO,GSM1147783,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114456,Female,White,VO_0000046,Fluvirin,BS630800,0.0,Days,Time of initial vaccine administration,PBMC,,ES571023,GEO,GSM1147788,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114457,Male,White,VO_0000046,Fluvirin,BS630801,0.0,Days,Time of initial vaccine administration,PBMC,,ES571024,GEO,GSM1147792,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114458,Male,White,VO_0000046,Fluvirin,BS630802,0.0,Days,Time of initial vaccine administration,PBMC,,ES571025,GEO,GSM1147796,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114459,Female,Asian,VO_0000046,Fluvirin,BS630803,0.0,Days,Time of initial vaccine administration,PBMC,,ES571026,GEO,GSM1147801,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114460,Female,Asian,VO_0000046,Fluvirin,BS630804,0.0,Days,Time of initial vaccine administration,PBMC,,ES571027,GEO,GSM1147806,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114461,Female,White,VO_0000046,Fluvirin,BS630805,0.0,Days,Time of initial vaccine administration,PBMC,,ES571028,GEO,GSM1147811,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114462,Female,Other,VO_0000046,Fluvirin,BS630806,0.0,Days,Time of initial vaccine administration,PBMC,,ES571029,GEO,GSM1147816,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114463,Male,White,VO_0000046,Fluvirin,BS630807,0.0,Days,Time of initial vaccine administration,PBMC,,ES571030,GEO,GSM1147821,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114464,Female,Asian,VO_0000046,Fluvirin,BS630808,0.0,Days,Time of initial vaccine administration,PBMC,,ES571031,GEO,GSM1147825,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114466,Female,White,VO_0000046,Fluvirin,BS630810,0.0,Days,Time of initial vaccine administration,PBMC,,ES571033,GEO,GSM1147834,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114467,Male,White,VO_0000046,Fluvirin,BS630811,0.0,Days,Time of initial vaccine administration,PBMC,,ES571034,GEO,GSM1147839,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114468,Male,White,VO_0000046,Fluvirin,BS630812,0.0,Days,Time of initial vaccine administration,PBMC,,ES571035,GEO,GSM1147844,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114469,Female,White,VO_0000046,Fluvirin,BS630813,0.0,Days,Time of initial vaccine administration,PBMC,,ES571036,GEO,GSM1147849,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114470,Female,White,VO_0000046,Fluvirin,BS630814,0.0,Days,Time of initial vaccine administration,PBMC,,ES571037,GEO,GSM1147854,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114471,Female,Asian,VO_0000046,Fluvirin,BS630815,0.0,Days,Time of initial vaccine administration,PBMC,,ES571038,GEO,GSM1147859,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114472,Male,Asian,VO_0000046,Fluvirin,BS630816,0.0,Days,Time of initial vaccine administration,PBMC,,ES571039,GEO,GSM1147864,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114473,Male,White,VO_0000046,Fluvirin,BS630817,0.0,Days,Time of initial vaccine administration,PBMC,,ES571040,GEO,GSM1147869,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114474,Male,Black or African American,VO_0000046,Fluvirin,BS630818,0.0,Days,Time of initial vaccine administration,PBMC,,ES571041,GEO,GSM1147874,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114475,Male,White,VO_0000046,Fluvirin,BS630819,0.0,Days,Time of initial vaccine administration,PBMC,,ES571042,GEO,GSM1147879,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114476,Male,White,VO_0000046,Fluvirin,BS630820,0.0,Days,Time of initial vaccine administration,PBMC,,ES571043,GEO,GSM1147884,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114477,Female,White,VO_0000046,Fluvirin,BS630821,0.0,Days,Time of initial vaccine administration,PBMC,,ES571044,GEO,GSM1147888,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114478,Male,White,VO_0000046,Fluvirin,BS630822,0.0,Days,Time of initial vaccine administration,PBMC,,ES571045,GEO,GSM1147892,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114481,Female,Asian,VO_0000046,Fluvirin,BS630825,0.0,Days,Time of initial vaccine administration,PBMC,,ES571048,GEO,GSM1147903,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114482,Female,White,VO_0000046,Fluvirin,BS630826,0.0,Days,Time of initial vaccine administration,PBMC,,ES571049,GEO,GSM1147908,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114483,Female,White,VO_0000046,Fluvirin,BS630827,0.0,Days,Time of initial vaccine administration,PBMC,,ES571050,GEO,GSM1147913,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114484,Female,Other,VO_0000046,Fluvirin,BS630828,0.0,Days,Time of initial vaccine administration,PBMC,,ES571051,GEO,GSM1147918,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114486,Female,White,VO_0000046,Fluvirin,BS630830,0.0,Days,Time of initial vaccine administration,PBMC,,ES571053,GEO,GSM1147925,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114487,Female,Asian,VO_0000046,Fluvirin,BS630831,0.0,Days,Time of initial vaccine administration,PBMC,,ES571054,GEO,GSM1147930,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114488,Female,Black or African American,VO_0000046,Fluvirin,BS630832,0.0,Days,Time of initial vaccine administration,PBMC,,ES571055,GEO,GSM1147935,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114489,Male,Asian,VO_0000046,Fluvirin,BS630833,0.0,Days,Time of initial vaccine administration,PBMC,,ES571056,GEO,GSM1147940,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114490,Female,White,VO_0000046,Fluvirin,BS630834,0.0,Days,Time of initial vaccine administration,PBMC,,ES571057,GEO,GSM1147945,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114491,Female,Black or African American,VO_0000046,Fluvirin,BS630835,0.0,Days,Time of initial vaccine administration,PBMC,,ES571058,GEO,GSM1147950,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114492,Female,White,VO_0000046,Fluvirin,BS630836,0.0,Days,Time of initial vaccine administration,PBMC,,ES571059,GEO,GSM1147955,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114493,Female,White,VO_0000046,Fluvirin,BS630837,0.0,Days,Time of initial vaccine administration,PBMC,,ES571060,GEO,GSM1147960,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114494,Female,Asian,VO_0000046,Fluvirin,BS630838,0.0,Days,Time of initial vaccine administration,PBMC,,ES571061,GEO,GSM1147965,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114495,Male,White,VO_0000046,Fluvirin,BS630839,0.0,Days,Time of initial vaccine administration,PBMC,,ES571062,GEO,GSM1147970,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114497,Male,Asian,VO_0000046,Fluvirin,BS630841,0.0,Days,Time of initial vaccine administration,PBMC,,ES571064,GEO,GSM1147976,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114498,Male,White,VO_0000046,Fluvirin,BS630842,0.0,Days,Time of initial vaccine administration,PBMC,,ES571065,GEO,GSM1147981,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114499,Female,Asian,VO_0000046,Fluvirin,BS630843,0.0,Days,Time of initial vaccine administration,PBMC,,ES571066,GEO,GSM1147986,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114500,Male,White,VO_0000046,Fluvirin,BS630844,0.0,Days,Time of initial vaccine administration,PBMC,,ES571067,GEO,GSM1147991,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114501,Female,Asian,VO_0000046,Fluvirin,BS630845,0.0,Days,Time of initial vaccine administration,PBMC,,ES571068,GEO,GSM1147996,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114502,Female,White,VO_0000046,Fluvirin,BS630846,0.0,Days,Time of initial vaccine administration,PBMC,,ES571069,GEO,GSM1148001,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114503,Female,Black or African American,VO_0000046,Fluvirin,BS630847,0.0,Days,Time of initial vaccine administration,PBMC,,ES571070,GEO,GSM1148006,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114505,Female,White,VO_0000046,Fluvirin,BS630849,0.0,Days,Time of initial vaccine administration,PBMC,,ES571072,GEO,GSM1148013,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114506,Male,Asian,VO_0000046,Fluvirin,BS630850,0.0,Days,Time of initial vaccine administration,PBMC,,ES571073,GEO,GSM1148016,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114507,Male,White,VO_0000046,Fluvirin,BS630851,0.0,Days,Time of initial vaccine administration,PBMC,,ES571074,GEO,GSM1148021,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114508,Female,Other,VO_0000046,Fluvirin,BS630852,0.0,Days,Time of initial vaccine administration,PBMC,,ES571075,GEO,GSM1148025,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114509,Male,White,VO_0000046,Fluvirin,BS630853,0.0,Days,Time of initial vaccine administration,PBMC,,ES571076,GEO,GSM1148030,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114510,Male,White,VO_0000046,Fluvirin,BS630854,0.0,Days,Time of initial vaccine administration,PBMC,,ES571077,GEO,GSM1148035,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114511,Female,White,VO_0000046,Fluvirin,BS630855,0.0,Days,Time of initial vaccine administration,PBMC,,ES571078,GEO,GSM1148040,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114512,Male,White,VO_0000046,Fluvirin,BS630856,0.0,Days,Time of initial vaccine administration,PBMC,,ES571079,GEO,GSM1148045,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114450,Male,White,VO_0000046,Fluvirin,BS630857,1.0,Days,Time of initial vaccine administration,PBMC,,ES571080,GEO,GSM1147759,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114451,Female,White,VO_0000046,Fluvirin,BS630858,1.0,Days,Time of initial vaccine administration,PBMC,,ES571081,GEO,GSM1147764,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114452,Male,Asian,VO_0000046,Fluvirin,BS630859,1.0,Days,Time of initial vaccine administration,PBMC,,ES571082,GEO,GSM1147769,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114453,Female,White,VO_0000046,Fluvirin,BS630860,1.0,Days,Time of initial vaccine administration,PBMC,,ES571083,GEO,GSM1147774,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114454,Female,White,VO_0000046,Fluvirin,BS630861,1.0,Days,Time of initial vaccine administration,PBMC,,ES571084,GEO,GSM1147779,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114455,Male,Asian,VO_0000046,Fluvirin,BS630862,1.0,Days,Time of initial vaccine administration,PBMC,,ES571085,GEO,GSM1147784,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114456,Female,White,VO_0000046,Fluvirin,BS630863,1.0,Days,Time of initial vaccine administration,PBMC,,ES571086,GEO,GSM1147789,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114457,Male,White,VO_0000046,Fluvirin,BS630864,1.0,Days,Time of initial vaccine administration,PBMC,,ES571087,GEO,GSM1147793,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114458,Male,White,VO_0000046,Fluvirin,BS630865,1.0,Days,Time of initial vaccine administration,PBMC,,ES571088,GEO,GSM1147797,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114459,Female,Asian,VO_0000046,Fluvirin,BS630866,1.0,Days,Time of initial vaccine administration,PBMC,,ES571089,GEO,GSM1147802,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114460,Female,Asian,VO_0000046,Fluvirin,BS630867,1.0,Days,Time of initial vaccine administration,PBMC,,ES571090,GEO,GSM1147807,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114461,Female,White,VO_0000046,Fluvirin,BS630868,1.0,Days,Time of initial vaccine administration,PBMC,,ES571091,GEO,GSM1147812,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114462,Female,Other,VO_0000046,Fluvirin,BS630869,1.0,Days,Time of initial vaccine administration,PBMC,,ES571092,GEO,GSM1147817,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114463,Male,White,VO_0000046,Fluvirin,BS630870,1.0,Days,Time of initial vaccine administration,PBMC,,ES571093,GEO,GSM1147822,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114464,Female,Asian,VO_0000046,Fluvirin,BS630871,1.0,Days,Time of initial vaccine administration,PBMC,,ES571094,GEO,GSM1147826,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114465,Male,White,VO_0000046,Fluvirin,BS630872,1.0,Days,Time of initial vaccine administration,PBMC,,ES571095,GEO,GSM1147830,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114466,Female,White,VO_0000046,Fluvirin,BS630873,1.0,Days,Time of initial vaccine administration,PBMC,,ES571096,GEO,GSM1147835,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114467,Male,White,VO_0000046,Fluvirin,BS630874,1.0,Days,Time of initial vaccine administration,PBMC,,ES571097,GEO,GSM1147840,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114468,Male,White,VO_0000046,Fluvirin,BS630875,1.0,Days,Time of initial vaccine administration,PBMC,,ES571098,GEO,GSM1147845,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114469,Female,White,VO_0000046,Fluvirin,BS630876,1.0,Days,Time of initial vaccine administration,PBMC,,ES571099,GEO,GSM1147850,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114470,Female,White,VO_0000046,Fluvirin,BS630877,1.0,Days,Time of initial vaccine administration,PBMC,,ES571100,GEO,GSM1147855,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114471,Female,Asian,VO_0000046,Fluvirin,BS630878,1.0,Days,Time of initial vaccine administration,PBMC,,ES571101,GEO,GSM1147860,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114472,Male,Asian,VO_0000046,Fluvirin,BS630879,1.0,Days,Time of initial vaccine administration,PBMC,,ES571102,GEO,GSM1147865,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114473,Male,White,VO_0000046,Fluvirin,BS630880,1.0,Days,Time of initial vaccine administration,PBMC,,ES571103,GEO,GSM1147870,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114474,Male,Black or African American,VO_0000046,Fluvirin,BS630881,1.0,Days,Time of initial vaccine administration,PBMC,,ES571104,GEO,GSM1147875,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114475,Male,White,VO_0000046,Fluvirin,BS630882,1.0,Days,Time of initial vaccine administration,PBMC,,ES571105,GEO,GSM1147880,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114476,Male,White,VO_0000046,Fluvirin,BS630883,1.0,Days,Time of initial vaccine administration,PBMC,,ES571106,GEO,GSM1147885,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114477,Female,White,VO_0000046,Fluvirin,BS630884,1.0,Days,Time of initial vaccine administration,PBMC,,ES571107,GEO,GSM1147889,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114478,Male,White,VO_0000046,Fluvirin,BS630885,1.0,Days,Time of initial vaccine administration,PBMC,,ES571108,GEO,GSM1147893,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114479,Male,White,VO_0000046,Fluvirin,BS630886,1.0,Days,Time of initial vaccine administration,PBMC,,ES571109,GEO,GSM1147897,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114480,Male,White,VO_0000046,Fluvirin,BS630887,1.0,Days,Time of initial vaccine administration,PBMC,,ES571110,GEO,GSM1147900,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114481,Female,Asian,VO_0000046,Fluvirin,BS630888,1.0,Days,Time of initial vaccine administration,PBMC,,ES571111,GEO,GSM1147904,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114482,Female,White,VO_0000046,Fluvirin,BS630889,1.0,Days,Time of initial vaccine administration,PBMC,,ES571112,GEO,GSM1147909,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114483,Female,White,VO_0000046,Fluvirin,BS630890,1.0,Days,Time of initial vaccine administration,PBMC,,ES571113,GEO,GSM1147914,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114484,Female,Other,VO_0000046,Fluvirin,BS630891,1.0,Days,Time of initial vaccine administration,PBMC,,ES571114,GEO,GSM1147919,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114486,Female,White,VO_0000046,Fluvirin,BS630893,1.0,Days,Time of initial vaccine administration,PBMC,,ES571116,GEO,GSM1147926,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114487,Female,Asian,VO_0000046,Fluvirin,BS630894,1.0,Days,Time of initial vaccine administration,PBMC,,ES571117,GEO,GSM1147931,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114488,Female,Black or African American,VO_0000046,Fluvirin,BS630895,1.0,Days,Time of initial vaccine administration,PBMC,,ES571118,GEO,GSM1147936,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114489,Male,Asian,VO_0000046,Fluvirin,BS630896,1.0,Days,Time of initial vaccine administration,PBMC,,ES571119,GEO,GSM1147941,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114490,Female,White,VO_0000046,Fluvirin,BS630897,1.0,Days,Time of initial vaccine administration,PBMC,,ES571120,GEO,GSM1147946,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114491,Female,Black or African American,VO_0000046,Fluvirin,BS630898,1.0,Days,Time of initial vaccine administration,PBMC,,ES571121,GEO,GSM1147951,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114492,Female,White,VO_0000046,Fluvirin,BS630899,1.0,Days,Time of initial vaccine administration,PBMC,,ES571122,GEO,GSM1147956,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114493,Female,White,VO_0000046,Fluvirin,BS630900,1.0,Days,Time of initial vaccine administration,PBMC,,ES571123,GEO,GSM1147961,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114494,Female,Asian,VO_0000046,Fluvirin,BS630901,1.0,Days,Time of initial vaccine administration,PBMC,,ES571124,GEO,GSM1147966,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114495,Male,White,VO_0000046,Fluvirin,BS630902,1.0,Days,Time of initial vaccine administration,PBMC,,ES571125,GEO,GSM1147971,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114497,Male,Asian,VO_0000046,Fluvirin,BS630904,1.0,Days,Time of initial vaccine administration,PBMC,,ES571127,GEO,GSM1147977,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114498,Male,White,VO_0000046,Fluvirin,BS630905,1.0,Days,Time of initial vaccine administration,PBMC,,ES571128,GEO,GSM1147982,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114499,Female,Asian,VO_0000046,Fluvirin,BS630906,1.0,Days,Time of initial vaccine administration,PBMC,,ES571129,GEO,GSM1147987,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114500,Male,White,VO_0000046,Fluvirin,BS630907,1.0,Days,Time of initial vaccine administration,PBMC,,ES571130,GEO,GSM1147992,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114501,Female,Asian,VO_0000046,Fluvirin,BS630908,1.0,Days,Time of initial vaccine administration,PBMC,,ES571131,GEO,GSM1147997,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114502,Female,White,VO_0000046,Fluvirin,BS630909,1.0,Days,Time of initial vaccine administration,PBMC,,ES571132,GEO,GSM1148002,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114503,Female,Black or African American,VO_0000046,Fluvirin,BS630910,1.0,Days,Time of initial vaccine administration,PBMC,,ES571133,GEO,GSM1148007,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114505,Female,White,VO_0000046,Fluvirin,BS630912,1.0,Days,Time of initial vaccine administration,PBMC,,ES571135,GEO,GSM1148014,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114506,Male,Asian,VO_0000046,Fluvirin,BS630913,1.0,Days,Time of initial vaccine administration,PBMC,,ES571136,GEO,GSM1148017,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114507,Male,White,VO_0000046,Fluvirin,BS630914,1.0,Days,Time of initial vaccine administration,PBMC,,ES571137,GEO,GSM1148022,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114508,Female,Other,VO_0000046,Fluvirin,BS630915,1.0,Days,Time of initial vaccine administration,PBMC,,ES571138,GEO,GSM1148026,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114509,Male,White,VO_0000046,Fluvirin,BS630916,1.0,Days,Time of initial vaccine administration,PBMC,,ES571139,GEO,GSM1148031,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114510,Male,White,VO_0000046,Fluvirin,BS630917,1.0,Days,Time of initial vaccine administration,PBMC,,ES571140,GEO,GSM1148036,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114511,Female,White,VO_0000046,Fluvirin,BS630918,1.0,Days,Time of initial vaccine administration,PBMC,,ES571141,GEO,GSM1148041,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114512,Male,White,VO_0000046,Fluvirin,BS630919,1.0,Days,Time of initial vaccine administration,PBMC,,ES571142,GEO,GSM1148046,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : NA,18.0 - 85.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661893,14.0,Days,Time of initial vaccine administration,Whole blood,,ES717776,GEO,GSM744868,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661896,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717779,GEO,GSM744835,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661897,21.0,Days,Time of initial vaccine administration,Whole blood,,ES717780,GEO,GSM744842,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661898,28.0,Days,Time of initial vaccine administration,Whole blood,,ES717781,GEO,GSM744888,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661901,3.0,Days,Time of initial vaccine administration,Whole blood,,ES717784,GEO,GSM744874,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661903,7.0,Days,Time of initial vaccine administration,Whole blood,,ES717786,GEO,GSM744839,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661904,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717787,GEO,GSM744872,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661906,7.0,Days,Time of initial vaccine administration,Whole blood,,ES717789,GEO,GSM744866,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661907,21.0,Days,Time of initial vaccine administration,Whole blood,,ES717790,GEO,GSM744851,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661908,7.0,Days,Time of initial vaccine administration,Whole blood,,ES717791,GEO,GSM744857,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661909,14.0,Days,Time of initial vaccine administration,Whole blood,,ES717792,GEO,GSM744886,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661913,28.0,Days,Time of initial vaccine administration,Whole blood,,ES717796,GEO,GSM744852,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661914,21.0,Days,Time of initial vaccine administration,Whole blood,,ES717797,GEO,GSM744878,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661915,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717798,GEO,GSM744854,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661918,14.0,Days,Time of initial vaccine administration,Whole blood,,ES717801,GEO,GSM744877,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661920,3.0,Days,Time of initial vaccine administration,Whole blood,,ES717803,GEO,GSM744856,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661923,10.0,Days,Time of initial vaccine administration,Whole blood,,ES717806,GEO,GSM744867,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661924,3.0,Days,Time of initial vaccine administration,Whole blood,,ES717807,GEO,GSM744847,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661925,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717808,GEO,GSM744837,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661927,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717810,GEO,GSM744846,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661928,21.0,Days,Time of initial vaccine administration,Whole blood,,ES717811,GEO,GSM744869,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661933,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717816,GEO,GSM744862,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661934,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717817,GEO,GSM744836,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661935,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717818,GEO,GSM744853,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661936,7.0,Days,Time of initial vaccine administration,Whole blood,,ES717819,GEO,GSM744875,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661940,28.0,Days,Time of initial vaccine administration,Whole blood,,ES717823,GEO,GSM744879,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661942,14.0,Days,Time of initial vaccine administration,Whole blood,,ES717825,GEO,GSM744850,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661944,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717827,GEO,GSM744882,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661947,28.0,Days,Time of initial vaccine administration,Whole blood,,ES717830,GEO,GSM744843,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661949,10.0,Days,Time of initial vaccine administration,Whole blood,,ES717832,GEO,GSM744876,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661951,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717834,GEO,GSM744863,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661955,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717838,GEO,GSM744864,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661958,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717841,GEO,GSM744871,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661960,3.0,Days,Time of initial vaccine administration,Whole blood,,ES717843,GEO,GSM744883,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661961,28.0,Days,Time of initial vaccine administration,Whole blood,,ES717844,GEO,GSM744870,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661965,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717848,GEO,GSM744855,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661967,14.0,Days,Time of initial vaccine administration,Whole blood,,ES717850,GEO,GSM744859,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661968,10.0,Days,Time of initial vaccine administration,Whole blood,,ES717851,GEO,GSM744858,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661971,28.0,Days,Time of initial vaccine administration,Whole blood,,ES717854,GEO,GSM744861,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661972,10.0,Days,Time of initial vaccine administration,Whole blood,,ES717855,GEO,GSM744840,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661977,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717860,GEO,GSM744880,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119286,Female,White,VO_0000088,Pneumovax 23 (USA),BS661980,21.0,Days,Time of initial vaccine administration,Whole blood,,ES717863,GEO,GSM744860,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661982,7.0,Days,Time of initial vaccine administration,Whole blood,,ES717865,GEO,GSM744848,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119287,Male,White,VO_0000088,Pneumovax 23 (USA),BS661984,3.0,Days,Time of initial vaccine administration,Whole blood,,ES717867,GEO,GSM744865,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661986,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717869,GEO,GSM744845,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661987,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717870,GEO,GSM744881,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661988,10.0,Days,Time of initial vaccine administration,Whole blood,,ES717871,GEO,GSM744885,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661989,10.0,Days,Time of initial vaccine administration,Whole blood,,ES717872,GEO,GSM744849,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661991,3.0,Days,Time of initial vaccine administration,Whole blood,,ES717874,GEO,GSM744838,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119281,Male,White,VO_0000088,Pneumovax 23 (USA),BS661993,14.0,Days,Time of initial vaccine administration,Whole blood,,ES717876,GEO,GSM744841,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119289,Male,Asian,VO_0000088,Pneumovax 23 (USA),BS661994,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717877,GEO,GSM744873,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661995,7.0,Days,Time of initial vaccine administration,Whole blood,,ES717878,GEO,GSM744884,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119285,Female,Asian,VO_0000088,Pneumovax 23 (USA),BS661998,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717881,GEO,GSM744844,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119290,Female,White,VO_0000088,Pneumovax 23 (USA),BS661999,21.0,Days,Time of initial vaccine administration,Whole blood,,ES717882,GEO,GSM744887,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_0,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662000,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717883,GEO,GSM745220,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662001,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717884,GEO,GSM745292,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662002,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717885,GEO,GSM745236,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662004,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717887,GEO,GSM745229,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662005,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717888,GEO,GSM745280,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662007,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717890,GEO,GSM745239,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662008,0.37,Days,Time of initial vaccine administration,Whole blood,,ES717891,GEO,GSM745284,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662010,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717893,GEO,GSM745222,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662011,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717894,GEO,GSM745244,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662012,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717895,GEO,GSM745214,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662013,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717896,GEO,GSM745290,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662015,2.0,Days,Time of initial vaccine administration,Whole blood,,ES717898,GEO,GSM745245,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662016,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717899,GEO,GSM745287,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662017,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717900,GEO,GSM745291,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662020,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717903,GEO,GSM745286,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662022,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717905,GEO,GSM745296,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662023,0.37,Days,Time of initial vaccine administration,Whole blood,,ES717906,GEO,GSM745295,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662024,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717907,GEO,GSM745240,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662026,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717909,GEO,GSM745293,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662029,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717912,GEO,GSM745232,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662030,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717913,GEO,GSM745225,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662032,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717915,GEO,GSM745228,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662033,0.37,Days,Time of initial vaccine administration,Whole blood,,ES717916,GEO,GSM745230,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662034,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717917,GEO,GSM745283,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662035,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717918,GEO,GSM745297,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662036,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717919,GEO,GSM745282,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662038,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717921,GEO,GSM745221,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662039,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717922,GEO,GSM745231,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662042,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717925,GEO,GSM745223,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662044,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717927,GEO,GSM745226,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662045,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717928,GEO,GSM745281,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662046,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717929,GEO,GSM745233,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662050,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717933,GEO,GSM745279,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662051,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717934,GEO,GSM745215,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662052,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717935,GEO,GSM745217,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662053,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717936,GEO,GSM745298,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662054,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717937,GEO,GSM745243,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662055,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717938,GEO,GSM745294,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662056,0.37,Days,Time of initial vaccine administration,Whole blood,,ES717939,GEO,GSM745219,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662057,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717940,GEO,GSM745216,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662058,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717941,GEO,GSM745227,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662059,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717942,GEO,GSM745241,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662060,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717943,GEO,GSM745285,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662061,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717944,GEO,GSM745288,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662062,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717945,GEO,GSM745218,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662063,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717946,GEO,GSM745242,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662066,2.0,Days,Time of initial vaccine administration,Whole blood,,ES717949,GEO,GSM745300,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662068,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717951,GEO,GSM745253,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662071,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717954,GEO,GSM745310,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662072,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717955,GEO,GSM745314,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662074,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717957,GEO,GSM745307,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662075,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717958,GEO,GSM745247,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662077,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717960,GEO,GSM745299,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662078,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717961,GEO,GSM745303,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662079,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717962,GEO,GSM745305,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662083,0.37,Days,Time of initial vaccine administration,Whole blood,,ES717966,GEO,GSM745317,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662084,0.62,Days,Time of initial vaccine administration,Whole blood,,ES717967,GEO,GSM745319,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662085,2.0,Days,Time of initial vaccine administration,Whole blood,,ES717968,GEO,GSM745224,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662087,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717970,GEO,GSM745246,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662089,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717972,GEO,GSM745237,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662091,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717974,GEO,GSM745304,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662093,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717976,GEO,GSM745234,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662094,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717977,GEO,GSM745320,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662095,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717978,GEO,GSM745248,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662096,0.37,Days,Time of initial vaccine administration,Whole blood,,ES717979,GEO,GSM745306,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662097,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717980,GEO,GSM745318,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662098,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717981,GEO,GSM745255,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662100,0.25,Days,Time of initial vaccine administration,Whole blood,,ES717983,GEO,GSM745316,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662101,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717984,GEO,GSM745313,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662102,2.0,Days,Time of initial vaccine administration,Whole blood,,ES717985,GEO,GSM745311,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662103,2.0,Days,Time of initial vaccine administration,Whole blood,,ES717986,GEO,GSM745289,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662105,0.12,Days,Time of initial vaccine administration,Whole blood,,ES717988,GEO,GSM745249,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662106,1.0,Days,Time of initial vaccine administration,Whole blood,,ES717989,GEO,GSM745309,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662107,0.06,Days,Time of initial vaccine administration,Whole blood,,ES717990,GEO,GSM745238,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662108,1.5,Days,Time of initial vaccine administration,Whole blood,,ES717991,GEO,GSM745321,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662109,0.0,Days,Time of initial vaccine administration,Whole blood,,ES717992,GEO,GSM745302,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662110,0.5,Days,Time of initial vaccine administration,Whole blood,,ES717993,GEO,GSM745252,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662115,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717998,GEO,GSM745301,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662116,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES717999,GEO,GSM745312,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662117,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718000,GEO,GSM745235,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662119,0.12,Days,Time of initial vaccine administration,Whole blood,,ES718002,GEO,GSM745315,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662123,0.37,Days,Time of initial vaccine administration,Whole blood,,ES718006,GEO,GSM745251,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662124,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718007,GEO,GSM745254,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662125,0.62,Days,Time of initial vaccine administration,Whole blood,,ES718008,GEO,GSM745308,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662126,0.25,Days,Time of initial vaccine administration,Whole blood,,ES718009,GEO,GSM745250,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662127,0.37,Days,Time of initial vaccine administration,Whole blood,,ES718010,GEO,GSM745273,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662129,0.06,Days,Time of initial vaccine administration,Whole blood,,ES718012,GEO,GSM745270,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662130,0.37,Days,Time of initial vaccine administration,Whole blood,,ES718013,GEO,GSM745328,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662132,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718015,GEO,GSM745265,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662133,0.62,Days,Time of initial vaccine administration,Whole blood,,ES718016,GEO,GSM745264,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662135,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718018,GEO,GSM745331,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662136,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718019,GEO,GSM745344,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662138,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718021,GEO,GSM745322,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662139,0.06,Days,Time of initial vaccine administration,Whole blood,,ES718022,GEO,GSM745259,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662140,0.25,Days,Time of initial vaccine administration,Whole blood,,ES718023,GEO,GSM745327,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662141,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718024,GEO,GSM745268,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662142,0.06,Days,Time of initial vaccine administration,Whole blood,,ES718025,GEO,GSM745336,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662143,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718026,GEO,GSM745278,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662144,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718027,GEO,GSM745263,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662145,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718028,GEO,GSM745274,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662147,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718030,GEO,GSM745340,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662148,0.62,Days,Time of initial vaccine administration,Whole blood,,ES718031,GEO,GSM745275,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662150,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718033,GEO,GSM745267,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662151,0.12,Days,Time of initial vaccine administration,Whole blood,,ES718034,GEO,GSM745337,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662152,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718035,GEO,GSM745276,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662153,0.12,Days,Time of initial vaccine administration,Whole blood,,ES718036,GEO,GSM745326,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662154,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718037,GEO,GSM745329,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662155,1.5,Days,Time of initial vaccine administration,Whole blood,,ES718038,GEO,GSM745266,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662157,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718040,GEO,GSM745333,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662158,0.37,Days,Time of initial vaccine administration,Whole blood,,ES718041,GEO,GSM745262,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662159,1.5,Days,Time of initial vaccine administration,Whole blood,,ES718042,GEO,GSM745343,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662161,1.5,Days,Time of initial vaccine administration,Whole blood,,ES718044,GEO,GSM745277,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662162,0.62,Days,Time of initial vaccine administration,Whole blood,,ES718045,GEO,GSM745330,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662163,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718046,GEO,GSM745342,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662164,0.25,Days,Time of initial vaccine administration,Whole blood,,ES718047,GEO,GSM745261,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662165,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718048,GEO,GSM745335,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662166,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718049,GEO,GSM745269,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662167,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718050,GEO,GSM745334,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662168,0.37,Days,Time of initial vaccine administration,Whole blood,,ES718051,GEO,GSM745339,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662169,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718052,GEO,GSM745323,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662171,0.25,Days,Time of initial vaccine administration,Whole blood,,ES718054,GEO,GSM745338,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662172,2.0,Days,Time of initial vaccine administration,Whole blood,,ES718055,GEO,GSM745256,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662175,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718058,GEO,GSM745258,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662176,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718059,GEO,GSM745324,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662177,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718060,GEO,GSM745257,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662178,0.12,Days,Time of initial vaccine administration,Whole blood,,ES718061,GEO,GSM745260,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662179,1.5,Days,Time of initial vaccine administration,Whole blood,,ES718062,GEO,GSM745332,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662180,0.25,Days,Time of initial vaccine administration,Whole blood,,ES718063,GEO,GSM745272,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662181,0.12,Days,Time of initial vaccine administration,Whole blood,,ES718064,GEO,GSM745271,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662183,0.62,Days,Time of initial vaccine administration,Whole blood,,ES718066,GEO,GSM745341,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662184,0.06,Days,Time of initial vaccine administration,Whole blood,,ES718067,GEO,GSM745325,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_2,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662185,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718068,GEO,GSM745136,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662186,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718069,GEO,GSM745107,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662187,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718070,GEO,GSM745111,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662189,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718072,GEO,GSM745129,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662190,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718073,GEO,GSM745059,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662192,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718075,GEO,GSM745131,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662193,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718076,GEO,GSM745065,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662194,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718077,GEO,GSM745051,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662198,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718081,GEO,GSM745105,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662199,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718082,GEO,GSM745143,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662201,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718084,GEO,GSM745086,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662202,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718085,GEO,GSM745064,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662206,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718089,GEO,GSM745120,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662208,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718091,GEO,GSM745101,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662210,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718093,GEO,GSM745085,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662214,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718097,GEO,GSM745069,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662216,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718099,GEO,GSM745077,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662217,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718100,GEO,GSM745103,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662219,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718102,GEO,GSM745116,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662221,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718104,GEO,GSM745106,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662222,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718105,GEO,GSM745062,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662224,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718107,GEO,GSM745141,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662225,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718108,GEO,GSM745049,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662226,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718109,GEO,GSM745125,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662228,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718111,GEO,GSM745076,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662229,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718112,GEO,GSM745099,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662230,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718113,GEO,GSM745108,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662231,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718114,GEO,GSM745093,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662233,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718116,GEO,GSM745138,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662234,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718117,GEO,GSM745073,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662235,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718118,GEO,GSM745057,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662237,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718120,GEO,GSM745083,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662238,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718121,GEO,GSM745128,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662240,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718123,GEO,GSM745142,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662241,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718124,GEO,GSM745102,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662242,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718125,GEO,GSM745113,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662244,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718127,GEO,GSM745082,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662245,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718128,GEO,GSM745121,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662246,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718129,GEO,GSM745124,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662248,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718131,GEO,GSM745096,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662250,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718133,GEO,GSM745127,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662251,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718134,GEO,GSM745054,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662254,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718137,GEO,GSM745079,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662255,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718138,GEO,GSM745123,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662256,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718139,GEO,GSM745090,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662257,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718140,GEO,GSM745072,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662258,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718141,GEO,GSM745068,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662260,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718143,GEO,GSM745135,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662261,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718144,GEO,GSM745112,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662262,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718145,GEO,GSM745094,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662264,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718147,GEO,GSM745058,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662266,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718149,GEO,GSM745053,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662267,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718150,GEO,GSM745097,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662268,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718151,GEO,GSM745060,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662269,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718152,GEO,GSM745084,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662270,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718153,GEO,GSM745098,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662271,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718154,GEO,GSM745061,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662272,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718155,GEO,GSM745133,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662274,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718157,GEO,GSM745080,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662275,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718158,GEO,GSM745050,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662278,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718161,GEO,GSM745078,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662280,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718163,GEO,GSM745139,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662282,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718165,GEO,GSM745074,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662283,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718166,GEO,GSM745087,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119267,Male,White,VO_0000047,Fluzone,BS662284,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718167,GEO,GSM745063,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662286,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718169,GEO,GSM745071,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662287,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718170,GEO,GSM745114,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662289,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718172,GEO,GSM745130,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662291,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718174,GEO,GSM745132,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662292,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718175,GEO,GSM745081,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662293,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718176,GEO,GSM745104,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662295,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718178,GEO,GSM745110,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662297,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718180,GEO,GSM745122,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662298,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718181,GEO,GSM745115,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662299,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718182,GEO,GSM745137,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662301,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718184,GEO,GSM745092,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119273,Male,White,VO_0000088,Pneumovax 23 (USA),BS662302,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718185,GEO,GSM745126,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662303,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718186,GEO,GSM745119,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662304,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718187,GEO,GSM745056,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662305,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718188,GEO,GSM745089,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662307,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718190,GEO,GSM745117,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119279,Female,White,VO_0000088,Pneumovax 23 (USA),BS662308,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718191,GEO,GSM745140,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119264,Female,White,VO_0000088,Pneumovax 23 (USA),BS662310,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718193,GEO,GSM745100,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119266,Female,White,VO_0000088,Pneumovax 23 (USA),BS662313,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718196,GEO,GSM745109,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662314,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718197,GEO,GSM745070,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119276,Male,White,VO_0000088,Pneumovax 23 (USA),BS662317,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718200,GEO,GSM745134,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662318,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718201,GEO,GSM745067,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119268,Male,White,VO_0000047,Fluzone,BS662319,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718202,GEO,GSM745066,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119277,Female,Asian,VO_0000047,Fluzone,BS662320,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718203,GEO,GSM745088,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119269,Male,Black or African American,VO_0000088,Pneumovax 23 (USA),BS662321,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718204,GEO,GSM745118,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662322,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718205,GEO,GSM745055,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119262,Female,Asian,VO_0000047,Fluzone,BS662323,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718206,GEO,GSM745052,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662325,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718208,GEO,GSM745095,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119274,Female,White,VO_0000047,Fluzone,BS662326,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718209,GEO,GSM745075,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119278,Male,Asian,VO_0000047,Fluzone,BS662327,0.5,Days,Time of initial vaccine administration,Whole blood,,ES718210,GEO,GSM745091,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662328,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718211,GEO,GSM744952,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662329,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718212,GEO,GSM744946,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662330,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718213,GEO,GSM744961,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662336,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718219,GEO,GSM744953,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662337,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718220,GEO,GSM744974,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662338,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718221,GEO,GSM744943,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662340,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718223,GEO,GSM744970,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662341,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718224,GEO,GSM744971,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662343,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718226,GEO,GSM744986,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662344,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718227,GEO,GSM744981,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662346,21.0,Days,Time of initial vaccine administration,Whole blood,,ES718229,GEO,GSM744958,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662347,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718230,GEO,GSM744959,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662348,14.0,Days,Time of initial vaccine administration,Whole blood,,ES718231,GEO,GSM744957,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662351,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718234,GEO,GSM744950,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662353,14.0,Days,Time of initial vaccine administration,Whole blood,,ES718236,GEO,GSM744984,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662357,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718240,GEO,GSM744945,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662360,14.0,Days,Time of initial vaccine administration,Whole blood,,ES718243,GEO,GSM744993,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662361,21.0,Days,Time of initial vaccine administration,Whole blood,,ES718244,GEO,GSM744976,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662362,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718245,GEO,GSM744947,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662363,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718246,GEO,GSM744963,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662366,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718249,GEO,GSM744992,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662367,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718250,GEO,GSM744972,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662368,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718251,GEO,GSM744968,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662370,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718253,GEO,GSM744983,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662371,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718254,GEO,GSM744978,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662372,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718255,GEO,GSM744987,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662374,21.0,Days,Time of initial vaccine administration,Whole blood,,ES718257,GEO,GSM744967,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662375,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718258,GEO,GSM744980,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662376,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718259,GEO,GSM744964,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662381,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718264,GEO,GSM744942,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662383,14.0,Days,Time of initial vaccine administration,Whole blood,,ES718266,GEO,GSM744966,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662387,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718270,GEO,GSM744989,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662388,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718271,GEO,GSM744955,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662391,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718274,GEO,GSM744951,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662392,14.0,Days,Time of initial vaccine administration,Whole blood,,ES718275,GEO,GSM744948,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662393,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718276,GEO,GSM744960,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662396,-7.0,Days,Time of initial vaccine administration,Whole blood,,ES718279,GEO,GSM744969,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662399,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718282,GEO,GSM744973,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662400,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718283,GEO,GSM744962,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662402,21.0,Days,Time of initial vaccine administration,Whole blood,,ES718285,GEO,GSM744994,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662403,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718286,GEO,GSM744956,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662405,1.0,Days,Time of initial vaccine administration,Whole blood,,ES718288,GEO,GSM744944,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662406,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718289,GEO,GSM744979,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662409,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718292,GEO,GSM744991,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119292,Female,Black or African American,VO_0000047,Fluzone,BS662410,21.0,Days,Time of initial vaccine administration,Whole blood,,ES718293,GEO,GSM744949,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119293,Male,White,VO_0000047,Fluzone,BS662411,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718294,GEO,GSM744954,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662413,7.0,Days,Time of initial vaccine administration,Whole blood,,ES718296,GEO,GSM744982,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662415,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718298,GEO,GSM744995,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119296,Male,Asian,VO_0000047,Fluzone,BS662416,21.0,Days,Time of initial vaccine administration,Whole blood,,ES718299,GEO,GSM744985,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662419,3.0,Days,Time of initial vaccine administration,Whole blood,,ES718302,GEO,GSM744990,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662422,28.0,Days,Time of initial vaccine administration,Whole blood,,ES718305,GEO,GSM744977,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119297,Female,Black or African American,VO_0000047,Fluzone,BS662423,0.0,Days,Time of initial vaccine administration,Whole blood,,ES718306,GEO,GSM744988,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119295,Female,White,VO_0000047,Fluzone,BS662426,14.0,Days,Time of initial vaccine administration,Whole blood,,ES718309,GEO,GSM744975,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY180,Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine,Systems approach to study immune response to seasonal influenza and 23-valent pneumoccocal vaccination in healthy adults.,22.0,49.0,SUB119294,Male,White,VO_0000047,Fluzone,BS662427,10.0,Days,Time of initial vaccine administration,Whole blood,,ES718310,GEO,GSM744965,false,GSE30101,GPL6947,Illumina HumanHT-12 V3.0 expression beadchip,GSE30101_1,Whole blood : NA,22.0 - 49.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS689463,0.0,Days,Time of initial vaccine administration,PBMC,,ES736192,GEO,GSM1441830,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS689464,2.0,Days,Time of initial vaccine administration,PBMC,,ES736193,GEO,GSM1441831,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS689465,7.0,Days,Time of initial vaccine administration,PBMC,,ES736194,GEO,GSM1441832,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS689466,28.0,Days,Time of initial vaccine administration,PBMC,,ES736195,GEO,GSM1441833,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS689467,0.0,Days,Time of initial vaccine administration,PBMC,,ES736196,GEO,GSM1441834,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS689468,2.0,Days,Time of initial vaccine administration,PBMC,,ES736197,GEO,GSM1441835,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS689469,7.0,Days,Time of initial vaccine administration,PBMC,,ES736198,GEO,GSM1441836,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS689470,28.0,Days,Time of initial vaccine administration,PBMC,,ES736199,GEO,GSM1441837,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS689471,0.0,Days,Time of initial vaccine administration,PBMC,,ES736200,GEO,GSM1441838,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS689472,2.0,Days,Time of initial vaccine administration,PBMC,,ES736201,GEO,GSM1441839,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS689473,7.0,Days,Time of initial vaccine administration,PBMC,,ES736202,GEO,GSM1441840,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS689474,28.0,Days,Time of initial vaccine administration,PBMC,,ES736203,GEO,GSM1441841,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS689475,0.0,Days,Time of initial vaccine administration,PBMC,,ES736204,GEO,GSM1441842,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS689476,2.0,Days,Time of initial vaccine administration,PBMC,,ES736205,GEO,GSM1441843,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS689477,7.0,Days,Time of initial vaccine administration,PBMC,,ES736206,GEO,GSM1441844,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS689478,28.0,Days,Time of initial vaccine administration,PBMC,,ES736207,GEO,GSM1441845,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120424,Male,White,VO_0000642,Influenza virus vaccine,BS689479,0.0,Days,Time of initial vaccine administration,PBMC,,ES736208,GEO,GSM1441846,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120424,Male,White,VO_0000642,Influenza virus vaccine,BS689480,2.0,Days,Time of initial vaccine administration,PBMC,,ES736209,GEO,GSM1441847,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120424,Male,White,VO_0000642,Influenza virus vaccine,BS689481,7.0,Days,Time of initial vaccine administration,PBMC,,ES736210,GEO,GSM1441848,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120424,Male,White,VO_0000642,Influenza virus vaccine,BS689482,28.0,Days,Time of initial vaccine administration,PBMC,,ES736211,GEO,GSM1441849,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS689483,0.0,Days,Time of initial vaccine administration,PBMC,,ES736212,GEO,GSM1441850,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS689484,2.0,Days,Time of initial vaccine administration,PBMC,,ES736213,GEO,GSM1441851,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS689485,7.0,Days,Time of initial vaccine administration,PBMC,,ES736214,GEO,GSM1441852,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS689486,28.0,Days,Time of initial vaccine administration,PBMC,,ES736215,GEO,GSM1441853,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120427,Male,White,VO_0000642,Influenza virus vaccine,BS689487,0.0,Days,Time of initial vaccine administration,PBMC,,ES736216,GEO,GSM1441854,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120427,Male,White,VO_0000642,Influenza virus vaccine,BS689488,2.0,Days,Time of initial vaccine administration,PBMC,,ES736217,GEO,GSM1441855,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120427,Male,White,VO_0000642,Influenza virus vaccine,BS689489,7.0,Days,Time of initial vaccine administration,PBMC,,ES736218,GEO,GSM1441856,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120427,Male,White,VO_0000642,Influenza virus vaccine,BS689490,28.0,Days,Time of initial vaccine administration,PBMC,,ES736219,GEO,GSM1441857,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS689491,0.0,Days,Time of initial vaccine administration,PBMC,,ES736220,GEO,GSM1441858,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS689492,2.0,Days,Time of initial vaccine administration,PBMC,,ES736221,GEO,GSM1441859,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS689493,7.0,Days,Time of initial vaccine administration,PBMC,,ES736222,GEO,GSM1441860,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS689494,28.0,Days,Time of initial vaccine administration,PBMC,,ES736223,GEO,GSM1441861,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS689495,0.0,Days,Time of initial vaccine administration,PBMC,,ES736224,GEO,GSM1441862,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS689496,2.0,Days,Time of initial vaccine administration,PBMC,,ES736225,GEO,GSM1441863,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS689497,7.0,Days,Time of initial vaccine administration,PBMC,,ES736226,GEO,GSM1441864,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS689498,28.0,Days,Time of initial vaccine administration,PBMC,,ES736227,GEO,GSM1441865,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS689499,0.0,Days,Time of initial vaccine administration,PBMC,,ES736228,GEO,GSM1441866,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS689500,2.0,Days,Time of initial vaccine administration,PBMC,,ES736229,GEO,GSM1441867,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS689501,7.0,Days,Time of initial vaccine administration,PBMC,,ES736230,GEO,GSM1441868,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS689502,28.0,Days,Time of initial vaccine administration,PBMC,,ES736231,GEO,GSM1441869,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS689503,0.0,Days,Time of initial vaccine administration,PBMC,,ES736232,GEO,GSM1441870,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS689504,2.0,Days,Time of initial vaccine administration,PBMC,,ES736233,GEO,GSM1441871,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS689505,7.0,Days,Time of initial vaccine administration,PBMC,,ES736234,GEO,GSM1441872,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS689506,28.0,Days,Time of initial vaccine administration,PBMC,,ES736235,GEO,GSM1441873,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS689507,0.0,Days,Time of initial vaccine administration,PBMC,,ES736236,GEO,GSM1441874,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS689508,2.0,Days,Time of initial vaccine administration,PBMC,,ES736237,GEO,GSM1441875,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS689509,7.0,Days,Time of initial vaccine administration,PBMC,,ES736238,GEO,GSM1441876,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS689510,28.0,Days,Time of initial vaccine administration,PBMC,,ES736239,GEO,GSM1441877,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS689511,0.0,Days,Time of initial vaccine administration,PBMC,,ES736240,GEO,GSM1441878,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS689512,2.0,Days,Time of initial vaccine administration,PBMC,,ES736241,GEO,GSM1441879,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS689513,7.0,Days,Time of initial vaccine administration,PBMC,,ES736242,GEO,GSM1441880,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS689514,28.0,Days,Time of initial vaccine administration,PBMC,,ES736243,GEO,GSM1441881,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS689515,0.0,Days,Time of initial vaccine administration,PBMC,,ES736244,GEO,GSM1441882,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS689516,2.0,Days,Time of initial vaccine administration,PBMC,,ES736245,GEO,GSM1441883,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS689517,7.0,Days,Time of initial vaccine administration,PBMC,,ES736246,GEO,GSM1441884,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS689518,28.0,Days,Time of initial vaccine administration,PBMC,,ES736247,GEO,GSM1441885,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS689519,0.0,Days,Time of initial vaccine administration,PBMC,,ES736248,GEO,GSM1441886,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS689520,2.0,Days,Time of initial vaccine administration,PBMC,,ES736249,GEO,GSM1441887,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS689521,7.0,Days,Time of initial vaccine administration,PBMC,,ES736250,GEO,GSM1441888,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS689522,28.0,Days,Time of initial vaccine administration,PBMC,,ES736251,GEO,GSM1441889,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS689523,0.0,Days,Time of initial vaccine administration,PBMC,,ES736252,GEO,GSM1441890,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS689524,2.0,Days,Time of initial vaccine administration,PBMC,,ES736253,GEO,GSM1441891,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS689525,7.0,Days,Time of initial vaccine administration,PBMC,,ES736254,GEO,GSM1441892,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS689526,28.0,Days,Time of initial vaccine administration,PBMC,,ES736255,GEO,GSM1441893,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS689527,0.0,Days,Time of initial vaccine administration,PBMC,,ES736256,GEO,GSM1441894,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS689528,2.0,Days,Time of initial vaccine administration,PBMC,,ES736257,GEO,GSM1441895,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS689529,7.0,Days,Time of initial vaccine administration,PBMC,,ES736258,GEO,GSM1441896,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS689530,28.0,Days,Time of initial vaccine administration,PBMC,,ES736259,GEO,GSM1441897,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS689531,0.0,Days,Time of initial vaccine administration,PBMC,,ES736260,GEO,GSM1441898,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS689532,2.0,Days,Time of initial vaccine administration,PBMC,,ES736261,GEO,GSM1441899,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS689533,7.0,Days,Time of initial vaccine administration,PBMC,,ES736262,GEO,GSM1441900,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS689534,28.0,Days,Time of initial vaccine administration,PBMC,,ES736263,GEO,GSM1441901,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS689535,0.0,Days,Time of initial vaccine administration,PBMC,,ES736264,GEO,GSM1441902,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS689536,2.0,Days,Time of initial vaccine administration,PBMC,,ES736265,GEO,GSM1441903,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS689537,7.0,Days,Time of initial vaccine administration,PBMC,,ES736266,GEO,GSM1441904,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS689538,28.0,Days,Time of initial vaccine administration,PBMC,,ES736267,GEO,GSM1441905,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS689539,0.0,Days,Time of initial vaccine administration,PBMC,,ES736268,GEO,GSM1441906,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS689540,2.0,Days,Time of initial vaccine administration,PBMC,,ES736269,GEO,GSM1441907,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS689541,7.0,Days,Time of initial vaccine administration,PBMC,,ES736270,GEO,GSM1441908,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS689542,28.0,Days,Time of initial vaccine administration,PBMC,,ES736271,GEO,GSM1441909,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS689543,0.0,Days,Time of initial vaccine administration,PBMC,,ES736272,GEO,GSM1441910,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS689544,2.0,Days,Time of initial vaccine administration,PBMC,,ES736273,GEO,GSM1441911,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS689545,7.0,Days,Time of initial vaccine administration,PBMC,,ES736274,GEO,GSM1441912,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS689546,28.0,Days,Time of initial vaccine administration,PBMC,,ES736275,GEO,GSM1441913,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS689547,0.0,Days,Time of initial vaccine administration,PBMC,,ES736276,GEO,GSM1441914,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS689548,2.0,Days,Time of initial vaccine administration,PBMC,,ES736277,GEO,GSM1441915,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS689549,7.0,Days,Time of initial vaccine administration,PBMC,,ES736278,GEO,GSM1441916,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS689550,28.0,Days,Time of initial vaccine administration,PBMC,,ES736279,GEO,GSM1441917,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS689551,0.0,Days,Time of initial vaccine administration,PBMC,,ES736280,GEO,GSM1441918,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS689552,2.0,Days,Time of initial vaccine administration,PBMC,,ES736281,GEO,GSM1441919,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS689553,7.0,Days,Time of initial vaccine administration,PBMC,,ES736282,GEO,GSM1441920,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS689554,28.0,Days,Time of initial vaccine administration,PBMC,,ES736283,GEO,GSM1441921,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS689555,0.0,Days,Time of initial vaccine administration,PBMC,,ES736284,GEO,GSM1441922,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS689556,2.0,Days,Time of initial vaccine administration,PBMC,,ES736285,GEO,GSM1441923,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS689557,7.0,Days,Time of initial vaccine administration,PBMC,,ES736286,GEO,GSM1441924,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS689558,28.0,Days,Time of initial vaccine administration,PBMC,,ES736287,GEO,GSM1441925,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120466,Female,White,VO_0000642,Influenza virus vaccine,BS689559,0.0,Days,Time of initial vaccine administration,PBMC,,ES736288,GEO,GSM1441926,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120466,Female,White,VO_0000642,Influenza virus vaccine,BS689560,2.0,Days,Time of initial vaccine administration,PBMC,,ES736289,GEO,GSM1441927,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120466,Female,White,VO_0000642,Influenza virus vaccine,BS689561,7.0,Days,Time of initial vaccine administration,PBMC,,ES736290,GEO,GSM1441928,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120466,Female,White,VO_0000642,Influenza virus vaccine,BS689562,28.0,Days,Time of initial vaccine administration,PBMC,,ES736291,GEO,GSM1441929,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS689563,0.0,Days,Time of initial vaccine administration,PBMC,,ES736292,GEO,GSM1441930,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS689564,2.0,Days,Time of initial vaccine administration,PBMC,,ES736293,GEO,GSM1441931,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS689565,7.0,Days,Time of initial vaccine administration,PBMC,,ES736294,GEO,GSM1441932,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS689566,28.0,Days,Time of initial vaccine administration,PBMC,,ES736295,GEO,GSM1441933,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS689567,0.0,Days,Time of initial vaccine administration,PBMC,,ES736296,GEO,GSM1441934,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS689568,2.0,Days,Time of initial vaccine administration,PBMC,,ES736297,GEO,GSM1441935,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS689569,7.0,Days,Time of initial vaccine administration,PBMC,,ES736298,GEO,GSM1441936,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS689570,28.0,Days,Time of initial vaccine administration,PBMC,,ES736299,GEO,GSM1441937,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS689571,0.0,Days,Time of initial vaccine administration,PBMC,,ES736300,GEO,GSM1441938,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS689572,2.0,Days,Time of initial vaccine administration,PBMC,,ES736301,GEO,GSM1441939,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS689573,7.0,Days,Time of initial vaccine administration,PBMC,,ES736302,GEO,GSM1441940,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS689574,24.0,Days,Time of initial vaccine administration,PBMC,,ES736303,GEO,GSM1441941,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS689575,0.0,Days,Time of initial vaccine administration,PBMC,,ES736304,GEO,GSM1441942,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS689576,2.0,Days,Time of initial vaccine administration,PBMC,,ES736305,GEO,GSM1441943,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS689577,7.0,Days,Time of initial vaccine administration,PBMC,,ES736306,GEO,GSM1441944,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS689578,32.0,Days,Time of initial vaccine administration,PBMC,,ES736307,GEO,GSM1441945,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS689579,0.0,Days,Time of initial vaccine administration,PBMC,,ES736308,GEO,GSM1441946,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS689580,2.0,Days,Time of initial vaccine administration,PBMC,,ES736309,GEO,GSM1441947,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS689581,7.0,Days,Time of initial vaccine administration,PBMC,,ES736310,GEO,GSM1441948,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS689582,28.0,Days,Time of initial vaccine administration,PBMC,,ES736311,GEO,GSM1441949,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS689583,0.0,Days,Time of initial vaccine administration,PBMC,,ES736312,GEO,GSM1441950,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS689584,2.0,Days,Time of initial vaccine administration,PBMC,,ES736313,GEO,GSM1441951,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS689585,7.0,Days,Time of initial vaccine administration,PBMC,,ES736314,GEO,GSM1441952,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS689586,28.0,Days,Time of initial vaccine administration,PBMC,,ES736315,GEO,GSM1441953,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS689587,0.0,Days,Time of initial vaccine administration,PBMC,,ES736316,GEO,GSM1441954,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS689588,2.0,Days,Time of initial vaccine administration,PBMC,,ES736317,GEO,GSM1441955,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS689589,7.0,Days,Time of initial vaccine administration,PBMC,,ES736318,GEO,GSM1441956,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS689590,28.0,Days,Time of initial vaccine administration,PBMC,,ES736319,GEO,GSM1441957,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120480,Female,White,VO_0000642,Influenza virus vaccine,BS689591,0.0,Days,Time of initial vaccine administration,PBMC,,ES736320,GEO,GSM1441958,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120480,Female,White,VO_0000642,Influenza virus vaccine,BS689592,4.0,Days,Time of initial vaccine administration,PBMC,,ES736321,GEO,GSM1441959,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120480,Female,White,VO_0000642,Influenza virus vaccine,BS689593,7.0,Days,Time of initial vaccine administration,PBMC,,ES736322,GEO,GSM1441960,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120480,Female,White,VO_0000642,Influenza virus vaccine,BS689594,28.0,Days,Time of initial vaccine administration,PBMC,,ES736323,GEO,GSM1441961,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120481,Male,White,VO_0000642,Influenza virus vaccine,BS689595,0.0,Days,Time of initial vaccine administration,PBMC,,ES736324,GEO,GSM1441962,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120481,Male,White,VO_0000642,Influenza virus vaccine,BS689596,4.0,Days,Time of initial vaccine administration,PBMC,,ES736325,GEO,GSM1441963,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120481,Male,White,VO_0000642,Influenza virus vaccine,BS689597,7.0,Days,Time of initial vaccine administration,PBMC,,ES736326,GEO,GSM1441964,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120481,Male,White,VO_0000642,Influenza virus vaccine,BS689598,28.0,Days,Time of initial vaccine administration,PBMC,,ES736327,GEO,GSM1441965,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120483,Male,White,VO_0000642,Influenza virus vaccine,BS689599,0.0,Days,Time of initial vaccine administration,PBMC,,ES736328,GEO,GSM1441966,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120483,Male,White,VO_0000642,Influenza virus vaccine,BS689600,4.0,Days,Time of initial vaccine administration,PBMC,,ES736329,GEO,GSM1441967,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120483,Male,White,VO_0000642,Influenza virus vaccine,BS689601,7.0,Days,Time of initial vaccine administration,PBMC,,ES736330,GEO,GSM1441968,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120483,Male,White,VO_0000642,Influenza virus vaccine,BS689602,28.0,Days,Time of initial vaccine administration,PBMC,,ES736331,GEO,GSM1441969,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120484,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS689603,0.0,Days,Time of initial vaccine administration,PBMC,,ES736332,GEO,GSM1441970,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120484,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS689604,4.0,Days,Time of initial vaccine administration,PBMC,,ES736333,GEO,GSM1441971,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120484,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS689605,7.0,Days,Time of initial vaccine administration,PBMC,,ES736334,GEO,GSM1441972,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120484,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS689606,28.0,Days,Time of initial vaccine administration,PBMC,,ES736335,GEO,GSM1441973,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS689607,0.0,Days,Time of initial vaccine administration,PBMC,,ES736336,GEO,GSM1441974,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS689608,4.0,Days,Time of initial vaccine administration,PBMC,,ES736337,GEO,GSM1441975,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS689609,7.0,Days,Time of initial vaccine administration,PBMC,,ES736338,GEO,GSM1441976,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS689610,28.0,Days,Time of initial vaccine administration,PBMC,,ES736339,GEO,GSM1441977,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120487,Male,White,VO_0000642,Influenza virus vaccine,BS689611,0.0,Days,Time of initial vaccine administration,PBMC,,ES736340,GEO,GSM1441978,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120487,Male,White,VO_0000642,Influenza virus vaccine,BS689612,4.0,Days,Time of initial vaccine administration,PBMC,,ES736341,GEO,GSM1441979,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120487,Male,White,VO_0000642,Influenza virus vaccine,BS689613,7.0,Days,Time of initial vaccine administration,PBMC,,ES736342,GEO,GSM1441980,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120487,Male,White,VO_0000642,Influenza virus vaccine,BS689614,28.0,Days,Time of initial vaccine administration,PBMC,,ES736343,GEO,GSM1441981,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120488,Female,White,VO_0000642,Influenza virus vaccine,BS689615,0.0,Days,Time of initial vaccine administration,PBMC,,ES736344,GEO,GSM1441982,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120488,Female,White,VO_0000642,Influenza virus vaccine,BS689616,4.0,Days,Time of initial vaccine administration,PBMC,,ES736345,GEO,GSM1441983,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120488,Female,White,VO_0000642,Influenza virus vaccine,BS689617,7.0,Days,Time of initial vaccine administration,PBMC,,ES736346,GEO,GSM1441984,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120488,Female,White,VO_0000642,Influenza virus vaccine,BS689618,28.0,Days,Time of initial vaccine administration,PBMC,,ES736347,GEO,GSM1441985,false,GSE59714,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59714_1,PBMC : NA,22.0 - 90.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118148,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713658,0.0,Days,Time of initial vaccine administration,Other,,ES773839,GEO,GSM1257234,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118148,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713659,1.0,Days,Time of initial vaccine administration,Other,,ES773840,GEO,GSM1257185,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118148,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713660,30.0,Days,Time of initial vaccine administration,Other,,ES773841,GEO,GSM1257137,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118148,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713661,7.0,Days,Time of initial vaccine administration,Other,,ES773842,GEO,GSM1257176,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118149,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713662,0.0,Days,Time of initial vaccine administration,Other,,ES773843,GEO,GSM1257199,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118149,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713663,1.0,Days,Time of initial vaccine administration,Other,,ES773844,GEO,GSM1257202,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118149,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713664,30.0,Days,Time of initial vaccine administration,Other,,ES773845,GEO,GSM1257189,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118149,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713665,7.0,Days,Time of initial vaccine administration,Other,,ES773846,GEO,GSM1257164,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118150,Male,White,VO_0001178,live attenuated influenza vaccine,BS713666,0.0,Days,Time of initial vaccine administration,Other,,ES773847,GEO,GSM1257177,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118150,Male,White,VO_0001178,live attenuated influenza vaccine,BS713667,1.0,Days,Time of initial vaccine administration,Other,,ES773848,GEO,GSM1257187,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118150,Male,White,VO_0001178,live attenuated influenza vaccine,BS713668,30.0,Days,Time of initial vaccine administration,Other,,ES773849,GEO,GSM1257173,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118150,Male,White,VO_0001178,live attenuated influenza vaccine,BS713669,7.0,Days,Time of initial vaccine administration,Other,,ES773850,GEO,GSM1257194,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118151,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713670,0.0,Days,Time of initial vaccine administration,Other,,ES773851,GEO,GSM1257200,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118151,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713671,1.0,Days,Time of initial vaccine administration,Other,,ES773852,GEO,GSM1257153,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118151,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713672,30.0,Days,Time of initial vaccine administration,Other,,ES773853,GEO,GSM1257161,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118151,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713673,7.0,Days,Time of initial vaccine administration,Other,,ES773854,GEO,GSM1257204,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118152,Male,White,VO_0001178,live attenuated influenza vaccine,BS713674,1.0,Days,Time of initial vaccine administration,Other,,ES773855,GEO,GSM1257243,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118152,Male,White,VO_0001178,live attenuated influenza vaccine,BS713675,30.0,Days,Time of initial vaccine administration,Other,,ES773856,GEO,GSM1257147,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118152,Male,White,VO_0001178,live attenuated influenza vaccine,BS713676,7.0,Days,Time of initial vaccine administration,Other,,ES773857,GEO,GSM1257138,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118153,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713677,0.0,Days,Time of initial vaccine administration,Other,,ES773858,GEO,GSM1257167,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118153,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713678,1.0,Days,Time of initial vaccine administration,Other,,ES773859,GEO,GSM1257226,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118153,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713679,30.0,Days,Time of initial vaccine administration,Other,,ES773860,GEO,GSM1257168,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118153,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713680,7.0,Days,Time of initial vaccine administration,Other,,ES773861,GEO,GSM1257229,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118154,Female,White,VO_0001178,live attenuated influenza vaccine,BS713681,0.0,Days,Time of initial vaccine administration,Other,,ES773862,GEO,GSM1257228,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118154,Female,White,VO_0001178,live attenuated influenza vaccine,BS713682,1.0,Days,Time of initial vaccine administration,Other,,ES773863,GEO,GSM1257156,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118154,Female,White,VO_0001178,live attenuated influenza vaccine,BS713683,30.0,Days,Time of initial vaccine administration,Other,,ES773864,GEO,GSM1257195,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118154,Female,White,VO_0001178,live attenuated influenza vaccine,BS713684,7.0,Days,Time of initial vaccine administration,Other,,ES773865,GEO,GSM1257212,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118155,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713685,0.0,Days,Time of initial vaccine administration,Other,,ES773866,GEO,GSM1257259,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118155,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713686,1.0,Days,Time of initial vaccine administration,Other,,ES773867,GEO,GSM1257216,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118155,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713687,30.0,Days,Time of initial vaccine administration,Other,,ES773868,GEO,GSM1257206,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118155,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713688,7.0,Days,Time of initial vaccine administration,Other,,ES773869,GEO,GSM1257239,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118156,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713689,0.0,Days,Time of initial vaccine administration,Other,,ES773870,GEO,GSM1257132,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118156,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713690,1.0,Days,Time of initial vaccine administration,Other,,ES773871,GEO,GSM1257160,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118156,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713691,30.0,Days,Time of initial vaccine administration,Other,,ES773872,GEO,GSM1257142,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118156,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713692,7.0,Days,Time of initial vaccine administration,Other,,ES773873,GEO,GSM1257155,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118157,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713693,0.0,Days,Time of initial vaccine administration,Other,,ES773874,GEO,GSM1257251,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118157,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713694,1.0,Days,Time of initial vaccine administration,Other,,ES773875,GEO,GSM1257230,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118157,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713695,30.0,Days,Time of initial vaccine administration,Other,,ES773876,GEO,GSM1257148,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118157,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713696,7.0,Days,Time of initial vaccine administration,Other,,ES773877,GEO,GSM1257254,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118158,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713697,0.0,Days,Time of initial vaccine administration,Other,,ES773878,GEO,GSM1257213,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118158,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713698,1.0,Days,Time of initial vaccine administration,Other,,ES773879,GEO,GSM1257223,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118158,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713699,30.0,Days,Time of initial vaccine administration,Other,,ES773880,GEO,GSM1257130,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118158,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713700,7.0,Days,Time of initial vaccine administration,Other,,ES773881,GEO,GSM1257233,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118159,Female,White,VO_0001178,live attenuated influenza vaccine,BS713701,0.0,Days,Time of initial vaccine administration,Other,,ES773882,GEO,GSM1257154,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118159,Female,White,VO_0001178,live attenuated influenza vaccine,BS713702,1.0,Days,Time of initial vaccine administration,Other,,ES773883,GEO,GSM1257197,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118159,Female,White,VO_0001178,live attenuated influenza vaccine,BS713703,30.0,Days,Time of initial vaccine administration,Other,,ES773884,GEO,GSM1257238,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118159,Female,White,VO_0001178,live attenuated influenza vaccine,BS713704,7.0,Days,Time of initial vaccine administration,Other,,ES773885,GEO,GSM1257184,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118160,Male,White,VO_0001178,live attenuated influenza vaccine,BS713705,0.0,Days,Time of initial vaccine administration,Other,,ES773886,GEO,GSM1257152,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118160,Male,White,VO_0001178,live attenuated influenza vaccine,BS713706,1.0,Days,Time of initial vaccine administration,Other,,ES773887,GEO,GSM1257172,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118160,Male,White,VO_0001178,live attenuated influenza vaccine,BS713707,30.0,Days,Time of initial vaccine administration,Other,,ES773888,GEO,GSM1257143,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118160,Male,White,VO_0001178,live attenuated influenza vaccine,BS713708,7.0,Days,Time of initial vaccine administration,Other,,ES773889,GEO,GSM1257260,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118161,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713709,0.0,Days,Time of initial vaccine administration,Other,,ES773890,GEO,GSM1257174,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118161,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713710,1.0,Days,Time of initial vaccine administration,Other,,ES773891,GEO,GSM1257247,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118161,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713711,30.0,Days,Time of initial vaccine administration,Other,,ES773892,GEO,GSM1257162,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118161,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713712,7.0,Days,Time of initial vaccine administration,Other,,ES773893,GEO,GSM1257182,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118162,Male,White,VO_0001178,live attenuated influenza vaccine,BS713713,0.0,Days,Time of initial vaccine administration,Other,,ES773894,GEO,GSM1257241,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118162,Male,White,VO_0001178,live attenuated influenza vaccine,BS713714,1.0,Days,Time of initial vaccine administration,Other,,ES773895,GEO,GSM1257224,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118162,Male,White,VO_0001178,live attenuated influenza vaccine,BS713715,30.0,Days,Time of initial vaccine administration,Other,,ES773896,GEO,GSM1257146,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118162,Male,White,VO_0001178,live attenuated influenza vaccine,BS713716,7.0,Days,Time of initial vaccine administration,Other,,ES773897,GEO,GSM1257141,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118163,Female,White,VO_0001178,live attenuated influenza vaccine,BS713717,0.0,Days,Time of initial vaccine administration,Other,,ES773898,GEO,GSM1257240,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118163,Female,White,VO_0001178,live attenuated influenza vaccine,BS713718,1.0,Days,Time of initial vaccine administration,Other,,ES773899,GEO,GSM1257221,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118163,Female,White,VO_0001178,live attenuated influenza vaccine,BS713719,30.0,Days,Time of initial vaccine administration,Other,,ES773900,GEO,GSM1257183,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118163,Female,White,VO_0001178,live attenuated influenza vaccine,BS713720,7.0,Days,Time of initial vaccine administration,Other,,ES773901,GEO,GSM1257231,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118164,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713721,0.0,Days,Time of initial vaccine administration,Other,,ES773902,GEO,GSM1257170,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118164,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713722,1.0,Days,Time of initial vaccine administration,Other,,ES773903,GEO,GSM1257246,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118164,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713723,30.0,Days,Time of initial vaccine administration,Other,,ES773904,GEO,GSM1257249,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118164,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713724,7.0,Days,Time of initial vaccine administration,Other,,ES773905,GEO,GSM1257179,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118165,Female,White,VO_0001178,live attenuated influenza vaccine,BS713725,0.0,Days,Time of initial vaccine administration,Other,,ES773906,GEO,GSM1257169,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118165,Female,White,VO_0001178,live attenuated influenza vaccine,BS713726,1.0,Days,Time of initial vaccine administration,Other,,ES773907,GEO,GSM1257227,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118165,Female,White,VO_0001178,live attenuated influenza vaccine,BS713727,30.0,Days,Time of initial vaccine administration,Other,,ES773908,GEO,GSM1257244,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118165,Female,White,VO_0001178,live attenuated influenza vaccine,BS713728,7.0,Days,Time of initial vaccine administration,Other,,ES773909,GEO,GSM1257180,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118166,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713730,1.0,Days,Time of initial vaccine administration,Other,,ES773911,GEO,GSM1257261,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118166,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713731,30.0,Days,Time of initial vaccine administration,Other,,ES773912,GEO,GSM1257210,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118166,Male,Other,VO_0001178,live attenuated influenza vaccine,BS713732,7.0,Days,Time of initial vaccine administration,Other,,ES773913,GEO,GSM1257145,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118167,Female,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713733,0.0,Days,Time of initial vaccine administration,Other,,ES773914,GEO,GSM1257211,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118167,Female,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713734,1.0,Days,Time of initial vaccine administration,Other,,ES773915,GEO,GSM1257157,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118167,Female,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713735,30.0,Days,Time of initial vaccine administration,Other,,ES773916,GEO,GSM1257190,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118167,Female,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713736,7.0,Days,Time of initial vaccine administration,Other,,ES773917,GEO,GSM1257201,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118168,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713737,30.0,Days,Time of initial vaccine administration,Other,,ES773918,GEO,GSM1257136,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118168,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713738,7.0,Days,Time of initial vaccine administration,Other,,ES773919,GEO,GSM1257207,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118169,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713739,0.0,Days,Time of initial vaccine administration,Other,,ES773920,GEO,GSM1257252,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118169,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713740,7.0,Days,Time of initial vaccine administration,Other,,ES773921,GEO,GSM1257151,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118170,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713741,0.0,Days,Time of initial vaccine administration,Other,,ES773922,GEO,GSM1257217,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118170,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713742,1.0,Days,Time of initial vaccine administration,Other,,ES773923,GEO,GSM1257242,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118170,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713743,30.0,Days,Time of initial vaccine administration,Other,,ES773924,GEO,GSM1257256,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118170,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713744,7.0,Days,Time of initial vaccine administration,Other,,ES773925,GEO,GSM1257140,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118171,Male,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713745,0.0,Days,Time of initial vaccine administration,Other,,ES773926,GEO,GSM1257262,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118171,Male,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713746,1.0,Days,Time of initial vaccine administration,Other,,ES773927,GEO,GSM1257128,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118171,Male,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713747,30.0,Days,Time of initial vaccine administration,Other,,ES773928,GEO,GSM1257250,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118171,Male,Asian,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713748,7.0,Days,Time of initial vaccine administration,Other,,ES773929,GEO,GSM1257175,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118172,Female,White,VO_0001178,live attenuated influenza vaccine,BS713749,0.0,Days,Time of initial vaccine administration,Other,,ES773930,GEO,GSM1257150,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118172,Female,White,VO_0001178,live attenuated influenza vaccine,BS713750,1.0,Days,Time of initial vaccine administration,Other,,ES773931,GEO,GSM1257203,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118172,Female,White,VO_0001178,live attenuated influenza vaccine,BS713751,30.0,Days,Time of initial vaccine administration,Other,,ES773932,GEO,GSM1257253,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118172,Female,White,VO_0001178,live attenuated influenza vaccine,BS713752,7.0,Days,Time of initial vaccine administration,Other,,ES773933,GEO,GSM1257208,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118173,Male,White,VO_0001178,live attenuated influenza vaccine,BS713753,0.0,Days,Time of initial vaccine administration,Other,,ES773934,GEO,GSM1257235,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118173,Male,White,VO_0001178,live attenuated influenza vaccine,BS713754,1.0,Days,Time of initial vaccine administration,Other,,ES773935,GEO,GSM1257139,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118174,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713755,0.0,Days,Time of initial vaccine administration,Other,,ES773936,GEO,GSM1257248,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118174,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713756,1.0,Days,Time of initial vaccine administration,Other,,ES773937,GEO,GSM1257198,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118174,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713757,30.0,Days,Time of initial vaccine administration,Other,,ES773938,GEO,GSM1257159,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118174,Male,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713758,7.0,Days,Time of initial vaccine administration,Other,,ES773939,GEO,GSM1257257,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118175,Male,Black or African American,VO_0001178,live attenuated influenza vaccine,BS713759,0.0,Days,Time of initial vaccine administration,Other,,ES773940,GEO,GSM1257255,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118175,Male,Black or African American,VO_0001178,live attenuated influenza vaccine,BS713760,30.0,Days,Time of initial vaccine administration,Other,,ES773941,GEO,GSM1257163,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118175,Male,Black or African American,VO_0001178,live attenuated influenza vaccine,BS713761,7.0,Days,Time of initial vaccine administration,Other,,ES773942,GEO,GSM1257232,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118176,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713762,0.0,Days,Time of initial vaccine administration,Other,,ES773943,GEO,GSM1257214,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118176,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713763,1.0,Days,Time of initial vaccine administration,Other,,ES773944,GEO,GSM1257196,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118176,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713764,30.0,Days,Time of initial vaccine administration,Other,,ES773945,GEO,GSM1257181,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118176,Female,White,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713765,7.0,Days,Time of initial vaccine administration,Other,,ES773946,GEO,GSM1257192,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118177,Female,White,VO_0001178,live attenuated influenza vaccine,BS713766,0.0,Days,Time of initial vaccine administration,Other,,ES773947,GEO,GSM1257191,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118177,Female,White,VO_0001178,live attenuated influenza vaccine,BS713767,1.0,Days,Time of initial vaccine administration,Other,,ES773948,GEO,GSM1257258,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118177,Female,White,VO_0001178,live attenuated influenza vaccine,BS713768,30.0,Days,Time of initial vaccine administration,Other,,ES773949,GEO,GSM1257135,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118177,Female,White,VO_0001178,live attenuated influenza vaccine,BS713769,7.0,Days,Time of initial vaccine administration,Other,,ES773950,GEO,GSM1257218,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118178,Female,White,VO_0001178,live attenuated influenza vaccine,BS713770,0.0,Days,Time of initial vaccine administration,Other,,ES773951,GEO,GSM1257158,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118178,Female,White,VO_0001178,live attenuated influenza vaccine,BS713771,1.0,Days,Time of initial vaccine administration,Other,,ES773952,GEO,GSM1257209,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118178,Female,White,VO_0001178,live attenuated influenza vaccine,BS713772,30.0,Days,Time of initial vaccine administration,Other,,ES773953,GEO,GSM1257186,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118178,Female,White,VO_0001178,live attenuated influenza vaccine,BS713773,7.0,Days,Time of initial vaccine administration,Other,,ES773954,GEO,GSM1257220,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118179,Female,White,VO_0001178,live attenuated influenza vaccine,BS713774,0.0,Days,Time of initial vaccine administration,Other,,ES773955,GEO,GSM1257171,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118179,Female,White,VO_0001178,live attenuated influenza vaccine,BS713775,1.0,Days,Time of initial vaccine administration,Other,,ES773956,GEO,GSM1257165,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118179,Female,White,VO_0001178,live attenuated influenza vaccine,BS713776,30.0,Days,Time of initial vaccine administration,Other,,ES773957,GEO,GSM1257236,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118179,Female,White,VO_0001178,live attenuated influenza vaccine,BS713777,7.0,Days,Time of initial vaccine administration,Other,,ES773958,GEO,GSM1257133,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118180,Female,Asian,VO_0001178,live attenuated influenza vaccine,BS713778,0.0,Days,Time of initial vaccine administration,Other,,ES773959,GEO,GSM1257131,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118180,Female,Asian,VO_0001178,live attenuated influenza vaccine,BS713779,1.0,Days,Time of initial vaccine administration,Other,,ES773960,GEO,GSM1257222,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118180,Female,Asian,VO_0001178,live attenuated influenza vaccine,BS713780,30.0,Days,Time of initial vaccine administration,Other,,ES773961,GEO,GSM1257144,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118180,Female,Asian,VO_0001178,live attenuated influenza vaccine,BS713781,7.0,Days,Time of initial vaccine administration,Other,,ES773962,GEO,GSM1257178,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118181,Female,White,VO_0001178,live attenuated influenza vaccine,BS713782,0.0,Days,Time of initial vaccine administration,Other,,ES773963,GEO,GSM1257193,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118181,Female,White,VO_0001178,live attenuated influenza vaccine,BS713783,1.0,Days,Time of initial vaccine administration,Other,,ES773964,GEO,GSM1257134,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118181,Female,White,VO_0001178,live attenuated influenza vaccine,BS713784,30.0,Days,Time of initial vaccine administration,Other,,ES773965,GEO,GSM1257166,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118181,Female,White,VO_0001178,live attenuated influenza vaccine,BS713785,7.0,Days,Time of initial vaccine administration,Other,,ES773966,GEO,GSM1257149,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118182,Male,White,VO_0001178,live attenuated influenza vaccine,BS713786,0.0,Days,Time of initial vaccine administration,Other,,ES773967,GEO,GSM1257219,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118182,Male,White,VO_0001178,live attenuated influenza vaccine,BS713787,1.0,Days,Time of initial vaccine administration,Other,,ES773968,GEO,GSM1257188,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118182,Male,White,VO_0001178,live attenuated influenza vaccine,BS713788,30.0,Days,Time of initial vaccine administration,Other,,ES773969,GEO,GSM1257263,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY522,"Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine (2011-12) Correlate With the Kinetics and Magnitude of Interferon Signaling in Children  (see companion studies SDY144, SDY360)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,3.0,14.0,SUB118182,Male,White,VO_0001178,live attenuated influenza vaccine,BS713789,7.0,Days,Time of initial vaccine administration,Other,,ES773970,GEO,GSM1257129,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,3.0 - 14.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118183,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713790,0.0,Days,Time of initial vaccine administration,Other,,ES773971,GEO,GSM1257215,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118183,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713791,1.0,Days,Time of initial vaccine administration,Other,,ES773972,GEO,GSM1257245,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118183,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713792,30.0,Days,Time of initial vaccine administration,Other,,ES773973,GEO,GSM1257205,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY144,"Systems Biology Approach to Study Influenza Vaccine 2011-12 in Healthy Children (see companion studies SDY364, SDY368, SDY387)",To characterize the cellular and transcriptional signatures of response to Flu vaccine in healthy children.,0.5,13.0,SUB118183,Male,Other,VO_0004810,"2011?2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)",BS713793,7.0,Days,Time of initial vaccine administration,Other,,ES773974,GEO,GSM1257225,false,GSE52005,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE52005,Other : NA,0.5 - 13.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134264,Female,White,VO_0000047,Fluzone,BS715481,0.0,Days,Time of initial vaccine administration,Other,,ES776571,GEO,GSM1422001,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134282,Female,White,VO_0000047,Fluzone,BS715482,0.0,Days,Time of initial vaccine administration,Other,,ES776572,GEO,GSM1422002,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134283,Female,White,VO_0000047,Fluzone,BS715483,0.0,Days,Time of initial vaccine administration,Other,,ES776573,GEO,GSM1422003,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134259,Male,White,VO_0000047,Fluzone,BS715484,0.0,Days,Time of initial vaccine administration,Other,,ES776574,GEO,GSM1422004,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134285,Female,White,VO_0000047,Fluzone,BS715485,0.0,Days,Time of initial vaccine administration,Other,,ES776575,GEO,GSM1422005,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134266,Male,White,VO_0000047,Fluzone,BS715486,0.0,Days,Time of initial vaccine administration,Other,,ES776576,GEO,GSM1422006,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134240,Female,White,VO_0000047,Fluzone,BS715487,0.0,Days,Time of initial vaccine administration,Other,,ES776577,GEO,GSM1422007,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134244,Male,White,VO_0000047,Fluzone,BS715488,0.0,Days,Time of initial vaccine administration,Other,,ES776578,GEO,GSM1422008,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134242,Male,White,VO_0000047,Fluzone,BS715489,0.0,Days,Time of initial vaccine administration,Other,,ES776579,GEO,GSM1422009,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134286,Female,White,VO_0000047,Fluzone,BS715490,0.0,Days,Time of initial vaccine administration,Other,,ES776580,GEO,GSM1422010,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134257,Female,White,VO_0000047,Fluzone,BS715491,0.0,Days,Time of initial vaccine administration,Other,,ES776581,GEO,GSM1422011,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134274,Female,White,VO_0000047,Fluzone,BS715492,0.0,Days,Time of initial vaccine administration,Other,,ES776582,GEO,GSM1422012,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134288,Male,White,VO_0000047,Fluzone,BS715493,0.0,Days,Time of initial vaccine administration,Other,,ES776583,GEO,GSM1422013,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134275,Male,White,VO_0000047,Fluzone,BS715494,0.0,Days,Time of initial vaccine administration,Other,,ES776584,GEO,GSM1422014,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134237,Male,Asian,VO_0000047,Fluzone,BS715495,0.0,Days,Time of initial vaccine administration,Other,,ES776585,GEO,GSM1422017,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134256,Female,White,VO_0000047,Fluzone,BS715496,0.0,Days,Time of initial vaccine administration,Other,,ES776586,GEO,GSM1422018,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134315,Female,White,VO_0000047,Fluzone,BS715497,0.0,Days,Time of initial vaccine administration,Other,,ES776587,GEO,GSM1422019,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134293,Female,White,VO_0000047,Fluzone,BS715498,0.0,Days,Time of initial vaccine administration,Other,,ES776588,GEO,GSM1422020,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134287,Female,White,VO_0000047,Fluzone,BS715499,0.0,Days,Time of initial vaccine administration,Other,,ES776589,GEO,GSM1422021,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134304,Female,Asian,VO_0000047,Fluzone,BS715500,0.0,Days,Time of initial vaccine administration,Other,,ES776590,GEO,GSM1422023,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134297,Male,White,VO_0000047,Fluzone,BS715501,0.0,Days,Time of initial vaccine administration,Other,,ES776591,GEO,GSM1422029,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134325,Female,White,VO_0000047,Fluzone,BS715502,0.0,Days,Time of initial vaccine administration,Other,,ES776592,GEO,GSM1422030,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134312,Male,White,VO_0000047,Fluzone,BS715503,0.0,Days,Time of initial vaccine administration,Other,,ES776593,GEO,GSM1422032,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134290,Female,White,VO_0000047,Fluzone,BS715504,0.0,Days,Time of initial vaccine administration,Other,,ES776594,GEO,GSM1422033,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134322,Female,Other,VO_0000047,Fluzone,BS715505,0.0,Days,Time of initial vaccine administration,Other,,ES776595,GEO,GSM1422034,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134276,Female,White,VO_0000047,Fluzone,BS715506,0.0,Days,Time of initial vaccine administration,Other,,ES776596,GEO,GSM1422036,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134300,Female,White,VO_0000047,Fluzone,BS715507,0.0,Days,Time of initial vaccine administration,Other,,ES776597,GEO,GSM1422037,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134323,Female,Other,VO_0000047,Fluzone,BS715508,0.0,Days,Time of initial vaccine administration,Other,,ES776598,GEO,GSM1422039,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134289,Male,White,VO_0000047,Fluzone,BS715509,0.0,Days,Time of initial vaccine administration,Other,,ES776599,GEO,GSM1422042,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134260,Female,White,VO_0000047,Fluzone,BS715510,0.0,Days,Time of initial vaccine administration,Other,,ES776600,GEO,GSM1422043,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134238,Female,White,VO_0000047,Fluzone,BS715511,0.0,Days,Time of initial vaccine administration,Other,,ES776601,GEO,GSM1422045,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134295,Male,White,VO_0000047,Fluzone,BS715512,0.0,Days,Time of initial vaccine administration,Other,,ES776602,GEO,GSM1422046,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134254,Male,White,VO_0000047,Fluzone,BS715513,0.0,Days,Time of initial vaccine administration,Other,,ES776603,GEO,GSM1422047,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134262,Male,American Indian or Alaska Native,VO_0000047,Fluzone,BS715514,0.0,Days,Time of initial vaccine administration,Other,,ES776604,GEO,GSM1422048,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134318,Female,Asian,VO_0000047,Fluzone,BS715515,0.0,Days,Time of initial vaccine administration,Other,,ES776605,GEO,GSM1422049,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134308,Female,Asian,VO_0000047,Fluzone,BS715516,0.0,Days,Time of initial vaccine administration,Other,,ES776606,GEO,GSM1422050,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134296,Female,White,VO_0000047,Fluzone,BS715517,0.0,Days,Time of initial vaccine administration,Other,,ES776607,GEO,GSM1422051,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134294,Male,White,VO_0000047,Fluzone,BS715518,0.0,Days,Time of initial vaccine administration,Other,,ES776608,GEO,GSM1422052,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134272,Male,White,VO_0000047,Fluzone,BS715519,0.0,Days,Time of initial vaccine administration,Other,,ES776609,GEO,GSM1422053,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134281,Female,White,VO_0000047,Fluzone,BS715520,0.0,Days,Time of initial vaccine administration,Other,,ES776610,GEO,GSM1422054,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134301,Female,White,VO_0000047,Fluzone,BS715521,0.0,Days,Time of initial vaccine administration,Other,,ES776611,GEO,GSM1422055,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134280,Female,White,VO_0000047,Fluzone,BS715522,0.0,Days,Time of initial vaccine administration,Other,,ES776612,GEO,GSM1422056,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134321,Male,White,VO_0000047,Fluzone,BS715523,0.0,Days,Time of initial vaccine administration,Other,,ES776613,GEO,GSM1422057,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134273,Female,White,VO_0000047,Fluzone,BS715524,0.0,Days,Time of initial vaccine administration,Other,,ES776614,GEO,GSM1422058,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134248,Male,White,VO_0000047,Fluzone,BS715525,0.0,Days,Time of initial vaccine administration,Other,,ES776615,GEO,GSM1422059,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB116449,Male,White,VO_0000047,Fluzone,BS715526,0.0,Days,Time of initial vaccine administration,Other,,ES776616,GEO,GSM1422060,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134251,Female,White,VO_0000047,Fluzone,BS715527,0.0,Days,Time of initial vaccine administration,Other,,ES776617,GEO,GSM1422061,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134258,Female,White,VO_0000047,Fluzone,BS715528,0.0,Days,Time of initial vaccine administration,Other,,ES776618,GEO,GSM1422062,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134309,Male,White,VO_0000047,Fluzone,BS715529,0.0,Days,Time of initial vaccine administration,Other,,ES776619,GEO,GSM1422063,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134267,Male,White,VO_0000047,Fluzone,BS715530,0.0,Days,Time of initial vaccine administration,Other,,ES776620,GEO,GSM1422064,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134261,Female,White,VO_0000047,Fluzone,BS715531,0.0,Days,Time of initial vaccine administration,Other,,ES776621,GEO,GSM1422065,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134310,Female,White,VO_0000047,Fluzone,BS715532,0.0,Days,Time of initial vaccine administration,Other,,ES776622,GEO,GSM1422066,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134279,Female,White,VO_0000047,Fluzone,BS715533,0.0,Days,Time of initial vaccine administration,Other,,ES776623,GEO,GSM1422067,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134307,Male,White,VO_0000047,Fluzone,BS715534,0.0,Days,Time of initial vaccine administration,Other,,ES776624,GEO,GSM1422068,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134249,Female,Other,VO_0000047,Fluzone,BS715535,0.0,Days,Time of initial vaccine administration,Other,,ES776625,GEO,GSM1422069,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134241,Male,White,VO_0000047,Fluzone,BS715536,0.0,Days,Time of initial vaccine administration,Other,,ES776626,GEO,GSM1422070,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134252,Male,Asian,VO_0000047,Fluzone,BS715537,0.0,Days,Time of initial vaccine administration,Other,,ES776627,GEO,GSM1422071,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134243,Female,White,VO_0000047,Fluzone,BS715538,0.0,Days,Time of initial vaccine administration,Other,,ES776628,GEO,GSM1422072,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134292,Female,White,VO_0000047,Fluzone,BS715539,0.0,Days,Time of initial vaccine administration,Other,,ES776629,GEO,GSM1422073,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134326,Male,White,VO_0000047,Fluzone,BS715540,0.0,Days,Time of initial vaccine administration,Other,,ES776630,GEO,GSM1422074,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134298,Male,White,VO_0000047,Fluzone,BS715541,0.0,Days,Time of initial vaccine administration,Other,,ES776631,GEO,GSM1422075,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134242,Male,White,VO_0000047,Fluzone,BS715542,28.0,Days,Time of initial vaccine administration,Other,,ES776632,GEO,GSM1422015,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134283,Female,White,VO_0000047,Fluzone,BS715543,28.0,Days,Time of initial vaccine administration,Other,,ES776633,GEO,GSM1422016,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134278,Female,White,VO_0000047,Fluzone,BS715544,28.0,Days,Time of initial vaccine administration,Other,,ES776634,GEO,GSM1422022,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134281,Female,White,VO_0000047,Fluzone,BS715545,28.0,Days,Time of initial vaccine administration,Other,,ES776635,GEO,GSM1422024,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134259,Male,White,VO_0000047,Fluzone,BS715546,28.0,Days,Time of initial vaccine administration,Other,,ES776636,GEO,GSM1422025,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134297,Male,White,VO_0000047,Fluzone,BS715547,28.0,Days,Time of initial vaccine administration,Other,,ES776637,GEO,GSM1422026,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134320,Male,White,VO_0000047,Fluzone,BS715548,28.0,Days,Time of initial vaccine administration,Other,,ES776638,GEO,GSM1422031,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134309,Male,White,VO_0000047,Fluzone,BS715549,28.0,Days,Time of initial vaccine administration,Other,,ES776639,GEO,GSM1422035,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134308,Female,Asian,VO_0000047,Fluzone,BS715550,28.0,Days,Time of initial vaccine administration,Other,,ES776640,GEO,GSM1422038,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134296,Female,White,VO_0000047,Fluzone,BS715551,28.0,Days,Time of initial vaccine administration,Other,,ES776641,GEO,GSM1422040,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134295,Male,White,VO_0000047,Fluzone,BS715552,28.0,Days,Time of initial vaccine administration,Other,,ES776642,GEO,GSM1422041,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY311,T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) SLVP015 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011),"Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.",18.0,90.0,SUB134315,Female,White,VO_0000047,Fluzone,BS715553,28.0,Days,Time of initial vaccine administration,Other,,ES776643,GEO,GSM1422044,false,GSE58898,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE58898,Other : NA,18.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719399,0.0,Days,Time of initial vaccine administration,B cell,B,ES784386,GEO,GSM1441474,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719400,2.0,Days,Time of initial vaccine administration,B cell,B,ES784387,GEO,GSM1441475,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719403,0.0,Days,Time of initial vaccine administration,B cell,B,ES784388,GEO,GSM1441476,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719404,2.0,Days,Time of initial vaccine administration,B cell,B,ES784389,GEO,GSM1441477,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719405,7.0,Days,Time of initial vaccine administration,B cell,B,ES784390,GEO,GSM1441478,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719406,28.0,Days,Time of initial vaccine administration,B cell,B,ES784391,GEO,GSM1441479,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719407,0.0,Days,Time of initial vaccine administration,B cell,B,ES784392,GEO,GSM1441480,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719408,2.0,Days,Time of initial vaccine administration,B cell,B,ES784393,GEO,GSM1441481,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719409,7.0,Days,Time of initial vaccine administration,B cell,B,ES784394,GEO,GSM1441482,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719410,28.0,Days,Time of initial vaccine administration,B cell,B,ES784395,GEO,GSM1441483,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719411,0.0,Days,Time of initial vaccine administration,B cell,B,ES784396,GEO,GSM1441484,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719412,2.0,Days,Time of initial vaccine administration,B cell,B,ES784397,GEO,GSM1441485,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719413,7.0,Days,Time of initial vaccine administration,B cell,B,ES784398,GEO,GSM1441486,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719414,28.0,Days,Time of initial vaccine administration,B cell,B,ES784399,GEO,GSM1441487,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719415,0.0,Days,Time of initial vaccine administration,B cell,B,ES784400,GEO,GSM1441488,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719416,2.0,Days,Time of initial vaccine administration,B cell,B,ES784401,GEO,GSM1441489,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719417,7.0,Days,Time of initial vaccine administration,B cell,B,ES784402,GEO,GSM1441490,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719418,28.0,Days,Time of initial vaccine administration,B cell,B,ES784403,GEO,GSM1441491,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719423,0.0,Days,Time of initial vaccine administration,B cell,B,ES784404,GEO,GSM1441492,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719424,2.0,Days,Time of initial vaccine administration,B cell,B,ES784405,GEO,GSM1441493,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719425,7.0,Days,Time of initial vaccine administration,B cell,B,ES784406,GEO,GSM1441494,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719426,28.0,Days,Time of initial vaccine administration,B cell,B,ES784407,GEO,GSM1441495,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719427,0.0,Days,Time of initial vaccine administration,B cell,B,ES784408,GEO,GSM1441496,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719428,2.0,Days,Time of initial vaccine administration,B cell,B,ES784409,GEO,GSM1441497,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719429,7.0,Days,Time of initial vaccine administration,B cell,B,ES784410,GEO,GSM1441498,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719430,28.0,Days,Time of initial vaccine administration,B cell,B,ES784411,GEO,GSM1441499,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719431,0.0,Days,Time of initial vaccine administration,B cell,B,ES784412,GEO,GSM1441500,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719432,2.0,Days,Time of initial vaccine administration,B cell,B,ES784413,GEO,GSM1441501,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719433,7.0,Days,Time of initial vaccine administration,B cell,B,ES784414,GEO,GSM1441502,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719434,28.0,Days,Time of initial vaccine administration,B cell,B,ES784415,GEO,GSM1441503,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719435,0.0,Days,Time of initial vaccine administration,B cell,B,ES784416,GEO,GSM1441504,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719436,2.0,Days,Time of initial vaccine administration,B cell,B,ES784417,GEO,GSM1441505,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719437,7.0,Days,Time of initial vaccine administration,B cell,B,ES784418,GEO,GSM1441506,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719438,28.0,Days,Time of initial vaccine administration,B cell,B,ES784419,GEO,GSM1441507,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719439,0.0,Days,Time of initial vaccine administration,B cell,B,ES784420,GEO,GSM1441508,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719440,2.0,Days,Time of initial vaccine administration,B cell,B,ES784421,GEO,GSM1441509,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719441,7.0,Days,Time of initial vaccine administration,B cell,B,ES784422,GEO,GSM1441510,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719442,28.0,Days,Time of initial vaccine administration,B cell,B,ES784423,GEO,GSM1441511,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719443,0.0,Days,Time of initial vaccine administration,B cell,B,ES784424,GEO,GSM1441512,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719444,2.0,Days,Time of initial vaccine administration,B cell,B,ES784425,GEO,GSM1441513,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719445,7.0,Days,Time of initial vaccine administration,B cell,B,ES784426,GEO,GSM1441514,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719446,28.0,Days,Time of initial vaccine administration,B cell,B,ES784427,GEO,GSM1441515,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719447,0.0,Days,Time of initial vaccine administration,B cell,B,ES784428,GEO,GSM1441516,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719448,2.0,Days,Time of initial vaccine administration,B cell,B,ES784429,GEO,GSM1441517,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719449,7.0,Days,Time of initial vaccine administration,B cell,B,ES784430,GEO,GSM1441518,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719451,0.0,Days,Time of initial vaccine administration,B cell,B,ES784431,GEO,GSM1441519,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719452,2.0,Days,Time of initial vaccine administration,B cell,B,ES784432,GEO,GSM1441520,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719453,7.0,Days,Time of initial vaccine administration,B cell,B,ES784433,GEO,GSM1441521,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719454,28.0,Days,Time of initial vaccine administration,B cell,B,ES784434,GEO,GSM1441522,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719455,0.0,Days,Time of initial vaccine administration,B cell,B,ES784435,GEO,GSM1441523,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719456,2.0,Days,Time of initial vaccine administration,B cell,B,ES784436,GEO,GSM1441524,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719457,7.0,Days,Time of initial vaccine administration,B cell,B,ES784437,GEO,GSM1441525,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719458,28.0,Days,Time of initial vaccine administration,B cell,B,ES784438,GEO,GSM1441526,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719459,0.0,Days,Time of initial vaccine administration,B cell,B,ES784439,GEO,GSM1441527,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719460,2.0,Days,Time of initial vaccine administration,B cell,B,ES784440,GEO,GSM1441528,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719461,7.0,Days,Time of initial vaccine administration,B cell,B,ES784441,GEO,GSM1441529,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719462,28.0,Days,Time of initial vaccine administration,B cell,B,ES784442,GEO,GSM1441530,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719463,0.0,Days,Time of initial vaccine administration,B cell,B,ES784443,GEO,GSM1441531,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719464,2.0,Days,Time of initial vaccine administration,B cell,B,ES784444,GEO,GSM1441532,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719465,7.0,Days,Time of initial vaccine administration,B cell,B,ES784445,GEO,GSM1441533,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719466,28.0,Days,Time of initial vaccine administration,B cell,B,ES784446,GEO,GSM1441534,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719467,0.0,Days,Time of initial vaccine administration,B cell,B,ES784447,GEO,GSM1441535,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719468,2.0,Days,Time of initial vaccine administration,B cell,B,ES784448,GEO,GSM1441536,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719469,7.0,Days,Time of initial vaccine administration,B cell,B,ES784449,GEO,GSM1441537,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719470,28.0,Days,Time of initial vaccine administration,B cell,B,ES784450,GEO,GSM1441538,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719471,0.0,Days,Time of initial vaccine administration,B cell,B,ES784451,GEO,GSM1441539,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719472,2.0,Days,Time of initial vaccine administration,B cell,B,ES784452,GEO,GSM1441540,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719473,7.0,Days,Time of initial vaccine administration,B cell,B,ES784453,GEO,GSM1441541,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719474,28.0,Days,Time of initial vaccine administration,B cell,B,ES784454,GEO,GSM1441542,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719475,0.0,Days,Time of initial vaccine administration,B cell,B,ES784455,GEO,GSM1441543,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719476,2.0,Days,Time of initial vaccine administration,B cell,B,ES784456,GEO,GSM1441544,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719477,7.0,Days,Time of initial vaccine administration,B cell,B,ES784457,GEO,GSM1441545,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719478,28.0,Days,Time of initial vaccine administration,B cell,B,ES784458,GEO,GSM1441546,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719479,0.0,Days,Time of initial vaccine administration,B cell,B,ES784459,GEO,GSM1441547,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719480,2.0,Days,Time of initial vaccine administration,B cell,B,ES784460,GEO,GSM1441548,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719481,7.0,Days,Time of initial vaccine administration,B cell,B,ES784461,GEO,GSM1441549,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719482,28.0,Days,Time of initial vaccine administration,B cell,B,ES784462,GEO,GSM1441550,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719483,0.0,Days,Time of initial vaccine administration,B cell,B,ES784463,GEO,GSM1441551,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719484,2.0,Days,Time of initial vaccine administration,B cell,B,ES784464,GEO,GSM1441552,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719485,7.0,Days,Time of initial vaccine administration,B cell,B,ES784465,GEO,GSM1441553,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719486,28.0,Days,Time of initial vaccine administration,B cell,B,ES784466,GEO,GSM1441554,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719487,0.0,Days,Time of initial vaccine administration,B cell,B,ES784467,GEO,GSM1441555,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719488,2.0,Days,Time of initial vaccine administration,B cell,B,ES784468,GEO,GSM1441556,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719489,7.0,Days,Time of initial vaccine administration,B cell,B,ES784469,GEO,GSM1441557,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719490,28.0,Days,Time of initial vaccine administration,B cell,B,ES784470,GEO,GSM1441558,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719491,0.0,Days,Time of initial vaccine administration,B cell,B,ES784471,GEO,GSM1441559,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719492,2.0,Days,Time of initial vaccine administration,B cell,B,ES784472,GEO,GSM1441560,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719493,7.0,Days,Time of initial vaccine administration,B cell,B,ES784473,GEO,GSM1441561,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719494,28.0,Days,Time of initial vaccine administration,B cell,B,ES784474,GEO,GSM1441562,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719495,0.0,Days,Time of initial vaccine administration,B cell,B,ES784475,GEO,GSM1441563,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719496,2.0,Days,Time of initial vaccine administration,B cell,B,ES784476,GEO,GSM1441564,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719497,7.0,Days,Time of initial vaccine administration,B cell,B,ES784477,GEO,GSM1441565,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719498,28.0,Days,Time of initial vaccine administration,B cell,B,ES784478,GEO,GSM1441566,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719499,0.0,Days,Time of initial vaccine administration,B cell,B,ES784479,GEO,GSM1441567,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719500,2.0,Days,Time of initial vaccine administration,B cell,B,ES784480,GEO,GSM1441568,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719501,7.0,Days,Time of initial vaccine administration,B cell,B,ES784481,GEO,GSM1441569,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719502,24.0,Days,Time of initial vaccine administration,B cell,B,ES784482,GEO,GSM1441570,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719503,0.0,Days,Time of initial vaccine administration,B cell,B,ES784483,GEO,GSM1441571,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719504,2.0,Days,Time of initial vaccine administration,B cell,B,ES784484,GEO,GSM1441572,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719505,7.0,Days,Time of initial vaccine administration,B cell,B,ES784485,GEO,GSM1441573,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719506,32.0,Days,Time of initial vaccine administration,B cell,B,ES784486,GEO,GSM1441574,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719507,0.0,Days,Time of initial vaccine administration,B cell,B,ES784487,GEO,GSM1441575,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719508,2.0,Days,Time of initial vaccine administration,B cell,B,ES784488,GEO,GSM1441576,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719509,7.0,Days,Time of initial vaccine administration,B cell,B,ES784489,GEO,GSM1441577,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719510,28.0,Days,Time of initial vaccine administration,B cell,B,ES784490,GEO,GSM1441578,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719511,0.0,Days,Time of initial vaccine administration,B cell,B,ES784491,GEO,GSM1441579,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719512,2.0,Days,Time of initial vaccine administration,B cell,B,ES784492,GEO,GSM1441580,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719513,7.0,Days,Time of initial vaccine administration,B cell,B,ES784493,GEO,GSM1441581,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719514,28.0,Days,Time of initial vaccine administration,B cell,B,ES784494,GEO,GSM1441582,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719515,0.0,Days,Time of initial vaccine administration,B cell,B,ES784495,GEO,GSM1441583,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719516,2.0,Days,Time of initial vaccine administration,B cell,B,ES784496,GEO,GSM1441584,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719517,7.0,Days,Time of initial vaccine administration,B cell,B,ES784497,GEO,GSM1441585,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719518,28.0,Days,Time of initial vaccine administration,B cell,B,ES784498,GEO,GSM1441586,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719519,0.0,Days,Time of initial vaccine administration,B cell,B,ES784499,GEO,GSM1441587,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719520,4.0,Days,Time of initial vaccine administration,B cell,B,ES784500,GEO,GSM1441588,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719521,7.0,Days,Time of initial vaccine administration,B cell,B,ES784501,GEO,GSM1441589,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719522,28.0,Days,Time of initial vaccine administration,B cell,B,ES784502,GEO,GSM1441590,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : B,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719523,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784503,GEO,GSM1441591,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719524,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784504,GEO,GSM1441592,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719525,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784505,GEO,GSM1441593,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719526,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784506,GEO,GSM1441594,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719527,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784507,GEO,GSM1441595,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719528,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784508,GEO,GSM1441596,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719529,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784509,GEO,GSM1441597,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719530,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784510,GEO,GSM1441598,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719531,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784511,GEO,GSM1441599,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719532,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784512,GEO,GSM1441600,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719533,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784513,GEO,GSM1441601,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719534,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784514,GEO,GSM1441602,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719535,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784515,GEO,GSM1441603,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719536,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784516,GEO,GSM1441604,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719537,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784517,GEO,GSM1441605,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719538,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784518,GEO,GSM1441606,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719539,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784519,GEO,GSM1441607,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719540,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784520,GEO,GSM1441608,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719541,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784521,GEO,GSM1441609,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719542,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784522,GEO,GSM1441610,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719547,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784523,GEO,GSM1441611,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719548,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784524,GEO,GSM1441612,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719549,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784525,GEO,GSM1441613,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719550,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784526,GEO,GSM1441614,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719551,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784527,GEO,GSM1441615,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719552,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784528,GEO,GSM1441616,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719553,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784529,GEO,GSM1441617,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719554,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784530,GEO,GSM1441618,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719555,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784531,GEO,GSM1441619,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719556,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784532,GEO,GSM1441620,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719557,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784533,GEO,GSM1441621,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719558,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784534,GEO,GSM1441622,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719559,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784535,GEO,GSM1441623,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719560,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784536,GEO,GSM1441624,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719561,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784537,GEO,GSM1441625,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719562,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784538,GEO,GSM1441626,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719563,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784539,GEO,GSM1441627,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719564,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784540,GEO,GSM1441628,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719565,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784541,GEO,GSM1441629,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719566,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784542,GEO,GSM1441630,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719567,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784543,GEO,GSM1441631,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719568,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784544,GEO,GSM1441632,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719569,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784545,GEO,GSM1441633,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719570,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784546,GEO,GSM1441634,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719571,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784547,GEO,GSM1441635,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719572,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784548,GEO,GSM1441636,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719573,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784549,GEO,GSM1441637,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719574,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784550,GEO,GSM1441638,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719575,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784551,GEO,GSM1441639,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719576,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784552,GEO,GSM1441640,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719577,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784553,GEO,GSM1441641,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719578,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784554,GEO,GSM1441642,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719579,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784555,GEO,GSM1441643,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719580,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784556,GEO,GSM1441644,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719581,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784557,GEO,GSM1441645,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719582,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784558,GEO,GSM1441646,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719583,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784559,GEO,GSM1441647,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719584,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784560,GEO,GSM1441648,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719585,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784561,GEO,GSM1441649,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719586,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784562,GEO,GSM1441650,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719587,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784563,GEO,GSM1441651,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719588,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784564,GEO,GSM1441652,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719589,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784565,GEO,GSM1441653,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719590,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784566,GEO,GSM1441654,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719591,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784567,GEO,GSM1441655,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719592,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784568,GEO,GSM1441656,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719593,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784569,GEO,GSM1441657,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719594,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784570,GEO,GSM1441658,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719595,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784571,GEO,GSM1441659,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719596,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784572,GEO,GSM1441660,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719597,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784573,GEO,GSM1441661,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719598,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784574,GEO,GSM1441662,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719599,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784575,GEO,GSM1441663,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719600,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784576,GEO,GSM1441664,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719601,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784577,GEO,GSM1441665,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719602,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784578,GEO,GSM1441666,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719603,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784579,GEO,GSM1441667,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719604,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784580,GEO,GSM1441668,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719605,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784581,GEO,GSM1441669,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719606,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784582,GEO,GSM1441670,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719607,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784583,GEO,GSM1441671,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719608,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784584,GEO,GSM1441672,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719609,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784585,GEO,GSM1441673,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719610,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784586,GEO,GSM1441674,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719611,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784587,GEO,GSM1441675,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719612,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784588,GEO,GSM1441676,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719613,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784589,GEO,GSM1441677,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719614,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784590,GEO,GSM1441678,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719615,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784591,GEO,GSM1441679,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719616,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784592,GEO,GSM1441680,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719617,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784593,GEO,GSM1441681,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719618,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784594,GEO,GSM1441682,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719619,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784595,GEO,GSM1441683,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719620,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784596,GEO,GSM1441684,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719621,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784597,GEO,GSM1441685,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719622,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784598,GEO,GSM1441686,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719623,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784599,GEO,GSM1441687,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719624,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784600,GEO,GSM1441688,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719625,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784601,GEO,GSM1441689,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719626,24.0,Days,Time of initial vaccine administration,B cell,CD4,ES784602,GEO,GSM1441690,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719627,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784603,GEO,GSM1441691,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719628,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784604,GEO,GSM1441692,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719629,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784605,GEO,GSM1441693,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719630,32.0,Days,Time of initial vaccine administration,B cell,CD4,ES784606,GEO,GSM1441694,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719631,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784607,GEO,GSM1441695,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719632,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784608,GEO,GSM1441696,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719633,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784609,GEO,GSM1441697,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719634,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784610,GEO,GSM1441698,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719635,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784611,GEO,GSM1441699,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719636,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784612,GEO,GSM1441700,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719637,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784613,GEO,GSM1441701,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719638,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784614,GEO,GSM1441702,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719639,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784615,GEO,GSM1441703,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719640,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784616,GEO,GSM1441704,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719641,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784617,GEO,GSM1441705,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719642,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784618,GEO,GSM1441706,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719643,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784619,GEO,GSM1441707,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719644,4.0,Days,Time of initial vaccine administration,B cell,CD4,ES784620,GEO,GSM1441708,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719645,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784621,GEO,GSM1441709,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719646,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784622,GEO,GSM1441710,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD4,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719647,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784623,GEO,GSM1441711,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719648,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784624,GEO,GSM1441712,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719649,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784625,GEO,GSM1441713,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120418,Male,Other,VO_0000642,Influenza virus vaccine,BS719650,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784626,GEO,GSM1441714,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719651,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784627,GEO,GSM1441715,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719652,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784628,GEO,GSM1441716,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719653,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784629,GEO,GSM1441717,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120420,Female,White,VO_0000642,Influenza virus vaccine,BS719654,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784630,GEO,GSM1441718,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719655,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784631,GEO,GSM1441719,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719656,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784632,GEO,GSM1441720,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719657,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784633,GEO,GSM1441721,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120421,Female,Asian,VO_0000642,Influenza virus vaccine,BS719658,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784634,GEO,GSM1441722,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719659,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784635,GEO,GSM1441723,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719660,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784636,GEO,GSM1441724,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719661,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784637,GEO,GSM1441725,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120422,Female,White,VO_0000642,Influenza virus vaccine,BS719662,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784638,GEO,GSM1441726,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719663,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784639,GEO,GSM1441727,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719664,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784640,GEO,GSM1441728,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719665,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784641,GEO,GSM1441729,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120425,Male,White,VO_0000642,Influenza virus vaccine,BS719666,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784642,GEO,GSM1441730,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719671,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784643,GEO,GSM1441731,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719672,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784644,GEO,GSM1441732,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719673,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784645,GEO,GSM1441733,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120428,Female,White,VO_0000642,Influenza virus vaccine,BS719674,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784646,GEO,GSM1441734,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719675,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784647,GEO,GSM1441735,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719676,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784648,GEO,GSM1441736,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719677,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784649,GEO,GSM1441737,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120430,Female,White,VO_0000642,Influenza virus vaccine,BS719678,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784650,GEO,GSM1441738,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719679,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784651,GEO,GSM1441739,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719680,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784652,GEO,GSM1441740,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719681,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784653,GEO,GSM1441741,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120435,Male,White,VO_0000642,Influenza virus vaccine,BS719682,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784654,GEO,GSM1441742,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719683,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784655,GEO,GSM1441743,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719684,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784656,GEO,GSM1441744,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719685,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784657,GEO,GSM1441745,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120436,Female,White,VO_0000642,Influenza virus vaccine,BS719686,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784658,GEO,GSM1441746,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719687,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784659,GEO,GSM1441747,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719688,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784660,GEO,GSM1441748,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719689,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784661,GEO,GSM1441749,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120437,Female,White,VO_0000642,Influenza virus vaccine,BS719690,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784662,GEO,GSM1441750,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719691,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784663,GEO,GSM1441751,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719692,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784664,GEO,GSM1441752,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719693,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784665,GEO,GSM1441753,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120440,Female,White,VO_0000642,Influenza virus vaccine,BS719694,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784666,GEO,GSM1441754,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719695,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784667,GEO,GSM1441755,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719696,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784668,GEO,GSM1441756,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719697,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784669,GEO,GSM1441757,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120441,Male,White,VO_0000642,Influenza virus vaccine,BS719698,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784670,GEO,GSM1441758,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719699,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784671,GEO,GSM1441759,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719700,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784672,GEO,GSM1441760,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719701,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784673,GEO,GSM1441761,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120442,Female,White,VO_0000642,Influenza virus vaccine,BS719702,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784674,GEO,GSM1441762,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719704,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784675,GEO,GSM1441763,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719705,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784676,GEO,GSM1441764,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120445,Male,Unknown,VO_0000642,Influenza virus vaccine,BS719706,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784677,GEO,GSM1441765,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719707,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784678,GEO,GSM1441766,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719708,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784679,GEO,GSM1441767,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719709,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784680,GEO,GSM1441768,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120446,Female,White,VO_0000642,Influenza virus vaccine,BS719710,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784681,GEO,GSM1441769,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719711,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784682,GEO,GSM1441770,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719712,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784683,GEO,GSM1441771,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719713,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784684,GEO,GSM1441772,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120450,Female,White,VO_0000642,Influenza virus vaccine,BS719714,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784685,GEO,GSM1441773,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719715,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784686,GEO,GSM1441774,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719716,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784687,GEO,GSM1441775,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719717,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784688,GEO,GSM1441776,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120452,Female,Other,VO_0000642,Influenza virus vaccine,BS719718,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784689,GEO,GSM1441777,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719719,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784690,GEO,GSM1441778,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719720,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784691,GEO,GSM1441779,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719721,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784692,GEO,GSM1441780,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120457,Female,White,VO_0000642,Influenza virus vaccine,BS719722,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784693,GEO,GSM1441781,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719723,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784694,GEO,GSM1441782,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719724,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784695,GEO,GSM1441783,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719725,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784696,GEO,GSM1441784,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120458,Male,White,VO_0000642,Influenza virus vaccine,BS719726,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784697,GEO,GSM1441785,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719727,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784698,GEO,GSM1441786,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719728,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784699,GEO,GSM1441787,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719729,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784700,GEO,GSM1441788,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120459,Female,Asian,VO_0000642,Influenza virus vaccine,BS719730,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784701,GEO,GSM1441789,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719731,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784702,GEO,GSM1441790,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719732,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784703,GEO,GSM1441791,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719733,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784704,GEO,GSM1441792,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120460,Female,White,VO_0000642,Influenza virus vaccine,BS719734,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784705,GEO,GSM1441793,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719735,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784706,GEO,GSM1441794,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719736,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784707,GEO,GSM1441795,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719737,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784708,GEO,GSM1441796,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120462,Male,White,VO_0000642,Influenza virus vaccine,BS719738,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784709,GEO,GSM1441797,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719739,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784710,GEO,GSM1441798,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719740,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784711,GEO,GSM1441799,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719741,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784712,GEO,GSM1441800,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120467,Male,White,VO_0000642,Influenza virus vaccine,BS719742,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784713,GEO,GSM1441801,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719743,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784714,GEO,GSM1441802,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719744,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784715,GEO,GSM1441803,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719745,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784716,GEO,GSM1441804,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120469,Male,White,VO_0000642,Influenza virus vaccine,BS719746,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784717,GEO,GSM1441805,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719747,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784718,GEO,GSM1441806,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719748,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784719,GEO,GSM1441807,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719749,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784720,GEO,GSM1441808,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120470,Female,White,VO_0000642,Influenza virus vaccine,BS719750,24.0,Days,Time of initial vaccine administration,B cell,CD8,ES784721,GEO,GSM1441809,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719751,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784722,GEO,GSM1441810,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719752,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784723,GEO,GSM1441811,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719753,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784724,GEO,GSM1441812,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120472,Male,Asian,VO_0000642,Influenza virus vaccine,BS719754,32.0,Days,Time of initial vaccine administration,B cell,CD8,ES784725,GEO,GSM1441813,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719755,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784726,GEO,GSM1441814,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719756,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784727,GEO,GSM1441815,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719757,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784728,GEO,GSM1441816,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120473,Male,White,VO_0000642,Influenza virus vaccine,BS719758,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784729,GEO,GSM1441817,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719759,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784730,GEO,GSM1441818,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719760,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784731,GEO,GSM1441819,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719761,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784732,GEO,GSM1441820,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120474,Female,White,VO_0000642,Influenza virus vaccine,BS719762,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784733,GEO,GSM1441821,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719763,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784734,GEO,GSM1441822,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719764,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784735,GEO,GSM1441823,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719765,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784736,GEO,GSM1441824,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120479,Female,White,VO_0000642,Influenza virus vaccine,BS719766,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784737,GEO,GSM1441825,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719767,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784738,GEO,GSM1441826,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719768,4.0,Days,Time of initial vaccine administration,B cell,CD8,ES784739,GEO,GSM1441827,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719769,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784740,GEO,GSM1441828,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY404,"Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011,22.0,90.0,SUB120485,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719770,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784741,GEO,GSM1441829,false,GSE65442,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE65442,B cell : CD8,22.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719771,0.0,Days,Time of initial vaccine administration,B cell,B,ES784782,GEO,GSM1445586,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719772,0.0,Days,Time of initial vaccine administration,B cell,B,ES784783,GEO,GSM1445590,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719773,0.0,Days,Time of initial vaccine administration,B cell,B,ES784784,GEO,GSM1445594,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719774,0.0,Days,Time of initial vaccine administration,B cell,B,ES784785,GEO,GSM1445598,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719775,0.0,Days,Time of initial vaccine administration,B cell,B,ES784786,GEO,GSM1445602,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719776,0.0,Days,Time of initial vaccine administration,B cell,B,ES784787,GEO,GSM1445606,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719777,0.0,Days,Time of initial vaccine administration,B cell,B,ES784788,GEO,GSM1445610,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719778,0.0,Days,Time of initial vaccine administration,B cell,B,ES784789,GEO,GSM1445614,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719779,0.0,Days,Time of initial vaccine administration,B cell,B,ES784790,GEO,GSM1445618,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719780,0.0,Days,Time of initial vaccine administration,B cell,B,ES784791,GEO,GSM1445622,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719781,0.0,Days,Time of initial vaccine administration,B cell,B,ES784792,GEO,GSM1445626,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719783,0.0,Days,Time of initial vaccine administration,B cell,B,ES784793,GEO,GSM1445632,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719784,0.0,Days,Time of initial vaccine administration,B cell,B,ES784794,GEO,GSM1445636,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719785,0.0,Days,Time of initial vaccine administration,B cell,B,ES784795,GEO,GSM1445640,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719786,0.0,Days,Time of initial vaccine administration,B cell,B,ES784796,GEO,GSM1445644,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719787,0.0,Days,Time of initial vaccine administration,B cell,B,ES784797,GEO,GSM1445648,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719788,0.0,Days,Time of initial vaccine administration,B cell,B,ES784798,GEO,GSM1445652,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719789,0.0,Days,Time of initial vaccine administration,B cell,B,ES784799,GEO,GSM1445656,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719790,0.0,Days,Time of initial vaccine administration,B cell,B,ES784800,GEO,GSM1445660,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719791,2.0,Days,Time of initial vaccine administration,B cell,B,ES784801,GEO,GSM1445587,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719792,2.0,Days,Time of initial vaccine administration,B cell,B,ES784802,GEO,GSM1445591,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719793,2.0,Days,Time of initial vaccine administration,B cell,B,ES784803,GEO,GSM1445599,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719794,2.0,Days,Time of initial vaccine administration,B cell,B,ES784804,GEO,GSM1445603,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719795,2.0,Days,Time of initial vaccine administration,B cell,B,ES784805,GEO,GSM1445607,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719796,2.0,Days,Time of initial vaccine administration,B cell,B,ES784806,GEO,GSM1445611,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719797,2.0,Days,Time of initial vaccine administration,B cell,B,ES784807,GEO,GSM1445615,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719798,2.0,Days,Time of initial vaccine administration,B cell,B,ES784808,GEO,GSM1445619,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719799,2.0,Days,Time of initial vaccine administration,B cell,B,ES784809,GEO,GSM1445623,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719800,2.0,Days,Time of initial vaccine administration,B cell,B,ES784810,GEO,GSM1445627,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719802,2.0,Days,Time of initial vaccine administration,B cell,B,ES784811,GEO,GSM1445633,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719803,2.0,Days,Time of initial vaccine administration,B cell,B,ES784812,GEO,GSM1445637,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719804,2.0,Days,Time of initial vaccine administration,B cell,B,ES784813,GEO,GSM1445641,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719805,2.0,Days,Time of initial vaccine administration,B cell,B,ES784814,GEO,GSM1445645,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719806,2.0,Days,Time of initial vaccine administration,B cell,B,ES784815,GEO,GSM1445649,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719807,2.0,Days,Time of initial vaccine administration,B cell,B,ES784816,GEO,GSM1445653,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719808,2.0,Days,Time of initial vaccine administration,B cell,B,ES784817,GEO,GSM1445657,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719809,2.0,Days,Time of initial vaccine administration,B cell,B,ES784818,GEO,GSM1445661,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719810,3.0,Days,Time of initial vaccine administration,B cell,B,ES784819,GEO,GSM1445595,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719811,7.0,Days,Time of initial vaccine administration,B cell,B,ES784820,GEO,GSM1445588,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719812,7.0,Days,Time of initial vaccine administration,B cell,B,ES784821,GEO,GSM1445592,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719813,7.0,Days,Time of initial vaccine administration,B cell,B,ES784822,GEO,GSM1445596,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719814,7.0,Days,Time of initial vaccine administration,B cell,B,ES784823,GEO,GSM1445600,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719815,7.0,Days,Time of initial vaccine administration,B cell,B,ES784824,GEO,GSM1445608,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719816,7.0,Days,Time of initial vaccine administration,B cell,B,ES784825,GEO,GSM1445612,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719817,7.0,Days,Time of initial vaccine administration,B cell,B,ES784826,GEO,GSM1445616,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719818,7.0,Days,Time of initial vaccine administration,B cell,B,ES784827,GEO,GSM1445620,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719819,7.0,Days,Time of initial vaccine administration,B cell,B,ES784828,GEO,GSM1445624,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719820,7.0,Days,Time of initial vaccine administration,B cell,B,ES784829,GEO,GSM1445628,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719821,7.0,Days,Time of initial vaccine administration,B cell,B,ES784830,GEO,GSM1445630,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719822,7.0,Days,Time of initial vaccine administration,B cell,B,ES784831,GEO,GSM1445634,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719823,7.0,Days,Time of initial vaccine administration,B cell,B,ES784832,GEO,GSM1445638,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719824,7.0,Days,Time of initial vaccine administration,B cell,B,ES784833,GEO,GSM1445642,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719825,7.0,Days,Time of initial vaccine administration,B cell,B,ES784834,GEO,GSM1445646,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719826,7.0,Days,Time of initial vaccine administration,B cell,B,ES784835,GEO,GSM1445650,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719827,7.0,Days,Time of initial vaccine administration,B cell,B,ES784836,GEO,GSM1445654,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719828,7.0,Days,Time of initial vaccine administration,B cell,B,ES784837,GEO,GSM1445658,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719829,8.0,Days,Time of initial vaccine administration,B cell,B,ES784838,GEO,GSM1445604,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719830,9.0,Days,Time of initial vaccine administration,B cell,B,ES784839,GEO,GSM1445662,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719831,28.0,Days,Time of initial vaccine administration,B cell,B,ES784840,GEO,GSM1445589,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719832,28.0,Days,Time of initial vaccine administration,B cell,B,ES784841,GEO,GSM1445593,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719833,28.0,Days,Time of initial vaccine administration,B cell,B,ES784842,GEO,GSM1445597,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719834,28.0,Days,Time of initial vaccine administration,B cell,B,ES784843,GEO,GSM1445601,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719835,28.0,Days,Time of initial vaccine administration,B cell,B,ES784844,GEO,GSM1445605,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719836,28.0,Days,Time of initial vaccine administration,B cell,B,ES784845,GEO,GSM1445609,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719837,28.0,Days,Time of initial vaccine administration,B cell,B,ES784846,GEO,GSM1445613,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719838,28.0,Days,Time of initial vaccine administration,B cell,B,ES784847,GEO,GSM1445617,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719839,28.0,Days,Time of initial vaccine administration,B cell,B,ES784848,GEO,GSM1445621,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719840,28.0,Days,Time of initial vaccine administration,B cell,B,ES784849,GEO,GSM1445625,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719841,28.0,Days,Time of initial vaccine administration,B cell,B,ES784850,GEO,GSM1445629,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719842,28.0,Days,Time of initial vaccine administration,B cell,B,ES784851,GEO,GSM1445631,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719843,28.0,Days,Time of initial vaccine administration,B cell,B,ES784852,GEO,GSM1445635,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719844,28.0,Days,Time of initial vaccine administration,B cell,B,ES784853,GEO,GSM1445639,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719845,28.0,Days,Time of initial vaccine administration,B cell,B,ES784854,GEO,GSM1445643,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719846,28.0,Days,Time of initial vaccine administration,B cell,B,ES784855,GEO,GSM1445647,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719847,28.0,Days,Time of initial vaccine administration,B cell,B,ES784856,GEO,GSM1445651,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719848,28.0,Days,Time of initial vaccine administration,B cell,B,ES784857,GEO,GSM1445655,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719849,28.0,Days,Time of initial vaccine administration,B cell,B,ES784858,GEO,GSM1445659,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719850,28.0,Days,Time of initial vaccine administration,B cell,B,ES784859,GEO,GSM1445663,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : B,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719851,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784860,GEO,GSM1445664,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719852,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784861,GEO,GSM1445668,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719853,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784862,GEO,GSM1445672,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719854,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784863,GEO,GSM1445676,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719855,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784864,GEO,GSM1445680,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719856,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784865,GEO,GSM1445684,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719857,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784866,GEO,GSM1445688,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719858,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784867,GEO,GSM1445692,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719859,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784868,GEO,GSM1445696,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719860,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784869,GEO,GSM1445700,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719861,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784870,GEO,GSM1445704,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719862,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784871,GEO,GSM1445708,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719863,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784872,GEO,GSM1445712,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719864,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784873,GEO,GSM1445716,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719865,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784874,GEO,GSM1445720,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719866,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784875,GEO,GSM1445724,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719867,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784876,GEO,GSM1445728,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719868,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784877,GEO,GSM1445732,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719869,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784878,GEO,GSM1445736,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719870,0.0,Days,Time of initial vaccine administration,B cell,CD4,ES784879,GEO,GSM1445740,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719871,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784880,GEO,GSM1445665,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719872,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784881,GEO,GSM1445669,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719873,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784882,GEO,GSM1445677,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719874,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784883,GEO,GSM1445681,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719875,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784884,GEO,GSM1445685,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719876,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784885,GEO,GSM1445689,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719877,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784886,GEO,GSM1445693,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719878,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784887,GEO,GSM1445697,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719879,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784888,GEO,GSM1445701,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719880,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784889,GEO,GSM1445705,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719881,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784890,GEO,GSM1445709,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719882,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784891,GEO,GSM1445713,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719883,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784892,GEO,GSM1445717,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719884,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784893,GEO,GSM1445721,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719885,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784894,GEO,GSM1445725,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719886,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784895,GEO,GSM1445729,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719887,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784896,GEO,GSM1445733,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719888,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784897,GEO,GSM1445737,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719889,2.0,Days,Time of initial vaccine administration,B cell,CD4,ES784898,GEO,GSM1445741,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719890,3.0,Days,Time of initial vaccine administration,B cell,CD4,ES784899,GEO,GSM1445673,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719891,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784900,GEO,GSM1445666,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719892,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784901,GEO,GSM1445670,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719893,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784902,GEO,GSM1445674,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719894,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784903,GEO,GSM1445678,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719895,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784904,GEO,GSM1445686,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719896,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784905,GEO,GSM1445690,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719897,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784906,GEO,GSM1445694,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719898,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784907,GEO,GSM1445698,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719899,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784908,GEO,GSM1445702,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719900,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784909,GEO,GSM1445706,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719901,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784910,GEO,GSM1445710,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719902,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784911,GEO,GSM1445714,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719903,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784912,GEO,GSM1445718,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719904,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784913,GEO,GSM1445722,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719905,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784914,GEO,GSM1445726,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719906,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784915,GEO,GSM1445730,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719907,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784916,GEO,GSM1445734,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719908,7.0,Days,Time of initial vaccine administration,B cell,CD4,ES784917,GEO,GSM1445738,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719909,8.0,Days,Time of initial vaccine administration,B cell,CD4,ES784918,GEO,GSM1445682,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719910,9.0,Days,Time of initial vaccine administration,B cell,CD4,ES784919,GEO,GSM1445742,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719911,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784920,GEO,GSM1445667,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719912,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784921,GEO,GSM1445671,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719913,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784922,GEO,GSM1445675,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719914,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784923,GEO,GSM1445679,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719915,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784924,GEO,GSM1445683,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719916,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784925,GEO,GSM1445687,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719917,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784926,GEO,GSM1445691,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719918,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784927,GEO,GSM1445695,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719919,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784928,GEO,GSM1445699,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719920,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784929,GEO,GSM1445703,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719921,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784930,GEO,GSM1445707,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719922,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784931,GEO,GSM1445711,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719923,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784932,GEO,GSM1445715,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719924,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784933,GEO,GSM1445719,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719925,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784934,GEO,GSM1445723,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719926,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784935,GEO,GSM1445727,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719927,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784936,GEO,GSM1445731,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719928,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784937,GEO,GSM1445735,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719929,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784938,GEO,GSM1445739,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719930,28.0,Days,Time of initial vaccine administration,B cell,CD4,ES784939,GEO,GSM1445743,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD4,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719931,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784940,GEO,GSM1445744,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719932,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784941,GEO,GSM1445748,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719933,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784942,GEO,GSM1445752,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719934,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784943,GEO,GSM1445755,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719935,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784944,GEO,GSM1445759,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719936,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784945,GEO,GSM1445763,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719937,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784946,GEO,GSM1445767,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719938,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784947,GEO,GSM1445771,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719939,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784948,GEO,GSM1445775,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719940,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784949,GEO,GSM1445779,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719941,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784950,GEO,GSM1445783,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719942,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784951,GEO,GSM1445787,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719943,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784952,GEO,GSM1445790,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719944,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784953,GEO,GSM1445794,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719945,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784954,GEO,GSM1445798,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719946,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784955,GEO,GSM1445802,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719947,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784956,GEO,GSM1445806,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719948,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784957,GEO,GSM1445810,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719949,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784958,GEO,GSM1445814,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719950,0.0,Days,Time of initial vaccine administration,B cell,CD8,ES784959,GEO,GSM1445818,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719951,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784960,GEO,GSM1445745,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719952,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784961,GEO,GSM1445749,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719953,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784962,GEO,GSM1445756,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719954,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784963,GEO,GSM1445760,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719955,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784964,GEO,GSM1445764,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719956,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784965,GEO,GSM1445768,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719957,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784966,GEO,GSM1445772,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719958,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784967,GEO,GSM1445776,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719959,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784968,GEO,GSM1445780,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719960,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784969,GEO,GSM1445784,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719962,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784970,GEO,GSM1445791,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719963,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784971,GEO,GSM1445795,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719964,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784972,GEO,GSM1445799,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719965,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784973,GEO,GSM1445803,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719966,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784974,GEO,GSM1445807,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719967,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784975,GEO,GSM1445811,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719968,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784976,GEO,GSM1445815,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719969,2.0,Days,Time of initial vaccine administration,B cell,CD8,ES784977,GEO,GSM1445819,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719971,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784978,GEO,GSM1445746,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719972,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784979,GEO,GSM1445750,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719973,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784980,GEO,GSM1445753,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719974,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784981,GEO,GSM1445757,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719975,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784982,GEO,GSM1445765,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719976,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784983,GEO,GSM1445769,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719977,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784984,GEO,GSM1445773,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719978,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784985,GEO,GSM1445777,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS719979,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784986,GEO,GSM1445781,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS719980,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784987,GEO,GSM1445785,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS719981,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784988,GEO,GSM1445788,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS719982,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784989,GEO,GSM1445792,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS719983,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784990,GEO,GSM1445796,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS719984,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784991,GEO,GSM1445800,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS719985,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784992,GEO,GSM1445804,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS719986,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784993,GEO,GSM1445808,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS719987,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784994,GEO,GSM1445812,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS719988,7.0,Days,Time of initial vaccine administration,B cell,CD8,ES784995,GEO,GSM1445816,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719989,8.0,Days,Time of initial vaccine administration,B cell,CD8,ES784996,GEO,GSM1445761,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS719990,9.0,Days,Time of initial vaccine administration,B cell,CD8,ES784997,GEO,GSM1445820,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS719991,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784998,GEO,GSM1445747,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS719992,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES784999,GEO,GSM1445751,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS719993,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785000,GEO,GSM1445754,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS719994,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785001,GEO,GSM1445758,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS719995,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785002,GEO,GSM1445762,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS719996,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785003,GEO,GSM1445766,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719997,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785004,GEO,GSM1445770,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS719998,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785005,GEO,GSM1445774,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS719999,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785006,GEO,GSM1445778,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS720000,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785007,GEO,GSM1445782,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS720001,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785008,GEO,GSM1445786,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS720002,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785009,GEO,GSM1445789,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS720003,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785010,GEO,GSM1445793,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS720004,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785011,GEO,GSM1445797,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS720005,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785012,GEO,GSM1445801,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS720006,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785013,GEO,GSM1445805,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS720007,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785014,GEO,GSM1445809,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS720008,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785015,GEO,GSM1445813,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123336,Female,Unknown,VO_0000642,Influenza virus vaccine,BS720009,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785016,GEO,GSM1445817,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS720010,28.0,Days,Time of initial vaccine administration,B cell,CD8,ES785017,GEO,GSM1445821,false,GSE95584,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE95584,B cell : CD8,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS720011,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785018,GEO,GSM1445822,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS720012,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785019,GEO,GSM1445826,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS720013,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785020,GEO,GSM1445830,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS720014,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785021,GEO,GSM1445834,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS720015,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785022,GEO,GSM1445838,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS720016,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785023,GEO,GSM1445842,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720017,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785024,GEO,GSM1445846,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720018,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785025,GEO,GSM1445850,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS720019,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785026,GEO,GSM1445855,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS720020,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785027,GEO,GSM1445864,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS720021,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785028,GEO,GSM1445870,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123310,Female,White,VO_0000642,Influenza virus vaccine,BS720022,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785029,GEO,GSM1445874,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123311,Male,White,VO_0000642,Influenza virus vaccine,BS720023,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785030,GEO,GSM1445878,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS720024,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785031,GEO,GSM1445882,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS720025,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785032,GEO,GSM1445886,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS720026,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785033,GEO,GSM1445890,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS720027,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785034,GEO,GSM1445894,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS720028,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785035,GEO,GSM1445898,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS720029,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785036,GEO,GSM1445902,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS720030,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785037,GEO,GSM1445906,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123340,Female,White,VO_0000642,Influenza virus vaccine,BS720031,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785038,GEO,GSM1445910,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123347,Male,White,VO_0000642,Influenza virus vaccine,BS720032,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785039,GEO,GSM1445914,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123350,Female,White,VO_0000642,Influenza virus vaccine,BS720033,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785040,GEO,GSM1445918,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123352,Female,Other,VO_0000642,Influenza virus vaccine,BS720034,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785041,GEO,GSM1445922,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123355,Male,White,VO_0000642,Influenza virus vaccine,BS720035,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785042,GEO,GSM1445926,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123356,Female,White,VO_0000642,Influenza virus vaccine,BS720036,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785043,GEO,GSM1445930,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123358,Male,White,VO_0000642,Influenza virus vaccine,BS720037,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785044,GEO,GSM1445934,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123361,Male,White,VO_0000642,Influenza virus vaccine,BS720038,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785045,GEO,GSM1445938,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS720039,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785046,GEO,GSM1445942,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123364,Male,White,VO_0000642,Influenza virus vaccine,BS720040,0.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785047,GEO,GSM1445946,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS720041,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785048,GEO,GSM1445823,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS720042,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785049,GEO,GSM1445827,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS720043,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785050,GEO,GSM1445835,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS720044,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785051,GEO,GSM1445839,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS720045,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785052,GEO,GSM1445843,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720046,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785053,GEO,GSM1445847,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720047,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785054,GEO,GSM1445851,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS720048,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785055,GEO,GSM1445857,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS720049,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785056,GEO,GSM1445866,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS720050,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785057,GEO,GSM1445871,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123310,Female,White,VO_0000642,Influenza virus vaccine,BS720051,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785058,GEO,GSM1445875,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123311,Male,White,VO_0000642,Influenza virus vaccine,BS720052,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785059,GEO,GSM1445879,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS720053,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785060,GEO,GSM1445883,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS720054,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785061,GEO,GSM1445887,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS720055,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785062,GEO,GSM1445891,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS720056,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785063,GEO,GSM1445895,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS720057,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785064,GEO,GSM1445899,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS720058,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785065,GEO,GSM1445903,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS720059,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785066,GEO,GSM1445907,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123347,Male,White,VO_0000642,Influenza virus vaccine,BS720060,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785067,GEO,GSM1445915,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123350,Female,White,VO_0000642,Influenza virus vaccine,BS720061,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785068,GEO,GSM1445919,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123352,Female,Other,VO_0000642,Influenza virus vaccine,BS720062,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785069,GEO,GSM1445923,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123355,Male,White,VO_0000642,Influenza virus vaccine,BS720063,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785070,GEO,GSM1445927,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123356,Female,White,VO_0000642,Influenza virus vaccine,BS720064,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785071,GEO,GSM1445931,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123358,Male,White,VO_0000642,Influenza virus vaccine,BS720065,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785072,GEO,GSM1445935,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123361,Male,White,VO_0000642,Influenza virus vaccine,BS720066,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785073,GEO,GSM1445939,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS720067,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785074,GEO,GSM1445943,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123364,Male,White,VO_0000642,Influenza virus vaccine,BS720068,2.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785075,GEO,GSM1445947,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS720069,3.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785076,GEO,GSM1445831,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123340,Female,White,VO_0000642,Influenza virus vaccine,BS720070,4.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785077,GEO,GSM1445911,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS720071,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785078,GEO,GSM1445824,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS720072,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785079,GEO,GSM1445828,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS720073,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785080,GEO,GSM1445832,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS720074,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785081,GEO,GSM1445836,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS720075,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785082,GEO,GSM1445844,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720076,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785083,GEO,GSM1445848,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720077,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785084,GEO,GSM1445852,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS720078,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785085,GEO,GSM1445860,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS720079,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785086,GEO,GSM1445868,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS720080,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785087,GEO,GSM1445872,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123310,Female,White,VO_0000642,Influenza virus vaccine,BS720081,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785088,GEO,GSM1445876,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123311,Male,White,VO_0000642,Influenza virus vaccine,BS720082,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785089,GEO,GSM1445880,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS720083,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785090,GEO,GSM1445884,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS720084,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785091,GEO,GSM1445888,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS720085,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785092,GEO,GSM1445892,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS720086,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785093,GEO,GSM1445896,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS720087,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785094,GEO,GSM1445900,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS720088,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785095,GEO,GSM1445904,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS720089,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785096,GEO,GSM1445908,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123340,Female,White,VO_0000642,Influenza virus vaccine,BS720090,7.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785097,GEO,GSM1445912,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS720091,8.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785098,GEO,GSM1445840,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123358,Male,White,VO_0000642,Influenza virus vaccine,BS720092,8.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785099,GEO,GSM1445936,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123347,Male,White,VO_0000642,Influenza virus vaccine,BS720093,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785100,GEO,GSM1445916,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123350,Female,White,VO_0000642,Influenza virus vaccine,BS720094,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785101,GEO,GSM1445920,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123352,Female,Other,VO_0000642,Influenza virus vaccine,BS720095,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785102,GEO,GSM1445924,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123355,Male,White,VO_0000642,Influenza virus vaccine,BS720096,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785103,GEO,GSM1445928,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123356,Female,White,VO_0000642,Influenza virus vaccine,BS720097,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785104,GEO,GSM1445932,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123361,Male,White,VO_0000642,Influenza virus vaccine,BS720098,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785105,GEO,GSM1445940,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS720099,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785106,GEO,GSM1445944,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123364,Male,White,VO_0000642,Influenza virus vaccine,BS720100,9.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785107,GEO,GSM1445948,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123268,Male,White,VO_0000642,Influenza virus vaccine,BS720101,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785108,GEO,GSM1445825,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123279,Female,White,VO_0000642,Influenza virus vaccine,BS720102,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785109,GEO,GSM1445829,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123281,Female,White,VO_0000642,Influenza virus vaccine,BS720103,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785110,GEO,GSM1445833,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123283,Female,White,VO_0000642,Influenza virus vaccine,BS720104,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785111,GEO,GSM1445837,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123284,Male,White,VO_0000642,Influenza virus vaccine,BS720105,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785112,GEO,GSM1445841,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123285,Female,White,VO_0000642,Influenza virus vaccine,BS720106,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785113,GEO,GSM1445845,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123287,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720107,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785114,GEO,GSM1445849,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123289,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS720108,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785115,GEO,GSM1445854,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123295,Female,White,VO_0000642,Influenza virus vaccine,BS720109,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785116,GEO,GSM1445862,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123296,Female,White,VO_0000642,Influenza virus vaccine,BS720110,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785117,GEO,GSM1445869,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123306,Female,White,VO_0000642,Influenza virus vaccine,BS720111,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785118,GEO,GSM1445873,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123310,Female,White,VO_0000642,Influenza virus vaccine,BS720112,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785119,GEO,GSM1445877,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123321,Male,White,VO_0000642,Influenza virus vaccine,BS720113,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785120,GEO,GSM1445885,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123322,Male,White,VO_0000642,Influenza virus vaccine,BS720114,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785121,GEO,GSM1445889,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123323,Male,White,VO_0000642,Influenza virus vaccine,BS720115,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785122,GEO,GSM1445893,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123324,Female,Asian,VO_0000642,Influenza virus vaccine,BS720116,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785123,GEO,GSM1445897,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123326,Female,White,VO_0000642,Influenza virus vaccine,BS720117,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785124,GEO,GSM1445901,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123333,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS720118,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785125,GEO,GSM1445905,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123335,Male,Other,VO_0000642,Influenza virus vaccine,BS720119,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785126,GEO,GSM1445909,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123340,Female,White,VO_0000642,Influenza virus vaccine,BS720120,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785127,GEO,GSM1445913,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123347,Male,White,VO_0000642,Influenza virus vaccine,BS720121,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785128,GEO,GSM1445917,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123350,Female,White,VO_0000642,Influenza virus vaccine,BS720122,35.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785129,GEO,GSM1445921,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123352,Female,Other,VO_0000642,Influenza virus vaccine,BS720123,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785130,GEO,GSM1445925,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123355,Male,White,VO_0000642,Influenza virus vaccine,BS720124,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785131,GEO,GSM1445929,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123356,Female,White,VO_0000642,Influenza virus vaccine,BS720125,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785132,GEO,GSM1445933,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123358,Male,White,VO_0000642,Influenza virus vaccine,BS720126,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785133,GEO,GSM1445937,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123361,Male,White,VO_0000642,Influenza virus vaccine,BS720127,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785134,GEO,GSM1445941,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123362,Female,White,VO_0000642,Influenza virus vaccine,BS720128,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785135,GEO,GSM1445945,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123364,Male,White,VO_0000642,Influenza virus vaccine,BS720129,28.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785136,GEO,GSM1445949,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY400,"Immunologic and genomic signatures of influenza vaccine response - 2012 (see companion studies SDY63, SDY404, SDY520)",Project 1: Immunologic and genomic signatures of influenza vaccine response - year3 2012,21.0,90.0,SUB123311,Male,White,VO_0000642,Influenza virus vaccine,BS720130,36.0,Days,Time of initial vaccine administration,PBMC,PBMC,ES785137,GEO,GSM1445881,false,GSE59743,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE59743,PBMC : PBMC,21.0 - 90.0
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116437,Male,White,VO_0000124,Zostavax,BS736530,3.0,Days,Time of initial vaccine administration,Other,,ES798244,GEO,GSM2300358,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116441,Male,White,VO_0000124,Zostavax,BS736537,0.0,Days,Time of initial vaccine administration,Other,,ES798245,GEO,GSM2300359,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116445,Male,Other,VO_0000124,Zostavax,BS736546,3.0,Days,Time of initial vaccine administration,Other,,ES798246,GEO,GSM2300360,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116445,Male,Other,VO_0000124,Zostavax,BS736545,0.0,Days,Time of initial vaccine administration,Other,,ES798247,GEO,GSM2300361,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116440,Male,White,VO_0000124,Zostavax,BS736536,3.0,Days,Time of initial vaccine administration,Other,,ES798248,GEO,GSM2300362,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116438,Female,White,VO_0000124,Zostavax,BS736532,3.0,Days,Time of initial vaccine administration,Other,,ES798249,GEO,GSM2300363,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116442,Female,Unknown,VO_0000124,Zostavax,BS736540,3.0,Days,Time of initial vaccine administration,Other,,ES798250,GEO,GSM2300364,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116440,Male,White,VO_0000124,Zostavax,BS736535,0.0,Days,Time of initial vaccine administration,Other,,ES798251,GEO,GSM2300365,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116437,Male,White,VO_0000124,Zostavax,BS736529,0.0,Days,Time of initial vaccine administration,Other,,ES798252,GEO,GSM2300366,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116441,Male,White,VO_0000124,Zostavax,BS736538,3.0,Days,Time of initial vaccine administration,Other,,ES798253,GEO,GSM2300367,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116446,Male,White,VO_0000124,Zostavax,BS736547,0.0,Days,Time of initial vaccine administration,Other,,ES798254,GEO,GSM2300368,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116446,Male,White,VO_0000124,Zostavax,BS736548,3.0,Days,Time of initial vaccine administration,Other,,ES798255,GEO,GSM2300369,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116443,Male,White,VO_0000124,Zostavax,BS736542,3.0,Days,Time of initial vaccine administration,Other,,ES798256,GEO,GSM2300370,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116438,Female,White,VO_0000124,Zostavax,BS736531,0.0,Days,Time of initial vaccine administration,Other,,ES798257,GEO,GSM2300371,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116444,Female,White,VO_0000124,Zostavax,BS736543,0.0,Days,Time of initial vaccine administration,Other,,ES798258,GEO,GSM2300372,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116443,Male,White,VO_0000124,Zostavax,BS736541,0.0,Days,Time of initial vaccine administration,Other,,ES798259,GEO,GSM2300373,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116439,Female,White,VO_0000124,Zostavax,BS736534,3.0,Days,Time of initial vaccine administration,Other,,ES798260,GEO,GSM2300374,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116444,Female,White,VO_0000124,Zostavax,BS736544,3.0,Days,Time of initial vaccine administration,Other,,ES798261,GEO,GSM2300375,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116439,Female,White,VO_0000124,Zostavax,BS736533,0.0,Days,Time of initial vaccine administration,Other,,ES798262,GEO,GSM2300376,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY111,VZV vaccination in the elderly SLVP020,Healthy adults (50+ years old) with history of varicella but no history of zoster are vaccinated with Zostavax. Blood and serum are taken prior to vaccination and at several points after. A systems biology approach will be used to identify age-related decreases in immune function and potential predictors and correlates of protection.,42.3,75.7,SUB116442,Female,Unknown,VO_0000124,Zostavax,BS736539,0.0,Days,Time of initial vaccine administration,Other,,ES798263,GEO,GSM2300377,false,GSE86331,GPL10558,Illumina HumanHT-12 V4.0 expression beadchip,GSE86331,Other : NA,42.3 - 75.7
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142617,Female,White,VO_0000642,Influenza virus vaccine,BS742325,0.0,Days,Time of initial vaccine administration,PBMC,,ES818423,GEO,GSM1934103,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142617,Female,White,VO_0000642,Influenza virus vaccine,BS749998,1.0,Days,Time of initial vaccine administration,PBMC,,ES818424,GEO,GSM1934106,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142617,Female,White,VO_0000642,Influenza virus vaccine,BS742326,3.0,Days,Time of initial vaccine administration,PBMC,,ES818425,GEO,GSM1934107,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142617,Female,White,VO_0000642,Influenza virus vaccine,BS742327,7.0,Days,Time of initial vaccine administration,PBMC,,ES818426,GEO,GSM1934105,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142618,Male,White,VO_0000642,Influenza virus vaccine,BS750001,1.0,Days,Time of initial vaccine administration,PBMC,,ES818429,GEO,GSM1934132,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142618,Male,White,VO_0000642,Influenza virus vaccine,BS742332,3.0,Days,Time of initial vaccine administration,PBMC,,ES818430,GEO,GSM1934135,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142618,Male,White,VO_0000642,Influenza virus vaccine,BS742333,7.0,Days,Time of initial vaccine administration,PBMC,,ES818431,GEO,GSM1934136,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142618,Male,White,VO_0000642,Influenza virus vaccine,BS742334,14.0,Days,Time of initial vaccine administration,PBMC,,ES818432,GEO,GSM1934134,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142619,Female,White,VO_0000642,Influenza virus vaccine,BS742337,0.0,Days,Time of initial vaccine administration,PBMC,,ES818433,GEO,GSM1934248,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142619,Female,White,VO_0000642,Influenza virus vaccine,BS742339,7.0,Days,Time of initial vaccine administration,PBMC,,ES818436,GEO,GSM1934310,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142620,Female,White,VO_0000642,Influenza virus vaccine,BS742344,3.0,Days,Time of initial vaccine administration,PBMC,,ES818439,GEO,GSM1934305,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142620,Female,White,VO_0000642,Influenza virus vaccine,BS742345,7.0,Days,Time of initial vaccine administration,PBMC,,ES818440,GEO,GSM1934307,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142620,Female,White,VO_0000642,Influenza virus vaccine,BS742346,14.0,Days,Time of initial vaccine administration,PBMC,,ES818441,GEO,GSM1934308,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142621,Male,White,VO_0000642,Influenza virus vaccine,BS742351,7.0,Days,Time of initial vaccine administration,PBMC,,ES818445,GEO,GSM1934183,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142621,Male,White,VO_0000642,Influenza virus vaccine,BS742352,14.0,Days,Time of initial vaccine administration,PBMC,,ES818446,GEO,GSM1934186,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142622,Male,White,VO_0000642,Influenza virus vaccine,BS742355,0.0,Days,Time of initial vaccine administration,PBMC,,ES818447,GEO,GSM1934187,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142622,Male,White,VO_0000642,Influenza virus vaccine,BS750013,1.0,Days,Time of initial vaccine administration,PBMC,,ES818448,GEO,GSM1934185,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142622,Male,White,VO_0000642,Influenza virus vaccine,BS742358,14.0,Days,Time of initial vaccine administration,PBMC,,ES818451,GEO,GSM1934188,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142624,Female,White,VO_0000642,Influenza virus vaccine,BS750019,1.0,Days,Time of initial vaccine administration,PBMC,,ES818457,GEO,GSM1934311,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142625,Male,White,VO_0000642,Influenza virus vaccine,BS742376,14.0,Days,Time of initial vaccine administration,PBMC,,ES818463,GEO,GSM1934251,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142626,Female,White,VO_0000642,Influenza virus vaccine,BS742379,0.0,Days,Time of initial vaccine administration,PBMC,,ES818464,GEO,GSM1934254,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142626,Female,White,VO_0000642,Influenza virus vaccine,BS750025,1.0,Days,Time of initial vaccine administration,PBMC,,ES818465,GEO,GSM1934255,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142626,Female,White,VO_0000642,Influenza virus vaccine,BS742380,3.0,Days,Time of initial vaccine administration,PBMC,,ES818466,GEO,GSM1934253,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142627,Male,White,VO_0000642,Influenza virus vaccine,BS750028,1.0,Days,Time of initial vaccine administration,PBMC,,ES818469,GEO,GSM1934256,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142627,Male,White,VO_0000642,Influenza virus vaccine,BS742386,3.0,Days,Time of initial vaccine administration,PBMC,,ES818470,GEO,GSM1934259,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142627,Male,White,VO_0000642,Influenza virus vaccine,BS742388,14.0,Days,Time of initial vaccine administration,PBMC,,ES818471,GEO,GSM1934260,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142628,Female,White,VO_0000642,Influenza virus vaccine,BS742391,0.0,Days,Time of initial vaccine administration,PBMC,,ES818472,GEO,GSM1934258,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142628,Female,White,VO_0000642,Influenza virus vaccine,BS742394,14.0,Days,Time of initial vaccine administration,PBMC,,ES818475,GEO,GSM1934312,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142629,Male,White,VO_0000642,Influenza virus vaccine,BS742403,0.0,Days,Time of initial vaccine administration,PBMC,,ES818476,GEO,GSM1934191,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142629,Male,White,VO_0000642,Influenza virus vaccine,BS750037,1.0,Days,Time of initial vaccine administration,PBMC,,ES818477,GEO,GSM1934192,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142629,Male,White,VO_0000642,Influenza virus vaccine,BS742404,3.0,Days,Time of initial vaccine administration,PBMC,,ES818478,GEO,GSM1934190,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142630,Female,White,VO_0000642,Influenza virus vaccine,BS742415,0.0,Days,Time of initial vaccine administration,PBMC,,ES818481,GEO,GSM1934193,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142630,Female,White,VO_0000642,Influenza virus vaccine,BS750043,1.0,Days,Time of initial vaccine administration,PBMC,,ES818482,GEO,GSM1934196,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142630,Female,White,VO_0000642,Influenza virus vaccine,BS742416,3.0,Days,Time of initial vaccine administration,PBMC,,ES818483,GEO,GSM1934197,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142630,Female,White,VO_0000642,Influenza virus vaccine,BS742417,7.0,Days,Time of initial vaccine administration,PBMC,,ES818484,GEO,GSM1934195,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142601,Female,Asian,VO_0000642,Influenza virus vaccine,BS750046,1.0,Days,Time of initial vaccine administration,PBMC,,ES818487,GEO,GSM1934372,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142601,Female,Asian,VO_0000642,Influenza virus vaccine,BS742422,3.0,Days,Time of initial vaccine administration,PBMC,,ES818488,GEO,GSM1934375,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142601,Female,Asian,VO_0000642,Influenza virus vaccine,BS742424,14.0,Days,Time of initial vaccine administration,PBMC,,ES818490,GEO,GSM1934374,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142631,Female,White,VO_0000642,Influenza virus vaccine,BS742428,3.0,Days,Time of initial vaccine administration,PBMC,,ES818493,GEO,GSM1934381,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142631,Female,White,VO_0000642,Influenza virus vaccine,BS742429,7.0,Days,Time of initial vaccine administration,PBMC,,ES818494,GEO,GSM1934384,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142632,Female,White,VO_0000642,Influenza virus vaccine,BS742433,0.0,Days,Time of initial vaccine administration,PBMC,,ES818496,GEO,GSM1934383,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142632,Female,White,VO_0000642,Influenza virus vaccine,BS742435,7.0,Days,Time of initial vaccine administration,PBMC,,ES818499,GEO,GSM1934385,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142632,Female,White,VO_0000642,Influenza virus vaccine,BS742436,14.0,Days,Time of initial vaccine administration,PBMC,,ES818500,GEO,GSM1934388,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142633,Male,White,VO_0000642,Influenza virus vaccine,BS750055,1.0,Days,Time of initial vaccine administration,PBMC,,ES818502,GEO,GSM1934387,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142633,Male,White,VO_0000642,Influenza virus vaccine,BS742442,14.0,Days,Time of initial vaccine administration,PBMC,,ES818505,GEO,GSM1934293,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142634,Male,White,VO_0000642,Influenza virus vaccine,BS742445,0.0,Days,Time of initial vaccine administration,PBMC,,ES818506,GEO,GSM1934296,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142634,Male,White,VO_0000642,Influenza virus vaccine,BS742446,3.0,Days,Time of initial vaccine administration,PBMC,,ES818508,GEO,GSM1934295,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142608,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS742451,0.0,Days,Time of initial vaccine administration,PBMC,,ES818511,GEO,GSM1934297,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142608,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS750061,1.0,Days,Time of initial vaccine administration,PBMC,,ES818512,GEO,GSM1934300,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142608,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS742453,7.0,Days,Time of initial vaccine administration,PBMC,,ES818514,GEO,GSM1934299,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142635,Female,White,VO_0000642,Influenza virus vaccine,BS750064,1.0,Days,Time of initial vaccine administration,PBMC,,ES818517,GEO,GSM1934301,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142635,Female,White,VO_0000642,Influenza virus vaccine,BS742458,3.0,Days,Time of initial vaccine administration,PBMC,,ES818518,GEO,GSM1934304,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142635,Female,White,VO_0000642,Influenza virus vaccine,BS742460,14.0,Days,Time of initial vaccine administration,PBMC,,ES818520,GEO,GSM1934303,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142636,Male,White,VO_0000642,Influenza virus vaccine,BS742471,7.0,Days,Time of initial vaccine administration,PBMC,,ES818529,GEO,GSM1934108,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142636,Male,White,VO_0000642,Influenza virus vaccine,BS742472,14.0,Days,Time of initial vaccine administration,PBMC,,ES818530,GEO,GSM1934111,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142637,Male,White,VO_0000642,Influenza virus vaccine,BS742475,0.0,Days,Time of initial vaccine administration,PBMC,,ES818531,GEO,GSM1934112,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142637,Male,White,VO_0000642,Influenza virus vaccine,BS750073,1.0,Days,Time of initial vaccine administration,PBMC,,ES818532,GEO,GSM1934110,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142640,Male,White,VO_0000642,Influenza virus vaccine,BS742493,0.0,Days,Time of initial vaccine administration,PBMC,,ES818541,GEO,GSM1934113,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142640,Male,White,VO_0000642,Influenza virus vaccine,BS750082,1.0,Days,Time of initial vaccine administration,PBMC,,ES818542,GEO,GSM1934116,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142640,Male,White,VO_0000642,Influenza virus vaccine,BS742495,7.0,Days,Time of initial vaccine administration,PBMC,,ES818544,GEO,GSM1934115,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142641,Male,White,VO_0000642,Influenza virus vaccine,BS750085,1.0,Days,Time of initial vaccine administration,PBMC,,ES818547,GEO,GSM1934117,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142641,Male,White,VO_0000642,Influenza virus vaccine,BS742500,3.0,Days,Time of initial vaccine administration,PBMC,,ES818548,GEO,GSM1934120,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142641,Male,White,VO_0000642,Influenza virus vaccine,BS742501,7.0,Days,Time of initial vaccine administration,PBMC,,ES818549,GEO,GSM1934121,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142641,Male,White,VO_0000642,Influenza virus vaccine,BS742502,14.0,Days,Time of initial vaccine administration,PBMC,,ES818550,GEO,GSM1934119,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142602,Female,Asian,VO_0000642,Influenza virus vaccine,BS742506,3.0,Days,Time of initial vaccine administration,PBMC,,ES818553,GEO,GSM1934122,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142602,Female,Asian,VO_0000642,Influenza virus vaccine,BS742507,7.0,Days,Time of initial vaccine administration,PBMC,,ES818554,GEO,GSM1934125,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142602,Female,Asian,VO_0000642,Influenza virus vaccine,BS742508,14.0,Days,Time of initial vaccine administration,PBMC,,ES818555,GEO,GSM1934126,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142642,Female,White,VO_0000642,Influenza virus vaccine,BS742511,0.0,Days,Time of initial vaccine administration,PBMC,,ES818556,GEO,GSM1934124,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142642,Female,White,VO_0000642,Influenza virus vaccine,BS742513,7.0,Days,Time of initial vaccine administration,PBMC,,ES818559,GEO,GSM1934127,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142642,Female,White,VO_0000642,Influenza virus vaccine,BS742514,14.0,Days,Time of initial vaccine administration,PBMC,,ES818560,GEO,GSM1934130,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142610,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742523,0.0,Days,Time of initial vaccine administration,PBMC,,ES818562,GEO,GSM1934131,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142610,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS750097,1.0,Days,Time of initial vaccine administration,PBMC,,ES818563,GEO,GSM1934129,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142610,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742526,14.0,Days,Time of initial vaccine administration,PBMC,,ES818566,GEO,GSM1934137,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142644,Female,White,VO_0000642,Influenza virus vaccine,BS742529,0.0,Days,Time of initial vaccine administration,PBMC,,ES818567,GEO,GSM1934140,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142644,Female,White,VO_0000642,Influenza virus vaccine,BS750100,1.0,Days,Time of initial vaccine administration,PBMC,,ES818568,GEO,GSM1934141,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142644,Female,White,VO_0000642,Influenza virus vaccine,BS742530,3.0,Days,Time of initial vaccine administration,PBMC,,ES818569,GEO,GSM1934139,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142646,Female,White,VO_0000642,Influenza virus vaccine,BS742541,0.0,Days,Time of initial vaccine administration,PBMC,,ES818572,GEO,GSM1934142,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142646,Female,White,VO_0000642,Influenza virus vaccine,BS750106,1.0,Days,Time of initial vaccine administration,PBMC,,ES818573,GEO,GSM1934145,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142646,Female,White,VO_0000642,Influenza virus vaccine,BS742542,3.0,Days,Time of initial vaccine administration,PBMC,,ES818574,GEO,GSM1934146,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142646,Female,White,VO_0000642,Influenza virus vaccine,BS742543,7.0,Days,Time of initial vaccine administration,PBMC,,ES818575,GEO,GSM1934144,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142647,Female,White,VO_0000642,Influenza virus vaccine,BS750109,1.0,Days,Time of initial vaccine administration,PBMC,,ES818578,GEO,GSM1934147,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142647,Female,White,VO_0000642,Influenza virus vaccine,BS742548,3.0,Days,Time of initial vaccine administration,PBMC,,ES818579,GEO,GSM1934150,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142647,Female,White,VO_0000642,Influenza virus vaccine,BS742549,7.0,Days,Time of initial vaccine administration,PBMC,,ES818580,GEO,GSM1934151,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142647,Female,White,VO_0000642,Influenza virus vaccine,BS742550,14.0,Days,Time of initial vaccine administration,PBMC,,ES818581,GEO,GSM1934149,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142603,Male,Asian,VO_0000642,Influenza virus vaccine,BS742554,3.0,Days,Time of initial vaccine administration,PBMC,,ES818584,GEO,GSM1934152,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142603,Male,Asian,VO_0000642,Influenza virus vaccine,BS742555,7.0,Days,Time of initial vaccine administration,PBMC,,ES818585,GEO,GSM1934155,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142603,Male,Asian,VO_0000642,Influenza virus vaccine,BS742556,14.0,Days,Time of initial vaccine administration,PBMC,,ES818586,GEO,GSM1934156,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142648,Female,White,VO_0000642,Influenza virus vaccine,BS742559,0.0,Days,Time of initial vaccine administration,PBMC,,ES818587,GEO,GSM1934154,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142648,Female,White,VO_0000642,Influenza virus vaccine,BS742561,7.0,Days,Time of initial vaccine administration,PBMC,,ES818590,GEO,GSM1934157,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142648,Female,White,VO_0000642,Influenza virus vaccine,BS742562,14.0,Days,Time of initial vaccine administration,PBMC,,ES818591,GEO,GSM1934160,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142649,Female,White,VO_0000642,Influenza virus vaccine,BS742571,0.0,Days,Time of initial vaccine administration,PBMC,,ES818592,GEO,GSM1934161,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142649,Female,White,VO_0000642,Influenza virus vaccine,BS750121,1.0,Days,Time of initial vaccine administration,PBMC,,ES818593,GEO,GSM1934159,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142649,Female,White,VO_0000642,Influenza virus vaccine,BS742574,14.0,Days,Time of initial vaccine administration,PBMC,,ES818596,GEO,GSM1934162,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142650,Female,White,VO_0000642,Influenza virus vaccine,BS742577,0.0,Days,Time of initial vaccine administration,PBMC,,ES818597,GEO,GSM1934165,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142650,Female,White,VO_0000642,Influenza virus vaccine,BS750124,1.0,Days,Time of initial vaccine administration,PBMC,,ES818598,GEO,GSM1934166,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142650,Female,White,VO_0000642,Influenza virus vaccine,BS742578,3.0,Days,Time of initial vaccine administration,PBMC,,ES818599,GEO,GSM1934164,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142612,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742595,0.0,Days,Time of initial vaccine administration,PBMC,,ES818604,GEO,GSM1934167,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142612,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS750133,1.0,Days,Time of initial vaccine administration,PBMC,,ES818605,GEO,GSM1934170,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142612,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742596,3.0,Days,Time of initial vaccine administration,PBMC,,ES818606,GEO,GSM1934171,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142612,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742597,7.0,Days,Time of initial vaccine administration,PBMC,,ES818607,GEO,GSM1934169,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142657,Male,White,VO_0000642,Influenza virus vaccine,BS742626,3.0,Days,Time of initial vaccine administration,PBMC,,ES818618,GEO,GSM1934172,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142657,Male,White,VO_0000642,Influenza virus vaccine,BS742627,7.0,Days,Time of initial vaccine administration,PBMC,,ES818619,GEO,GSM1934175,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142657,Male,White,VO_0000642,Influenza virus vaccine,BS742628,14.0,Days,Time of initial vaccine administration,PBMC,,ES818620,GEO,GSM1934176,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142658,Male,White,VO_0000642,Influenza virus vaccine,BS742631,0.0,Days,Time of initial vaccine administration,PBMC,,ES818621,GEO,GSM1934174,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142658,Male,White,VO_0000642,Influenza virus vaccine,BS742633,7.0,Days,Time of initial vaccine administration,PBMC,,ES818624,GEO,GSM1934177,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142658,Male,White,VO_0000642,Influenza virus vaccine,BS742634,14.0,Days,Time of initial vaccine administration,PBMC,,ES818625,GEO,GSM1934180,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142659,Female,White,VO_0000642,Influenza virus vaccine,BS742637,0.0,Days,Time of initial vaccine administration,PBMC,,ES818626,GEO,GSM1934181,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142659,Female,White,VO_0000642,Influenza virus vaccine,BS750154,1.0,Days,Time of initial vaccine administration,PBMC,,ES818627,GEO,GSM1934179,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142659,Female,White,VO_0000642,Influenza virus vaccine,BS742640,14.0,Days,Time of initial vaccine administration,PBMC,,ES818630,GEO,GSM1934182,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142660,Female,White,VO_0000642,Influenza virus vaccine,BS742643,0.0,Days,Time of initial vaccine administration,PBMC,,ES818631,GEO,GSM1934200,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142660,Female,White,VO_0000642,Influenza virus vaccine,BS750157,1.0,Days,Time of initial vaccine administration,PBMC,,ES818632,GEO,GSM1934201,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142660,Female,White,VO_0000642,Influenza virus vaccine,BS742644,3.0,Days,Time of initial vaccine administration,PBMC,,ES818633,GEO,GSM1934199,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142661,Female,White,VO_0000642,Influenza virus vaccine,BS742649,0.0,Days,Time of initial vaccine administration,PBMC,,ES818636,GEO,GSM1934202,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142661,Female,White,VO_0000642,Influenza virus vaccine,BS750160,1.0,Days,Time of initial vaccine administration,PBMC,,ES818637,GEO,GSM1934205,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142661,Female,White,VO_0000642,Influenza virus vaccine,BS742650,3.0,Days,Time of initial vaccine administration,PBMC,,ES818638,GEO,GSM1934206,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142661,Female,White,VO_0000642,Influenza virus vaccine,BS742651,7.0,Days,Time of initial vaccine administration,PBMC,,ES818639,GEO,GSM1934204,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142604,Male,Asian,VO_0000642,Influenza virus vaccine,BS750163,1.0,Days,Time of initial vaccine administration,PBMC,,ES818642,GEO,GSM1934207,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142604,Male,Asian,VO_0000642,Influenza virus vaccine,BS742656,3.0,Days,Time of initial vaccine administration,PBMC,,ES818643,GEO,GSM1934210,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142604,Male,Asian,VO_0000642,Influenza virus vaccine,BS742657,7.0,Days,Time of initial vaccine administration,PBMC,,ES818644,GEO,GSM1934211,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142604,Male,Asian,VO_0000642,Influenza virus vaccine,BS742658,14.0,Days,Time of initial vaccine administration,PBMC,,ES818645,GEO,GSM1934209,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142613,Female,Black or African American,VO_0000642,Influenza virus vaccine,BS742662,3.0,Days,Time of initial vaccine administration,PBMC,,ES818648,GEO,GSM1934309,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142662,Female,White,VO_0000642,Influenza virus vaccine,BS742669,7.0,Days,Time of initial vaccine administration,PBMC,,ES818654,GEO,GSM1934212,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142662,Female,White,VO_0000642,Influenza virus vaccine,BS742670,14.0,Days,Time of initial vaccine administration,PBMC,,ES818655,GEO,GSM1934215,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142663,Female,White,VO_0000642,Influenza virus vaccine,BS742673,0.0,Days,Time of initial vaccine administration,PBMC,,ES818656,GEO,GSM1934216,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142663,Female,White,VO_0000642,Influenza virus vaccine,BS750172,1.0,Days,Time of initial vaccine administration,PBMC,,ES818657,GEO,GSM1934214,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142663,Female,White,VO_0000642,Influenza virus vaccine,BS742676,14.0,Days,Time of initial vaccine administration,PBMC,,ES818660,GEO,GSM1934217,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142605,Female,Asian,VO_0000642,Influenza virus vaccine,BS742679,0.0,Days,Time of initial vaccine administration,PBMC,,ES818661,GEO,GSM1934220,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142605,Female,Asian,VO_0000642,Influenza virus vaccine,BS742680,3.0,Days,Time of initial vaccine administration,PBMC,,ES818663,GEO,GSM1934219,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142665,Female,White,VO_0000642,Influenza virus vaccine,BS750181,1.0,Days,Time of initial vaccine administration,PBMC,,ES818672,GEO,GSM1934221,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142665,Female,White,VO_0000642,Influenza virus vaccine,BS742692,3.0,Days,Time of initial vaccine administration,PBMC,,ES818673,GEO,GSM1934224,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142665,Female,White,VO_0000642,Influenza virus vaccine,BS742693,7.0,Days,Time of initial vaccine administration,PBMC,,ES818674,GEO,GSM1934225,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142665,Female,White,VO_0000642,Influenza virus vaccine,BS742694,14.0,Days,Time of initial vaccine administration,PBMC,,ES818675,GEO,GSM1934223,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142614,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742698,3.0,Days,Time of initial vaccine administration,PBMC,,ES818678,GEO,GSM1934226,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142614,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742699,7.0,Days,Time of initial vaccine administration,PBMC,,ES818679,GEO,GSM1934229,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142614,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742700,14.0,Days,Time of initial vaccine administration,PBMC,,ES818680,GEO,GSM1934230,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142666,Male,White,VO_0000642,Influenza virus vaccine,BS742703,0.0,Days,Time of initial vaccine administration,PBMC,,ES818681,GEO,GSM1934228,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142666,Male,White,VO_0000642,Influenza virus vaccine,BS742705,7.0,Days,Time of initial vaccine administration,PBMC,,ES818684,GEO,GSM1934231,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142666,Male,White,VO_0000642,Influenza virus vaccine,BS742706,14.0,Days,Time of initial vaccine administration,PBMC,,ES818685,GEO,GSM1934234,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142667,Male,White,VO_0000642,Influenza virus vaccine,BS742709,0.0,Days,Time of initial vaccine administration,PBMC,,ES818686,GEO,GSM1934235,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142667,Male,White,VO_0000642,Influenza virus vaccine,BS750190,1.0,Days,Time of initial vaccine administration,PBMC,,ES818687,GEO,GSM1934233,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142667,Male,White,VO_0000642,Influenza virus vaccine,BS742712,14.0,Days,Time of initial vaccine administration,PBMC,,ES818690,GEO,GSM1934236,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142668,Male,White,VO_0000642,Influenza virus vaccine,BS742715,0.0,Days,Time of initial vaccine administration,PBMC,,ES818691,GEO,GSM1934239,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142668,Male,White,VO_0000642,Influenza virus vaccine,BS750193,1.0,Days,Time of initial vaccine administration,PBMC,,ES818692,GEO,GSM1934240,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142668,Male,White,VO_0000642,Influenza virus vaccine,BS742716,3.0,Days,Time of initial vaccine administration,PBMC,,ES818693,GEO,GSM1934238,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142670,Male,White,VO_0000642,Influenza virus vaccine,BS750202,1.0,Days,Time of initial vaccine administration,PBMC,,ES818702,GEO,GSM1934241,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142670,Male,White,VO_0000642,Influenza virus vaccine,BS742734,3.0,Days,Time of initial vaccine administration,PBMC,,ES818703,GEO,GSM1934244,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142670,Male,White,VO_0000642,Influenza virus vaccine,BS742735,7.0,Days,Time of initial vaccine administration,PBMC,,ES818704,GEO,GSM1934245,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142670,Male,White,VO_0000642,Influenza virus vaccine,BS742736,14.0,Days,Time of initial vaccine administration,PBMC,,ES818705,GEO,GSM1934243,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142616,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742740,3.0,Days,Time of initial vaccine administration,PBMC,,ES818708,GEO,GSM1934246,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142616,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742741,7.0,Days,Time of initial vaccine administration,PBMC,,ES818709,GEO,GSM1934249,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY56,"Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011)","Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.",25.0,85.0,SUB142616,Male,Black or African American,VO_0000642,Influenza virus vaccine,BS742742,14.0,Days,Time of initial vaccine administration,PBMC,,ES818710,GEO,GSM1934250,false,GSE74817,GPL13158,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,GSE74817,PBMC : NA,25.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114450,Male,White,VO_0000046,Fluvirin,BS808205,-7.0,Days,Time of initial vaccine administration,PBMC,200.Blood.RNA-MicroArray.PV4267,ES983916,GEO,GSM1147762,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 200.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114451,Female,White,VO_0000046,Fluvirin,BS808206,-7.0,Days,Time of initial vaccine administration,PBMC,201.Blood.RNA-MicroArray.PV4267,ES983917,GEO,GSM1147767,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 201.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114452,Male,Asian,VO_0000046,Fluvirin,BS808207,-7.0,Days,Time of initial vaccine administration,PBMC,202.Blood.RNA-MicroArray.PV4267,ES983918,GEO,GSM1147772,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 202.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114453,Female,White,VO_0000046,Fluvirin,BS808208,-7.0,Days,Time of initial vaccine administration,PBMC,204.Blood.RNA-MicroArray.PV4267,ES983919,GEO,GSM1147777,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 204.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114454,Female,White,VO_0000046,Fluvirin,BS808209,-7.0,Days,Time of initial vaccine administration,PBMC,205.Blood.RNA-MicroArray.PV4267,ES983920,GEO,GSM1147782,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 205.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114455,Male,Asian,VO_0000046,Fluvirin,BS808210,-7.0,Days,Time of initial vaccine administration,PBMC,206.Blood.RNA-MicroArray.PV4267,ES983921,GEO,GSM1147787,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 206.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114456,Female,White,VO_0000046,Fluvirin,BS808211,-7.0,Days,Time of initial vaccine administration,PBMC,207.Blood.RNA-MicroArray.PV4267,ES983922,GEO,GSM1147791,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 207.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114457,Male,White,VO_0000046,Fluvirin,BS808212,-7.0,Days,Time of initial vaccine administration,PBMC,209.Blood.RNA-MicroArray.PV4267,ES983923,GEO,GSM1147795,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 209.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114458,Male,White,VO_0000046,Fluvirin,BS808213,-7.0,Days,Time of initial vaccine administration,PBMC,212.Blood.RNA-MicroArray.PV4267,ES983924,GEO,GSM1147800,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 212.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114459,Female,Asian,VO_0000046,Fluvirin,BS808214,-7.0,Days,Time of initial vaccine administration,PBMC,213.Blood.RNA-MicroArray.PV4267,ES983925,GEO,GSM1147805,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 213.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114460,Female,Asian,VO_0000046,Fluvirin,BS808215,-7.0,Days,Time of initial vaccine administration,PBMC,215.Blood.RNA-MicroArray.PV4267,ES983926,GEO,GSM1147810,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 215.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114461,Female,White,VO_0000046,Fluvirin,BS808216,-7.0,Days,Time of initial vaccine administration,PBMC,217.Blood.RNA-MicroArray.PV4267,ES983927,GEO,GSM1147815,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 217.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114462,Female,Other,VO_0000046,Fluvirin,BS808217,-7.0,Days,Time of initial vaccine administration,PBMC,218.Blood.RNA-MicroArray.PV4267,ES983928,GEO,GSM1147820,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 218.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114463,Male,White,VO_0000046,Fluvirin,BS808218,-7.0,Days,Time of initial vaccine administration,PBMC,221.Blood.RNA-MicroArray.PV4267,ES983929,GEO,GSM1147824,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 221.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114464,Female,Asian,VO_0000046,Fluvirin,BS808219,-7.0,Days,Time of initial vaccine administration,PBMC,222.Blood.RNA-MicroArray.PV4267,ES983930,GEO,GSM1147829,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 222.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114465,Male,White,VO_0000046,Fluvirin,BS808220,-7.0,Days,Time of initial vaccine administration,PBMC,224.Blood.RNA-MicroArray.PV4267,ES983931,GEO,GSM1147833,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 224.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114466,Female,White,VO_0000046,Fluvirin,BS808221,-7.0,Days,Time of initial vaccine administration,PBMC,226.Blood.RNA-MicroArray.PV4267,ES983932,GEO,GSM1147838,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 226.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114467,Male,White,VO_0000046,Fluvirin,BS808222,-7.0,Days,Time of initial vaccine administration,PBMC,227.Blood.RNA-MicroArray.PV4267,ES983933,GEO,GSM1147843,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 227.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114468,Male,White,VO_0000046,Fluvirin,BS808223,-7.0,Days,Time of initial vaccine administration,PBMC,228.Blood.RNA-MicroArray.PV4267,ES983934,GEO,GSM1147848,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 228.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114469,Female,White,VO_0000046,Fluvirin,BS808224,-7.0,Days,Time of initial vaccine administration,PBMC,229.Blood.RNA-MicroArray.PV4267,ES983935,GEO,GSM1147853,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 229.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114470,Female,White,VO_0000046,Fluvirin,BS808225,-7.0,Days,Time of initial vaccine administration,PBMC,230.Blood.RNA-MicroArray.PV4267,ES983936,GEO,GSM1147858,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 230.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114471,Female,Asian,VO_0000046,Fluvirin,BS808226,-7.0,Days,Time of initial vaccine administration,PBMC,231.Blood.RNA-MicroArray.PV4267,ES983937,GEO,GSM1147863,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 231.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114472,Male,Asian,VO_0000046,Fluvirin,BS808227,-7.0,Days,Time of initial vaccine administration,PBMC,232.Blood.RNA-MicroArray.PV4267,ES983938,GEO,GSM1147868,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 232.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114473,Male,White,VO_0000046,Fluvirin,BS808228,-7.0,Days,Time of initial vaccine administration,PBMC,233.Blood.RNA-MicroArray.PV4267,ES983939,GEO,GSM1147873,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 233.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114474,Male,Black or African American,VO_0000046,Fluvirin,BS808229,-7.0,Days,Time of initial vaccine administration,PBMC,234.Blood.RNA-MicroArray.PV4267,ES983940,GEO,GSM1147878,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 234.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114475,Male,White,VO_0000046,Fluvirin,BS808230,-7.0,Days,Time of initial vaccine administration,PBMC,235.Blood.RNA-MicroArray.PV4267,ES983941,GEO,GSM1147883,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 235.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114477,Female,White,VO_0000046,Fluvirin,BS808231,-7.0,Days,Time of initial vaccine administration,PBMC,237.Blood.RNA-MicroArray.PV4267,ES983942,GEO,GSM1147891,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 237.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114478,Male,White,VO_0000046,Fluvirin,BS808232,-7.0,Days,Time of initial vaccine administration,PBMC,241.Blood.RNA-MicroArray.PV4267,ES983943,GEO,GSM1147896,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 241.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114481,Female,Asian,VO_0000046,Fluvirin,BS808233,-7.0,Days,Time of initial vaccine administration,PBMC,244.Blood.RNA-MicroArray.PV4267,ES983944,GEO,GSM1147907,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 244.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114482,Female,White,VO_0000046,Fluvirin,BS808234,-7.0,Days,Time of initial vaccine administration,PBMC,245.Blood.RNA-MicroArray.PV4267,ES983945,GEO,GSM1147912,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 245.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114483,Female,White,VO_0000046,Fluvirin,BS808235,-7.0,Days,Time of initial vaccine administration,PBMC,246.Blood.RNA-MicroArray.PV4267,ES983946,GEO,GSM1147917,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 246.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114484,Female,Other,VO_0000046,Fluvirin,BS808236,-7.0,Days,Time of initial vaccine administration,PBMC,247.Blood.RNA-MicroArray.PV4267,ES983947,GEO,GSM1147922,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 247.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114485,Female,White,VO_0000046,Fluvirin,BS808237,-7.0,Days,Time of initial vaccine administration,PBMC,248.Blood.RNA-MicroArray.PV4267,ES983948,GEO,GSM1147924,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 248.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114486,Female,White,VO_0000046,Fluvirin,BS808238,-7.0,Days,Time of initial vaccine administration,PBMC,249.Blood.RNA-MicroArray.PV4267,ES983949,GEO,GSM1147929,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 249.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114487,Female,Asian,VO_0000046,Fluvirin,BS808239,-7.0,Days,Time of initial vaccine administration,PBMC,250.Blood.RNA-MicroArray.PV4267,ES983950,GEO,GSM1147934,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 250.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114488,Female,Black or African American,VO_0000046,Fluvirin,BS808240,-7.0,Days,Time of initial vaccine administration,PBMC,251.Blood.RNA-MicroArray.PV4267,ES983951,GEO,GSM1147939,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 251.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114489,Male,Asian,VO_0000046,Fluvirin,BS808241,-7.0,Days,Time of initial vaccine administration,PBMC,252.Blood.RNA-MicroArray.PV4267,ES983952,GEO,GSM1147944,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 252.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114490,Female,White,VO_0000046,Fluvirin,BS808242,-7.0,Days,Time of initial vaccine administration,PBMC,254.Blood.RNA-MicroArray.PV4267,ES983953,GEO,GSM1147949,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 254.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114491,Female,Black or African American,VO_0000046,Fluvirin,BS808243,-7.0,Days,Time of initial vaccine administration,PBMC,256.Blood.RNA-MicroArray.PV4267,ES983954,GEO,GSM1147954,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 256.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114492,Female,White,VO_0000046,Fluvirin,BS808244,-7.0,Days,Time of initial vaccine administration,PBMC,257.Blood.RNA-MicroArray.PV4267,ES983955,GEO,GSM1147959,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 257.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114493,Female,White,VO_0000046,Fluvirin,BS808245,-7.0,Days,Time of initial vaccine administration,PBMC,259.Blood.RNA-MicroArray.PV4267,ES983956,GEO,GSM1147964,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 259.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114494,Female,Asian,VO_0000046,Fluvirin,BS808246,-7.0,Days,Time of initial vaccine administration,PBMC,260.Blood.RNA-MicroArray.PV4267,ES983957,GEO,GSM1147969,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 260.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114495,Male,White,VO_0000046,Fluvirin,BS808247,-7.0,Days,Time of initial vaccine administration,PBMC,261.Blood.RNA-MicroArray.PV4267,ES983958,GEO,GSM1147974,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 261.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114496,Female,White,VO_0000046,Fluvirin,BS808248,-7.0,Days,Time of initial vaccine administration,PBMC,262.Blood.RNA-MicroArray.PV4267,ES983959,GEO,GSM1147975,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 262.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114497,Male,Asian,VO_0000046,Fluvirin,BS808249,-7.0,Days,Time of initial vaccine administration,PBMC,263.Blood.RNA-MicroArray.PV4267,ES983960,GEO,GSM1147980,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 263.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114498,Male,White,VO_0000046,Fluvirin,BS808250,-7.0,Days,Time of initial vaccine administration,PBMC,265.Blood.RNA-MicroArray.PV4267,ES983961,GEO,GSM1147985,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 265.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114499,Female,Asian,VO_0000046,Fluvirin,BS808251,-7.0,Days,Time of initial vaccine administration,PBMC,267.Blood.RNA-MicroArray.PV4267,ES983962,GEO,GSM1147990,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 267.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114500,Male,White,VO_0000046,Fluvirin,BS808252,-7.0,Days,Time of initial vaccine administration,PBMC,268.Blood.RNA-MicroArray.PV4267,ES983963,GEO,GSM1147995,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 268.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114501,Female,Asian,VO_0000046,Fluvirin,BS808253,-7.0,Days,Time of initial vaccine administration,PBMC,270.Blood.RNA-MicroArray.PV4267,ES983964,GEO,GSM1148000,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 270.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114502,Female,White,VO_0000046,Fluvirin,BS808254,-7.0,Days,Time of initial vaccine administration,PBMC,272.Blood.RNA-MicroArray.PV4267,ES983965,GEO,GSM1148005,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 272.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114503,Female,Black or African American,VO_0000046,Fluvirin,BS808255,-7.0,Days,Time of initial vaccine administration,PBMC,273.Blood.RNA-MicroArray.PV4267,ES983966,GEO,GSM1148010,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 273.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114504,Female,White,VO_0000046,Fluvirin,BS808256,-7.0,Days,Time of initial vaccine administration,PBMC,274.Blood.RNA-MicroArray.PV4267,ES983967,GEO,GSM1148012,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 274.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114505,Female,White,VO_0000046,Fluvirin,BS808257,-7.0,Days,Time of initial vaccine administration,PBMC,275.Blood.RNA-MicroArray.PV4267,ES983968,GEO,GSM1148015,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 275.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114506,Male,Asian,VO_0000046,Fluvirin,BS808258,-7.0,Days,Time of initial vaccine administration,PBMC,277.Blood.RNA-MicroArray.PV4267,ES983969,GEO,GSM1148020,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 277.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114507,Male,White,VO_0000046,Fluvirin,BS808259,-7.0,Days,Time of initial vaccine administration,PBMC,279.Blood.RNA-MicroArray.PV4267,ES983970,GEO,GSM1148024,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 279.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114508,Female,Other,VO_0000046,Fluvirin,BS808260,-7.0,Days,Time of initial vaccine administration,PBMC,280.Blood.RNA-MicroArray.PV4267,ES983971,GEO,GSM1148029,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 280.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114509,Male,White,VO_0000046,Fluvirin,BS808261,-7.0,Days,Time of initial vaccine administration,PBMC,281.Blood.RNA-MicroArray.PV4267,ES983972,GEO,GSM1148034,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 281.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114510,Male,White,VO_0000046,Fluvirin,BS808262,-7.0,Days,Time of initial vaccine administration,PBMC,282.Blood.RNA-MicroArray.PV4267,ES983973,GEO,GSM1148039,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 282.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114511,Female,White,VO_0000046,Fluvirin,BS808263,-7.0,Days,Time of initial vaccine administration,PBMC,283.Blood.RNA-MicroArray.PV4267,ES983974,GEO,GSM1148044,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 283.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114512,Male,White,VO_0000046,Fluvirin,BS808264,-7.0,Days,Time of initial vaccine administration,PBMC,284.Blood.RNA-MicroArray.PV4267,ES983975,GEO,GSM1148049,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 284.Blood.RNA-MicroArray.PV4267,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114450,Male,White,VO_0000046,Fluvirin,BS808265,7.0,Days,Time of initial vaccine administration,PBMC,200.Blood.RNA-MicroArray.PV4268,ES983976,GEO,GSM1147761,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 200.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114451,Female,White,VO_0000046,Fluvirin,BS808266,7.0,Days,Time of initial vaccine administration,PBMC,201.Blood.RNA-MicroArray.PV4268,ES983977,GEO,GSM1147766,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 201.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114452,Male,Asian,VO_0000046,Fluvirin,BS808267,7.0,Days,Time of initial vaccine administration,PBMC,202.Blood.RNA-MicroArray.PV4268,ES983978,GEO,GSM1147771,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 202.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114453,Female,White,VO_0000046,Fluvirin,BS808268,7.0,Days,Time of initial vaccine administration,PBMC,204.Blood.RNA-MicroArray.PV4268,ES983979,GEO,GSM1147776,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 204.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114454,Female,White,VO_0000046,Fluvirin,BS808269,7.0,Days,Time of initial vaccine administration,PBMC,205.Blood.RNA-MicroArray.PV4268,ES983980,GEO,GSM1147781,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 205.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114455,Male,Asian,VO_0000046,Fluvirin,BS808270,7.0,Days,Time of initial vaccine administration,PBMC,206.Blood.RNA-MicroArray.PV4268,ES983981,GEO,GSM1147786,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 206.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114458,Male,White,VO_0000046,Fluvirin,BS808271,7.0,Days,Time of initial vaccine administration,PBMC,212.Blood.RNA-MicroArray.PV4268,ES983982,GEO,GSM1147799,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 212.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114459,Female,Asian,VO_0000046,Fluvirin,BS808272,7.0,Days,Time of initial vaccine administration,PBMC,213.Blood.RNA-MicroArray.PV4268,ES983983,GEO,GSM1147804,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 213.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114460,Female,Asian,VO_0000046,Fluvirin,BS808273,7.0,Days,Time of initial vaccine administration,PBMC,215.Blood.RNA-MicroArray.PV4268,ES983984,GEO,GSM1147809,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 215.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114461,Female,White,VO_0000046,Fluvirin,BS808274,7.0,Days,Time of initial vaccine administration,PBMC,217.Blood.RNA-MicroArray.PV4268,ES983985,GEO,GSM1147814,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 217.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114462,Female,Other,VO_0000046,Fluvirin,BS808275,7.0,Days,Time of initial vaccine administration,PBMC,218.Blood.RNA-MicroArray.PV4268,ES983986,GEO,GSM1147819,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 218.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114463,Male,White,VO_0000046,Fluvirin,BS808276,7.0,Days,Time of initial vaccine administration,PBMC,221.Blood.RNA-MicroArray.PV4268,ES983987,GEO,GSM1147823,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 221.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114464,Female,Asian,VO_0000046,Fluvirin,BS808277,7.0,Days,Time of initial vaccine administration,PBMC,222.Blood.RNA-MicroArray.PV4268,ES983988,GEO,GSM1147828,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 222.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114465,Male,White,VO_0000046,Fluvirin,BS808278,7.0,Days,Time of initial vaccine administration,PBMC,224.Blood.RNA-MicroArray.PV4268,ES983989,GEO,GSM1147832,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 224.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114466,Female,White,VO_0000046,Fluvirin,BS808279,7.0,Days,Time of initial vaccine administration,PBMC,226.Blood.RNA-MicroArray.PV4268,ES983990,GEO,GSM1147837,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 226.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114467,Male,White,VO_0000046,Fluvirin,BS808280,7.0,Days,Time of initial vaccine administration,PBMC,227.Blood.RNA-MicroArray.PV4268,ES983991,GEO,GSM1147842,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 227.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114468,Male,White,VO_0000046,Fluvirin,BS808281,7.0,Days,Time of initial vaccine administration,PBMC,228.Blood.RNA-MicroArray.PV4268,ES983992,GEO,GSM1147847,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 228.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114469,Female,White,VO_0000046,Fluvirin,BS808282,7.0,Days,Time of initial vaccine administration,PBMC,229.Blood.RNA-MicroArray.PV4268,ES983993,GEO,GSM1147852,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 229.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114470,Female,White,VO_0000046,Fluvirin,BS808283,7.0,Days,Time of initial vaccine administration,PBMC,230.Blood.RNA-MicroArray.PV4268,ES983994,GEO,GSM1147857,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 230.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114471,Female,Asian,VO_0000046,Fluvirin,BS808284,7.0,Days,Time of initial vaccine administration,PBMC,231.Blood.RNA-MicroArray.PV4268,ES983995,GEO,GSM1147862,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 231.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114472,Male,Asian,VO_0000046,Fluvirin,BS808285,7.0,Days,Time of initial vaccine administration,PBMC,232.Blood.RNA-MicroArray.PV4268,ES983996,GEO,GSM1147867,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 232.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114473,Male,White,VO_0000046,Fluvirin,BS808286,7.0,Days,Time of initial vaccine administration,PBMC,233.Blood.RNA-MicroArray.PV4268,ES983997,GEO,GSM1147872,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 233.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114474,Male,Black or African American,VO_0000046,Fluvirin,BS808287,7.0,Days,Time of initial vaccine administration,PBMC,234.Blood.RNA-MicroArray.PV4268,ES983998,GEO,GSM1147877,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 234.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114475,Male,White,VO_0000046,Fluvirin,BS808288,7.0,Days,Time of initial vaccine administration,PBMC,235.Blood.RNA-MicroArray.PV4268,ES983999,GEO,GSM1147882,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 235.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114476,Male,White,VO_0000046,Fluvirin,BS808289,7.0,Days,Time of initial vaccine administration,PBMC,236.Blood.RNA-MicroArray.PV4268,ES984000,GEO,GSM1147887,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 236.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114477,Female,White,VO_0000046,Fluvirin,BS808290,7.0,Days,Time of initial vaccine administration,PBMC,237.Blood.RNA-MicroArray.PV4268,ES984001,GEO,GSM1147890,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 237.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114478,Male,White,VO_0000046,Fluvirin,BS808291,7.0,Days,Time of initial vaccine administration,PBMC,241.Blood.RNA-MicroArray.PV4268,ES984002,GEO,GSM1147895,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 241.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114479,Male,White,VO_0000046,Fluvirin,BS808292,7.0,Days,Time of initial vaccine administration,PBMC,242.Blood.RNA-MicroArray.PV4268,ES984003,GEO,GSM1147899,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 242.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114480,Male,White,VO_0000046,Fluvirin,BS808293,7.0,Days,Time of initial vaccine administration,PBMC,243.Blood.RNA-MicroArray.PV4268,ES984004,GEO,GSM1147902,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 243.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114481,Female,Asian,VO_0000046,Fluvirin,BS808294,7.0,Days,Time of initial vaccine administration,PBMC,244.Blood.RNA-MicroArray.PV4268,ES984005,GEO,GSM1147906,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 244.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114482,Female,White,VO_0000046,Fluvirin,BS808295,7.0,Days,Time of initial vaccine administration,PBMC,245.Blood.RNA-MicroArray.PV4268,ES984006,GEO,GSM1147911,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 245.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114483,Female,White,VO_0000046,Fluvirin,BS808296,7.0,Days,Time of initial vaccine administration,PBMC,246.Blood.RNA-MicroArray.PV4268,ES984007,GEO,GSM1147916,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 246.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114484,Female,Other,VO_0000046,Fluvirin,BS808297,7.0,Days,Time of initial vaccine administration,PBMC,247.Blood.RNA-MicroArray.PV4268,ES984008,GEO,GSM1147921,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 247.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114485,Female,White,VO_0000046,Fluvirin,BS808298,7.0,Days,Time of initial vaccine administration,PBMC,248.Blood.RNA-MicroArray.PV4268,ES984009,GEO,GSM1147923,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 248.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114486,Female,White,VO_0000046,Fluvirin,BS808299,7.0,Days,Time of initial vaccine administration,PBMC,249.Blood.RNA-MicroArray.PV4268,ES984010,GEO,GSM1147928,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 249.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114487,Female,Asian,VO_0000046,Fluvirin,BS808300,7.0,Days,Time of initial vaccine administration,PBMC,250.Blood.RNA-MicroArray.PV4268,ES984011,GEO,GSM1147933,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 250.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114488,Female,Black or African American,VO_0000046,Fluvirin,BS808301,7.0,Days,Time of initial vaccine administration,PBMC,251.Blood.RNA-MicroArray.PV4268,ES984012,GEO,GSM1147938,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 251.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114489,Male,Asian,VO_0000046,Fluvirin,BS808302,7.0,Days,Time of initial vaccine administration,PBMC,252.Blood.RNA-MicroArray.PV4268,ES984013,GEO,GSM1147943,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 252.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114490,Female,White,VO_0000046,Fluvirin,BS808303,7.0,Days,Time of initial vaccine administration,PBMC,254.Blood.RNA-MicroArray.PV4268,ES984014,GEO,GSM1147948,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 254.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114491,Female,Black or African American,VO_0000046,Fluvirin,BS808304,7.0,Days,Time of initial vaccine administration,PBMC,256.Blood.RNA-MicroArray.PV4268,ES984015,GEO,GSM1147953,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 256.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114492,Female,White,VO_0000046,Fluvirin,BS808305,7.0,Days,Time of initial vaccine administration,PBMC,257.Blood.RNA-MicroArray.PV4268,ES984016,GEO,GSM1147958,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 257.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114493,Female,White,VO_0000046,Fluvirin,BS808306,7.0,Days,Time of initial vaccine administration,PBMC,259.Blood.RNA-MicroArray.PV4268,ES984017,GEO,GSM1147963,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 259.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114494,Female,Asian,VO_0000046,Fluvirin,BS808307,7.0,Days,Time of initial vaccine administration,PBMC,260.Blood.RNA-MicroArray.PV4268,ES984018,GEO,GSM1147968,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 260.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114495,Male,White,VO_0000046,Fluvirin,BS808308,7.0,Days,Time of initial vaccine administration,PBMC,261.Blood.RNA-MicroArray.PV4268,ES984019,GEO,GSM1147973,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 261.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114497,Male,Asian,VO_0000046,Fluvirin,BS808309,7.0,Days,Time of initial vaccine administration,PBMC,263.Blood.RNA-MicroArray.PV4268,ES984020,GEO,GSM1147979,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 263.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114498,Male,White,VO_0000046,Fluvirin,BS808310,7.0,Days,Time of initial vaccine administration,PBMC,265.Blood.RNA-MicroArray.PV4268,ES984021,GEO,GSM1147984,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 265.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114499,Female,Asian,VO_0000046,Fluvirin,BS808311,7.0,Days,Time of initial vaccine administration,PBMC,267.Blood.RNA-MicroArray.PV4268,ES984022,GEO,GSM1147989,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 267.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114500,Male,White,VO_0000046,Fluvirin,BS808312,7.0,Days,Time of initial vaccine administration,PBMC,268.Blood.RNA-MicroArray.PV4268,ES984023,GEO,GSM1147994,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 268.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114501,Female,Asian,VO_0000046,Fluvirin,BS808313,7.0,Days,Time of initial vaccine administration,PBMC,270.Blood.RNA-MicroArray.PV4268,ES984024,GEO,GSM1147999,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 270.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114502,Female,White,VO_0000046,Fluvirin,BS808314,7.0,Days,Time of initial vaccine administration,PBMC,272.Blood.RNA-MicroArray.PV4268,ES984025,GEO,GSM1148004,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 272.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114503,Female,Black or African American,VO_0000046,Fluvirin,BS808315,7.0,Days,Time of initial vaccine administration,PBMC,273.Blood.RNA-MicroArray.PV4268,ES984026,GEO,GSM1148009,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 273.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114506,Male,Asian,VO_0000046,Fluvirin,BS808316,7.0,Days,Time of initial vaccine administration,PBMC,277.Blood.RNA-MicroArray.PV4268,ES984027,GEO,GSM1148019,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 277.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114508,Female,Other,VO_0000046,Fluvirin,BS808317,7.0,Days,Time of initial vaccine administration,PBMC,280.Blood.RNA-MicroArray.PV4268,ES984028,GEO,GSM1148028,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 280.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114509,Male,White,VO_0000046,Fluvirin,BS808318,7.0,Days,Time of initial vaccine administration,PBMC,281.Blood.RNA-MicroArray.PV4268,ES984029,GEO,GSM1148033,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 281.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114510,Male,White,VO_0000046,Fluvirin,BS808319,7.0,Days,Time of initial vaccine administration,PBMC,282.Blood.RNA-MicroArray.PV4268,ES984030,GEO,GSM1148038,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 282.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114511,Female,White,VO_0000046,Fluvirin,BS808320,7.0,Days,Time of initial vaccine administration,PBMC,283.Blood.RNA-MicroArray.PV4268,ES984031,GEO,GSM1148043,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 283.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114512,Male,White,VO_0000046,Fluvirin,BS808321,7.0,Days,Time of initial vaccine administration,PBMC,284.Blood.RNA-MicroArray.PV4268,ES984032,GEO,GSM1148048,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 284.Blood.RNA-MicroArray.PV4268,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114450,Male,White,VO_0000046,Fluvirin,BS808322,70.0,Days,Time of initial vaccine administration,PBMC,200.Blood.RNA-MicroArray.PV4269,ES984033,GEO,GSM1147760,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 200.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114451,Female,White,VO_0000046,Fluvirin,BS808323,70.0,Days,Time of initial vaccine administration,PBMC,201.Blood.RNA-MicroArray.PV4269,ES984034,GEO,GSM1147765,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 201.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114452,Male,Asian,VO_0000046,Fluvirin,BS808324,70.0,Days,Time of initial vaccine administration,PBMC,202.Blood.RNA-MicroArray.PV4269,ES984035,GEO,GSM1147770,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 202.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114453,Female,White,VO_0000046,Fluvirin,BS808325,70.0,Days,Time of initial vaccine administration,PBMC,204.Blood.RNA-MicroArray.PV4269,ES984036,GEO,GSM1147775,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 204.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114454,Female,White,VO_0000046,Fluvirin,BS808326,70.0,Days,Time of initial vaccine administration,PBMC,205.Blood.RNA-MicroArray.PV4269,ES984037,GEO,GSM1147780,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 205.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114455,Male,Asian,VO_0000046,Fluvirin,BS808327,70.0,Days,Time of initial vaccine administration,PBMC,206.Blood.RNA-MicroArray.PV4269,ES984038,GEO,GSM1147785,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 206.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114456,Female,White,VO_0000046,Fluvirin,BS808328,70.0,Days,Time of initial vaccine administration,PBMC,207.Blood.RNA-MicroArray.PV4269,ES984039,GEO,GSM1147790,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 207.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114457,Male,White,VO_0000046,Fluvirin,BS808329,70.0,Days,Time of initial vaccine administration,PBMC,209.Blood.RNA-MicroArray.PV4269,ES984040,GEO,GSM1147794,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 209.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114458,Male,White,VO_0000046,Fluvirin,BS808330,70.0,Days,Time of initial vaccine administration,PBMC,212.Blood.RNA-MicroArray.PV4269,ES984041,GEO,GSM1147798,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 212.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114459,Female,Asian,VO_0000046,Fluvirin,BS808331,70.0,Days,Time of initial vaccine administration,PBMC,213.Blood.RNA-MicroArray.PV4269,ES984042,GEO,GSM1147803,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 213.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114460,Female,Asian,VO_0000046,Fluvirin,BS808332,70.0,Days,Time of initial vaccine administration,PBMC,215.Blood.RNA-MicroArray.PV4269,ES984043,GEO,GSM1147808,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 215.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114461,Female,White,VO_0000046,Fluvirin,BS808333,70.0,Days,Time of initial vaccine administration,PBMC,217.Blood.RNA-MicroArray.PV4269,ES984044,GEO,GSM1147813,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 217.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114462,Female,Other,VO_0000046,Fluvirin,BS808334,70.0,Days,Time of initial vaccine administration,PBMC,218.Blood.RNA-MicroArray.PV4269,ES984045,GEO,GSM1147818,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 218.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114464,Female,Asian,VO_0000046,Fluvirin,BS808335,70.0,Days,Time of initial vaccine administration,PBMC,222.Blood.RNA-MicroArray.PV4269,ES984046,GEO,GSM1147827,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 222.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114465,Male,White,VO_0000046,Fluvirin,BS808336,70.0,Days,Time of initial vaccine administration,PBMC,224.Blood.RNA-MicroArray.PV4269,ES984047,GEO,GSM1147831,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 224.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114466,Female,White,VO_0000046,Fluvirin,BS808337,70.0,Days,Time of initial vaccine administration,PBMC,226.Blood.RNA-MicroArray.PV4269,ES984048,GEO,GSM1147836,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 226.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114467,Male,White,VO_0000046,Fluvirin,BS808338,70.0,Days,Time of initial vaccine administration,PBMC,227.Blood.RNA-MicroArray.PV4269,ES984049,GEO,GSM1147841,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 227.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114468,Male,White,VO_0000046,Fluvirin,BS808339,70.0,Days,Time of initial vaccine administration,PBMC,228.Blood.RNA-MicroArray.PV4269,ES984050,GEO,GSM1147846,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 228.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114469,Female,White,VO_0000046,Fluvirin,BS808340,70.0,Days,Time of initial vaccine administration,PBMC,229.Blood.RNA-MicroArray.PV4269,ES984051,GEO,GSM1147851,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 229.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114470,Female,White,VO_0000046,Fluvirin,BS808341,70.0,Days,Time of initial vaccine administration,PBMC,230.Blood.RNA-MicroArray.PV4269,ES984052,GEO,GSM1147856,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 230.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114471,Female,Asian,VO_0000046,Fluvirin,BS808342,70.0,Days,Time of initial vaccine administration,PBMC,231.Blood.RNA-MicroArray.PV4269,ES984053,GEO,GSM1147861,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 231.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114472,Male,Asian,VO_0000046,Fluvirin,BS808343,70.0,Days,Time of initial vaccine administration,PBMC,232.Blood.RNA-MicroArray.PV4269,ES984054,GEO,GSM1147866,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 232.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114473,Male,White,VO_0000046,Fluvirin,BS808344,70.0,Days,Time of initial vaccine administration,PBMC,233.Blood.RNA-MicroArray.PV4269,ES984055,GEO,GSM1147871,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 233.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114474,Male,Black or African American,VO_0000046,Fluvirin,BS808345,70.0,Days,Time of initial vaccine administration,PBMC,234.Blood.RNA-MicroArray.PV4269,ES984056,GEO,GSM1147876,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 234.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114475,Male,White,VO_0000046,Fluvirin,BS808346,70.0,Days,Time of initial vaccine administration,PBMC,235.Blood.RNA-MicroArray.PV4269,ES984057,GEO,GSM1147881,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 235.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114476,Male,White,VO_0000046,Fluvirin,BS808347,70.0,Days,Time of initial vaccine administration,PBMC,236.Blood.RNA-MicroArray.PV4269,ES984058,GEO,GSM1147886,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 236.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114478,Male,White,VO_0000046,Fluvirin,BS808348,70.0,Days,Time of initial vaccine administration,PBMC,241.Blood.RNA-MicroArray.PV4269,ES984059,GEO,GSM1147894,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 241.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114479,Male,White,VO_0000046,Fluvirin,BS808349,70.0,Days,Time of initial vaccine administration,PBMC,242.Blood.RNA-MicroArray.PV4269,ES984060,GEO,GSM1147898,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 242.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114480,Male,White,VO_0000046,Fluvirin,BS808350,70.0,Days,Time of initial vaccine administration,PBMC,243.Blood.RNA-MicroArray.PV4269,ES984061,GEO,GSM1147901,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 243.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114481,Female,Asian,VO_0000046,Fluvirin,BS808351,70.0,Days,Time of initial vaccine administration,PBMC,244.Blood.RNA-MicroArray.PV4269,ES984062,GEO,GSM1147905,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 244.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114482,Female,White,VO_0000046,Fluvirin,BS808352,70.0,Days,Time of initial vaccine administration,PBMC,245.Blood.RNA-MicroArray.PV4269,ES984063,GEO,GSM1147910,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 245.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114483,Female,White,VO_0000046,Fluvirin,BS808353,70.0,Days,Time of initial vaccine administration,PBMC,246.Blood.RNA-MicroArray.PV4269,ES984064,GEO,GSM1147915,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 246.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114484,Female,Other,VO_0000046,Fluvirin,BS808354,70.0,Days,Time of initial vaccine administration,PBMC,247.Blood.RNA-MicroArray.PV4269,ES984065,GEO,GSM1147920,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 247.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114486,Female,White,VO_0000046,Fluvirin,BS808355,70.0,Days,Time of initial vaccine administration,PBMC,249.Blood.RNA-MicroArray.PV4269,ES984066,GEO,GSM1147927,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 249.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114487,Female,Asian,VO_0000046,Fluvirin,BS808356,70.0,Days,Time of initial vaccine administration,PBMC,250.Blood.RNA-MicroArray.PV4269,ES984067,GEO,GSM1147932,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 250.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114488,Female,Black or African American,VO_0000046,Fluvirin,BS808357,70.0,Days,Time of initial vaccine administration,PBMC,251.Blood.RNA-MicroArray.PV4269,ES984068,GEO,GSM1147937,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 251.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114489,Male,Asian,VO_0000046,Fluvirin,BS808358,70.0,Days,Time of initial vaccine administration,PBMC,252.Blood.RNA-MicroArray.PV4269,ES984069,GEO,GSM1147942,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 252.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114490,Female,White,VO_0000046,Fluvirin,BS808359,70.0,Days,Time of initial vaccine administration,PBMC,254.Blood.RNA-MicroArray.PV4269,ES984070,GEO,GSM1147947,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 254.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114491,Female,Black or African American,VO_0000046,Fluvirin,BS808360,70.0,Days,Time of initial vaccine administration,PBMC,256.Blood.RNA-MicroArray.PV4269,ES984071,GEO,GSM1147952,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 256.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114492,Female,White,VO_0000046,Fluvirin,BS808361,70.0,Days,Time of initial vaccine administration,PBMC,257.Blood.RNA-MicroArray.PV4269,ES984072,GEO,GSM1147957,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 257.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114493,Female,White,VO_0000046,Fluvirin,BS808362,70.0,Days,Time of initial vaccine administration,PBMC,259.Blood.RNA-MicroArray.PV4269,ES984073,GEO,GSM1147962,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 259.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114494,Female,Asian,VO_0000046,Fluvirin,BS808363,70.0,Days,Time of initial vaccine administration,PBMC,260.Blood.RNA-MicroArray.PV4269,ES984074,GEO,GSM1147967,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 260.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114495,Male,White,VO_0000046,Fluvirin,BS808364,70.0,Days,Time of initial vaccine administration,PBMC,261.Blood.RNA-MicroArray.PV4269,ES984075,GEO,GSM1147972,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 261.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114497,Male,Asian,VO_0000046,Fluvirin,BS808365,70.0,Days,Time of initial vaccine administration,PBMC,263.Blood.RNA-MicroArray.PV4269,ES984076,GEO,GSM1147978,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 263.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114498,Male,White,VO_0000046,Fluvirin,BS808366,70.0,Days,Time of initial vaccine administration,PBMC,265.Blood.RNA-MicroArray.PV4269,ES984077,GEO,GSM1147983,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 265.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114499,Female,Asian,VO_0000046,Fluvirin,BS808367,70.0,Days,Time of initial vaccine administration,PBMC,267.Blood.RNA-MicroArray.PV4269,ES984078,GEO,GSM1147988,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 267.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114500,Male,White,VO_0000046,Fluvirin,BS808368,70.0,Days,Time of initial vaccine administration,PBMC,268.Blood.RNA-MicroArray.PV4269,ES984079,GEO,GSM1147993,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 268.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114501,Female,Asian,VO_0000046,Fluvirin,BS808369,70.0,Days,Time of initial vaccine administration,PBMC,270.Blood.RNA-MicroArray.PV4269,ES984080,GEO,GSM1147998,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 270.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114502,Female,White,VO_0000046,Fluvirin,BS808370,70.0,Days,Time of initial vaccine administration,PBMC,272.Blood.RNA-MicroArray.PV4269,ES984081,GEO,GSM1148003,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 272.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114503,Female,Black or African American,VO_0000046,Fluvirin,BS808371,70.0,Days,Time of initial vaccine administration,PBMC,273.Blood.RNA-MicroArray.PV4269,ES984082,GEO,GSM1148008,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 273.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114504,Female,White,VO_0000046,Fluvirin,BS808372,70.0,Days,Time of initial vaccine administration,PBMC,274.Blood.RNA-MicroArray.PV4269,ES984083,GEO,GSM1148011,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 274.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114506,Male,Asian,VO_0000046,Fluvirin,BS808373,70.0,Days,Time of initial vaccine administration,PBMC,277.Blood.RNA-MicroArray.PV4269,ES984084,GEO,GSM1148018,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 277.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114507,Male,White,VO_0000046,Fluvirin,BS808374,70.0,Days,Time of initial vaccine administration,PBMC,279.Blood.RNA-MicroArray.PV4269,ES984085,GEO,GSM1148023,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 279.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114508,Female,Other,VO_0000046,Fluvirin,BS808375,70.0,Days,Time of initial vaccine administration,PBMC,280.Blood.RNA-MicroArray.PV4269,ES984086,GEO,GSM1148027,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 280.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114509,Male,White,VO_0000046,Fluvirin,BS808376,70.0,Days,Time of initial vaccine administration,PBMC,281.Blood.RNA-MicroArray.PV4269,ES984087,GEO,GSM1148032,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 281.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114510,Male,White,VO_0000046,Fluvirin,BS808377,70.0,Days,Time of initial vaccine administration,PBMC,282.Blood.RNA-MicroArray.PV4269,ES984088,GEO,GSM1148037,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 282.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114511,Female,White,VO_0000046,Fluvirin,BS808378,70.0,Days,Time of initial vaccine administration,PBMC,283.Blood.RNA-MicroArray.PV4269,ES984089,GEO,GSM1148042,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 283.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
SDY80,Cellular and molecular characterization of the immune response in healthy NIH employees at baseline and after immunization with the H1N1 or seasonal influenza vaccines,"The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases proposes this protocol designed to obtain blood from healthy adult subjects (NIH employees) prior to vaccination and then at various time points after receiving the FDA-licensed seasonal and H1N1 influenza vaccine. These samples will be used to perform a comprehensive and detailed analysis of the immune system at baseline and in response to vaccination. To our knowledge, this protocol will be the first study to characterize the human cellular and molecular immune system parameters, or immunome, in a large number of healthy adults (NIH employees). This information may be useful in designing newer, more effective vaccines to prevent the spread of H1N1 influenza.",18.0,85.0,SUB114512,Male,White,VO_0000046,Fluvirin,BS808379,70.0,Days,Time of initial vaccine administration,PBMC,284.Blood.RNA-MicroArray.PV4269,ES984090,GEO,GSM1148047,false,GSE47353,GPL6244,[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version],GSE47353,PBMC : 284.Blood.RNA-MicroArray.PV4269,18.0 - 85.0
